# Session I: Strategies and FDA Considerations for U.S. Market Entry

**01:00 PM ~ 02:40 PM**

---

## Table of Contents

1. [Haja Sittana El Mubarak](#1-haja-sittana-el-mubarak) - FDA Trends & Global Regulation Insights
2. [ByungSik Chang](#2-byungsik-chang) - FDA Approval Strategies and Success Cases
3. [JungYoup Han](#3-jungyoup-han) - FDA Preparation and Approval Strategy (CRO)
4. [Sung Park](#4-sung-park) - Appropriate Risk Allocation in the FDA World

---

## Key Takeaways

> ### FDA Í∑úÏ†ú Ìä∏Î†åÎìú
> - COVID-19Î°ú Ïù∏Ìïú EUA Ï†úÏ∂ú Í∏∞Î°ùÏ†Å Ï¶ùÍ∞Ä - Ïù¥Ï†Ñ Î™®Îì† Í∏¥Í∏âÏÉÅÌô© Ìï©Í≥Ñ Ï¥àÍ≥º
> - LDT(Laboratory Developed Tests) Í∑úÏ†ú Î≥ÄÌôî Ï§ÄÎπÑ ÌïÑÏöî - 2024ÎÖÑ 4Ïõî ÏµúÏ¢Ö Í∑úÏπô Î∞úÌëú
> - Í∏ÄÎ°úÎ≤å IVD ÏãúÏû• 2024ÎÖÑ $108.3B ÏòàÏÉÅ
>
> ### FDA ÏäπÏù∏ Ï†ÑÎûµ
> - FDA Ï†ïÏãù ÏäπÏù∏Îêú ÎπÑÍµê Ï†úÌíà ÏÑ†Ï†ï ÌïÑÏàò
> - ÎØ∏Íµ≠ ÎÇ¥ ÏµúÏÜå 3Í∞ú ÏßÄÏó≠ÏóêÏÑú ÏûÑÏÉÅ ÏÉòÌîå ÏàòÏßë ÌïÑÏöî
> - eSTAR/pre-eSTAR ÏãúÏä§ÌÖú ÌôúÏö© Í∂åÏû•
>
> ### ÌïµÏã¨ ÏÑ±Í≥µ ÏöîÏù∏
> - Ï¥àÍ∏∞ Îã®Í≥ÑÎ∂ÄÌÑ∞ FDA Ï†ÑÎûµ ÏàòÎ¶Ω (Reverse Planning)
> - Ï≤†Ï†ÄÌïú Î¨∏ÏÑúÌôî - "Î¨∏ÏÑúÌôîÎêòÏßÄ ÏïäÏùÄ Í≤ÉÏùÄ Î∞úÏÉùÌïòÏßÄ ÏïäÏùÄ Í≤É"
> - Pre-submission ÎØ∏ÌåÖ Ï†ÅÍ∑π ÌôúÏö©
> - ÎîîÏßÄÌÑ∏Ìó¨Ïä§ Í∑úÏ†ú ÏßÄÎ¢∞Î∞≠ ÌååÏïÖ Î∞è ÌöåÌîº

---

## 1. Haja Sittana El Mubarak

| | |
|---|---|
| ‚è∞ | **01:00 PM ~ 01:40 PM** |
| üè¢ | Wasela Diagnostics LLC |
| üìå | "FDA Trends & Global Regulation Insights" |
| üí° | 12ÎÖÑ Ïù¥ÏÉÅ FDA ÏàòÏÑù Ïã¨ÏÇ¨Í¥Ä Í≤ΩÎ†• |

---

### Summary

#### Overview
- 2020-2025ÎÖÑ IVD(Ï≤¥Ïô∏ÏßÑÎã®) Í∑úÏ†ú ÌôòÍ≤ΩÏùÑ ÌòïÏÑ±Ìïú Ï£ºÏöî ÏöîÏù∏ Î∂ÑÏÑù
- 4ÎåÄ Ï£ºÏöî ÎèôÏù∏: COVID-19 ÎåÄÏùë, Í∏∞Ïà† ÏßÑÌôî, LDT Í∑úÏ†ú Î≥ÄÌôî, Í∏ÄÎ°úÎ≤å ÏãúÏû• ÏòÅÌñ•

#### COVID-19 Impact
- 2020.3 ~ 2023.5 EUA Ï†úÏ∂úÏù¥ Ïù¥Ï†Ñ Î™®Îì† Í∏¥Í∏âÏÉÅÌô© Ìï©Í≥Ñ Ï¥àÍ≥º
- Home use test Ìå®Îü¨Îã§ÏûÑ Î≥ÄÌôî - ÏïàÏ†ÑÏÑ± Ï†ÄÌïò ÏóÜÏù¥ Í∑úÏ†ú Ïû•Î≤Ω Í∑πÎ≥µ
- Ïã¨ÏÇ¨ ÏãúÍ∞Ñ Îã®Ï∂ïÏù¥ ÏÉàÎ°úÏö¥ ÌëúÏ§ÄÏúºÎ°ú Ï†ïÏ∞©

#### LDT Regulatory Changes
- 2024ÎÖÑ 4Ïõî ÏµúÏ¢Ö Í∑úÏπô Î∞úÌëú - LDTÎ•º ÏùºÎ∞ò IVDÏôÄ ÎèôÏùºÌïòÍ≤å Í∑úÏ†ú
- 2025ÎÖÑ 4Ïõî Ïó∞Î∞©Î≤ïÏõê Ï∞®Îã® - ÌòÑÏû¨ Î∂àÌôïÏã§ÏÑ± ÏÉÅÌÉú
- 4ÎÖÑ Îã®Í≥ÑÏ†Å ÏãúÌñâ Í≥ÑÌöç: MDR/COBRA ‚Üí Îì±Î°ù ‚Üí QMS ‚Üí Í≥†ÏúÑÌóò ÌóàÍ∞Ä ‚Üí Ï†ÑÏ≤¥ ÌóàÍ∞Ä

#### Technology & Market Evolution
- Î∂ÑÏûêÏßÑÎã®, Ïï°Ï≤¥ÏÉùÍ≤Ä, AI/ML, ÎèôÎ∞òÏßÑÎã® ÏÑ±Ïû•
- ÎîîÏßÄÌÑ∏Ìó¨Ïä§ Î∞è ÏÇ¨Ïù¥Î≤ÑÎ≥¥Ïïà Ï§ëÏöîÏÑ± Ï¶ùÍ∞Ä
- EU IVDRÎ°ú Ïù∏Ìïú Í∏ÄÎ°úÎ≤å Í∑úÏ†ú Ï°∞Ìôî ÌïÑÏöîÏÑ±

#### Impact on Stakeholders
- ÏûÑÏÉÅ Í≤ÄÏÇ¨Ïã§: $100M Ïù¥ÏÉÅ Ï§ÄÏàò ÎπÑÏö©, 40-60% QMS ÏóÖÍ∑∏Î†àÏù¥Îìú ÌïÑÏöî
- FDA: 3,000-5,000Í±¥ Ïã†Í∑ú LDT Ï†úÏ∂ú ÏòàÏÉÅ
- IVD Ï†úÏ°∞ÏóÖÏ≤¥: Í∏∞Ï°¥ Í∑úÏ†ú Ïó≠ÎüâÏúºÎ°ú ÏãúÏû• ÌôïÎåÄ Í∏∞Ìöå

#### Action Items
- [ ] ÏûÑÏÉÅ Í≤ÄÏÇ¨Ïã§: LDT Í∑úÏ†ú ÎåÄÎπÑ QMS Í∞úÎ∞ú Ìà¨Ïûê
- [ ] Ï†úÏ°∞ÏóÖÏ≤¥: Í∞úÎ∞ú Ï¥àÍ∏∞Î∂ÄÌÑ∞ Í∏ÄÎ°úÎ≤å Í¥ÄÏ†ê Ï±ÑÌÉù
- [ ] AI/ML, ÏÇ¨Ïù¥Î≤ÑÎ≥¥Ïïà Ïó≠Îüâ Ìà¨ÏûêÎ°ú Ï∞®Î≥ÑÌôî
- [ ] Í∑úÏ†ú Îì±Í∏â Ïã§ÏÑ∏Í≥Ñ Ï¶ùÍ±∞(RWE) Ï§ÄÎπÑ

---

### Slides

#### Slide 1
![page_001](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_001_3._Trends_in_US_Regulation_of_IVDS_2020_to_2025_HS_ELMUBARAK_102325.jpg)

**ÏöîÏïΩ**
> It's an honor to be presenting the first meeting for CAMDA and I wish all the success. For all of you who have been working in this space and know that it was revolutionized, basically.

<details>
<summary>üìÑ Slide Transcript</summary>

It's an honor to be presenting the first meeting for CAMDA and I wish all the success.

and the regulatory space.

For all of you who have been working in this space and know that it was revolutionized, basically. It went through the things that happened in the last five years. It reshaped the landscape for the regulations to be developed.

I hope to discuss with you in brief the major players or forces that led to this revolution in the regulatory space for in vitro diagnostics and to discuss

future opportunities.

</details>

#### Slide 2
![page_002](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_002_3._Trends_in_US_Regulation_of_IVDS_2020_to_2025_HS_ELMUBARAK_102325.jpg)

**ÏöîÏïΩ**
> My talk will be structured in a way that's to help us. First, we'll sort of take an executive summary to go over. We will set the stage for today's presentation and then we will dive into the regulatory landscape in this period from 2020 to 2025.

<details>
<summary>üìÑ Slide Transcript</summary>

My talk will be structured in a way that's to help us. First, we'll sort of take an executive summary to go over. We will set the stage for today's presentation and then we will dive into the regulatory landscape in this period from 2020 to 2025.

on the LDT regulatory oversight and the oversight shift, discuss changes in the technologies and how it impacted the regulatory landscape, and also the evolution of the IVD market. The impact of global markets and global regulations and talk about the CDRH strategic direction.

And it impacts on different stakeholders, after which we are going to finally close with some emerging trends and takeaways for different stakeholders.

</details>

#### Slide 3
![page_003](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_003_3._Trends_in_US_Regulation_of_IVDS_2020_to_2025_HS_ELMUBARAK_102325.jpg)

**ÏöîÏïΩ**
> So in the past five years, like we said, there was like a huge change. And I would say there are some major forces. Today I will discuss these four. Starting with the COVID-19 emergency use and emergency response, the digital evolution and technology evolution.

<details>
<summary>üìÑ Slide Transcript</summary>

So in the past five years, like we said, there was like a huge change. And I would say there are some major forces. Today I will discuss these four. Starting with the COVID-19 emergency use and emergency response, the digital evolution and technology evolution.

The LDT regulatory oversight shifts the impact of global markets, which collectively led to this period, which is characterised by the rapid innovation and growth of global markets. and unprecedented regulatory adaptation and flexibility demonstrated by the FDA, particularly in response to the COVID.

</details>

#### Slide 4
![page_004](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_004_3._Trends_in_US_Regulation_of_IVDS_2020_to_2025_HS_ELMUBARAK_102325.jpg)

**ÏöîÏïΩ**
> I will start by just sharing the numbers, because truly the numbers in this case, they tell the story. There is a record-breaking EUA submissions between March 2020 to May 2023. The number of EUA submissions was more than all EUA submissions from all previous emergencies combined.

<details>
<summary>üìÑ Slide Transcript</summary>

I will start by just sharing the numbers, because truly the numbers in this case, they tell the story. There is a record-breaking EUA submissions between March 2020 to May 2023. The number of EUA submissions was more than all EUA submissions from all previous emergencies combined.

So, this in and of itself is something to be appreciated. And this is one of the biggest forces that Because changes, which I believe some of them will be long lasting, to the system from throughout the system of the regulatory system. Due to the nature of the virus and the nature of the emergency, it being an acute viral infection, and the need for a diagnostic method, so the primary categories of the technologies that are needed are

And then finally the serology tests. The biggest change to the paradigm is home use tests. Over the years, if you go back from Since I joined the FDA and until 2020, there's talks about What's point of care, definition of point of care, home use, how to meet the case, which indications could be used at home, the risks of putting results in the hands of end users, how will the results be interpreted?

In this short time period, this gap was completely crossed and not in a way that compromises anything. Safety, the outcomes are amazing and the technologies.

It just, it pressure tested the whole system and it showed that it could work. So, also the time to review, which makes sense because it's an emergency use, so already they were in a shorter timeline. However, these were shorter than what usually happens in emergency uses. Subsequent submissions were also easier to get through the agency when the EUA ended.

The regulatory system is now prepared for this, for shorter reviewer times, more effective time to market.

Like I said, not compromising safety and effectiveness. The advancement in technologies, particularly in the home use. It has been edited to include proper punctuation. to produce the results that were approved by the agency in the hands of lay users, and also the ability to share results in a short time.

using all the advances in artificial intelligence and the technological advances opened the door for expansion of diagnostics in general. So now the framework is ready for many, many, many areas that are known and could use it to improve, and also to open for me.

This was a lot of work on the side of the FDA.

Before I leave the slide, I want to touch on the fact that

If you go back in history, for example, viral diagnostics was not really something that is done. It was considered something that is like, the virus is not...

If it's not, it's probably a virus. The result will come two weeks later, for example, if you take that. But with advances of technology and being able to say, OK, it's a virus early on, what happens? Lots of things started to become anti-viral.

And now with this boost, a lot of things are expected to come. And the preparedness of the agency should also augment.

So this is a spin, the LDD. Now the LDD regulatory situation is one of the biggest, I would say, From a regulatory perspective, the biggest developments of this time. This has been for decades. In the making. Until finally in April of 2024, the final rule came, which closed the gap. And now lab-developed tests...

We're supposedly going to be reviewed just as in future diagnostic tests. So lab developers are manufacturers of tests which are used for the same intended use as other devices.

This shift, or policy shift, did not last long, because in April of 2025, the federal court blocked And so, now we're back to the uncertainty. However, the policy, the final rule, is still there. So the idea is, whenever this block goes away, the implementation of the rule is going to come back. When that happens, that's the ambiguity.

</details>

#### Slide 5
![page_005](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_005_3._Trends_in_US_Regulation_of_IVDS_2020_to_2025_HS_ELMUBARAK_102325.jpg)

**ÏöîÏïΩ**
> That's the uncertainty. And this, what you see here, is the implementation timeline. So a four-year phase-out. First year will be MDR and COBRA requirements. And then registration and listing, and then the full quality system, the pre-market review for only the high-risk devices followed by pre-market review.

<details>
<summary>üìÑ Slide Transcript</summary>

That's the uncertainty. And this, what you see here, is the implementation timeline.

that was discussed in the final rule here. So a four-year phase-out. First year will be NDR and COBRA requirements. And then registration and listing, and then the full quality system, the pre-market review for only the high-risk devices followed by pre-market review.

So the question now is, like, what are labs supposed to do? Is this going to happen? What do they do in this period of uncertainty? Most clinical labs are preparing for it. Because the biggest things you have to adjust now, labs have to invest on quality system, developing a quality system, design inputs, all the different aspects of quality system that they were not previously prepared for.

So...

So basically now, what it means to the labs is that preparing for the implementation is the biggest task. Eventually, this will happen. So this is not going away. There is a final ruling.

So the best thing to do is use this time to prepare for the implementation.

</details>

#### Slide 6
![page_006](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_006_3._Trends_in_US_Regulation_of_IVDS_2020_to_2025_HS_ELMUBARAK_102325.jpg)

**ÏöîÏïΩ**
> Another big player is the technology evolution in drugs and the market evolution. First of all, the molecular diagnostic, the advances in the molecular diagnostic method over the time, particularly as sparked by COVID.

<details>
<summary>üìÑ Slide Transcript</summary>

Another big player is the technology evolution in drugs and the market evolution. And I would say that there is a four main...

...happened that shaped the IVD regulatory situation.

First of all, the molecular diagnostic, the advances in the molecular diagnostic method over the time, particularly as sparked by COVID.

This was one of the biggest highlights in growth in technology related to imaging diagnostics. And it's not only COVID now. We see technological growth in different areas, like oncology. We see the sensitivity and the specificity and the rapidity of these methodologies, opening doors and applications for different things.

You can see the liquid biopsies. There's the minimal residual.

We are putting pressure on the agency for developing the appropriate regulatory pathways. And this is here to stay because it helped a lot.

This is a test that will say simple, you know, yes or no, and you have to wait days for them. Now there's different things such as quantitative, rapid quantitative, network systems, integrating with the electronic health records, and enabling... clinical decision support, so actually actionable results that are benefiting the patients, closing the circles on cycles on different things.

So, yeah.

This is a second major influencer, in my opinion, and the digital health, the software as a medical device component, they are evolving and growing.

The very first considerations and FDA is actively reviewing in the pre-market and also requesting post-market follow-up and compliance related to cybersecurity aspects. Last one is the companion diagnostics. Now that we have the diagnostics which are capable of with sensitivity and specificity, they are reliable to guide

The state of the science or state of the medicine. So there is an expansion in different technologies, in different applications, including gene therapy, cell and tissue therapies, and other oncology applications.

Check it out.

</details>

#### Slide 7
![page_007](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_007_3._Trends_in_US_Regulation_of_IVDS_2020_to_2025_HS_ELMUBARAK_102325.jpg)

**ÏöîÏïΩ**
> I'm going to focus on the EU and the situation of the IVD. The US IVD market is the biggest market, but it is not a stand-alone market. It cannot exist in a vacuum anymore. Most of the manufacturers have products in the U.S. and outside the U.S.

<details>
<summary>üìÑ Slide Transcript</summary>

I'm going to focus on the EU and the situation of the IVD. So we can no longer, like the FDA, the US IVD market is The biggest market, but it is not a stand-alone market. It cannot exist in a vacuum anymore. Most of the manufacturers have products in the U.S. and outside the U.S.

And hence, it's also affected by what's happening in the regulatory bodies outside. What happened is shift. to the IVDR. IVDR is now significantly more stringent than what was there before. It's requiring more clinical evidence, more oversight, and...

And this has its own impact. So there's negative things because companies will have to at some point make decisions to drop one of the markets if the resource allocation is not helping. The supply chain issues and disruptions could also be a result of that. And for a long time, also from the early 2000s, the FDA is working on harmonization.

This movement towards aligning standards and regulatory requirements on the long-term

There is also a potential change to the way the FDA is doing things when it comes to in vitro diagnostics. The takeaway, for example, for companies, for manufacturers, is that don't think about the local market when you are in the early stages of development.

You need to think globally. You need to think about global market and start wherever you want to start. So even if you're starting in the U.S., From day one, keep in mind the global perspective. So while you're designing your regulatory strategy Who is that in mind?

Now back to the FDA and what is CDRH doing? So typically, CDRH puts out the strategic priorities, right?

For the period of 2022 to 2025, FDA did put out strategic priorities, but they're not on the website anymore. They were announced in February of 2022. And they included these three main ones. Promoting a modern and diverse workforce. And actually applications happened. There was hiring announced of many, you know, people with technical, artificial intelligence expertise and all of that.

Enhancing organizational agility and resilience, and advancing health equity. Like I said, these priorities are currently not on the website, right? However, what does this mean? And since January of 2025, it is of note that there has been major organizational changes and other significant changes within FDA's CDRH. We all know now we are in the government.

From the standpoint of where is the center going, there is organizational changes, even at higher levels of the center. So, my current, what I believe would be happening here is that, These strategic priorities will not be revisited this year, but what's most likely to happen is that early next year, new strategic priorities would be

It has been publicly available for 2026 and beyond. So, most likely there will be some changes. The AI experts, we've seen that some of them came back, you know, there's still the hiring, the people who are retained include the artificial intelligence experts.

You can predict what the priorities will be based on what's happening in the market also.

</details>

#### Slide 8
![page_008](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_008_3._Trends_in_US_Regulation_of_IVDS_2020_to_2025_HS_ELMUBARAK_102325.jpg)

**ÏöîÏïΩ**
> For the period of 2022 to 2025, FDA did put out strategic priorities. Promoting a modern and diverse workforce. Enhancing organizational agility and resilience, and advancing health equity.

<details>
<summary>üìÑ Slide Transcript</summary>

So some things will go and some things will stay, but if you think about what...

</details>

#### Slide 9
![page_009](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_009_3._Trends_in_US_Regulation_of_IVDS_2020_to_2025_HS_ELMUBARAK_102325.jpg)

**ÏöîÏïΩ**
> From an in vitro diagnostic perspective, what's there to stay? Device reclassification program will continue. Third party program is growing. Guidance modernization is in the best interest of companies as well.

<details>
<summary>üìÑ Slide Transcript</summary>

From an in vitro diagnostic perspective, what's there to stay? So, most likely, predicting that the device reclassification program will continue. So the agency's effort to sort of down-classify many of the Class 3 devices and just, you know, continue to review what could be down-classified. And so that was also the effort or puts the pressure on the industry to think and to prepare the case for the FDA.

You know, evidence of what are the risks. Why do we believe it's moderators? Subject matter-based evidence. What are the special controls that could be available to mitigate the remaining risks? Okay? And this, in particular, was in those areas that we said are here to grow, like companion diagnostics.

Some infectious disease agents, and also reducing the regulatory burden like this third party program. It was growing. There's lots of areas which the agency is shifting submissions to third parties. That's likely also going to be there to stay. It also includes modernization of guidance, which is in the best interest of companies as well. So, again, another effort or initiative.

Keeping it is in the best interest of the agency and the industry. And that's one of the areas where industry could feed. You know, the ambiguous guidance documents, They're not helpful for the FDA. They're not helpful for the companies. So, the FDA was planning a 50% deduction of the pre-2019 guidance documents, which were all over the place. I'm moving to more...

It's not binding and the messaging in it is not very specific, okay. So taking that and providing from the technical expertise from the The hands, the people who have their hands on the product to develop what would be the specific special controls and provide sufficient justifications to back them, that's good information, you know. These are going to be the publications, these are going to be the things that the agency will go back to in the guidance modernization.

Also, which will hopefully improve the regulatory clarity and help improve the whole regulatory cycle. So, what does this mean? So, yeah.

is to set or lay the ground for these foundational changes which are in the best interest of Promoting innovation.

So these policies are most likely going to stay.

Okay, I'm gonna... I think I might be...

Please feel free to ask questions if you want to stop me at any time. Now, I'm going to move to the impact on the different stakeholders. So, what does all this mean to different stakeholders? And I just, I focus on the clinical labs, which are potentially IVD manufacturers as well. They are going to get the big hit, right? The compliance costs are estimated to be anywhere between $100 million.

40-60% of the clinical labs require significant changes to upgrade their quality system. And this will potentially cause...

It has been edited to include proper punctuation. And so there will also be a burden on the FDA. There's an expectation that there will be 3,000 to 5,000 new LTT submissions projected. The burden on the labs is that they will need to start hiring. We are developing regulatory expertise in-house or figuring out how to source it out because putting together regulatory submissions is not something that clinical labs do carefully.

So they need to figure out how to develop this regulatory expertise, and the agency will have to deal with this. So, most likely the agency will be sourcing out a lot of these after they've carved out the product codes that go to third parties, right?

Then anything that falls in the product code... It will probably end up being disseminated somehow, the same way as devices developed by manufacturers to serve the party, but otherwise this is a huge burden on the agency as well. Now, this challenge for clinical labs actually favors or, you know, it comes in the favor of the IVD manufacturers.

Because the market expansion is expected, because these are already seasoned players, they know what to do, they know how to develop, they have it all ready.

</details>

#### Slide 10
![page_010](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_010_3._Trends_in_US_Regulation_of_IVDS_2020_to_2025_HS_ELMUBARAK_102325.jpg)

**ÏöîÏïΩ**
> Clinical labs face compliance costs estimated between $100 million, with 40-60% requiring significant quality system upgrades. FDA anticipates 3,000-5,000 new LDT submissions, creating burden on both labs and the agency.

<details>
<summary>üìÑ Slide Transcript</summary>

It's a challenging thing for if a manufacturer, actually, most of the lab-developed tests, they start doing clinicals as lab-developed tests, and then... They form the concept that the manufacturer uses at the end, so it can change a little bit how business is run or done.

The FDA review process, I don't anticipate that it will change much. Still, the review times and the approval rates are maintained. One big impact of all of these challenges on industry is that industry needs to develop their grade and develop their AI.

So step up their AI, artificial intelligence, and machine learning, and cyber security, and the quality considerations around these. Because that's where you are going to stand out from other industries. The global IVD market is projected to be valued at between $108.3 billion in 2024. Sorry, this is...

So basically, what would an IVD manufacturer, so the strategic, I mean, what would an IVD The takeaways here is to invest in capabilities that differentiate your particular industry, including, for example, advancement in technologies, the robust quality systems.

It has been edited to include proper punctuation. It has been edited to include proper punctuation. For those who can navigate these complex regulatory challenges.

</details>

#### Slide 11
![page_011](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_011_3._Trends_in_US_Regulation_of_IVDS_2020_to_2025_HS_ELMUBARAK_102325.jpg)

**ÏöîÏïΩ**
> In the short term, we're waiting to see what happens with the LDT. In the long term, evolution towards sophisticated risk-based approaches. Greater emphasis on AI/ML, cybersecurity, and transparency.

<details>
<summary>üìÑ Slide Transcript</summary>

Okay, I'm going to wrap up with some emerging trends in tickles. So, in the short term... We're waiting to see what happens with the LDT because that's going to cause a big change, like we just said. Potentially, the valid act movement might be the first one.

And the industry will have to gradually adapt to that. In the meanwhile, labs are starting to work on their quality systems. And industry, you know, should also try to see how to bridge the gaps of the different reliability on lab-developed tests and how that would change after the regulation comes in place.

In the long term, like first evolution towards like sophisticated risk-based approaches. For example, right now FDA is getting better at... Sizing the regulation to the risk, so not everything is blown into FOS3, PMA, you know, or applying sort of the one-size-fits-all.

And since that's a direction that's here to stay, and it's in the best interest of both parts, this is where we are. The greater emphasis on artificial intelligence and machine learning, cybersecurity, transparency. There's also the issue of expanded real world.

The clinical study design itself is changing. So the ability for FDA to require these clinical studies, the typical clinical study design, is not. It's not going to hold for the expectations, so real-world evidence is expanding and expected to expand more if the use case or the case for use is well established.

And so investing on actually having real world evidence that's usable for regulatory grade is an important thing to do and to have. We have that in consideration in early stages of development.

I think the COVID, the pressure test for the COVID-19 has been like a proof for FDA's ability to adapt.

You should just start from there, not go back. The LDT regulation thing, I think we talked about it enough. The precision medicine grows.

So now the FDA works with more advanced pre-submission strategies, there's ongoing dialogue, the breakthrough, Submissions and all of these things are important. Takeaways that happened. The digital health and cybersecurity are now priorities to consider. And voice development and the harmonization efforts.

</details>

#### Slide 12
![page_012](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_012_3._Trends_in_US_Regulation_of_IVDS_2020_to_2025_HS_ELMUBARAK_102325.jpg)

**ÏöîÏïΩ**
> This is my last slide. Thank you all for your attention. We will be distributing flyers. Please reach out. We'll be happy to be part of your journeys in IVD development.

<details>
<summary>üìÑ Slide Transcript</summary>

This is my last slide. So thank you all for your attention.

And I just wanted to share, this is my QR code. I work in IVD Consulting, as I think I talked to many of you. And we will be distributing also flyers for people who don't have them. Please let us know, you know, just reach out. We'll be happy to be part of your journeys in IP development.

And I thank the organization for doing it for me.

Does anyone have any questions?

Thank you for keeping your time. We have 10 minutes more. I have one question.

As you know, in case of LDT, it's very important for us because, as you know, it's easier to enter into the United States market, and LDT is a very good solution. I'm just surprised by your opinion. Because currently, as you know, Texas County, they have to block the LDT process for FDA.

How do you think in the future, continuous blocking is easy to LDT or FDA? So as of now, in this period of uncertainty, I think people can continue to do the previous thing of putting it in LTE. So it's going to happen. So LDT, the way it was used in the past, it's not going to halt. So starting to look about what is the alternative strategy, right? What do you put there so you can use things which are here to stay, like the real world evidence situation?

Like where would you put the device so it's not like a research use? It's going to be under the FDA regulation. Of course, the FDA made exemptions, so if you are within those exemptions, like rare diseases, all of these, like, the device types that the FDA will not take out because of their need and they cannot subject them to the process yet, then that will continue.

But anything other than that, this is the time now to...

For example, we prefer it to the FDA, or some clinical data from the United States. However, IVDR, we use 100% United States clinical data. Or, secondly, we need to do more testing in the United States.

So I just have a question. Yeah, we usually do 100% using our United States data, or do we need extra testing for clinical testing in Europe? I can't say definitively for a broader thing, but what I've seen so far is that the U.S. is more... You have to have 70% of EU-based data. Okay. Thank you so much. Thank you.

Any questions?

Okay, thank you for your time.

</details>

---

<details>
<summary>üìù Full Transcript</summary>

It's an honor to be presenting the first meeting for CAMDA and I wish all the success. For all of you who have been working in this space and know that it was revolutionized, basically. It went through the things that happened in the last five years. It reshaped the landscape for the regulations to be developed.

I hope to discuss with you in brief the major players or forces that led to this revolution in the regulatory space for in vitro diagnostics and to discuss future opportunities.

My talk will be structured in a way that's to help us. First, we'll sort of take an executive summary to go over. We will set the stage for today's presentation and then we will dive into the regulatory landscape in this period from 2020 to 2025.

on the LDT regulatory oversight and the oversight shift, discuss changes in the technologies and how it impacted the regulatory landscape, and also the evolution of the IVD market. The impact of global markets and global regulations and talk about the CDRH strategic direction.

And it impacts on different stakeholders, after which we are going to finally close with some emerging trends and takeaways for different stakeholders.

So in the past five years, like we said, there was like a huge change. And I would say there are some major forces. Today I will discuss these four. Starting with the COVID-19 emergency use and emergency response, the digital evolution and technology evolution.

The LDT regulatory oversight shifts the impact of global markets, which collectively led to this period, which is characterised by the rapid innovation and growth of global markets. and unprecedented regulatory adaptation and flexibility demonstrated by the FDA, particularly in response to the COVID.

I will start by just sharing the numbers, because truly the numbers in this case, they tell the story. There is a record-breaking EUA submissions between March 2020 to May 2023. The number of EUA submissions was more than all EUA submissions from all previous emergencies combined.

So, this in and of itself is something to be appreciated. And this is one of the biggest forces that Because changes, which I believe some of them will be long lasting, to the system from throughout the system of the regulatory system. Due to the nature of the virus and the nature of the emergency, it being an acute viral infection, and the need for a diagnostic method, so the primary categories of the technologies that are needed are

And then finally the serology tests. The biggest change to the paradigm is home use tests. Over the years, if you go back from Since I joined the FDA and until 2020, there's talks about What's point of care, definition of point of care, home use, how to meet the case, which indications could be used at home, the risks of putting results in the hands of end users, how will the results be interpreted?

In this short time period, this gap was completely crossed and not in a way that compromises anything. Safety, the outcomes are amazing and the technologies.

It just, it pressure tested the whole system and it showed that it could work. So, also the time to review, which makes sense because it's an emergency use, so already they were in a shorter timeline. However, these were shorter than what usually happens in emergency uses. Subsequent submissions were also easier to get through the agency when the EUA ended.

The regulatory system is now prepared for this, for shorter reviewer times, more effective time to market.

Like I said, not compromising safety and effectiveness. The advancement in technologies, particularly in the home use. It has been edited to include proper punctuation. to produce the results that were approved by the agency in the hands of lay users, and also the ability to share results in a short time.

using all the advances in artificial intelligence and the technological advances opened the door for expansion of diagnostics in general. So now the framework is ready for many, many, many areas that are known and could use it to improve, and also to open for me.

This was a lot of work on the side of the FDA.

Before I leave the slide, I want to touch on the fact that

If you go back in history, for example, viral diagnostics was not really something that is done. It was considered something that is like, the virus is not...

If it's not, it's probably a virus. The result will come two weeks later, for example, if you take that. But with advances of technology and being able to say, OK, it's a virus early on, what happens? Lots of things started to become anti-viral.

And now with this boost, a lot of things are expected to come. And the preparedness of the agency should also augment.

So this is a spin, the LDD. Now the LDD regulatory situation is one of the biggest, I would say, From a regulatory perspective, the biggest developments of this time. This has been for decades. In the making. Until finally in April of 2024, the final rule came, which closed the gap. And now lab-developed tests...

We're supposedly going to be reviewed just as in future diagnostic tests. So lab developers are manufacturers of tests which are used for the same intended use as other devices.

This shift, or policy shift, did not last long, because in April of 2025, the federal court blocked And so, now we're back to the uncertainty. However, the policy, the final rule, is still there. So the idea is, whenever this block goes away, the implementation of the rule is going to come back. When that happens, that's the ambiguity.

That's the uncertainty. And this, what you see here, is the implementation timeline.

that was discussed in the final rule here. So a four-year phase-out. First year will be NDR and COBRA requirements. And then registration and listing, and then the full quality system, the pre-market review for only the high-risk devices followed by pre-market review.

So the question now is, like, what are labs supposed to do? Is this going to happen? What do they do in this period of uncertainty? Most clinical labs are preparing for it. Because the biggest things you have to adjust now, labs have to invest on quality system, developing a quality system, design inputs, all the different aspects of quality system that they were not previously prepared for.

So basically now, what it means to the labs is that preparing for the implementation is the biggest task. Eventually, this will happen. So this is not going away. There is a final ruling.

So the best thing to do is use this time to prepare for the implementation.

Another big player is the technology evolution in drugs and the market evolution. And I would say that there is a four main...

...happened that shaped the IVD regulatory situation.

First of all, the molecular diagnostic, the advances in the molecular diagnostic method over the time, particularly as sparked by COVID.

This was one of the biggest highlights in growth in technology related to imaging diagnostics. And it's not only COVID now. We see technological growth in different areas, like oncology. We see the sensitivity and the specificity and the rapidity of these methodologies, opening doors and applications for different things.

You can see the liquid biopsies. There's the minimal residual.

We are putting pressure on the agency for developing the appropriate regulatory pathways. And this is here to stay because it helped a lot.

This is a test that will say simple, you know, yes or no, and you have to wait days for them. Now there's different things such as quantitative, rapid quantitative, network systems, integrating with the electronic health records, and enabling... clinical decision support, so actually actionable results that are benefiting the patients, closing the circles on cycles on different things.

This is a second major influencer, in my opinion, and the digital health, the software as a medical device component, they are evolving and growing.

The very first considerations and FDA is actively reviewing in the pre-market and also requesting post-market follow-up and compliance related to cybersecurity aspects. Last one is the companion diagnostics. Now that we have the diagnostics which are capable of with sensitivity and specificity, they are reliable to guide

The state of the science or state of the medicine. So there is an expansion in different technologies, in different applications, including gene therapy, cell and tissue therapies, and other oncology applications.

I'm going to focus on the EU and the situation of the IVD. So we can no longer, like the FDA, the US IVD market is The biggest market, but it is not a stand-alone market. It cannot exist in a vacuum anymore. Most of the manufacturers have products in the U.S. and outside the U.S.

And hence, it's also affected by what's happening in the regulatory bodies outside. What happened is shift. to the IVDR. IVDR is now significantly more stringent than what was there before. It's requiring more clinical evidence, more oversight, and...

And this has its own impact. So there's negative things because companies will have to at some point make decisions to drop one of the markets if the resource allocation is not helping. The supply chain issues and disruptions could also be a result of that. And for a long time, also from the early 2000s, the FDA is working on harmonization.

This movement towards aligning standards and regulatory requirements on the long-term

There is also a potential change to the way the FDA is doing things when it comes to in vitro diagnostics. The takeaway, for example, for companies, for manufacturers, is that don't think about the local market when you are in the early stages of development.

You need to think globally. You need to think about global market and start wherever you want to start. So even if you're starting in the U.S., From day one, keep in mind the global perspective. So while you're designing your regulatory strategy Who is that in mind?

Now back to the FDA and what is CDRH doing? So typically, CDRH puts out the strategic priorities, right?

For the period of 2022 to 2025, FDA did put out strategic priorities, but they're not on the website anymore. They were announced in February of 2022. And they included these three main ones. Promoting a modern and diverse workforce. And actually applications happened. There was hiring announced of many, you know, people with technical, artificial intelligence expertise and all of that.

Enhancing organizational agility and resilience, and advancing health equity. Like I said, these priorities are currently not on the website, right? However, what does this mean? And since January of 2025, it is of note that there has been major organizational changes and other significant changes within FDA's CDRH. We all know now we are in the government.

From the standpoint of where is the center going, there is organizational changes, even at higher levels of the center. So, my current, what I believe would be happening here is that, These strategic priorities will not be revisited this year, but what's most likely to happen is that early next year, new strategic priorities would be

It has been publicly available for 2026 and beyond. So, most likely there will be some changes. The AI experts, we've seen that some of them came back, you know, there's still the hiring, the people who are retained include the artificial intelligence experts.

You can predict what the priorities will be based on what's happening in the market also.

So some things will go and some things will stay, but if you think about what...

From an in vitro diagnostic perspective, what's there to stay? So, most likely, predicting that the device reclassification program will continue. So the agency's effort to sort of down-classify many of the Class 3 devices and just, you know, continue to review what could be down-classified. And so that was also the effort or puts the pressure on the industry to think and to prepare the case for the FDA.

You know, evidence of what are the risks. Why do we believe it's moderators? Subject matter-based evidence. What are the special controls that could be available to mitigate the remaining risks? Okay? And this, in particular, was in those areas that we said are here to grow, like companion diagnostics.

Some infectious disease agents, and also reducing the regulatory burden like this third party program. It was growing. There's lots of areas which the agency is shifting submissions to third parties. That's likely also going to be there to stay. It also includes modernization of guidance, which is in the best interest of companies as well. So, again, another effort or initiative.

Keeping it is in the best interest of the agency and the industry. And that's one of the areas where industry could feed. You know, the ambiguous guidance documents, They're not helpful for the FDA. They're not helpful for the companies. So, the FDA was planning a 50% deduction of the pre-2019 guidance documents, which were all over the place. I'm moving to more...

It's not binding and the messaging in it is not very specific, okay. So taking that and providing from the technical expertise from the The hands, the people who have their hands on the product to develop what would be the specific special controls and provide sufficient justifications to back them, that's good information, you know. These are going to be the publications, these are going to be the things that the agency will go back to in the guidance modernization.

Also, which will hopefully improve the regulatory clarity and help improve the whole regulatory cycle. So, what does this mean? So, yeah.

is to set or lay the ground for these foundational changes which are in the best interest of Promoting innovation.

So these policies are most likely going to stay.

Now, I'm going to move to the impact on the different stakeholders. So, what does all this mean to different stakeholders? And I just, I focus on the clinical labs, which are potentially IVD manufacturers as well. They are going to get the big hit, right? The compliance costs are estimated to be anywhere between $100 million.

40-60% of the clinical labs require significant changes to upgrade their quality system. And this will potentially cause...

It has been edited to include proper punctuation. And so there will also be a burden on the FDA. There's an expectation that there will be 3,000 to 5,000 new LTT submissions projected. The burden on the labs is that they will need to start hiring. We are developing regulatory expertise in-house or figuring out how to source it out because putting together regulatory submissions is not something that clinical labs do carefully.

So they need to figure out how to develop this regulatory expertise, and the agency will have to deal with this. So, most likely the agency will be sourcing out a lot of these after they've carved out the product codes that go to third parties, right?

Then anything that falls in the product code... It will probably end up being disseminated somehow, the same way as devices developed by manufacturers to serve the party, but otherwise this is a huge burden on the agency as well. Now, this challenge for clinical labs actually favors or, you know, it comes in the favor of the IVD manufacturers.

Because the market expansion is expected, because these are already seasoned players, they know what to do, they know how to develop, they have it all ready.

It's a challenging thing for if a manufacturer, actually, most of the lab-developed tests, they start doing clinicals as lab-developed tests, and then... They form the concept that the manufacturer uses at the end, so it can change a little bit how business is run or done.

The FDA review process, I don't anticipate that it will change much. Still, the review times and the approval rates are maintained. One big impact of all of these challenges on industry is that industry needs to develop their grade and develop their AI.

So step up their AI, artificial intelligence, and machine learning, and cyber security, and the quality considerations around these. Because that's where you are going to stand out from other industries. The global IVD market is projected to be valued at between $108.3 billion in 2024. Sorry, this is...

So basically, what would an IVD manufacturer, so the strategic, I mean, what would an IVD The takeaways here is to invest in capabilities that differentiate your particular industry, including, for example, advancement in technologies, the robust quality systems.

It has been edited to include proper punctuation. It has been edited to include proper punctuation. For those who can navigate these complex regulatory challenges.

Okay, I'm going to wrap up with some emerging trends in tickles. So, in the short term... We're waiting to see what happens with the LDT because that's going to cause a big change, like we just said. Potentially, the valid act movement might be the first one.

And the industry will have to gradually adapt to that. In the meanwhile, labs are starting to work on their quality systems. And industry, you know, should also try to see how to bridge the gaps of the different reliability on lab-developed tests and how that would change after the regulation comes in place.

In the long term, like first evolution towards like sophisticated risk-based approaches. For example, right now FDA is getting better at... Sizing the regulation to the risk, so not everything is blown into FOS3, PMA, you know, or applying sort of the one-size-fits-all.

And since that's a direction that's here to stay, and it's in the best interest of both parts, this is where we are. The greater emphasis on artificial intelligence and machine learning, cybersecurity, transparency. There's also the issue of expanded real world.

The clinical study design itself is changing. So the ability for FDA to require these clinical studies, the typical clinical study design, is not. It's not going to hold for the expectations, so real-world evidence is expanding and expected to expand more if the use case or the case for use is well established.

And so investing on actually having real world evidence that's usable for regulatory grade is an important thing to do and to have. We have that in consideration in early stages of development.

I think the COVID, the pressure test for the COVID-19 has been like a proof for FDA's ability to adapt.

You should just start from there, not go back. The LDT regulation thing, I think we talked about it enough. The precision medicine grows.

So now the FDA works with more advanced pre-submission strategies, there's ongoing dialogue, the breakthrough, Submissions and all of these things are important. Takeaways that happened. The digital health and cybersecurity are now priorities to consider. And voice development and the harmonization efforts.

This is my last slide. So thank you all for your attention.

And I just wanted to share, this is my QR code. I work in IVD Consulting, as I think I talked to many of you. And we will be distributing also flyers for people who don't have them. Please let us know, you know, just reach out. We'll be happy to be part of your journeys in IP development.

And I thank the organization for doing it for me.

Does anyone have any questions?

Thank you for keeping your time. We have 10 minutes more. I have one question.

As you know, in case of LDT, it's very important for us because, as you know, it's easier to enter into the United States market, and LDT is a very good solution. I'm just surprised by your opinion. Because currently, as you know, Texas County, they have to block the LDT process for FDA.

How do you think in the future, continuous blocking is easy to LDT or FDA? So as of now, in this period of uncertainty, I think people can continue to do the previous thing of putting it in LTE. So it's going to happen. So LDT, the way it was used in the past, it's not going to halt. So starting to look about what is the alternative strategy, right? What do you put there so you can use things which are here to stay, like the real world evidence situation?

Like where would you put the device so it's not like a research use? It's going to be under the FDA regulation. Of course, the FDA made exemptions, so if you are within those exemptions, like rare diseases, all of these, like, the device types that the FDA will not take out because of their need and they cannot subject them to the process yet, then that will continue.

But anything other than that, this is the time now to...

For example, we prefer it to the FDA, or some clinical data from the United States. However, IVDR, we use 100% United States clinical data. Or, secondly, we need to do more testing in the United States.

So I just have a question. Yeah, we usually do 100% using our United States data, or do we need extra testing for clinical testing in Europe? I can't say definitively for a broader thing, but what I've seen so far is that the U.S. is more... You have to have 70% of EU-based data. Okay. Thank you so much. Thank you.

Any questions?

Okay, thank you for your time.

</details>

---

## 2. ByungSik Chang

| | |
|---|---|
| ‚è∞ | **01:40 PM ~ 02:00 PM** |
| üè¢ | CEO Nano-Ditech, Co-Chair KAMDA |
| üìå | "FDA Approval Strategies and Success Cases" |
| üí° | 1ÎÖÑ Î∞ò ÎèôÏïà 3Í∞ú Ï†úÌíà FDA ÏäπÏù∏ ÏÑ±Í≥º |

---

### Summary

#### ÌöåÏÇ¨ ÏÜåÍ∞ú
- 2002ÎÖÑ Îâ¥Ï†ÄÏßÄ ÏÑ§Î¶Ω, ÏßÑÎã® Ï†úÌíà Í∞úÎ∞ú/ÏÉùÏÇ∞/ÌåêÎß§
- ÏÑ±Í≥º: 2022.2 COVID, 2022.7 RSV(ÏòÅÏú†ÏïÑÏö©), 2023.6 COVID+Flu ÎèôÏãúÍ≤ÄÏÇ¨

#### ÌïµÏã¨ Ïã§Ïàò Î∞©ÏßÄ Ìè¨Ïù∏Ìä∏

**1. ÎπÑÍµê Ï†úÌíà ÏÑ†Ï†ï**
- Î∞òÎìúÏãú FDA Ï†ïÏãù ÏäπÏù∏ Ï†úÌíà ÏÑ†Ï†ï
- Ï£ºÏ†ïÎ∂Ä(Îâ¥Ïöï Ìó¨Ïä§ÌÇ∑) vs Ïó∞Î∞©Ï†ïÎ∂Ä(FDA) ÏäπÏù∏ Ï∞®Ïù¥ Ïù¥Ìï¥
- ÎåÄÌòï Í∏∞Í¥Ä Ï†úÌíàÎèÑ FDA ÏäπÏù∏ Ïó¨Î∂Ä Î∞òÎìúÏãú ÌôïÏù∏

**2. ÏûÑÏÉÅÏãúÌóò ÏÑ§Í≥Ñ**
- 1Í∞ú ÏûÑÏÉÅÏãúÌóò = 1Í∞ú ÎπÑÍµê Ï†úÌíà ÏÇ¨Ïö©
- Ïó¨Îü¨ Ïû•ÎπÑ ÏÇ¨Ïö© Ïãú ÎèôÎì±ÏÑ± Ïù∏Ï¶ù ÌïÑÏöî
- Î∞òÎ≥µ ÌôòÏûê ÏÉòÌîå Ï£ºÏùò (Í≤∞Í≥º ÏôúÍ≥°)

**3. ÏßÄÏó≠Ï†Å Îã§ÏñëÏÑ±**
- ÎØ∏Íµ≠ ÎÇ¥ ÏµúÏÜå 3Í∞ú ÏßÄÏó≠ÏóêÏÑú ÏÉòÌîå ÏàòÏßë
- ÎèôÏÑúÎÇ®Î∂Å Ï§ëÎ∂Ä Ï§ë ÏÑ†ÌÉù Í∂åÏû•
- ÌïúÍµ≠ ÏûÑÏÉÅ Îç∞Ïù¥ÌÑ∞Îäî ÎØ∏Íµ≠ FDA ÏäπÏù∏Ïóê ÏÇ¨Ïö© Î∂àÍ∞Ä

**4. Ïù∏Íµ¨ÌÜµÍ≥ÑÌïôÏ†Å Í∑†Ìòï**
- Ïó∞Î†π: Î™©Ìëú ÏßàÎ≥ëÏóê ÎßûÎäî Î∂ÑÌè¨ (ÏÜåÏïÑ RSVÎäî 10ÏÑ∏ ÎØ∏Îßå ÎπÑÏú®)
- ÏÑ±Î≥Ñ: Î™©Ï†ÅÏóê ÎßûÎäî ÎÇ®ÎÖÄ ÎπÑÏú®
- Ïù∏Ï¢Ö: ÌûàÏä§Ìå®Îãâ Îì± Îã§ÏñëÏÑ± Ìè¨Ìï®

#### FDA Ï†úÏ∂ú ÎèÑÍµ¨
- eSTAR / pre-eSTAR ÏãúÏä§ÌÖú ÌôúÏö© Í∂åÏû•
- ÌîÑÎ°úÏÑ∏Ïä§ Í∞ÑÏÜåÌôî + FDA ÏöîÍµ¨ÏÇ¨Ìï≠ ÌÖúÌîåÎ¶ø Ìè¨Ìï®

#### Action Items
- [ ] FDA Ï†ïÏãù ÏäπÏù∏Îêú ÎπÑÍµê Ï†úÌíà ÌôïÏù∏
- [ ] ÏßÄÏó≠Ï†Å Îã§ÏñëÏÑ± ÌôïÎ≥¥ (ÏµúÏÜå 3Í∞ú ÎØ∏Íµ≠ ÏßÄÏó≠)
- [ ] ÌôòÏûê ÏÉòÌîå Ï§ëÎ≥µ Í≤ÄÏ¶ù ÏãúÏä§ÌÖú Íµ¨Ï∂ï
- [ ] Ïù∏Íµ¨ÌÜµÍ≥ÑÌïôÏ†Å Í∑†Ìòï Ï†ÑÎûµ ÏàòÎ¶Ω
- [ ] eSTAR/pre-eSTAR ÏãúÏä§ÌÖú ÌôúÏö©

---

### Slides

#### Slide 1
![page_001](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_001_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> ÎÑ§, ÏïàÎÖïÌïòÏã≠ÎãàÍπå. ÎÇòÎÖ∏Îã§Ïù¥ÌÖåÏùº Ïû•Î≥ëÏãùÏûÖÎãàÎã§. FDA ÏÑ±Í≥µ Ï†ÑÎûµÏóê ÎåÄÌï¥ÏÑú Î∞úÌëú ÎìúÎ¶¨Í≤†ÏäµÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

ÎÑ§, ÏïàÎÖïÌïòÏã≠ÎãàÍπå. ÎÇòÎÖ∏Îã§Ïù¥ÌÖåÏùº Ïû•Î≥ëÏãùÏûÖÎãàÎã§. ÏßÄÍ∏à ÎßêÏîÄÌï¥Ï£ºÏã† Í≤É Í∞ôÏù¥ FDA ÏÑ±Í≥µ Ï†ÑÏïΩ, ÏÑ±Í≥µÏ†ÅÏù∏ Ïä§ÌÅ¨Î¶∞ ÌîåÎùºÏä§Ìã±ÏùÑ ÎìúÎ¶¨Í≤†ÏäµÎãàÎã§.

</details>

#### Slide 2
![page_002](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_002_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> Ï†ÄÌù¨ ÌöåÏÇ¨Îäî 2002ÎÖÑÎèÑÏóê Îâ¥Ï†ÄÏßÄÏóêÏÑú ÏÑ§Î¶ΩÎêòÏóàÍµ¨Ïöî. ÌòÑÏû¨ Í≥ÑÏÜçÌï¥ÏÑú ÏßÑÎã® Ï†úÌíàÏùÑ Í∞úÎ∞úÌïòÍ≥† ÏÉùÏÇ∞ ÌåêÎß§Î•º ÌïòÍ≥† ÏûàÏäµÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Ï†ÄÌù¨ ÌöåÏÇ¨Îäî 2002ÎÖÑÎèÑÏóê Îâ¥Ï†ÄÏßÄÏóêÏÑú ÏÑ§Î¶ΩÎêòÏóàÍµ¨Ïöî. ÌòÑÏû¨ Í≥ÑÏÜçÌï¥ÏÑú ÎùºÏù¥Î∏åÎãà Ï†úÌíàÏùÄ Í∞úÎ∞úÌïòÍ≥† ÏÉùÏÇ∞ Ïû¨Î£å ÌåêÎß§Î•º ÌïòÍ≥† ÏûàÏäµÎãàÎã§.

</details>

#### Slide 3
![page_003](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_003_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> Ï†úÍ∞Ä Ïò§Îäò Ïù¥ ÏûêÎ¶¨Ïóê ÏÑúÍ≤å Îêú Ïù¥Ïú†Í∞Ä ÏûëÎÖÑ 2ÏõîÎ∂ÄÌÑ∞ Ìïú 1ÎÖÑ Î∞ò Ï†ïÎèÑ Í±∏Ï≥êÏÑú 3Í∞úÏùò Ï†úÌíàÏùÑ FDA ÏäπÏù∏ Î∞õÏïòÏäµÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Ï†úÍ∞Ä Ïò§Îäò Ïù¥ ÏûêÎ¶¨Ïóê ÏÑúÍ≤å Îêú Ïù¥Ïú†Í∞Ä ÏûëÎÖÑ 2ÏõîÎã¨ Î∂ÄÌÑ∞ Ìïú 1ÎÖÑ Î∞òÏ†ïÎèÑ Í±∏Ï≥êÍ∞ÄÏßÄÍ≥† 3Í∞úÏùò Ï†úÌíàÏùÑ FK Îπ®ÎåÄÍ∏∞ ÏäπÎ¶¨ Î∞õÏïòÏäµÎãàÎã§. Ï†Ñ ÏïÑÏßÅ Ï¢Ä Î∞∞Í≥†ÌîÑÍ≥† Îçî ÎßéÏù¥ Î∞õÍ≥† Ïã∂ÏùÄÎç∞ ÏòÜÏóêÏÑú Î≥¥Ïã§ Í≤ΩÏö∞ÏóêÎäî Ï¢Ä ÏßßÏùÄ ÏãúÍ∞Ñ ÎÇ¥Ïóê ÏÑ±Í≥ºÎ•º Ïù¥Î§òÎã§Í≥† ÏÉùÍ∞ÅÌïòÏãúÎäî Î∂ÑÎì§Ïù¥ ÎßéÏúºÏÖîÍ∞ÄÏßÄÍ≥†

Ïñ¥ÎñªÍ≤å ÌñàÎäîÏßÄ Í∑∏ Î∞©Î≤ïÏù¥ Í∂ÅÍ∏àÌïòÏã† Í≤ÉÎèÑ ÏûàÏúºÏã§ Í≤É Í∞ôÍ≥† Ï†ÄÌù¨ Í∑∏ ÎπÑÎ≤ïÏùÑ Ï†ÑÏàòÌïòÍ≥† Ïã∂ÏùÄ Í≤å ÏûàÎã§Í≥† ÌïòÎ©¥ Ïù¥Î≤à Í∏∞ÌöåÏóê Ï†ïÎ¶¨ÌïòÎ©¥ Ï¢ãÍ≤†Îã§ ÏÉùÍ∞ÅÌï¥ÏÑú ÌïòÍ≤†Îã§ ÎßêÏîÄÎìúÎ†∏ÎäîÎç∞Ïöî. ÏùºÎã® Ï†ÄÌù¨Îäî ÏûëÎÖÑÎèÑ 2ÏõîÏóê ÏΩîÎπÑÎìú Ï†úÌíàÏóê ÎåÄÌï¥ÏÑú ÌååÏù¥ÌåÖÏùÑ Î∞õÏïòÍ≥† ÏûëÎÖÑ 7ÏõîÎã¨ Ï†ïÎèÑÏóêÎäî Ï†ÄÌù¨Í∞Ä RSVÏ†úÌíà 6ÏÑ∏ÎØ∏Îßå ÏòÅÏú†ÏïÑÏóêÏÑú Í∞êÏóºÎêòÎäî Ï†úÌíàÏóê ÎåÄÌï¥ÏÑú Ï†ÄÌù¨Í∞Ä Îî∏Ìã¥Ìä∏Î•º Î∞õÏïòÏäµÎãàÎã§. ÎòêÌïú Í∏àÎÖÑ 6ÏõîÎã¨Ïóê ÏΩîÎπÑÎìúÌïòÍ≥† ÌîåÎ£ªÏùÑ ÎèôÏãúÏóê Í≤ÄÏÇ¨Ìï† Ïàò ÏûàÎäî Ï†úÌíà ÏäπÏù∏Î∞õÏïòÏäµÎãàÎã§. Í∑∏ÎûòÏÑú ÎòêÌïú Ï†ÄÌù¨Í∞Ä ÏßÄÍ∏à Ìïú Í∞úÏùò Ï†úÌíàÏùÑ Îçî Î¶¨Î∑∞ÌïòÍ≥† ÏûàÍ≥† Ï°∞ÎßåÍ∞Ñ ÏäπÏù∏Î∞õÏùÑ Í±∞ ÏòàÏÉÅÌïòÍ≥† ÏûàÎäîÎç∞Ïöî.

</details>

#### Slide 4
![page_004](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_004_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> Ï†ÄÎèÑ Ïñ¥Îñ§ FDA ÏÑ±Í≥µ Ï†ÑÎûµÏóê ÎåÄÌï¥ÏÑú Ï†ïÌôïÌïòÍ≤å ÎãµÏù¥ ÏóÜÏäµÎãàÎã§. ÌäπÎ≥ÑÌïú ÎπÑÎ≤ïÎ≥¥Îã§Îäî Í∏∞Ï¥àÏ†ÅÏù¥ÏßÄÎßå ÏûêÏ£º Í∞ÑÍ≥ºÎêòÎäî Ï§ëÏöî ÏÇ¨Ìï≠Îì§Ïóê Ï¥àÏ†êÏùÑ ÎßûÏ∂îÍ≤†ÏäµÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Í∑∏ÎûòÏÑú Ï†ÄÎèÑ Ïù¥Îü∞ ÏßàÎ¨∏ Î∞õÏùÑ ÎïåÎßàÎã§ ÎÇòÌïúÌÖå Î¨¥Ïä® ÌäπÎ≥Ñ ÎπÑÎ≤ïÏù¥ ÏûàÏùÑÍπå ÏïÑÎãàÎ©¥ ÎÇòÌïúÌÖå Ïñ¥Îñ§ ÏÑ±Í≥µ Ï†ÑÎûµÏù¥ ÏûàÏùÑÍπå Ï†ïÎßê Í≥†ÎØºÏùÑ Ìï¥Î¥§Í±∞Îì†Ïöî

Ïã¨ÏßÄÏñ¥Îäî ÌöåÏÇ¨ÏóêÏÑú ÌîÑÎ¶¨Ï††ÌÖåÏù¥ÏÖò Ï§ÄÎπÑÌï† Îïå ÏßÅÏõêÎì§ Í∑∏Îïå Í∞ôÏù¥ ÌïòÏÖ®Îçò Î∂ÑÎì§ÌïúÌÖå Ïó¨Ï≠§Î¥§ÏäµÎãàÎã§. ÏïÑÍπå Ïñ¥ÎñªÍ≤å ÌñàÍ∏∞ ÎïåÎ¨∏Ïóê Ïö∞Î¶¨Í∞Ä Ïù¥Î†áÍ≤å Í∑∏Î¶¨Í≥† Ï†úÌíàÏùÑ ÏàòÏûÖ Î∞õÏïòÏúºÎãàÍπå ÎßéÏùÄ ÏãúÍ∞ÑÏùÑ Í∞ÄÏ°åÏñ¥ÎèÑ ÌäπÎ≥ÑÌïòÍ≤å ÎãµÏù¥ ÏóÜÏäµÎãàÎã§. Í∑∏ÎûòÏÑú Ï†ÄÌù¨Í∞Ä ÏÉùÍ∞ÅÌï¥ Î¥êÎèÑ Í∑∏ÎÉ• FDAÏóêÏÑú ÏöîÍµ¨ÌïòÍ≥† ÏûàÎäî Î≠ê ÏÑ∏Ïù¥ÌîÑÌÇ§ÎÇò Ïù¥ÌéôÌä∏ Î¶¨Ïä§Ïóê ÎØøÎã§ÎäîÏßÄ ÏûêÏ≤¥ Í≤ÄÏÇ¨Î•º ÌïòÍ≥† ÌôïÏù∏ÌïòÍ≥† ÎòêÎäî FDAÏóêÏÑú Ï†úÍ≥µÌïòÍ≥† ÏûàÎäî Í∞ÄÏù¥Îç¥Ïä§ÎÇò Îòê ÌîºÎîîÏºÄÏù¥Ìä∏ Í≤∞Í≥º Î≥¥Í≥†ÏÑú Ïñ¥ Ïö∞Î¶¨Í∞Ä Îçî Ï¢ãÎã§ Ïïà Ï¢ãÎã§ ÌèâÍ∞ÄÌï† Ïàò Î∞ñÏóê ÏóÜÎäî ÏûÖÏû•Ïù¥Í±∞Îì†Ïöî. Í∑∏ÎûòÏÑú ÏûòÌïòÎ©¥ ÎêòÎäîÎç∞ Ïñ¥ÎñªÍ≤å ÏûòÌï¥Ïïº ÎêòÏßÄ? ÎÇòÎäî ÎãµÏù¥ ÏóÜÎäî Í≤É Í∞ôÏäµÎãàÎã§. Í∑∏ÎûòÏÑú Ìïú Î≤à Ïñ¥Îñ§ Î£®ÏÖò Î≥¥ÏãúÎäîÎç∞ Ï†ïÎßê ÎãµÏù¥ ÏóÜÏñ¥Í∞ÄÏßÄÍ≥†

Î≠ê Ïö¥Ïù¥ Ï¢ãÏïÑÏÑú ÎÇòÏò§Í∏∞Ïóê ÎåÄÎãµÌïú Ï†ÅÎèÑ ÏûàÍ≥† ÏïÑÎãàÎ©¥ ÏïÑÎãàÎ©¥ÏùÄ ÌïòÎÇòÎãòÏù¥ ÎèÑÏö∞ÏÖîÍ∞ÄÏßÄÍ≥† Ïù¥Î†áÍ≤å ÎåÄÎãµÌïú ÏàòÎ∞ñÏóê ÏóÜÏóàÍ≥†Ïöî. Í∑∏ÎûòÏÑú Ï†ÄÎäî Ïò§Îäò Í∑∏ ÏûêÎ¶¨ÏóêÏÑú ÌäπÎ≥ÑÌïòÍ≤å Î∞©Î≤ïÎ≥¥Îã§Îäî

Ï†ÄÌù¨Í∞Ä Ïù¥Í≤ÉÎßåÏùÄ Ï¢Ä Ïã§ÏàòÌïòÏßÄ ÎßêÏûê Í∑∏ÎûòÏïºÏßÄÎßå ÏÑ±Í≥µÏùÑ Ï¢Ä Îï°Í∏∏ Ïàò ÏûàÏßÄ ÏïäÏùÑÍπå Ïö∞Î¶¨Í∞Ä ÌùîÌûà Í∏∞Ï¥àÏ†ÅÏù∏ Í±∞ÏßÄÎßåÏùÄ ÏûêÏ£º Ï£ºÏùòÍπäÍ≤å Ïïà Î¥êÍ∞ÄÏßÄÍ≥† ÎÑòÏñ¥Í∞ÄÎäî Î∂ÄÎ∂ÑÎì§Ïù¥ ÎßéÏù¥ ÏûàÎäî Í≤É Í∞ôÏäµÎãàÎã§. Í∑∏Í±∞Ïóê ÎåÄÌï¥ÏÑú Ï†úÍ∞Ä Ìïú 5ÎÖÑ Ï†ïÎèÑ ÏΩîÎπÑÎìúÎ•º Í≤™ÏúºÎ©¥ÏÑú Ìå©Ìä∏ÌñàÎçò Í±∞Ïóê ÎåÄÌï¥ÏÑú Ï°∞Í∏à Í≥µÏú† ÎìúÎ¶¨Î©¥ÏùÄ ÏÉàÎ°≠Í≤å ÏãúÏûëÌïòÏãúÎäî Î∂ÑÎì§ ÎòêÎäî ÏßÄÍ∏à ÌïòÏãúÎäî Î∂ÑÎì§ÌïúÌÖå ÎèÑÏõÄÏù¥ ÎêòÏßÄ ÏïäÏùÑÍπå ÏÉùÍ∞ÅÏù¥ Îì≠ÎãàÎã§.

</details>

#### Slide 5
![page_005](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_005_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> Ï†ÄÌù¨ Ï†úÌíàÏùÄ ÎûòÌîºÎìú Ï†úÌíàÏù¥Ïñ¥ÏÑú Í∏∞Ï°¥ ÏäπÏù∏Îêú Ï†úÌíàÍ≥º ÎπÑÍµêÌïòÍ≤å ÎêòÏñ¥ÏûàÏäµÎãàÎã§. FDA Ï†ïÏãù ÏäπÏù∏Îêú Ï†úÌíàÏùÑ Ï≤´Î≤àÏß∏Î°ú ÏÑ†Ï†ïÌïòÏÖîÏïº Ìï©ÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Ï†ÄÌù¨ Ï†úÌíàÏùÄ Î†àÌîºÎìú Ï†úÌíàÏù¥Ïñ¥ÏÑú Í∏∞Ï°¥Ïóê ÏäπÏù∏Î∞õÏùÄ Ï†úÌíàÍ≥º ÌîÑÎ¶¨Ïä§ÏºÄÏù¥ÏßÄ Ï†úÌíàÍ≥º ÎπÑÍµêÌïòÍ≤å ÎêòÏñ¥ÏûàÏäµÎãàÎã§. Í∑∏ ÎπÑÍµêÎ•º ÌÜµÌï¥Í∞ÄÏßÄÍ≥† Ïñ¥Îäê ÎßåÌÅº ÎØºÍ∞êÌïúÏßÄ, Ïñ¥Îäê ÎßåÌÅº Ï†ïÌôïÌïúÏßÄ

Ìò∏ÎπàÏóîÌã∞Ï¶åÏùÑ Í≤ÄÏÇ¨ÌñàÏùÑ Ï†úÌíà Í∞úÎ∞úÌï¥Í∞ÄÏßÄÍ≥† ÏûÑÏÇ¨ Îã§ ÎÅùÎÇú Îã§ÏùåÏóê Ïïº, Ïù¥Î†áÍ≤å FDA Ï†úÏ∂úÌïòÍ≥† ÏäπÏù∏Î∞õÏùÑ Í±∞Ïïº. ÏôúÎÉêÌïòÎ©¥ Îã§Î•∏ Ï†úÌíàÎì§Î≥¥Îã§ ÏÑ±Îä•Ïù¥ Ï¢ãÏïòÍ±∞Îì†Ïöî. Í∑∏ÎûòÏÑú Ïó¥Ïã¨Ìûà Ï§ÄÎπÑÌï¥Í∞ÄÏßÄÍ≥† 2021ÎÖÑÎèÑÏóê Ï†úÏ∂úÌñàÏäµÎãàÎã§. Í∑ºÎç∞ ÎãµÏùÑ Î∞õÏùÄÍ≤å ÎÇ¥Í∞Ä Ïì¥ ÌÅ¨Î¶¨Ìã∞ÏºÄÏù¥Ìä∏ Ï†úÌíàÏùÄ FD3 Î∞õÏùÄ Ï†úÌíàÏù¥ ÏïÑÎãàÏïº. Ïôú? ÏïÑÎãà Ïôú? Ïù¥Î†áÍ≤å ÌÅ∞ ÎçîÎ∏îÌîºÏÖú Ïôú Ï†úÌíà, ÌîºÏÖú Ï†úÌíàÏù¥ ÏïûÏóê ÏûàÍ≥† ÎÇòÎäî ÏïÑÌì®Ìã∞Ïä§Ìïú Îû©ÏóêÏÑú ÌèâÍ∞ÄÌñàÎäîÎç∞ Ïôú? ÎÑàÎ¨¥ ÎãπÌô©Ïä§ÎüΩÍ∏∞ÎèÑ ÌïòÍ≥† Ïù¥Í≤å Ïñ¥ÎñªÍ≤å ÎÇ¥Í∞Ä Í∑∏Îü∞Í±∏ ÎÜìÏ≥§ÏùÑÍπå Ïôú ÌÅ∞ ÌöåÏÇ¨ ÎßàÏºÄÌåÖÏÇ¨ ÎÇ¥Î∂ÄÏóêÏÑúÎäî Ïù¥Îü∞ Ï†úÌíàÏùÑ

</details>

#### Slide 6
![page_006](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_006_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> ÎØ∏Íµ≠ÏùÄ Ï£ºÏ†ïÎ∂ÄÌïòÍ≥† Ïó∞Î∞©Ï†ïÎ∂Ä Ï∞®Ïù¥Í∞Ä Ïã¨Ìï©ÎãàÎã§. Îâ¥Ïöï Ìó¨Ïä§ÌÇ∑ ÏäπÏù∏ÏùÄ Îâ¥Ïöï Ï£º ÎÇ¥ÏóêÏÑúÎßå ÏÇ¨Ïö© Í∞ÄÎä•Ìï©ÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Ïì∞Í≥† ÏûàÏßÄ?ÎùºÎäî ÏßàÎ¨∏Ïù¥ ÏÉùÍ≤ºÏäµÎãàÎã§. Í≤∞Íµ≠ÏùÄ Ï†ÄÌù¨Îäî FDAÎ°ú ÏõåÌÅ¨ÏóÖÏùÑ Ìï† Ïàò ÏóÜÍ∏∞ ÎïåÎ¨∏Ïóê ÎÇ¥Í∞Ä ÎßàÏºì FDA Ï†ïÏãù ÏäπÏù∏Îêú Ï†úÌíàÏùÑ Ï≤´Î≤àÏß∏ ÏÑ†Ï†ïÌïòÏÖîÏïº ÎêúÎã§ÎäîÍ≤å Ï†úÍ∞Ä ÏßÄÍ∏à ÎßêÏîÄÎìúÎ¶¨Í≥† Ïã∂ÏäµÎãàÎã§. Í∑∏Îüº ÎßêÏîÄÎìúÎ¶∞Í±∞Í∞ôÏù¥ Í∑∏Îü¨Î©¥ Ïù¥ ÏïÑÌîºÎÅºÏä§ Îû©ÏóêÏÑúÎäî Ïôú Ïù¥ Ï†úÌíàÏùÑ Ïì∏ÏàòÍ∞Ä ÏûàÏóàÏßÄ? Í∑∏ Îã§ÏùåÏóê ÎëêÎ≤àÏß∏ ÏßàÎ¨∏ Í∑∏Îü∞Îç∞ ÌïúÍµ≠ Í∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî ÌÅ¨Í≤å ÏßÄÎ∞©Ï†ïÎ∂Ä, Ïó∞Î∞©Ï†ïÎ∂Ä, Ï§ëÏïôÏ†ïÎ∂Ä Ï∞®Ïù¥Í∞Ä ÏóÜÏßÄÎßå ÎØ∏Íµ≠ÏùÄ ÏïÑÏâΩÍ≤åÎèÑ Ï£ºÏ†ïÎ∂ÄÌïòÍ≥† ÏòÅÍ¥ëÏûÖÎãàÎã§. ÏßÄÍ∏àÍπåÏßÄ ÎßàÏπòÍ≤†ÏäµÎãàÎã§.

Í∑∏ÎûòÏÑú ÏïÑÌì®Ìã∞Ïä§ÏóêÏÑú Ïì∞Îäî Ï†úÌíà Í∞ôÏùÄ Í≤ΩÏö∞Îäî Ïù¥Î†áÍ≤å FDA ÏäπÏù∏Îêú Ï†úÌíàÎßåÏúºÎ°ú Î∂ÑÎ™ÖÌûà ÎÖπÏ∑®ÎêòÏñ¥ ÏûàÏäµÎãàÎã§. ÌïòÏßÄÎßå Îâ¥Ïöï Ìó¨Ïä§ÌÇ∑ Í∞ôÏùÄ ÏóÖÏ≤¥ÏóêÏÑú ÏäπÏù∏Îêú Ï†úÌíàÏù¥Îã§. Í∑∏ÎûòÏÑú Îâ¥Ïöï Ï£ºÏöî ÎÇ¥ÏóêÏÑúÎäî Ïì∏ ÏàòÍ∞Ä ÏûàÏäµÎãàÎã§. ÏÇ¨Ïö©Ìï† Ïàò ÏûàÏäµÎãàÎã§. Î≠ê Í∑∏Îïå EUA, ÏΩîÎπÑÎìú Îïå Ïù¥Í∏∞ ÎïåÎ¨∏Ïóê Îòê

ÎØ∏Íµ≠Ïù¥ Ïó∞Î∞©Ï†ïÎ∂ÄÌïòÍ≥† Ï£ºÏ†ïÎ∂ÄÌïòÍ≥† Ï∞®Ïù¥Í∞Ä Ïã¨ÌïòÍµ¨ÎÇò Í∑∏ÎûòÏÑú Î¨¥Ï°∞Í±¥ ÌÅ∞ Î†àÎ≤®ÏóêÏÑú ÏÇ¨Ïö©ÌïúÎã§Í≥† ÌïòÎçîÎùºÎèÑ Í∑∏ Ï†úÌíàÏóê ÎåÄÌï¥ÏÑúÎäî Ìïú Î≤àÏ†ïÎèÑÎäî Ï†ïÎßê FD3D Ï†úÌíàÏù∏ÏßÄÎ•º Íº≠ ÌôïÏù∏ÌïòÍ≥† ÏßÑÌñâÌï¥ÏïºÍ≤†Îã§Îäî ÏÉùÍ∞ÅÏù¥ Îì§ÏóàÏäµÎãàÎã§.

</details>

#### Slide 7
![page_007](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_007_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> ÌïúÍµ≠ÏóêÏÑú ÏßÑÏ∂úÌïòÏã§ Îïå ÌÅ¥Î¶¨Ïñ¥ Îû©ÏùÑ ÌÜµÌï¥ ÎßéÏù¥ ÏßÑÏ∂úÌïòÏãúÎäî Í≤É Í∞ôÏïÑÏöî. ÌÅ∞ Í∏∞Í¥ÄÏù¥ÎùºÎèÑ FDA ÏäπÏù∏ Ïó¨Î∂Ä Î∞òÎìúÏãú ÌôïÏù∏ÌïòÏÑ∏Ïöî.

<details>
<summary>üìÑ Slide Transcript</summary>

ÌïúÍµ≠ÏóêÏÑú ÏßÑÏ∂úÌïòÏã§ Îïå ÌÅ¥Î¶¨Ïñ¥ Îû©ÏùÑ ÌÜµÌï¥ ÎßéÏù¥ ÏßÑÏ∂úÌïòÏãúÎäî Í≤É Í∞ôÏïÑÏöî. Í∑ºÎç∞ Ï†ÄÌù¨ Í∞ôÏùÄ ÏûÖÏû•ÏóêÏÑúÎäî ÌÅ¥Î¶¨Ïñ¥ Îû© ÎòêÎäî ÌÅ∞ ÏãúÏÑ§ Í∞ôÏùÄ Í≤ΩÏö∞Îäî Î¨¥Ï°∞Í±¥ 100% Ïã§ÎÇ¥ÌïòÎ©¥ÏÑú Í∑∏ Í≤∞Í≥º ÎäòÎ¶¥ Ïàò Î∞ñÏóê ÏóÜÏäµÎãàÎã§. ÌôïÏù∏ÌïúÎã§. Î≠ê Îã§ ÎπÑÏ©ç ÏïÑÏö∞ Ï†Ä ÌÅ∞ Ïï†Îì§ ÏÇ¨ÎäîÎç∞ ÏÑ§Îßà Ïï†ÌîåÏù¥ ÏäπÎ¶¨ Î∞õÏßÄ ÏïäÏßÄ Î∏åÏù¥ÏòÄÏñ¥? ÎùºÎäîÍ≤å Ï†ÄÌù¨Îäî ÌïúÍµ≠ÏóêÏÑú Ïò§Ïã† Î∂ÑÎì§ Îòê Ï†ÄÍ∞ôÏù¥ Ï≤òÏùå ÏãúÏûëÌïú ÏÇ¨ÎûåÎì§ÌïúÌÖåÎäî ÎßéÏù¥ Ï∫êÏä§ÌåÖ ÏÉùÍ∏∞Îäî Î∂ÑÏïºÍ±∞Îì†Ïöî

ÌïòÏßÄÎßå ÏóëÏä§ÌÖåÏù¥ÏóêÏÑúÎäî Îã®ÏßÄ Îû©ÏóêÏÑú Í≤®Îã§ÎãàÎäî LBT ÌÖåÏä§Ìä∏Í∞Ä ÎèºÏÑú Í∑∏Í±∏ Í≥µÏãù Îç∞Ïù¥ÌÑ∞Î°ú Ïù∏Ï†ïÌï¥Ï§¨Îã§. Î¨ºÎ°† Ïù¥ Îç∞Ïù¥ÌÑ∞Í∞Ä ÌôòÏûêÍ∞Ä ÏùòÏÇ¨ÌïúÌÖå Ï†úÍ≥µÌï¥Í∞ÄÏßÄÍ≥† Ïñ¥ÎñªÍ≤å Ìï†Í±∞ÎÉê, Î≠ê Ï†úÍ∞Ä ÏïåÎ†§ÎìúÎ¶∞Í≤É Í∞ôÏù¥ D-NOÎ°ú ÌÜµÌï¥ÏÑú Í∞àÏàòÎèÑ ÏûàÎäîÎç∞Ïöî, Í∑∏Ï†ÑÏóê Q-SUBÏùÑ ÌÜµÌï¥ÏÑú X-RAYÎ•º Ìï†Í±∞ÏóêÏöî.

Í∑∏ÎûòÏÑú ÎßåÏïΩÏóê Í∑∏Îü∞ ÎπÑÍµê Ïã§ÌóòÎèÑ ÏóÜÎã§Í≥† ÌïòÏãúÎ©¥ Îòê Îã§ÏùåÏóê Ï†ÄÌù¨Í∞Ä Îû©ÏóêÏÑú Í≤ÄÏÇ¨Ìïú Í≤∞Í≥º Í∞ñÍ≥† Î™®ÏïÑÏÑú Ïû¨Ï∂îÏÇ¨Ïã†Îã§Í≥† ÌïòÎ©¥ Í∑∏ Ï†ÑÏóê ÌÅ∞ ÏúôÏä§... ÏÇ¨ÏóÖÏùÑ ÌïòÏãúÍ∏∞ Ï†ÑÏóê, Îç∞Ïù¥ÌÑ∞Î•º Î™®ÏúºÏãúÍ∏∞ Ï†ÑÏóê, Î∞òÎìúÏãú 2Í∞úÏùò Ïó≠ÏÇ¨ÌïôÏùÑ ÌïòÏãúÎäî Í≤å Ï≤´ Î≤àÏß∏ ÏàòÎã®Ïù∏ Í≤É Í∞ôÏäµÎãàÎã§.

</details>

#### Slide 8
![page_008](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_008_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> Ïó¨Îü¨ ÏÇ¨Ïù¥Ìä∏ÏóêÏÑú ÏÇ¨Ïö©Ìïú PCR Î∞©Î≤ïÏù¥ Îã§Î•¥Î©¥ ÎèôÎì±ÏÑ±ÏùÑ ÏûÖÏ¶ùÌï¥Ïïº Ìï©ÎãàÎã§. Í∞ÄÎä•ÌïòÏãúÎ©¥ 1Í∞úÏùò ÏûÑÏÉÅÏãúÌóòÏóêÎäî 1Í∞úÏùò ÎπÑÍµê Ï†úÌíàÏùÑ ÏÇ¨Ïö©ÌïòÏãúÍ∏∞ Î∞îÎûçÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Îã§ÏùåÏóî Ïù¥Í±¥ Ï†ÄÌù¨Í∞Ä Ï°∞Í∏àÏùÄ Ï†ú ÏºÄÏù¥Ïä§Ïù∏Îç∞Ïöî, Í≥ºÍ±∞Ïä§ÎüΩÍ≤å Ï†úÍ∞Ä Ï†ïÎ¶¨ÌñàÍµ¨ÎÇòÎùºÎäî Í∞ÑÏÑ≠Ïù¥ ÏûàÎäî Î∂ÄÎ∂ÑÏù¥Ï£†. Ï†ÄÌù¨Îäî Ïûò Î™∞ÎûêÏóàÎçò Í≤É Í∞ôÏïÑÏöî. Í∑∏Îïå ÏãúÏ†êÏóêÏÑúÎäî. ÏΩîÎπÑÎìú ÏÉòÌîåÏùÑ Î™®ÏïòÎäîÎç∞Ïöî, Ïù¥Î†áÍ≤å Ï†ÄÌù¨Í∞Ä ÏÉòÌîå Î≥ëÏõêÏù¥ÎÇò ÏÉòÌîåÎßµÏù¥ÎÇò Ïú†ÌéúÏù¥ÎÇò ÌÄòÏä§Ìä∏Î°ú ÎÜÄ Ïàò ÏûàÏóàÎçò ÌÅ∞ Î≥ëÏõêÏóêÏÑú ÏÉòÌîåÏùÑ Î™®ÏïòÏäµÎãàÎã§. Í≤ÄÏÉâÏùÑ Ìï¥Î≥¥ÎãàÍπå ÎÑàÎ¨¥ÎÑàÎ¨¥ Í≤∞Í≥ºÍ∞Ä Ï¢ãÏùÄÍ±∞ÏóêÏöî. Í∑∏ÎûòÏÑú Ïù¥ Îç∞Ïù¥ÌÑ∞Î•º ÎòëÍ∞ôÏù¥ FDÏóê ÎÉàÏäµÎãàÎã§. Í∑ºÎç∞ FD Îç∞Ïù¥ÌÑ∞Îäî Ïó¨Í∏∞ÏÑú Í∞ÅÍ∞Å ÏÇ¨Ïù¥Ìä∏ÏóêÏÑú ÏÇ¨Ïö©Ìïú PCR Î∞©Î≤ïÏù¥ Îã§ ÎòëÍ∞ôÏïÑ. ÎÑ§Í∞Ä ÎèôÎì±ÌïòÎã§Îäî Í±∏ Ïú†Ï∂îÌï† ÏàòÍ∞Ä ÏûàÏñ¥. ÎèôÎì±ÌïòÎã§Îäî Í±∏ Ïú†Ï∂îÌïú ÏÉÅÌÉúÏóêÏÑú Ïù¥Îü∞ Îç∞Ïù¥ÌÑ∞Í∞Ä Î∂ÑÏÑùÏù¥ ÎèºÏïº ÎêòÎäîÎç∞

Í∑∏Í±∏ ÎãàÍ∞Ä ÏûÖÏ¶ùÌï† Ïàò ÏûàÎãà? ÎùºÎäî ÏßàÎ¨∏ÏùÑ Î∞õÏïòÍ±∞Îì†Ïöî. Î¨ºÎ°† Ïù¥ Í∞ÅÍ∞ÅÏùò Ï†úÌíàÏùÄ Í∑∏ Ï§ëÏóêÏÑú FD ÏäπÏù∏Îêú Ï†úÌíàÎèÑ ÏûàÏäµÎãàÎã§. ÌïòÏßÄÎßå ÏäπÏù∏Îêú Ï†úÌíàÏù¥ 3Í∞úÏùò Ï†úÌíàÏù¥ ÏûàÏùÑ Í≤ΩÏö∞Ïóê 3Í∞úÍ∞Ä Îã§ ÎòëÍ∞ôÏùÄ ÏÑ±Ï†ÅÏùÑ Í≤∞Í≥ºÎ•º Î≥¥Ïùº Ïàò ÏûàÎäêÎÉê Ïù¥Î†áÍ≤å ÌïòÎäî Í≤ÉÏùÄ ÏïÑÎãàÍ±∞Îì†Ïöî. Í∑∏ÎûòÏÑú Í∞ÄÎä•ÌïòÏãúÎ©¥ÏùÄ 1Í∞úÏùò ÌÅ¥Î¶¨ÎãâÏπºÏùÑ ÏßÑÌñâÌïòÏã§ÎïåÎäî 1Í∞úÏùò Ïª¥Ìì®ÌÑ∞Î•º ÏÇ¨Ïö©ÌïòÏãúÍ∏∞ Î∞îÎûçÎãàÎã§.

Ïó¨Îü¨Í∞ÄÏßÄ Ï¢ÖÎ•òÏùò ÌîºÏÖú Î®∏Ïã†, ÌîÑÎ¶¨Ìã∞Ïºì Îì±ÏùÑ Ïù¥Ïö©Ìï¥ÏÑú ÎèôÎì±ÏÑ± Ïù∏Ï¶ùÌïòÎäî ÏûëÏóÖÏùÑ Ï§ÄÎπÑÌïòÏÖîÏïº Ìï©ÎãàÎã§.

</details>

#### Slide 9
![page_009](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_009_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> Í∞ôÏùÄ ÌôòÏûêÍ∞Ä Î∞òÎ≥µÌï¥ÏÑú ÏÉòÌîåÏùÑ Ï†úÍ≥µÌïòÎ©¥ Î∞òÎ≥µÎêú ÏÉòÌîåÏù¥ ÎêòÏñ¥ Í≤∞Í≥ºÍ∞Ä ÏôúÍ≥°Îê† Ïàò ÏûàÏäµÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

ÏßÄÍ∏àÎ∂ÄÌÑ∞Îäî Ï°∞Í∏à Ìé∏ÌïòÍ≤å ÎßêÏîÄÎìúÎ¶¨Í≤†ÏäµÎãàÎã§. Ï†ÄÌù¨Í∞Ä Ïù∏ÏÉÅÏùÑ ÌïòÍ≤å ÎêòÎ©¥ Ìïú Î™ÖÏùò ÌôòÏûêÏóêÏÑú Ìïú Î™ÖÏùÑ ÏÑ∏ÌåÖÌï©ÎãàÎã§.

Ìïú 3Í∞úÏõîÎèôÏïà 300Í∞úÎßå Î™®ÏïÑÏ£ºÏÑ∏Ïöî, 500Í∞ú Î™®ÏïÑÏ£ºÏÑ∏Ïöî ÎùºÍ≥† Ï†ÄÌù¨Í∞Ä ÏñòÍ∏∞Ìï† Ïàò Î∞ñÏóê ÏóÜÍ±∞Îì†Ïöî Í∑∏Ï™ΩÎèÑ Í∑∏ÎûòÏïºÏßÄÎßå Í∑∏ Í∏∞Í∞ÑÏóê ÎßûÏ∂∞Í∞ÄÏßÄÍ≥† ÏÉòÌîåÏùÑ Î™®ÏïÑÏÑú Ìï¥Ï§Ñ Ïàò Î∞ñÏóê ÏóÜÏúºÎãàÍπåÏöî Í∑∏Îü¨Î©¥ Í∑∏ ÏÇ¨Ïù¥Ïóê Í∞ôÏùÄ ÌôòÏûêÍ∞Ä Í≥ÑÏÜç ÏôÄÍ∞ÄÏßÄÍ≥† Ïù¥ÏÉÅÏùº Í∞êÎèÖÏù¥ Ïò§ÏÖîÍ∞ÄÏßÄÍ≥† ÏÉòÌîåÏùÑ Ïç®ÏÑú ÏÉòÌîåÏùÑ Î™®ÏúºÎäîÍ±∞Ï£† ÏÉòÌîåÏùÑ Î™®ÏïÑÏûàÎäîÎç∞ ÎãàÍ∞Ä Í∑∏ÎÉ• Ïó¨Í∏∞ÏÑú Î∞ò Íµ¨Ïó≠ Î∞ò Ìï¥Í∞ÄÏßÄÍ≥† ÏÉòÌîå ÏùºÏ£ºÏùº Í∞ÑÍ≤©ÏúºÎ°ú ÌïòÎ©¥ Í∑∏Î∂ÑÏù¥ Î¶¨ÌîºÌã¥Ïùò ÌôòÏûêÍ∞Ä ÎêòÎäî ÏÉòÌîåÏù¥ Îê† Ïàò ÏûàÍ∏∞ÎïåÎ¨∏Ïóê ÌÅ¨Í≤å ÎåÄÍ∞ÄÏùò Î∞îÏù¥Îü¨Ïä§Í∞Ä ÏÉùÍ∏∏ Ïàò ÏûàÏäµÎãàÎã§. ÌäπÌûà Ï£ºÏùòÌï¥Ïïº Îê† Ï†êÏùÄ

Ï†ÄÌù¨Í∞Ä Îâ¥ÏöïÏóê ÏûàÎäî MÎ≥ëÏõêÏóêÏÑú ÏÉòÌîåÏùÑ Î∞õÏïòÎäîÎç∞Ïöî. Ï†ÄÌù¨Îäî ÌîåÎùºÏ¶àÎßàÎ•º Î∞õÏïòÎäîÎç∞ Ïù¥ Î≥ëÏõê ÎÇ¥ÏóêÏÑúÎäî Ï†ÄÌù¨Í∞Ä Ïù¥Î†áÍ≤å 3Ïõî 29ÏùºÏóê ÏûÖÏõêÌïú Îã§ÏùåÏóê 15, 16, 17, Ìïú Í∞ÑÍ≤©ÏúºÎ°ú Ïù¥Î†áÍ≤å ÎΩëÏùÄ Í≤ÅÎãàÎã§. Î™á Î∂ÑÏù¥ ÎΩëÏïÑÍ∞ÄÏßÄÍ≥†, Î≤ÑÎ¶∞ Í∑∏ Î≥ëÏõê ÎÇ¥ÏóêÏÑúÎäî Í±∞Í∏∞Ïóê Ìï≠Ï≤¥Í∞Ä ÏûàÎäîÏßÄ Í≤ÄÏÇ¨Ìï¥Ïïº ÎêòÍ∏∞ ÎïåÎ¨∏Ïóê Í∞ñÍ≥† ÏôÄÏÑú Í≤ÄÏÇ¨Î•º ÌñàÎäîÎç∞ Ï†úÍ∞Ä Ïù¥ ÏÉòÌîåÏùÑ Îß•Î∂ÅÏúºÎ°ú Î∞õÏïòÎäîÎç∞, Ïù¥Í≤å Î∞òÎ≥µÎêú ÏÉòÌîåÏù¥ ÎêòÍ∏∞ ÏãúÏûëÌï©ÎãàÎã§.

Í∑∏ÎûòÏÑú Ï†ÄÌù¨Í∞Ä Ïù¥ ÏÉòÌîåÏùÑ Î≥∏ Îã§ÏùåÏóê Î∞òÎ≥µÎêú ÏÉòÌîåÏù¥ ÏûàÎã§Í≥† ÌïòÎ©¥ Î≥¥ÏãúÎäî Í≤ÉÍ≥º Í∞ôÏù¥ ÏÉòÌîå ÏÇ¨Ïù¥Ï¶àÍ∞Ä Ïù¥Î¶¨Ï†ÄÎ¶¨ Ï°∞ÏûëÎèº. Ïù¥ Í∑ºÏÉÅÎåÄÏùò Í≤∞Í≥ºÎ•º Î≥º ÏàòÍ∞Ä ÏûàÍ≥† Ïù¥ Í≤∞Í≥ºÍ∞Ä Ï†ïÎßê ÎØºÍ∞ÑÎèÑÎÇò ÌäπÍ∏∞ÎèÑÏóê Ï†ïÌôïÌûà Î∞òÏòÅÌï† Ïàò ÏûàÏùÑÍπå ÌïòÎäî Í∂ÅÍ∏àÏ¶ùÏù¥ ÏÉùÍ∏∏ Ïàò Î∞ñÏóê ÏóÜÏùÑ Í≤É Í∞ôÏäµÎãàÎã§.

</details>

#### Slide 10
![page_010](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_010_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> ÎØ∏Íµ≠ÏùÄ ÎïÖÏù¥ ÌÅ¨Í∏∞ ÎïåÎ¨∏Ïóê 3Í∞ú ÏßÄÏó≠ Ïù¥ÏÉÅÏóêÏÑú ÏÉòÌîåÏùÑ Î™®ÏïÑÏïº Ìï©ÎãàÎã§. ÎèôÏÑúÎÇ®Î∂Å Ï§ëÎ∂Ä Ï§ë 3Í∞úÎ•º ÏÑ†ÌÉùÌïòÏãúÎäî Í≤å Ï¢ãÏäµÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Í∑∏ÎûòÏÑú Í∑∏ Îã§ÏùåÏóê Ï†úÍ∞Ä Ï°∞Í∏à ÎßêÏîÄÎìúÎ¶∞ ÎÇ¥Ïö©ÏùÄ ÎØ∏Íµ≠ Í∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî Ï¢Ä ÎïÖÏù¥ ÌÅΩÎãàÎã§. ÌïúÍµ≠Ïóê ÎπÑÌï¥ÏÑúÎäî ÎÑàÎ¨¥ ÌÅ¨Í∏∞ ÎïåÎ¨∏ÏóêÏöî. Ïö∞Î¶¨ Î∞îÏù¥Îü¨Ïä§Î•º Î≥∏Îã§Í≥† ÌïòÎçîÎùºÎèÑ 3Í∞ú ÏßÄÏó≠ Ïù¥ÏÉÅÏóêÏÑú ÏÉòÌîåÏùÑ Î™®ÏïÑÏÑú Í≤ÄÏÇ¨ÌïòÍ≤å ÎêòÏñ¥ÏûàÏäµÎãàÎã§. Í∑∏Îüº Ï†ÄÌù¨Í∞Ä ÏÉùÍ∞ÅÌï† Îïå 3Í∞ú ÏßÄÏó≠Ïù¥Î©¥ Ïñ¥Îñ§ Î∂ÄÎ∂Ñ Ï†ïÎèÑ Ìï¥Ïïº Îê†ÍπåÏöî?

Îâ¥Ïöï, Îâ¥Ï†ÄÏßÄ, ÌéúÏã†ÎπÑÏïÑÎãàÏïÑ, ÏÑ∏Í≥ÑÏ§ëÏöîÌïú ÏóëÏÑ∏Ïù¥Í∞Ä ÎßûÏ∂îÍ≥† ÏûàÎÇòÏöî?

Î≥¥ÌÜµ Ï†ÄÌù¨Í∞Ä Ïì∏ Í≤ΩÏö∞ÏóêÎäî ÏµúÏÜåÌïú Ïù¥Ïä§Ìä∏Î≥¥Ïä§, Ïõ®Ïä§Ìä∏Î≥¥Ïä§, ÎÇ®Î∂Å, Î∂ÅÎ∂Å, Ï§ëÍµ≠ Îã§ÏÑØÍ∞ú Î£¨ÏùÑ ÏÇ¨Ïö©Ìï©ÎãàÎã§. ÎÇòÎàÑÏã† Îã§ÏùåÏóê Í∑∏ Ï§ëÏóê 3Í∞úÎ•º ÏÑ†ÌÉùÌïòÏãúÎäî Í≤å Í∞ÄÏû• Ï¢ãÏùÄ Î∞©Î≤ïÏûÖÎãàÎã§. Í∞ÄÏû• Ï¢ãÏùÄ Í≤ÉÏùÄ ÎèôÏÑúÎÇ®Î∂ÅÌïú Í≤å Ï¢ãÍ∏¥ Ï¢ãÏùÄÎç∞Ïöî. Í∑∏Î†áÍ≤åÍπåÏßÄ ÏâΩÏßÄ ÏïäÎã§Í≥† ÌïòÎçîÎùºÎèÑ ÏµúÏÑ† 3Í∞ú ÏßÄÏó≠ÏùÑ Íµ¨Î∂ÑÌïòÏÖîÍ∞ÄÏßÄÍ≥† ÌïòÏãúÎäî Í≤å Ï¢ãÏäµÎãàÎã§.

Ìïú ÏßÄÏó≠Îßå ÎØ∏ÏàòÌïòÏã†Îã§Í≥† ÌïòÎ©¥ÏùÄ Í∑∏ ÎåÄÌëúÏÑ±ÏóêÏÑú Î¨∏Ï†úÍ∞Ä Îê† ÏàòÎ∞ñÏóê ÏóÜÍ∏∞ ÎïåÎ¨∏Ïóê 3Í∞ú Ïù¥ÏÉÅ ÌïòÏÖîÏïº Îê† Í≤É Í∞ôÍ≥† ÎòêÌïú Ïñ¥Îñ§ ÌäπÏ†ï ÏßàÎ≥ëÍ∞ôÏùÄ Í≤ΩÏö∞Ïóê Ïù¥Î†áÍ≤å ÌôòÍ≤ΩÏóê ÏùòÌï¥ÏÑú ÎßéÏù¥ Ï∞®Ïù¥Í∞Ä ÎÇ† ÏàòÎèÑ ÏûàÏäµÎãàÎã§. ÌôòÍ≤ΩÎèÑ Î≥¥Ïú†ÌïòÏÖîÏïº ÎêòÍ≥† ÌïúÍµ≠ÏóêÏÑú Í≤ÄÏÇ¨Ìïú Îç∞Ïù¥ÌÑ∞Î•º, ÏûÑÏÉÅ Îç∞Ïù¥ÌÑ∞Î•º ÎØ∏Íµ≠Ïóê Ïì∏ ÏàòÍ∞Ä ÏûàÎäêÎÉê, Ï∞∏Í≤¨Ìï† Ïàò ÏûàÎäîÎç∞ Ïì∞ÏãúÎäî Î∂ÑÎì§ÏùÄ ÏïÑÏã≠ÎãàÎã§. Î∞òÎìúÏãú ÎØ∏Íµ≠ Î≤†Ïù¥Ïä§ ÌÅ¨Î†àÏù¥Îçî Ïä§ÌååÏù¥Í∞Ä ÎêòÏÖîÏïº Ìï©ÎãàÎã§. Î¨ºÎ°† Í∑∏ Ïà´ÏûêÎÇò ÏÇ¨Ïù¥Ìä∏ Ïà´Ïûê Í∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî Ï†ÑÏ≤¥ ÏÉåÎìú Ïà´ÏûêÎÇò ÏÇ¨Ïù¥Ìä∏ Ïà´ÏûêÎäî FDAÏóêÏÑú ÌôïÏù∏ÌïòÏã§ ÏàòÍ∞Ä ÏûàÏßÄÎßå Î∞òÎìúÏãú ÎØ∏Íµ≠ ÎÇ¥ ÎåÄÌëúÏÑ± Í∞ñÍ≥† ÏûàÎäî ÏÇ¨Ïù¥Ìä∏ÏóêÏÑú ÌïòÏÖîÏïº Îê©ÎãàÎã§.

</details>

#### Slide 11
![page_011](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_011_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> Ïó∞Î†πÎåÄÍ∞Ä Î™©Ìëú ÏßàÎ≥ëÏóê ÎßûÏïÑÏïº Ìï©ÎãàÎã§. ÏÜåÏïÑ RSVÎäî 10ÏÑ∏ ÎØ∏Îßå ÏïÑÏù¥Ïóê ÎåÄÌïú ÎπÑÏú®Ïù¥ Ï†ÅÌï©Ìï¥Ïïº Ìï©ÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Îòê Îã§ÏùåÏóê ÎßêÏîÄÎìúÎ¶¨Îäî ÎÇ¥Ïö©ÏùÄ ÌôòÏûê AÏßÄÏùò ÌååÌîÑÎ¶¨ÏóêÏù¥ÏÖòÏù∏Îç∞Ïöî. ÌïúÏ™ΩÏóê ÏπòÏö∞ÏπòÍ±∞ÎÇò ÌïòÏãúÏßÄ ÏïäÏúºÏãúÎ©¥ ÏïàÎê©ÎãàÎã§. ÎßåÏïΩÏóê Ï†ÄÌù¨Í∞Ä ÏÉòÌîåÏùÑ Î™®ÏïòÏùÑ Í≤ΩÏö∞Ïóê ÌäπÏ†ï 20ÎåÄ, 30ÎåÄ Îç∞Ïù¥ÌÑ∞ Í∞ñÍ≥†ÏÑú Ïù¥Í≤å 10ÏÑ∏ ÎØ∏Îßå ÏïÑÏù¥Ïóê Ï†ÅÏö©Ìï† Ïàò ÏûàÎã§ ÎòêÎäî 60ÏÑ∏ Ïù¥ÏÉÅÏóê Ï†ÅÏö©Ìï† Ïàò ÏûàÎã§ÎùºÍ≥†

ÏÜåÏïÑ RSVÎÇò ÌîåÎ£® Í∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî ÌäπÌûà ÏÜåÏïÑÏóê ÎßéÏù¥ Í¥ÄÎ†®Ïù¥ ÎêòÍ∏∞ ÎïåÎ¨∏Ïóê ÏÜåÏïÑ 10ÏÑ∏ ÎØ∏Îßå ÏïÑÏù¥Ïóê ÎåÄÌïú ÎπÑÏú®Ïù¥ Ï†ïÌôïÌûà Ï†ÅÌï©ÌïòÏÖîÏïºÎê©ÎãàÎã§. ÌïòÏßÄÎßå Îç∞Ïù¥ÌÑ∞Îäî Ïù∏Ï†ïÎ∞õÏúºÏã§ ÏàòÍ∞Ä ÏûàÏäµÎãàÎã§. Í∑∏ÎûòÏÑú Ïñ∏Ï†úÎÇò AÏãú Î≥¥Îäî ÏïÑÏù¥Îì§, Ïãú Ïñ¥Î≤åÌä∏ÍπåÏßÄ Ìè¨Ìï®Îêú Îç∞Ïù¥ÌÑ∞Í∞Ä ÎÇòÏôÄÏïº ÌïòÏßÄÎßå

</details>

#### Slide 12
![page_012](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_012_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> ÏÑ±Î≥Ñ ÎπÑÏú®ÎèÑ Î™©Ï†ÅÏóê ÎßûÍ≤å ÎßûÏ∂îÏÖîÏïº Ìï©ÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

ÏöîÏÉà ÎßéÏù¥ Î¨∏Ï†úÏãú ÎêòÍ≥† ÏûàÎäî Ï††ÎçîÏûÖÎãàÎã§. Í∑∏Ï†ÄÍªò Îâ¥Ïä§Ïù∏Í∞ÄÏöî? ÏúÑÍ≥†ÎπÑÎùºÎäî Ïù¥ÏïºÍ∏∞Í∞Ä ÎÇòÏôîÏäµÎãàÎã§. Îç∞Ïù¥Ìä∏ÌïòÎäîÍ±¥ Ïã†Î¢∞ÌïòÍ≤†ÏßÄÎßå Ïã§Ï†ú ÏûÑÏÉÅ Îç∞Ïù¥ÌÑ∞Í∞Ä Ïó¨ÏÑ±Ïù¥ ÎÇ®ÏÑ±Î≥¥Îã§ 2Î∞∞ Îçî ÎßéÏù¥ Ï∞∏Í∞ÄÌñàÎãµÎãàÎã§. Í∑∏ÎûòÏÑú Ïó¨ÏÑ±Ïù¥ Îçî ÎπÑÎßåÏóê ÎßéÏù¥ Îπ†ÏßÄÎäîÍ±¥Í∞Ä? ÏïÑÎãàÎ©¥ Ïôú Ïó¨ÏÑ±Ïù¥ ÎßéÏù¥ Ï∞∏Í∞ÄÌñàÏßÄ? ÎùºÎäî ÏßàÎ¨∏Ïù¥ ÏÉùÍ∏∏ Ïàò ÏûàÍ≤†ÏßÄÎßå Ï†ÄÌù¨ ÏûÖÏû•ÏóêÏÑúÎäî ÎÇ®ÏÑ± Ïó¨ÏÑ± ÎπÑÏú®Ïù¥ Ïö∞Î¶¨Í∞Ä Î™©Ï†ÅÌïú

Ïñ¥Îñ§ ÏßàÎ≥ë Í∞ôÏùÄ Í≤ΩÏö∞Ïóê Ïñ¥Îñ§ ÌÉÄÍ≤üÌåÖ ÌïòÎäî ÎåÄÏÉÅ Í∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî ÌïúÏ™Ω ÏÑ±Ïóê ÏπòÏö∞Ïπ† Í∞ÄÎä•ÏÑ±Ïù¥ ÏûàÎäîÎç∞ Í∑∏ Î™©Ï†ÅÏóê ÎßûÍ≤å ÎßûÏ∂îÏÖîÏïº Îê† Í≤É Í∞ôÍ≥† ÏöîÏÉà Ï†úÍ∞Ä Ï§ÄÎπÑÌïú, Ïû¨Î∞åÍ≤å ÎßåÎì†Í±∞Îäî Ï††Îçî Ïù¥Ïäà Ï§ëÏóêÏÑú ÎßåÏïΩÏóê Î∞îÏù¥Ïò¨Î°úÏßÄÏπº Ï††ÎçîÌïòÍ≥† ÏûêÍ∏∞ ÏÉùÍ∞ÅÌïòÎäî Ï††ÎçîÍ∞Ä Îã§ Îã¨ÎûêÏùÑÎïå ÏàòÏà†ÏùÑ ÌÜµÌï¥ÏÑú Î∞îÎÄî Ïàò ÏûàÎäî Í≤ΩÏö∞Îäî Ïñ¥ÎñªÍ≤å Ìï† Í±∞ÎÉêÏóê ÎåÄÌïú Í≥†ÎØºÎèÑ Ìïú Î≤à Ï†ïÎèÑÎäî Ï†ÄÌù¨Í∞Ä ÎÇòÏ§ëÏóêÎäî ÌïòÍ≤å ÎêòÏßÄ ÏïäÏùÑÍπå

</details>

#### Slide 13
![page_013](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_013_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> ÌûàÏä§Ìå®Îãâ Ïù∏Íµ¨Í∞Ä ÎäòÏñ¥ÎÇòÍ≥† ÏûàÏñ¥ÏÑú Ïù∏Ï¢Ö Í∞ÑÏùò Î∞∏Îü∞Ïä§ÎèÑ ÎßûÏ∂∞Ïïº Ìï©ÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

ÎßàÏßÄÎßâ, Ï†úÍ∞Ä ÏóêÏñ¥ Ï™ΩÏùò ÎßàÏßÄÎßâ Î∂ÄÎ∂ÑÏù∏Îç∞Ïöî, Îçî ÌÅ¨Í≤åÎäî Î¨∏Ï†úÎäî ÏóÜÏúºÏã§ Í≤É Í∞ôÏïÑÏöî.

Ï†ÄÌù¨Í∞Ä Ï°∞Í∏àÏùÄ Ìä∏Î†åÎìúÎ•º Î≥¥ÏÖîÏïº Ìï† Í≤É Ï§ë ÌïòÎÇòÍ∞Ä ÏßÄÍ∏à ÏòõÎÇ†Î≥¥Îã§Îäî Ïù¥Î†áÍ≤å ÌûàÏä§Ìå®Îãâ ÏãúÏ≤≠Ìï¥Ï£ºÏÖîÏÑú Í∞êÏÇ¨Ìï©ÎãàÎã§.

Í∑úÎ™®Í∞Ä Î≥¥Ïù¥Í∏∞ ÎïåÎ¨∏Ïóê Îç∞Ïù¥ÌÑ∞ ÎÇ¥ÏóêÏÑú Ïù∏Ï¢Ö Í∞ÑÏùò Î∞∏Îü∞Ïä§ÍπåÏßÄ ÎßûÏ∂∞Ïïº ÌïúÎã§Í≥† ÏÉùÍ∞ÅÌï©ÎãàÎã§. ÎëêÎ≤àÏß∏Îäî ÎåÄÎ∂ÄÎ∂Ñ ÌïúÏù∏Ïù¥ÏãúÍ∏∞ ÎïåÎ¨∏Ïóê Ïù∏ÏÇ¨Îäî ÌïòÍ≤å Îê† Ïàò ÏûàÍ∏∞ ÎïåÎ¨∏Ïóê Î≥¥ÌÜµ ÌïúÏù∏Ïù¥ Ïö¥ÏòÅÌïòÎäî Îã•ÌÑ∞Ïò§ÌîºÏä§Ïóê Í∞ÄÏÑú ÎßéÏù¥ ÌïòÏã§Í±∞ÏóêÏöî. Í∑∏Îü¨Î©¥ LCP

Í∑∏Í±∞Ïóê ÎåÄÌïú ÎîîÌéúÏä§ÎèÑ Í≥†ÎØºÌïòÏÖîÏïº Ìï©ÎãàÎã§. Í∑∏ÎûòÏÑú Í∞ÄÎä•ÌïòÏãúÎ©¥ÏùÄ Î≠ê Ìï†Ïù∏ Î∂ÄÏù∏ Îòê ÌïòÏã§ ÏàòÎèÑ ÏûàÍ≤†ÏßÄÎßå Í∞ÄÎä•ÌïòÏãúÎ©¥ÏùÄ

</details>

#### Slide 14
![page_014](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_014_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> Í∞ÄÏû• ÏâΩÍ≥† ÌôïÏã§Ìïú Î∞©Î≤ïÏùÄ eSTARÎÇò pre-eSTARÎ•º ÏÇ¨Ïö©ÌïòÎäî Í≤ÉÏûÖÎãàÎã§. FDA ÏöîÍµ¨ÏÇ¨Ìï≠Ïù¥ ÌÖúÌîåÎ¶øÏóê Îã§ Îì§Ïñ¥ÏûàÏäµÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

ÎÑ§, Í∑∏ÎûòÏÑú ÏïûÏóê ÎßêÏîÄÎìúÎ¶∞ Í≤É Í∞ôÏù¥ ÏûÑÏÉÅÏ§ÄÎπÑÎ•º ÎßéÏù¥ ÌïòÏãúÎã§ Î≥¥Î©¥ ÎêòÍ≤å Í∂ÅÍ∏àÌïúÍ≤å ÎßéÏúºÏã§Í±∞ÏóêÏöî. ÎÑ§, Ïù¥Îü∞ Î™®ÏûÑÏùÑ ÌÜµÌï¥ÏÑú Ï†ÄÌù¨Í∞Ä ÎãµÏùÑ Î∞õÏùÑ Ïàò ÏûàÏßÄÎßå Í∞ÄÏû• ÏâΩÍ≥† ÌôïÏã§Ìïú Î∞©Î≤ïÏùÄ Ï¢Ä ÏãúÍ∞ÑÏùÄ 70Î∂Ñ Ï†ïÎèÑ Í±∏Î¶¨ÏßÄÎßå Í∞ÄÏû• ÌôïÏã§Ìïú Î∞©Î≤ïÏùÄ

Ï†ÄÎèÑ ÏßÄÍ∏à 5DD Ï†úÏ∂úÌï†ÎïåÎäî E-STAR Î≤ÑÏ†ÑÏùÑ ÎßéÏù¥ Ïù¥Ïö©ÌïòÍ≥† ÏûàÍ≥† ÎòêÎäî Q-SERVE Ìï†ÎïåÎäî ÌîÑÎ¶¨-E-STAR Î≤ÑÏ†ÑÏùÑ ÎßéÏù¥ Ïù¥Ïö©ÌïòÍ≥† ÏûàÎäîÎç∞Ïöî. Í∞ÄÏû• Ï¢ãÏùÄ Ï†êÏùÄ ÏòõÎÇ†Í∞ôÏùÄ Í≤ΩÏö∞ Ìå©Ïä§ Î≥¥ÎÇ¥Í≥†, Î™©ÌëúÎ≥¥ÎÇ¥Í≥†, Ï±Ö Ïç®Í∞ÄÏßÄÍ≥† Î≥¥ÎÇ¥Í≥†, ÌÅ¥Î¶¨Ïñ¥ ÎêúÎã§Îäî Í±∞ Îã§ ÌïòÎ©¥ÏÑú ÏßÑÌñâÏùÑ ÌñàÏóàÎäîÎç∞, Í∞ÄÏû• Ïâ¨Ïö¥Í±∞Îäî Í∑∏ ÌîÑÎ°úÏÑ∏Ïä§Î•º Î™∞ÏûÖÌï† Ïàò ÏûàÎäîÍ≤å ÎÑàÎ¨¥ Ï¢ãÍ≥†. ÎëêÎ≤àÏß∏Îäî Í∑∏ ÌÖúÌîåÎ¶øÏïàÏóê Ïï†ÌîåÎ¶¨ÏºÄÏù¥ÏÖòÏùò sÎãµÏù¥ ÏûàÎäî ÏöîÍµ¨ÌïòÍ≥† ÏûàÎäî Î¶¨ÌÄòÏù¥Î®ºÌä∏Í∞Ä ÌïòÎÇòÏî© Îã§ Îì§Ïñ¥ÏûàÏäµÎãàÎã§. Í∑∏Í±∏ Î≥¥Îã§ Í∑∏ Í∞ÅÏùÑ Ïì∞ÏãúÎ©¥ÏÑú Î≥¥Îã§Î≥¥Î©¥ÏùÄ

Ï†ïÌôïÌïòÍ≤å FBAÏóêÏÑú Î¶¨ÌîåÎ†àÏù¥ Ìï† ÏàòÍ∞Ä ÏûàÍ≥† Ï†ÄÌù¨Í∞Ä Í∑∏Í±∏ Î≥¥Î©¥ÏÑú Îπ†ÏßÑ Î∂ÄÎ∂Ñ ÏóÜÏù¥ ÏãúÍ∞ÑÏùÑ Ïûò ÎÇÆÏ∂ú Ïàò ÏûàÎäî ÌîåÎû´ÌèºÏúºÎ°ú ÏÇ¨Ïö©Ìï† Ïàò ÏûàÏùÑ Í≤É Í∞ôÏäµÎãàÎã§. Í∞ÄÎä•ÌïòÏãúÎ©¥ Ïù¥Ïä§ÌÉÄÎÇò Ìä∏Î¶¨Ïä§ÌÉÄÎ•º ÏÇ¨Ïö©ÌïòÏãúÎ©¥ Í∞ÄÏû• Ï¢ãÏùÄ Î∞©Î≤ïÏûÖÎãàÎã§.

Îã§ÌÅêÎ©òÌÑ∞Î¶¨Î•º Ï†úÍ∞Ä ÌîÑÎ¶∞Ìä∏ Ìï† ÌïÑÏöîÍ∞Ä ÏóÜÏäµÎãàÎã§. Ïñ¥Îñ§ Í≤ΩÏö∞ÏóêÎäî Î°úÏö∞ Îç∞Ïù¥ÌÑ∞Í∞Ä ÏóëÏÖÄÏù¥ÎÇò ÌïòÎã§Î≥¥Î©¥ Î™áÍ∞úÏî© ÎêòÎäîÎç∞Ïöî. Í∑∏Í±∞ Í∞ñÍ≥† ÏûàÎäî Í≤ÉÏù¥ ÏâΩÏßÄ ÏïäÍ±∞Îì†Ïöî. Í∑∏ÎÉ• Í∑∏Í±∞ Î≥¥ÎÇ¥Îäî Í≤ÉÎèÑ ÏâΩÏßÄÍ∞Ä ÏïäÏùÄÎç∞. ÏÉàÌï¥ Î≥µ ÎßéÏù¥ Î∞õÏúºÏãúÍ≥†, ÌûòÎì†Îç∞ Ï†ÄÎäî Ï†ïÎßê ÏòàÏÅòÍ≤å Í∞êÏÇ¨ÌïòÍ≥† ÏûàÏäµÎãàÎã§. ÎÑàÎ¨¥ Ïûò ÏñòÍ∏∞Ìï¥Ï£ºÏÖîÏÑú Í∞êÏÇ¨Ìï©ÎãàÎã§.

</details>

#### Slide 15
![page_015](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_015_4._FDA_Approval_Strategies_and_Success_Cases(JBC).jpg)

**ÏöîÏïΩ**
> ÌäπÎ≥ÑÌïú ÎπÑÎ≤ïÎ≥¥Îã§Îäî Ïã§ÏàòÎ•º Î∞©ÏßÄÌïòÎäî Í≤ÉÏù¥ Ï§ëÏöîÌï©ÎãàÎã§. ÎØ∏Íµ≠ÏùÑ ÎåÄÌëúÌï† Ïàò ÏûàÎäî ÏûÑÏÉÅ Îç∞Ïù¥ÌÑ∞Í∞Ä ÏäπÏù∏Ïùò ÌïµÏã¨ÏûÖÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

ÏßÄÍ∏àÍπåÏßÄ ÎßêÏîÄÎìúÎ¶∞ Í≤É Í∞ôÏù¥ Ï†ÄÎèÑ Ïñ¥Îñ§ FDA ÏÑ±Í≥µ Ï†ÑÎûµÏóê ÎåÄÌï¥ÏÑú Ï†ïÌôïÌïòÍ≤å AÏûÖÎãàÎã§, ÎßêÏîÄÌï¥Ï£ºÏÖ®ÏßÄÎßå

ÌöåÏÇ¨Î≥ÑÎ°ú Í∑∏ Î™©Ï†ÅÏóê ÎßûÍ≤å Ï§ÄÎπÑÌï† ÏàòÎ∞ñÏóê ÏóÜÎã§ ÎùºÍ≥† Ï¢Ä ÎßêÏîÄÎìúÎ¶¨Í≥† Ïã∂Í≥†

Îëê Í∞ÄÏßÄ Ï†ïÎèÑÎäî Ï¢Ä ÎßêÏîÄÎìúÎ¶¨Í≥† Ïã∂ÏäµÎãàÎã§. Ìïú Í∞ÄÏßÄÎäî

ÏãúÏ≤≠Ìï¥Ï£ºÏÖîÏÑú Í∞êÏÇ¨Ìï©ÎãàÎã§.

ÎëêÎ≤àÏß∏Îäî ÎØ∏Íµ≠ÏùÑ ÎåÄÌëúÌï† Ïàò ÏûàÎäî ÏãúÏÑ± Îç∞Ïù¥ÌÑ∞Í∞Ä ÎÇòÏôÄÏïºÏßÄÎßå ÌÅ¨Í≤å Î¨∏Ï†úÏóÜÏù¥ ÏäπÏù∏ Î∞õÏúºÏã§ Ïàò ÏûàÎäî Í≤É Í∞ôÏäµÎãàÎã§.

Ïó¨Í∏∞ÍπåÏßÄ Ï§ÄÎπÑÌï¥ Ï£ºÏÖîÏÑú Í∞êÏÇ¨Ìï©ÎãàÎã§.

ÏÇ¨Ïã§ Ï≤òÏùåÏóê Ï†úÍ∞Ä Í∂ÅÍ∏àÌñàÎçò Í≤ÉÎèÑ.

</details>

---

<details>
<summary>üìù Full Transcript</summary>

ÎÑ§, ÏïàÎÖïÌïòÏã≠ÎãàÍπå. ÎÇòÎÖ∏Îã§Ïù¥ÌÖåÏùº Ïû•Î≥ëÏãùÏûÖÎãàÎã§. ÏßÄÍ∏à ÎßêÏîÄÌï¥Ï£ºÏã† Í≤É Í∞ôÏù¥ FDA ÏÑ±Í≥µ Ï†ÑÏïΩ, ÏÑ±Í≥µÏ†ÅÏù∏ Ïä§ÌÅ¨Î¶∞ ÌîåÎùºÏä§Ìã±ÏùÑ ÎìúÎ¶¨Í≤†ÏäµÎãàÎã§.

Ï†ÄÌù¨ ÌöåÏÇ¨Îäî 2002ÎÖÑÎèÑÏóê Îâ¥Ï†ÄÏßÄÏóêÏÑú ÏÑ§Î¶ΩÎêòÏóàÍµ¨Ïöî. ÌòÑÏû¨ Í≥ÑÏÜçÌï¥ÏÑú ÎùºÏù¥Î∏åÎãà Ï†úÌíàÏùÄ Í∞úÎ∞úÌïòÍ≥† ÏÉùÏÇ∞ Ïû¨Î£å ÌåêÎß§Î•º ÌïòÍ≥† ÏûàÏäµÎãàÎã§.

Ï†úÍ∞Ä Ïò§Îäò Ïù¥ ÏûêÎ¶¨Ïóê ÏÑúÍ≤å Îêú Ïù¥Ïú†Í∞Ä ÏûëÎÖÑ 2ÏõîÎã¨ Î∂ÄÌÑ∞ Ìïú 1ÎÖÑ Î∞òÏ†ïÎèÑ Í±∏Ï≥êÍ∞ÄÏßÄÍ≥† 3Í∞úÏùò Ï†úÌíàÏùÑ FK Îπ®ÎåÄÍ∏∞ ÏäπÎ¶¨ Î∞õÏïòÏäµÎãàÎã§. Ï†Ñ ÏïÑÏßÅ Ï¢Ä Î∞∞Í≥†ÌîÑÍ≥† Îçî ÎßéÏù¥ Î∞õÍ≥† Ïã∂ÏùÄÎç∞ ÏòÜÏóêÏÑú Î≥¥Ïã§ Í≤ΩÏö∞ÏóêÎäî Ï¢Ä ÏßßÏùÄ ÏãúÍ∞Ñ ÎÇ¥Ïóê ÏÑ±Í≥ºÎ•º Ïù¥Î§òÎã§Í≥† ÏÉùÍ∞ÅÌïòÏãúÎäî Î∂ÑÎì§Ïù¥ ÎßéÏúºÏÖîÍ∞ÄÏßÄÍ≥†

Ïñ¥ÎñªÍ≤å ÌñàÎäîÏßÄ Í∑∏ Î∞©Î≤ïÏù¥ Í∂ÅÍ∏àÌïòÏã† Í≤ÉÎèÑ ÏûàÏúºÏã§ Í≤É Í∞ôÍ≥† Ï†ÄÌù¨ Í∑∏ ÎπÑÎ≤ïÏùÑ Ï†ÑÏàòÌïòÍ≥† Ïã∂ÏùÄ Í≤å ÏûàÎã§Í≥† ÌïòÎ©¥ Ïù¥Î≤à Í∏∞ÌöåÏóê Ï†ïÎ¶¨ÌïòÎ©¥ Ï¢ãÍ≤†Îã§ ÏÉùÍ∞ÅÌï¥ÏÑú ÌïòÍ≤†Îã§ ÎßêÏîÄÎìúÎ†∏ÎäîÎç∞Ïöî. ÏùºÎã® Ï†ÄÌù¨Îäî ÏûëÎÖÑÎèÑ 2ÏõîÏóê ÏΩîÎπÑÎìú Ï†úÌíàÏóê ÎåÄÌï¥ÏÑú ÌååÏù¥ÌåÖÏùÑ Î∞õÏïòÍ≥† ÏûëÎÖÑ 7ÏõîÎã¨ Ï†ïÎèÑÏóêÎäî Ï†ÄÌù¨Í∞Ä RSVÏ†úÌíà 6ÏÑ∏ÎØ∏Îßå ÏòÅÏú†ÏïÑÏóêÏÑú Í∞êÏóºÎêòÎäî Ï†úÌíàÏóê ÎåÄÌï¥ÏÑú Ï†ÄÌù¨Í∞Ä Îî∏Ìã¥Ìä∏Î•º Î∞õÏïòÏäµÎãàÎã§. ÎòêÌïú Í∏àÎÖÑ 6ÏõîÎã¨Ïóê ÏΩîÎπÑÎìúÌïòÍ≥† ÌîåÎ£ªÏùÑ ÎèôÏãúÏóê Í≤ÄÏÇ¨Ìï† Ïàò ÏûàÎäî Ï†úÌíà ÏäπÏù∏Î∞õÏïòÏäµÎãàÎã§. Í∑∏ÎûòÏÑú ÎòêÌïú Ï†ÄÌù¨Í∞Ä ÏßÄÍ∏à Ìïú Í∞úÏùò Ï†úÌíàÏùÑ Îçî Î¶¨Î∑∞ÌïòÍ≥† ÏûàÍ≥† Ï°∞ÎßåÍ∞Ñ ÏäπÏù∏Î∞õÏùÑ Í±∞ ÏòàÏÉÅÌïòÍ≥† ÏûàÎäîÎç∞Ïöî.

Í∑∏ÎûòÏÑú Ï†ÄÎèÑ Ïù¥Îü∞ ÏßàÎ¨∏ Î∞õÏùÑ ÎïåÎßàÎã§ ÎÇòÌïúÌÖå Î¨¥Ïä® ÌäπÎ≥Ñ ÎπÑÎ≤ïÏù¥ ÏûàÏùÑÍπå ÏïÑÎãàÎ©¥ ÎÇòÌïúÌÖå Ïñ¥Îñ§ ÏÑ±Í≥µ Ï†ÑÎûµÏù¥ ÏûàÏùÑÍπå Ï†ïÎßê Í≥†ÎØºÏùÑ Ìï¥Î¥§Í±∞Îì†Ïöî

Ïã¨ÏßÄÏñ¥Îäî ÌöåÏÇ¨ÏóêÏÑú ÌîÑÎ¶¨Ï††ÌÖåÏù¥ÏÖò Ï§ÄÎπÑÌï† Îïå ÏßÅÏõêÎì§ Í∑∏Îïå Í∞ôÏù¥ ÌïòÏÖ®Îçò Î∂ÑÎì§ÌïúÌÖå Ïó¨Ï≠§Î¥§ÏäµÎãàÎã§. ÏïÑÍπå Ïñ¥ÎñªÍ≤å ÌñàÍ∏∞ ÎïåÎ¨∏Ïóê Ïö∞Î¶¨Í∞Ä Ïù¥Î†áÍ≤å Í∑∏Î¶¨Í≥† Ï†úÌíàÏùÑ ÏàòÏûÖ Î∞õÏïòÏúºÎãàÍπå ÎßéÏùÄ ÏãúÍ∞ÑÏùÑ Í∞ÄÏ°åÏñ¥ÎèÑ ÌäπÎ≥ÑÌïòÍ≤å ÎãµÏù¥ ÏóÜÏäµÎãàÎã§. Í∑∏ÎûòÏÑú Ï†ÄÌù¨Í∞Ä ÏÉùÍ∞ÅÌï¥ Î¥êÎèÑ Í∑∏ÎÉ• FDAÏóêÏÑú ÏöîÍµ¨ÌïòÍ≥† ÏûàÎäî Î≠ê ÏÑ∏Ïù¥ÌîÑÌÇ§ÎÇò Ïù¥ÌéôÌä∏ Î¶¨Ïä§Ïóê ÎØøÎã§ÎäîÏßÄ ÏûêÏ≤¥ Í≤ÄÏÇ¨Î•º ÌïòÍ≥† ÌôïÏù∏ÌïòÍ≥† ÎòêÎäî FDAÏóêÏÑú Ï†úÍ≥µÌïòÍ≥† ÏûàÎäî Í∞ÄÏù¥Îç¥Ïä§ÎÇò Îòê ÌîºÎîîÏºÄÏù¥Ìä∏ Í≤∞Í≥º Î≥¥Í≥†ÏÑú Ïñ¥ Ïö∞Î¶¨Í∞Ä Îçî Ï¢ãÎã§ Ïïà Ï¢ãÎã§ ÌèâÍ∞ÄÌï† Ïàò Î∞ñÏóê ÏóÜÎäî ÏûÖÏû•Ïù¥Í±∞Îì†Ïöî. Í∑∏ÎûòÏÑú ÏûòÌïòÎ©¥ ÎêòÎäîÎç∞ Ïñ¥ÎñªÍ≤å ÏûòÌï¥Ïïº ÎêòÏßÄ? ÎÇòÎäî ÎãµÏù¥ ÏóÜÎäî Í≤É Í∞ôÏäµÎãàÎã§. Í∑∏ÎûòÏÑú Ìïú Î≤à Ïñ¥Îñ§ Î£®ÏÖò Î≥¥ÏãúÎäîÎç∞ Ï†ïÎßê ÎãµÏù¥ ÏóÜÏñ¥Í∞ÄÏßÄÍ≥†

Î≠ê Ïö¥Ïù¥ Ï¢ãÏïÑÏÑú ÎÇòÏò§Í∏∞Ïóê ÎåÄÎãµÌïú Ï†ÅÎèÑ ÏûàÍ≥† ÏïÑÎãàÎ©¥ ÏïÑÎãàÎ©¥ÏùÄ ÌïòÎÇòÎãòÏù¥ ÎèÑÏö∞ÏÖîÍ∞ÄÏßÄÍ≥† Ïù¥Î†áÍ≤å ÎåÄÎãµÌïú ÏàòÎ∞ñÏóê ÏóÜÏóàÍ≥†Ïöî. Í∑∏ÎûòÏÑú Ï†ÄÎäî Ïò§Îäò Í∑∏ ÏûêÎ¶¨ÏóêÏÑú ÌäπÎ≥ÑÌïòÍ≤å Î∞©Î≤ïÎ≥¥Îã§Îäî

Ï†ÄÌù¨Í∞Ä Ïù¥Í≤ÉÎßåÏùÄ Ï¢Ä Ïã§ÏàòÌïòÏßÄ ÎßêÏûê Í∑∏ÎûòÏïºÏßÄÎßå ÏÑ±Í≥µÏùÑ Ï¢Ä Îï°Í∏∏ Ïàò ÏûàÏßÄ ÏïäÏùÑÍπå Ïö∞Î¶¨Í∞Ä ÌùîÌûà Í∏∞Ï¥àÏ†ÅÏù∏ Í±∞ÏßÄÎßåÏùÄ ÏûêÏ£º Ï£ºÏùòÍπäÍ≤å Ïïà Î¥êÍ∞ÄÏßÄÍ≥† ÎÑòÏñ¥Í∞ÄÎäî Î∂ÄÎ∂ÑÎì§Ïù¥ ÎßéÏù¥ ÏûàÎäî Í≤É Í∞ôÏäµÎãàÎã§. Í∑∏Í±∞Ïóê ÎåÄÌï¥ÏÑú Ï†úÍ∞Ä Ìïú 5ÎÖÑ Ï†ïÎèÑ ÏΩîÎπÑÎìúÎ•º Í≤™ÏúºÎ©¥ÏÑú Ìå©Ìä∏ÌñàÎçò Í±∞Ïóê ÎåÄÌï¥ÏÑú Ï°∞Í∏à Í≥µÏú† ÎìúÎ¶¨Î©¥ÏùÄ ÏÉàÎ°≠Í≤å ÏãúÏûëÌïòÏãúÎäî Î∂ÑÎì§ ÎòêÎäî ÏßÄÍ∏à ÌïòÏãúÎäî Î∂ÑÎì§ÌïúÌÖå ÎèÑÏõÄÏù¥ ÎêòÏßÄ ÏïäÏùÑÍπå ÏÉùÍ∞ÅÏù¥ Îì≠ÎãàÎã§.

Ï†ÄÌù¨ Ï†úÌíàÏùÄ Î†àÌîºÎìú Ï†úÌíàÏù¥Ïñ¥ÏÑú Í∏∞Ï°¥Ïóê ÏäπÏù∏Î∞õÏùÄ Ï†úÌíàÍ≥º ÌîÑÎ¶¨Ïä§ÏºÄÏù¥ÏßÄ Ï†úÌíàÍ≥º ÎπÑÍµêÌïòÍ≤å ÎêòÏñ¥ÏûàÏäµÎãàÎã§. Í∑∏ ÎπÑÍµêÎ•º ÌÜµÌï¥Í∞ÄÏßÄÍ≥† Ïñ¥Îäê ÎßåÌÅº ÎØºÍ∞êÌïúÏßÄ, Ïñ¥Îäê ÎßåÌÅº Ï†ïÌôïÌïúÏßÄ

Ìò∏ÎπàÏóîÌã∞Ï¶åÏùÑ Í≤ÄÏÇ¨ÌñàÏùÑ Ï†úÌíà Í∞úÎ∞úÌï¥Í∞ÄÏßÄÍ≥† ÏûÑÏÇ¨ Îã§ ÎÅùÎÇú Îã§ÏùåÏóê Ïïº, Ïù¥Î†áÍ≤å FDA Ï†úÏ∂úÌïòÍ≥† ÏäπÏù∏Î∞õÏùÑ Í±∞Ïïº. ÏôúÎÉêÌïòÎ©¥ Îã§Î•∏ Ï†úÌíàÎì§Î≥¥Îã§ ÏÑ±Îä•Ïù¥ Ï¢ãÏïòÍ±∞Îì†Ïöî. Í∑∏ÎûòÏÑú Ïó¥Ïã¨Ìûà Ï§ÄÎπÑÌï¥Í∞ÄÏßÄÍ≥† 2021ÎÖÑÎèÑÏóê Ï†úÏ∂úÌñàÏäµÎãàÎã§. Í∑ºÎç∞ ÎãµÏùÑ Î∞õÏùÄÍ≤å ÎÇ¥Í∞Ä Ïì¥ ÌÅ¨Î¶¨Ìã∞ÏºÄÏù¥Ìä∏ Ï†úÌíàÏùÄ FD3 Î∞õÏùÄ Ï†úÌíàÏù¥ ÏïÑÎãàÏïº. Ïôú? ÏïÑÎãà Ïôú? Ïù¥Î†áÍ≤å ÌÅ∞ ÎçîÎ∏îÌîºÏÖú Ïôú Ï†úÌíà, ÌîºÏÖú Ï†úÌíàÏù¥ ÏïûÏóê ÏûàÍ≥† ÎÇòÎäî ÏïÑÌì®Ìã∞Ïä§Ìïú Îû©ÏóêÏÑú ÌèâÍ∞ÄÌñàÎäîÎç∞ Ïôú? ÎÑàÎ¨¥ ÎãπÌô©Ïä§ÎüΩÍ∏∞ÎèÑ ÌïòÍ≥† Ïù¥Í≤å Ïñ¥ÎñªÍ≤å ÎÇ¥Í∞Ä Í∑∏Îü∞Í±∏ ÎÜìÏ≥§ÏùÑÍπå Ïôú ÌÅ∞ ÌöåÏÇ¨ ÎßàÏºÄÌåÖÏÇ¨ ÎÇ¥Î∂ÄÏóêÏÑúÎäî Ïù¥Îü∞ Ï†úÌíàÏùÑ

Ïì∞Í≥† ÏûàÏßÄ?ÎùºÎäî ÏßàÎ¨∏Ïù¥ ÏÉùÍ≤ºÏäµÎãàÎã§. Í≤∞Íµ≠ÏùÄ Ï†ÄÌù¨Îäî FDAÎ°ú ÏõåÌÅ¨ÏóÖÏùÑ Ìï† Ïàò ÏóÜÍ∏∞ ÎïåÎ¨∏Ïóê ÎÇ¥Í∞Ä ÎßàÏºì FDA Ï†ïÏãù ÏäπÏù∏Îêú Ï†úÌíàÏùÑ Ï≤´Î≤àÏß∏ ÏÑ†Ï†ïÌïòÏÖîÏïº ÎêúÎã§ÎäîÍ≤å Ï†úÍ∞Ä ÏßÄÍ∏à ÎßêÏîÄÎìúÎ¶¨Í≥† Ïã∂ÏäµÎãàÎã§. Í∑∏Îüº ÎßêÏîÄÎìúÎ¶∞Í±∞Í∞ôÏù¥ Í∑∏Îü¨Î©¥ Ïù¥ ÏïÑÌîºÎÅºÏä§ Îû©ÏóêÏÑúÎäî Ïôú Ïù¥ Ï†úÌíàÏùÑ Ïì∏ÏàòÍ∞Ä ÏûàÏóàÏßÄ? Í∑∏ Îã§ÏùåÏóê ÎëêÎ≤àÏß∏ ÏßàÎ¨∏ Í∑∏Îü∞Îç∞ ÌïúÍµ≠ Í∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî ÌÅ¨Í≤å ÏßÄÎ∞©Ï†ïÎ∂Ä, Ïó∞Î∞©Ï†ïÎ∂Ä, Ï§ëÏïôÏ†ïÎ∂Ä Ï∞®Ïù¥Í∞Ä ÏóÜÏßÄÎßå ÎØ∏Íµ≠ÏùÄ ÏïÑÏâΩÍ≤åÎèÑ Ï£ºÏ†ïÎ∂ÄÌïòÍ≥† ÏòÅÍ¥ëÏûÖÎãàÎã§. ÏßÄÍ∏àÍπåÏßÄ ÎßàÏπòÍ≤†ÏäµÎãàÎã§.

Í∑∏ÎûòÏÑú ÏïÑÌì®Ìã∞Ïä§ÏóêÏÑú Ïì∞Îäî Ï†úÌíà Í∞ôÏùÄ Í≤ΩÏö∞Îäî Ïù¥Î†áÍ≤å FDA ÏäπÏù∏Îêú Ï†úÌíàÎßåÏúºÎ°ú Î∂ÑÎ™ÖÌûà ÎÖπÏ∑®ÎêòÏñ¥ ÏûàÏäµÎãàÎã§. ÌïòÏßÄÎßå Îâ¥Ïöï Ìó¨Ïä§ÌÇ∑ Í∞ôÏùÄ ÏóÖÏ≤¥ÏóêÏÑú ÏäπÏù∏Îêú Ï†úÌíàÏù¥Îã§. Í∑∏ÎûòÏÑú Îâ¥Ïöï Ï£ºÏöî ÎÇ¥ÏóêÏÑúÎäî Ïì∏ ÏàòÍ∞Ä ÏûàÏäµÎãàÎã§. ÏÇ¨Ïö©Ìï† Ïàò ÏûàÏäµÎãàÎã§. Î≠ê Í∑∏Îïå EUA, ÏΩîÎπÑÎìú Îïå Ïù¥Í∏∞ ÎïåÎ¨∏Ïóê Îòê

ÎØ∏Íµ≠Ïù¥ Ïó∞Î∞©Ï†ïÎ∂ÄÌïòÍ≥† Ï£ºÏ†ïÎ∂ÄÌïòÍ≥† Ï∞®Ïù¥Í∞Ä Ïã¨ÌïòÍµ¨ÎÇò Í∑∏ÎûòÏÑú Î¨¥Ï°∞Í±¥ ÌÅ∞ Î†àÎ≤®ÏóêÏÑú ÏÇ¨Ïö©ÌïúÎã§Í≥† ÌïòÎçîÎùºÎèÑ Í∑∏ Ï†úÌíàÏóê ÎåÄÌï¥ÏÑúÎäî Ìïú Î≤àÏ†ïÎèÑÎäî Ï†ïÎßê FD3D Ï†úÌíàÏù∏ÏßÄÎ•º Íº≠ ÌôïÏù∏ÌïòÍ≥† ÏßÑÌñâÌï¥ÏïºÍ≤†Îã§Îäî ÏÉùÍ∞ÅÏù¥ Îì§ÏóàÏäµÎãàÎã§.

ÌïúÍµ≠ÏóêÏÑú ÏßÑÏ∂úÌïòÏã§ Îïå ÌÅ¥Î¶¨Ïñ¥ Îû©ÏùÑ ÌÜµÌï¥ ÎßéÏù¥ ÏßÑÏ∂úÌïòÏãúÎäî Í≤É Í∞ôÏïÑÏöî. Í∑ºÎç∞ Ï†ÄÌù¨ Í∞ôÏùÄ ÏûÖÏû•ÏóêÏÑúÎäî ÌÅ¥Î¶¨Ïñ¥ Îû© ÎòêÎäî ÌÅ∞ ÏãúÏÑ§ Í∞ôÏùÄ Í≤ΩÏö∞Îäî Î¨¥Ï°∞Í±¥ 100% Ïã§ÎÇ¥ÌïòÎ©¥ÏÑú Í∑∏ Í≤∞Í≥º ÎäòÎ¶¥ Ïàò Î∞ñÏóê ÏóÜÏäµÎãàÎã§. ÌôïÏù∏ÌïúÎã§. Î≠ê Îã§ ÎπÑÏ©ç ÏïÑÏö∞ Ï†Ä ÌÅ∞ Ïï†Îì§ ÏÇ¨ÎäîÎç∞ ÏÑ§Îßà Ïï†ÌîåÏù¥ ÏäπÎ¶¨ Î∞õÏßÄ ÏïäÏßÄ Î∏åÏù¥ÏòÄÏñ¥? ÎùºÎäîÍ≤å Ï†ÄÌù¨Îäî ÌïúÍµ≠ÏóêÏÑú Ïò§Ïã† Î∂ÑÎì§ Îòê Ï†ÄÍ∞ôÏù¥ Ï≤òÏùå ÏãúÏûëÌïú ÏÇ¨ÎûåÎì§ÌïúÌÖåÎäî ÎßéÏù¥ Ï∫êÏä§ÌåÖ ÏÉùÍ∏∞Îäî Î∂ÑÏïºÍ±∞Îì†Ïöî

ÌïòÏßÄÎßå ÏóëÏä§ÌÖåÏù¥ÏóêÏÑúÎäî Îã®ÏßÄ Îû©ÏóêÏÑú Í≤®Îã§ÎãàÎäî LBT ÌÖåÏä§Ìä∏Í∞Ä ÎèºÏÑú Í∑∏Í±∏ Í≥µÏãù Îç∞Ïù¥ÌÑ∞Î°ú Ïù∏Ï†ïÌï¥Ï§¨Îã§. Î¨ºÎ°† Ïù¥ Îç∞Ïù¥ÌÑ∞Í∞Ä ÌôòÏûêÍ∞Ä ÏùòÏÇ¨ÌïúÌÖå Ï†úÍ≥µÌï¥Í∞ÄÏßÄÍ≥† Ïñ¥ÎñªÍ≤å Ìï†Í±∞ÎÉê, Î≠ê Ï†úÍ∞Ä ÏïåÎ†§ÎìúÎ¶∞Í≤É Í∞ôÏù¥ D-NOÎ°ú ÌÜµÌï¥ÏÑú Í∞àÏàòÎèÑ ÏûàÎäîÎç∞Ïöî, Í∑∏Ï†ÑÏóê Q-SUBÏùÑ ÌÜµÌï¥ÏÑú X-RAYÎ•º Ìï†Í±∞ÏóêÏöî.

Í∑∏ÎûòÏÑú ÎßåÏïΩÏóê Í∑∏Îü∞ ÎπÑÍµê Ïã§ÌóòÎèÑ ÏóÜÎã§Í≥† ÌïòÏãúÎ©¥ Îòê Îã§ÏùåÏóê Ï†ÄÌù¨Í∞Ä Îû©ÏóêÏÑú Í≤ÄÏÇ¨Ìïú Í≤∞Í≥º Í∞ñÍ≥† Î™®ÏïÑÏÑú Ïû¨Ï∂îÏÇ¨Ïã†Îã§Í≥† ÌïòÎ©¥ Í∑∏ Ï†ÑÏóê ÌÅ∞ ÏúôÏä§... ÏÇ¨ÏóÖÏùÑ ÌïòÏãúÍ∏∞ Ï†ÑÏóê, Îç∞Ïù¥ÌÑ∞Î•º Î™®ÏúºÏãúÍ∏∞ Ï†ÑÏóê, Î∞òÎìúÏãú 2Í∞úÏùò Ïó≠ÏÇ¨ÌïôÏùÑ ÌïòÏãúÎäî Í≤å Ï≤´ Î≤àÏß∏ ÏàòÎã®Ïù∏ Í≤É Í∞ôÏäµÎãàÎã§.

Îã§ÏùåÏóî Ïù¥Í±¥ Ï†ÄÌù¨Í∞Ä Ï°∞Í∏àÏùÄ Ï†ú ÏºÄÏù¥Ïä§Ïù∏Îç∞Ïöî, Í≥ºÍ±∞Ïä§ÎüΩÍ≤å Ï†úÍ∞Ä Ï†ïÎ¶¨ÌñàÍµ¨ÎÇòÎùºÎäî Í∞ÑÏÑ≠Ïù¥ ÏûàÎäî Î∂ÄÎ∂ÑÏù¥Ï£†. Ï†ÄÌù¨Îäî Ïûò Î™∞ÎûêÏóàÎçò Í≤É Í∞ôÏïÑÏöî. Í∑∏Îïå ÏãúÏ†êÏóêÏÑúÎäî. ÏΩîÎπÑÎìú ÏÉòÌîåÏùÑ Î™®ÏïòÎäîÎç∞Ïöî, Ïù¥Î†áÍ≤å Ï†ÄÌù¨Í∞Ä ÏÉòÌîå Î≥ëÏõêÏù¥ÎÇò ÏÉòÌîåÎßµÏù¥ÎÇò Ïú†ÌéúÏù¥ÎÇò ÌÄòÏä§Ìä∏Î°ú ÎÜÄ Ïàò ÏûàÏóàÎçò ÌÅ∞ Î≥ëÏõêÏóêÏÑú ÏÉòÌîåÏùÑ Î™®ÏïòÏäµÎãàÎã§. Í≤ÄÏÉâÏùÑ Ìï¥Î≥¥ÎãàÍπå ÎÑàÎ¨¥ÎÑàÎ¨¥ Í≤∞Í≥ºÍ∞Ä Ï¢ãÏùÄÍ±∞ÏóêÏöî. Í∑∏ÎûòÏÑú Ïù¥ Îç∞Ïù¥ÌÑ∞Î•º ÎòëÍ∞ôÏù¥ FDÏóê ÎÉàÏäµÎãàÎã§. Í∑ºÎç∞ FD Îç∞Ïù¥ÌÑ∞Îäî Ïó¨Í∏∞ÏÑú Í∞ÅÍ∞Å ÏÇ¨Ïù¥Ìä∏ÏóêÏÑú ÏÇ¨Ïö©Ìïú PCR Î∞©Î≤ïÏù¥ Îã§ ÎòëÍ∞ôÏïÑ. ÎÑ§Í∞Ä ÎèôÎì±ÌïòÎã§Îäî Í±∏ Ïú†Ï∂îÌï† ÏàòÍ∞Ä ÏûàÏñ¥. ÎèôÎì±ÌïòÎã§Îäî Í±∏ Ïú†Ï∂îÌïú ÏÉÅÌÉúÏóêÏÑú Ïù¥Îü∞ Îç∞Ïù¥ÌÑ∞Í∞Ä Î∂ÑÏÑùÏù¥ ÎèºÏïº ÎêòÎäîÎç∞

Í∑∏Í±∏ ÎãàÍ∞Ä ÏûÖÏ¶ùÌï† Ïàò ÏûàÎãà? ÎùºÎäî ÏßàÎ¨∏ÏùÑ Î∞õÏïòÍ±∞Îì†Ïöî. Î¨ºÎ°† Ïù¥ Í∞ÅÍ∞ÅÏùò Ï†úÌíàÏùÄ Í∑∏ Ï§ëÏóêÏÑú FD ÏäπÏù∏Îêú Ï†úÌíàÎèÑ ÏûàÏäµÎãàÎã§. ÌïòÏßÄÎßå ÏäπÏù∏Îêú Ï†úÌíàÏù¥ 3Í∞úÏùò Ï†úÌíàÏù¥ ÏûàÏùÑ Í≤ΩÏö∞Ïóê 3Í∞úÍ∞Ä Îã§ ÎòëÍ∞ôÏùÄ ÏÑ±Ï†ÅÏùÑ Í≤∞Í≥ºÎ•º Î≥¥Ïùº Ïàò ÏûàÎäêÎÉê Ïù¥Î†áÍ≤å ÌïòÎäî Í≤ÉÏùÄ ÏïÑÎãàÍ±∞Îì†Ïöî. Í∑∏ÎûòÏÑú Í∞ÄÎä•ÌïòÏãúÎ©¥ÏùÄ 1Í∞úÏùò ÌÅ¥Î¶¨ÎãâÏπºÏùÑ ÏßÑÌñâÌïòÏã§ÎïåÎäî 1Í∞úÏùò Ïª¥Ìì®ÌÑ∞Î•º ÏÇ¨Ïö©ÌïòÏãúÍ∏∞ Î∞îÎûçÎãàÎã§.

Ïó¨Îü¨Í∞ÄÏßÄ Ï¢ÖÎ•òÏùò ÌîºÏÖú Î®∏Ïã†, ÌîÑÎ¶¨Ìã∞Ïºì Îì±ÏùÑ Ïù¥Ïö©Ìï¥ÏÑú ÎèôÎì±ÏÑ± Ïù∏Ï¶ùÌïòÎäî ÏûëÏóÖÏùÑ Ï§ÄÎπÑÌïòÏÖîÏïº Ìï©ÎãàÎã§.

ÏßÄÍ∏àÎ∂ÄÌÑ∞Îäî Ï°∞Í∏à Ìé∏ÌïòÍ≤å ÎßêÏîÄÎìúÎ¶¨Í≤†ÏäµÎãàÎã§. Ï†ÄÌù¨Í∞Ä Ïù∏ÏÉÅÏùÑ ÌïòÍ≤å ÎêòÎ©¥ Ìïú Î™ÖÏùò ÌôòÏûêÏóêÏÑú Ìïú Î™ÖÏùÑ ÏÑ∏ÌåÖÌï©ÎãàÎã§.

Ìïú 3Í∞úÏõîÎèôÏïà 300Í∞úÎßå Î™®ÏïÑÏ£ºÏÑ∏Ïöî, 500Í∞ú Î™®ÏïÑÏ£ºÏÑ∏Ïöî ÎùºÍ≥† Ï†ÄÌù¨Í∞Ä ÏñòÍ∏∞Ìï† Ïàò Î∞ñÏóê ÏóÜÍ±∞Îì†Ïöî Í∑∏Ï™ΩÎèÑ Í∑∏ÎûòÏïºÏßÄÎßå Í∑∏ Í∏∞Í∞ÑÏóê ÎßûÏ∂∞Í∞ÄÏßÄÍ≥† ÏÉòÌîåÏùÑ Î™®ÏïÑÏÑú Ìï¥Ï§Ñ Ïàò Î∞ñÏóê ÏóÜÏúºÎãàÍπåÏöî Í∑∏Îü¨Î©¥ Í∑∏ ÏÇ¨Ïù¥Ïóê Í∞ôÏùÄ ÌôòÏûêÍ∞Ä Í≥ÑÏÜç ÏôÄÍ∞ÄÏßÄÍ≥† Ïù¥ÏÉÅÏùº Í∞êÎèÖÏù¥ Ïò§ÏÖîÍ∞ÄÏßÄÍ≥† ÏÉòÌîåÏùÑ Ïç®ÏÑú ÏÉòÌîåÏùÑ Î™®ÏúºÎäîÍ±∞Ï£† ÏÉòÌîåÏùÑ Î™®ÏïÑÏûàÎäîÎç∞ ÎãàÍ∞Ä Í∑∏ÎÉ• Ïó¨Í∏∞ÏÑú Î∞ò Íµ¨Ïó≠ Î∞ò Ìï¥Í∞ÄÏßÄÍ≥† ÏÉòÌîå ÏùºÏ£ºÏùº Í∞ÑÍ≤©ÏúºÎ°ú ÌïòÎ©¥ Í∑∏Î∂ÑÏù¥ Î¶¨ÌîºÌã¥Ïùò ÌôòÏûêÍ∞Ä ÎêòÎäî ÏÉòÌîåÏù¥ Îê† Ïàò ÏûàÍ∏∞ÎïåÎ¨∏Ïóê ÌÅ¨Í≤å ÎåÄÍ∞ÄÏùò Î∞îÏù¥Îü¨Ïä§Í∞Ä ÏÉùÍ∏∏ Ïàò ÏûàÏäµÎãàÎã§. ÌäπÌûà Ï£ºÏùòÌï¥Ïïº Îê† Ï†êÏùÄ

Ï†ÄÌù¨Í∞Ä Îâ¥ÏöïÏóê ÏûàÎäî MÎ≥ëÏõêÏóêÏÑú ÏÉòÌîåÏùÑ Î∞õÏïòÎäîÎç∞Ïöî. Ï†ÄÌù¨Îäî ÌîåÎùºÏ¶àÎßàÎ•º Î∞õÏïòÎäîÎç∞ Ïù¥ Î≥ëÏõê ÎÇ¥ÏóêÏÑúÎäî Ï†ÄÌù¨Í∞Ä Ïù¥Î†áÍ≤å 3Ïõî 29ÏùºÏóê ÏûÖÏõêÌïú Îã§ÏùåÏóê 15, 16, 17, Ìïú Í∞ÑÍ≤©ÏúºÎ°ú Ïù¥Î†áÍ≤å ÎΩëÏùÄ Í≤ÅÎãàÎã§. Î™á Î∂ÑÏù¥ ÎΩëÏïÑÍ∞ÄÏßÄÍ≥†, Î≤ÑÎ¶∞ Í∑∏ Î≥ëÏõê ÎÇ¥ÏóêÏÑúÎäî Í±∞Í∏∞Ïóê Ìï≠Ï≤¥Í∞Ä ÏûàÎäîÏßÄ Í≤ÄÏÇ¨Ìï¥Ïïº ÎêòÍ∏∞ ÎïåÎ¨∏Ïóê Í∞ñÍ≥† ÏôÄÏÑú Í≤ÄÏÇ¨Î•º ÌñàÎäîÎç∞ Ï†úÍ∞Ä Ïù¥ ÏÉòÌîåÏùÑ Îß•Î∂ÅÏúºÎ°ú Î∞õÏïòÎäîÎç∞, Ïù¥Í≤å Î∞òÎ≥µÎêú ÏÉòÌîåÏù¥ ÎêòÍ∏∞ ÏãúÏûëÌï©ÎãàÎã§.

Í∑∏ÎûòÏÑú Ï†ÄÌù¨Í∞Ä Ïù¥ ÏÉòÌîåÏùÑ Î≥∏ Îã§ÏùåÏóê Î∞òÎ≥µÎêú ÏÉòÌîåÏù¥ ÏûàÎã§Í≥† ÌïòÎ©¥ Î≥¥ÏãúÎäî Í≤ÉÍ≥º Í∞ôÏù¥ ÏÉòÌîå ÏÇ¨Ïù¥Ï¶àÍ∞Ä Ïù¥Î¶¨Ï†ÄÎ¶¨ Ï°∞ÏûëÎèº. Ïù¥ Í∑ºÏÉÅÎåÄÏùò Í≤∞Í≥ºÎ•º Î≥º ÏàòÍ∞Ä ÏûàÍ≥† Ïù¥ Í≤∞Í≥ºÍ∞Ä Ï†ïÎßê ÎØºÍ∞ÑÎèÑÎÇò ÌäπÍ∏∞ÎèÑÏóê Ï†ïÌôïÌûà Î∞òÏòÅÌï† Ïàò ÏûàÏùÑÍπå ÌïòÎäî Í∂ÅÍ∏àÏ¶ùÏù¥ ÏÉùÍ∏∏ Ïàò Î∞ñÏóê ÏóÜÏùÑ Í≤É Í∞ôÏäµÎãàÎã§.

Í∑∏ÎûòÏÑú Í∑∏ Îã§ÏùåÏóê Ï†úÍ∞Ä Ï°∞Í∏à ÎßêÏîÄÎìúÎ¶∞ ÎÇ¥Ïö©ÏùÄ ÎØ∏Íµ≠ Í∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî Ï¢Ä ÎïÖÏù¥ ÌÅΩÎãàÎã§. ÌïúÍµ≠Ïóê ÎπÑÌï¥ÏÑúÎäî ÎÑàÎ¨¥ ÌÅ¨Í∏∞ ÎïåÎ¨∏ÏóêÏöî. Ïö∞Î¶¨ Î∞îÏù¥Îü¨Ïä§Î•º Î≥∏Îã§Í≥† ÌïòÎçîÎùºÎèÑ 3Í∞ú ÏßÄÏó≠ Ïù¥ÏÉÅÏóêÏÑú ÏÉòÌîåÏùÑ Î™®ÏïÑÏÑú Í≤ÄÏÇ¨ÌïòÍ≤å ÎêòÏñ¥ÏûàÏäµÎãàÎã§. Í∑∏Îüº Ï†ÄÌù¨Í∞Ä ÏÉùÍ∞ÅÌï† Îïå 3Í∞ú ÏßÄÏó≠Ïù¥Î©¥ Ïñ¥Îñ§ Î∂ÄÎ∂Ñ Ï†ïÎèÑ Ìï¥Ïïº Îê†ÍπåÏöî?

Îâ¥Ïöï, Îâ¥Ï†ÄÏßÄ, ÌéúÏã†ÎπÑÏïÑÎãàÏïÑ, ÏÑ∏Í≥ÑÏ§ëÏöîÌïú ÏóëÏÑ∏Ïù¥Í∞Ä ÎßûÏ∂îÍ≥† ÏûàÎÇòÏöî?

Î≥¥ÌÜµ Ï†ÄÌù¨Í∞Ä Ïì∏ Í≤ΩÏö∞ÏóêÎäî ÏµúÏÜåÌïú Ïù¥Ïä§Ìä∏Î≥¥Ïä§, Ïõ®Ïä§Ìä∏Î≥¥Ïä§, ÎÇ®Î∂Å, Î∂ÅÎ∂Å, Ï§ëÍµ≠ Îã§ÏÑØÍ∞ú Î£¨ÏùÑ ÏÇ¨Ïö©Ìï©ÎãàÎã§. ÎÇòÎàÑÏã† Îã§ÏùåÏóê Í∑∏ Ï§ëÏóê 3Í∞úÎ•º ÏÑ†ÌÉùÌïòÏãúÎäî Í≤å Í∞ÄÏû• Ï¢ãÏùÄ Î∞©Î≤ïÏûÖÎãàÎã§. Í∞ÄÏû• Ï¢ãÏùÄ Í≤ÉÏùÄ ÎèôÏÑúÎÇ®Î∂ÅÌïú Í≤å Ï¢ãÍ∏¥ Ï¢ãÏùÄÎç∞Ïöî. Í∑∏Î†áÍ≤åÍπåÏßÄ ÏâΩÏßÄ ÏïäÎã§Í≥† ÌïòÎçîÎùºÎèÑ ÏµúÏÑ† 3Í∞ú ÏßÄÏó≠ÏùÑ Íµ¨Î∂ÑÌïòÏÖîÍ∞ÄÏßÄÍ≥† ÌïòÏãúÎäî Í≤å Ï¢ãÏäµÎãàÎã§.

Ìïú ÏßÄÏó≠Îßå ÎØ∏ÏàòÌïòÏã†Îã§Í≥† ÌïòÎ©¥ÏùÄ Í∑∏ ÎåÄÌëúÏÑ±ÏóêÏÑú Î¨∏Ï†úÍ∞Ä Îê† ÏàòÎ∞ñÏóê ÏóÜÍ∏∞ ÎïåÎ¨∏Ïóê 3Í∞ú Ïù¥ÏÉÅ ÌïòÏÖîÏïº Îê† Í≤É Í∞ôÍ≥† ÎòêÌïú Ïñ¥Îñ§ ÌäπÏ†ï ÏßàÎ≥ëÍ∞ôÏùÄ Í≤ΩÏö∞Ïóê Ïù¥Î†áÍ≤å ÌôòÍ≤ΩÏóê ÏùòÌï¥ÏÑú ÎßéÏù¥ Ï∞®Ïù¥Í∞Ä ÎÇ† ÏàòÎèÑ ÏûàÏäµÎãàÎã§. ÌôòÍ≤ΩÎèÑ Î≥¥Ïú†ÌïòÏÖîÏïº ÎêòÍ≥† ÌïúÍµ≠ÏóêÏÑú Í≤ÄÏÇ¨Ìïú Îç∞Ïù¥ÌÑ∞Î•º, ÏûÑÏÉÅ Îç∞Ïù¥ÌÑ∞Î•º ÎØ∏Íµ≠Ïóê Ïì∏ ÏàòÍ∞Ä ÏûàÎäêÎÉê, Ï∞∏Í≤¨Ìï† Ïàò ÏûàÎäîÎç∞ Ïì∞ÏãúÎäî Î∂ÑÎì§ÏùÄ ÏïÑÏã≠ÎãàÎã§. Î∞òÎìúÏãú ÎØ∏Íµ≠ Î≤†Ïù¥Ïä§ ÌÅ¨Î†àÏù¥Îçî Ïä§ÌååÏù¥Í∞Ä ÎêòÏÖîÏïº Ìï©ÎãàÎã§. Î¨ºÎ°† Í∑∏ Ïà´ÏûêÎÇò ÏÇ¨Ïù¥Ìä∏ Ïà´Ïûê Í∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî Ï†ÑÏ≤¥ ÏÉåÎìú Ïà´ÏûêÎÇò ÏÇ¨Ïù¥Ìä∏ Ïà´ÏûêÎäî FDAÏóêÏÑú ÌôïÏù∏ÌïòÏã§ ÏàòÍ∞Ä ÏûàÏßÄÎßå Î∞òÎìúÏãú ÎØ∏Íµ≠ ÎÇ¥ ÎåÄÌëúÏÑ± Í∞ñÍ≥† ÏûàÎäî ÏÇ¨Ïù¥Ìä∏ÏóêÏÑú ÌïòÏÖîÏïº Îê©ÎãàÎã§.

Îòê Îã§ÏùåÏóê ÎßêÏîÄÎìúÎ¶¨Îäî ÎÇ¥Ïö©ÏùÄ ÌôòÏûê AÏßÄÏùò ÌååÌîÑÎ¶¨ÏóêÏù¥ÏÖòÏù∏Îç∞Ïöî. ÌïúÏ™ΩÏóê ÏπòÏö∞ÏπòÍ±∞ÎÇò ÌïòÏãúÏßÄ ÏïäÏúºÏãúÎ©¥ ÏïàÎê©ÎãàÎã§. ÎßåÏïΩÏóê Ï†ÄÌù¨Í∞Ä ÏÉòÌîåÏùÑ Î™®ÏïòÏùÑ Í≤ΩÏö∞Ïóê ÌäπÏ†ï 20ÎåÄ, 30ÎåÄ Îç∞Ïù¥ÌÑ∞ Í∞ñÍ≥†ÏÑú Ïù¥Í≤å 10ÏÑ∏ ÎØ∏Îßå ÏïÑÏù¥Ïóê Ï†ÅÏö©Ìï† Ïàò ÏûàÎã§ ÎòêÎäî 60ÏÑ∏ Ïù¥ÏÉÅÏóê Ï†ÅÏö©Ìï† Ïàò ÏûàÎã§ÎùºÍ≥†

ÏÜåÏïÑ RSVÎÇò ÌîåÎ£® Í∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî ÌäπÌûà ÏÜåÏïÑÏóê ÎßéÏù¥ Í¥ÄÎ†®Ïù¥ ÎêòÍ∏∞ ÎïåÎ¨∏Ïóê ÏÜåÏïÑ 10ÏÑ∏ ÎØ∏Îßå ÏïÑÏù¥Ïóê ÎåÄÌïú ÎπÑÏú®Ïù¥ Ï†ïÌôïÌûà Ï†ÅÌï©ÌïòÏÖîÏïºÎê©ÎãàÎã§. ÌïòÏßÄÎßå Îç∞Ïù¥ÌÑ∞Îäî Ïù∏Ï†ïÎ∞õÏúºÏã§ ÏàòÍ∞Ä ÏûàÏäµÎãàÎã§. Í∑∏ÎûòÏÑú Ïñ∏Ï†úÎÇò AÏãú Î≥¥Îäî ÏïÑÏù¥Îì§, Ïãú Ïñ¥Î≤åÌä∏ÍπåÏßÄ Ìè¨Ìï®Îêú Îç∞Ïù¥ÌÑ∞Í∞Ä ÎÇòÏôÄÏïº ÌïòÏßÄÎßå

ÏöîÏÉà ÎßéÏù¥ Î¨∏Ï†úÏãú ÎêòÍ≥† ÏûàÎäî Ï††ÎçîÏûÖÎãàÎã§. Í∑∏Ï†ÄÍªò Îâ¥Ïä§Ïù∏Í∞ÄÏöî? ÏúÑÍ≥†ÎπÑÎùºÎäî Ïù¥ÏïºÍ∏∞Í∞Ä ÎÇòÏôîÏäµÎãàÎã§. Îç∞Ïù¥Ìä∏ÌïòÎäîÍ±¥ Ïã†Î¢∞ÌïòÍ≤†ÏßÄÎßå Ïã§Ï†ú ÏûÑÏÉÅ Îç∞Ïù¥ÌÑ∞Í∞Ä Ïó¨ÏÑ±Ïù¥ ÎÇ®ÏÑ±Î≥¥Îã§ 2Î∞∞ Îçî ÎßéÏù¥ Ï∞∏Í∞ÄÌñàÎãµÎãàÎã§. Í∑∏ÎûòÏÑú Ïó¨ÏÑ±Ïù¥ Îçî ÎπÑÎßåÏóê ÎßéÏù¥ Îπ†ÏßÄÎäîÍ±¥Í∞Ä? ÏïÑÎãàÎ©¥ Ïôú Ïó¨ÏÑ±Ïù¥ ÎßéÏù¥ Ï∞∏Í∞ÄÌñàÏßÄ? ÎùºÎäî ÏßàÎ¨∏Ïù¥ ÏÉùÍ∏∏ Ïàò ÏûàÍ≤†ÏßÄÎßå Ï†ÄÌù¨ ÏûÖÏû•ÏóêÏÑúÎäî ÎÇ®ÏÑ± Ïó¨ÏÑ± ÎπÑÏú®Ïù¥ Ïö∞Î¶¨Í∞Ä Î™©Ï†ÅÌïú

Ïñ¥Îñ§ ÏßàÎ≥ë Í∞ôÏùÄ Í≤ΩÏö∞Ïóê Ïñ¥Îñ§ ÌÉÄÍ≤üÌåÖ ÌïòÎäî ÎåÄÏÉÅ Í∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî ÌïúÏ™Ω ÏÑ±Ïóê ÏπòÏö∞Ïπ† Í∞ÄÎä•ÏÑ±Ïù¥ ÏûàÎäîÎç∞ Í∑∏ Î™©Ï†ÅÏóê ÎßûÍ≤å ÎßûÏ∂îÏÖîÏïº Îê† Í≤É Í∞ôÍ≥† ÏöîÏÉà Ï†úÍ∞Ä Ï§ÄÎπÑÌïú, Ïû¨Î∞åÍ≤å ÎßåÎì†Í±∞Îäî Ï††Îçî Ïù¥Ïäà Ï§ëÏóêÏÑú ÎßåÏïΩÏóê Î∞îÏù¥Ïò¨Î°úÏßÄÏπº Ï††ÎçîÌïòÍ≥† ÏûêÍ∏∞ ÏÉùÍ∞ÅÌïòÎäî Ï††ÎçîÍ∞Ä Îã§ Îã¨ÎûêÏùÑÎïå ÏàòÏà†ÏùÑ ÌÜµÌï¥ÏÑú Î∞îÎÄî Ïàò ÏûàÎäî Í≤ΩÏö∞Îäî Ïñ¥ÎñªÍ≤å Ìï† Í±∞ÎÉêÏóê ÎåÄÌïú Í≥†ÎØºÎèÑ Ìïú Î≤à Ï†ïÎèÑÎäî Ï†ÄÌù¨Í∞Ä ÎÇòÏ§ëÏóêÎäî ÌïòÍ≤å ÎêòÏßÄ ÏïäÏùÑÍπå

ÎßàÏßÄÎßâ, Ï†úÍ∞Ä ÏóêÏñ¥ Ï™ΩÏùò ÎßàÏßÄÎßâ Î∂ÄÎ∂ÑÏù∏Îç∞Ïöî, Îçî ÌÅ¨Í≤åÎäî Î¨∏Ï†úÎäî ÏóÜÏúºÏã§ Í≤É Í∞ôÏïÑÏöî.

Ï†ÄÌù¨Í∞Ä Ï°∞Í∏àÏùÄ Ìä∏Î†åÎìúÎ•º Î≥¥ÏÖîÏïº Ìï† Í≤É Ï§ë ÌïòÎÇòÍ∞Ä ÏßÄÍ∏à ÏòõÎÇ†Î≥¥Îã§Îäî Ïù¥Î†áÍ≤å ÌûàÏä§Ìå®Îãâ ÏãúÏ≤≠Ìï¥Ï£ºÏÖîÏÑú Í∞êÏÇ¨Ìï©ÎãàÎã§.

Í∑úÎ™®Í∞Ä Î≥¥Ïù¥Í∏∞ ÎïåÎ¨∏Ïóê Îç∞Ïù¥ÌÑ∞ ÎÇ¥ÏóêÏÑú Ïù∏Ï¢Ö Í∞ÑÏùò Î∞∏Îü∞Ïä§ÍπåÏßÄ ÎßûÏ∂∞Ïïº ÌïúÎã§Í≥† ÏÉùÍ∞ÅÌï©ÎãàÎã§. ÎëêÎ≤àÏß∏Îäî ÎåÄÎ∂ÄÎ∂Ñ ÌïúÏù∏Ïù¥ÏãúÍ∏∞ ÎïåÎ¨∏Ïóê Ïù∏ÏÇ¨Îäî ÌïòÍ≤å Îê† Ïàò ÏûàÍ∏∞ ÎïåÎ¨∏Ïóê Î≥¥ÌÜµ ÌïúÏù∏Ïù¥ Ïö¥ÏòÅÌïòÎäî Îã•ÌÑ∞Ïò§ÌîºÏä§Ïóê Í∞ÄÏÑú ÎßéÏù¥ ÌïòÏã§Í±∞ÏóêÏöî. Í∑∏Îü¨Î©¥ LCP

Í∑∏Í±∞Ïóê ÎåÄÌïú ÎîîÌéúÏä§ÎèÑ Í≥†ÎØºÌïòÏÖîÏïº Ìï©ÎãàÎã§. Í∑∏ÎûòÏÑú Í∞ÄÎä•ÌïòÏãúÎ©¥ÏùÄ Î≠ê Ìï†Ïù∏ Î∂ÄÏù∏ Îòê ÌïòÏã§ ÏàòÎèÑ ÏûàÍ≤†ÏßÄÎßå Í∞ÄÎä•ÌïòÏãúÎ©¥ÏùÄ

ÎÑ§, Í∑∏ÎûòÏÑú ÏïûÏóê ÎßêÏîÄÎìúÎ¶∞ Í≤É Í∞ôÏù¥ ÏûÑÏÉÅÏ§ÄÎπÑÎ•º ÎßéÏù¥ ÌïòÏãúÎã§ Î≥¥Î©¥ ÎêòÍ≤å Í∂ÅÍ∏àÌïúÍ≤å ÎßéÏúºÏã§Í±∞ÏóêÏöî. ÎÑ§, Ïù¥Îü∞ Î™®ÏûÑÏùÑ ÌÜµÌï¥ÏÑú Ï†ÄÌù¨Í∞Ä ÎãµÏùÑ Î∞õÏùÑ Ïàò ÏûàÏßÄÎßå Í∞ÄÏû• ÏâΩÍ≥† ÌôïÏã§Ìïú Î∞©Î≤ïÏùÄ Ï¢Ä ÏãúÍ∞ÑÏùÄ 70Î∂Ñ Ï†ïÎèÑ Í±∏Î¶¨ÏßÄÎßå Í∞ÄÏû• ÌôïÏã§Ìïú Î∞©Î≤ïÏùÄ

Ï†ÄÎèÑ ÏßÄÍ∏à 5DD Ï†úÏ∂úÌï†ÎïåÎäî E-STAR Î≤ÑÏ†ÑÏùÑ ÎßéÏù¥ Ïù¥Ïö©ÌïòÍ≥† ÏûàÍ≥† ÎòêÎäî Q-SERVE Ìï†ÎïåÎäî ÌîÑÎ¶¨-E-STAR Î≤ÑÏ†ÑÏùÑ ÎßéÏù¥ Ïù¥Ïö©ÌïòÍ≥† ÏûàÎäîÎç∞Ïöî. Í∞ÄÏû• Ï¢ãÏùÄ Ï†êÏùÄ ÏòõÎÇ†Í∞ôÏùÄ Í≤ΩÏö∞ Ìå©Ïä§ Î≥¥ÎÇ¥Í≥†, Î™©ÌëúÎ≥¥ÎÇ¥Í≥†, Ï±Ö Ïç®Í∞ÄÏßÄÍ≥† Î≥¥ÎÇ¥Í≥†, ÌÅ¥Î¶¨Ïñ¥ ÎêúÎã§Îäî Í±∞ Îã§ ÌïòÎ©¥ÏÑú ÏßÑÌñâÏùÑ ÌñàÏóàÎäîÎç∞, Í∞ÄÏû• Ïâ¨Ïö¥Í±∞Îäî Í∑∏ ÌîÑÎ°úÏÑ∏Ïä§Î•º Î™∞ÏûÖÌï† Ïàò ÏûàÎäîÍ≤å ÎÑàÎ¨¥ Ï¢ãÍ≥†. ÎëêÎ≤àÏß∏Îäî Í∑∏ ÌÖúÌîåÎ¶øÏïàÏóê Ïï†ÌîåÎ¶¨ÏºÄÏù¥ÏÖòÏùò sÎãµÏù¥ ÏûàÎäî ÏöîÍµ¨ÌïòÍ≥† ÏûàÎäî Î¶¨ÌÄòÏù¥Î®ºÌä∏Í∞Ä ÌïòÎÇòÏî© Îã§ Îì§Ïñ¥ÏûàÏäµÎãàÎã§. Í∑∏Í±∏ Î≥¥Îã§ Í∑∏ Í∞ÅÏùÑ Ïì∞ÏãúÎ©¥ÏÑú Î≥¥Îã§Î≥¥Î©¥ÏùÄ

Ï†ïÌôïÌïòÍ≤å FBAÏóêÏÑú Î¶¨ÌîåÎ†àÏù¥ Ìï† ÏàòÍ∞Ä ÏûàÍ≥† Ï†ÄÌù¨Í∞Ä Í∑∏Í±∏ Î≥¥Î©¥ÏÑú Îπ†ÏßÑ Î∂ÄÎ∂Ñ ÏóÜÏù¥ ÏãúÍ∞ÑÏùÑ Ïûò ÎÇÆÏ∂ú Ïàò ÏûàÎäî ÌîåÎû´ÌèºÏúºÎ°ú ÏÇ¨Ïö©Ìï† Ïàò ÏûàÏùÑ Í≤É Í∞ôÏäµÎãàÎã§. Í∞ÄÎä•ÌïòÏãúÎ©¥ Ïù¥Ïä§ÌÉÄÎÇò Ìä∏Î¶¨Ïä§ÌÉÄÎ•º ÏÇ¨Ïö©ÌïòÏãúÎ©¥ Í∞ÄÏû• Ï¢ãÏùÄ Î∞©Î≤ïÏûÖÎãàÎã§.

Îã§ÌÅêÎ©òÌÑ∞Î¶¨Î•º Ï†úÍ∞Ä ÌîÑÎ¶∞Ìä∏ Ìï† ÌïÑÏöîÍ∞Ä ÏóÜÏäµÎãàÎã§. Ïñ¥Îñ§ Í≤ΩÏö∞ÏóêÎäî Î°úÏö∞ Îç∞Ïù¥ÌÑ∞Í∞Ä ÏóëÏÖÄÏù¥ÎÇò ÌïòÎã§Î≥¥Î©¥ Î™áÍ∞úÏî© ÎêòÎäîÎç∞Ïöî. Í∑∏Í±∞ Í∞ñÍ≥† ÏûàÎäî Í≤ÉÏù¥ ÏâΩÏßÄ ÏïäÍ±∞Îì†Ïöî. Í∑∏ÎÉ• Í∑∏Í±∞ Î≥¥ÎÇ¥Îäî Í≤ÉÎèÑ ÏâΩÏßÄÍ∞Ä ÏïäÏùÄÎç∞. ÏÉàÌï¥ Î≥µ ÎßéÏù¥ Î∞õÏúºÏãúÍ≥†, ÌûòÎì†Îç∞ Ï†ÄÎäî Ï†ïÎßê ÏòàÏÅòÍ≤å Í∞êÏÇ¨ÌïòÍ≥† ÏûàÏäµÎãàÎã§. ÎÑàÎ¨¥ Ïûò ÏñòÍ∏∞Ìï¥Ï£ºÏÖîÏÑú Í∞êÏÇ¨Ìï©ÎãàÎã§.

ÏßÄÍ∏àÍπåÏßÄ ÎßêÏîÄÎìúÎ¶∞ Í≤É Í∞ôÏù¥ Ï†ÄÎèÑ Ïñ¥Îñ§ FDA ÏÑ±Í≥µ Ï†ÑÎûµÏóê ÎåÄÌï¥ÏÑú Ï†ïÌôïÌïòÍ≤å AÏûÖÎãàÎã§, ÎßêÏîÄÌï¥Ï£ºÏÖ®ÏßÄÎßå

ÌöåÏÇ¨Î≥ÑÎ°ú Í∑∏ Î™©Ï†ÅÏóê ÎßûÍ≤å Ï§ÄÎπÑÌï† ÏàòÎ∞ñÏóê ÏóÜÎã§ ÎùºÍ≥† Ï¢Ä ÎßêÏîÄÎìúÎ¶¨Í≥† Ïã∂Í≥†

Îëê Í∞ÄÏßÄ Ï†ïÎèÑÎäî Ï¢Ä ÎßêÏîÄÎìúÎ¶¨Í≥† Ïã∂ÏäµÎãàÎã§. Ìïú Í∞ÄÏßÄÎäî

ÏãúÏ≤≠Ìï¥Ï£ºÏÖîÏÑú Í∞êÏÇ¨Ìï©ÎãàÎã§.

ÎëêÎ≤àÏß∏Îäî ÎØ∏Íµ≠ÏùÑ ÎåÄÌëúÌï† Ïàò ÏûàÎäî ÏãúÏÑ± Îç∞Ïù¥ÌÑ∞Í∞Ä ÎÇòÏôÄÏïºÏßÄÎßå ÌÅ¨Í≤å Î¨∏Ï†úÏóÜÏù¥ ÏäπÏù∏ Î∞õÏúºÏã§ Ïàò ÏûàÎäî Í≤É Í∞ôÏäµÎãàÎã§.

Ïó¨Í∏∞ÍπåÏßÄ Ï§ÄÎπÑÌï¥ Ï£ºÏÖîÏÑú Í∞êÏÇ¨Ìï©ÎãàÎã§.

</details>

---

## 3. JungYoup Han

| | |
|---|---|
| ‚è∞ | **02:00 PM ~ 02:20 PM** |
| üè¢ | CSO Target Health, Treasurer KAMDA |
| üìå | "FDA Preparation and Approval Strategy (CRO)" |

---

### Summary

#### ÎØ∏Íµ≠ ÏãúÏû•Ïùò Ï§ëÏöîÏÑ±
- Í∏ÄÎ°úÎ≤å ÏùòÎ£åÍ∏∞Í∏∞ ÏãúÏû• ÏïΩ $500B, ÎØ∏Íµ≠ ÏãúÏû•Ïù¥ 40-45% Ï†êÏú†
- ÌïúÍµ≠ ÏãúÏû•ÏùÄ 1.6%Ïóê Î∂àÍ≥º
- FDA ÏäπÏù∏ = Í∏ÄÎ°úÎ≤å ÏãúÏû• Ï†ëÍ∑ºÏùò ÌïµÏã¨ Ïó¥Ïá†

#### FDAÏùò ÏùòÎ£åÍ∏∞Í∏∞ Í∑úÏ†ú Í¥ÄÏ†ê
- 21 CFR 820 Quality System Regulation (QSR)
- Í∑úÏ†úÎäî Ïû•Î≤ΩÏù¥Ïûê Í∏∞Ìöå - FDA Í∞ÄÏù¥ÎìúÎùºÏù∏ÏùÄ ÏÉÅÏÑ∏Ìïú Î∞©Ìñ• Ï†úÏãú
- ÏùòÎ£åÍ∏∞Í∏∞ Í∑úÏ†úÎäî Î≤ïÎ•† Í∏∞Î∞ò - Ï†ïÌôïÌûà Îî∞ÎùºÏïº Ìï®

#### FDA ÏäπÏù∏ Ï§ÄÎπÑ Ï†ÑÎûµ
- **Reverse Planning**: ÏÉÅÏö©ÌôîÎ∂ÄÌÑ∞ Ïó≠ÏàúÏúºÎ°ú Í≥ÑÌöç
- Îëê Í∞ÄÏßÄ ÌïÑÏàò ÌïÑÎü¨: Quality(Ï†úÏ°∞) + Regulation(Í∑úÏ†ú)
- **Pre-submission ÎØ∏ÌåÖ**: Îß§Ïö∞ Ï§ëÏöîÌïòÍ≥† Í∞ïÎ†•Ìïú Ï†ÑÎûµ
- Î™®Îì† Ïù¥Ìï¥Í¥ÄÍ≥ÑÏûê Í≥†Î†§: ÏÇ¨Ïö©Ïûê, ÌÖåÏä§ÌÑ∞, Íµ¨Îß§Ïûê, ÏãúÏÑ§, Î≥¥Ìóò

#### Î¨∏ÏÑúÌôî ÏöîÍµ¨ÏÇ¨Ìï≠
- **"Î¨∏ÏÑúÌôîÎêòÏßÄ ÏïäÏùÄ Í≤ÉÏùÄ Î∞úÏÉùÌïòÏßÄ ÏïäÏùÄ Í≤É"**
- Development ÏãúÏûëÎ∂ÄÌÑ∞ Design Control ÏãúÏûë
- Gap Analysis: ÌöåÏÇ¨ Î¨∏ÏÑú vs FDA ÏöîÍµ¨ÏÇ¨Ìï≠ ÎπÑÍµê

#### ÌîºÌï¥Ïïº Ìï† Ïã§Ïàò
- Î™ÖÌôïÌïú Regulatory Pathway ÏóÜÏù¥ Í∞úÎ∞ú ÏãúÏûë
- Design Control ÏóÜÏù¥ Îç∞Ïù¥ÌÑ∞ ÏàòÏßë
- Îç∞Ïù¥ÌÑ∞ Traceability Î∂ÄÏ°±
- FDA ÏûÑÏÉÅ ÏãúÌóò Ïã§Ìå®Îäî ÌÅ∞ ÌÉÄÍ≤©

#### Action Items
- [ ] Ï†úÌíà ÎîîÏûêÏù∏ Ï¥àÍ∏∞Î∂ÄÌÑ∞ FDA Ï†ÑÎûµ Í≥†Î†§
- [ ] Design Control Î¨∏ÏÑúÌôî ÏöîÍµ¨ÏÇ¨Ìï≠ Ï§ÄÏàò
- [ ] Gap Analysis ÏàòÌñâ
- [ ] Pre-submission ÎØ∏ÌåÖ Í≥ÑÌöç
- [ ] Reimbursement Ï†ÑÎûµ Ï¥àÍ∏∞Î∂ÄÌÑ∞ Í≥ÑÌöç

---

### Slides

#### Slide 1-3
![page_001](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_001_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_002](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_002_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_003](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_003_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

**ÏöîÏïΩ**
> Ïò§Îäò Ïª§Î≤ÑÌï† Í±¥ Ï≤´Î≤àÏß∏ Ïôú ÎØ∏Íµ≠ ÎßàÏºìÏù∏Í∞Ä, FDAÍ∞Ä ÏùòÎ£åÍ∏∞Í∏∞Î•º Î∞îÎùºÎ≥¥Îäî Í¥ÄÏ†êÏù¥ Î¨¥ÏóáÏù∏Í∞Ä, Í∑∏Í±∏ Ï∂©Ï°±ÌïòÍ∏∞ ÏúÑÌï¥ÏÑú Î≠ò Ìï¥Ïïº ÎêòÎäêÎÉêÏûÖÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

ÎÑàÎ¨¥ Ïûò Ï§ÄÎπÑÌï¥ Ï£ºÏÖîÍ∞ÄÏßÄÍ≥† Ïñ¥ÎñªÍ≤å Ìï¥Ïïº Îê†ÏßÄ Î™®Î•¥Í≤†ÎÑ§Ïöî.

Ï†úÎ™©ÏùÄ FDA ÌîÑÎûúÏª§Î¶¨ÏÖò Í∏ÄÎ°úÎ≤å Ïä§ÌÖåÏù¥ÎçîÏßÄ ÎØ∏Íµ≠ ÎßàÏºìÏùÑ ÏúÑÌï¥ÏÑú Ïù¥Î†áÍ≤å ÏûëÏÑ±ÌñàÏäµÎãàÎã§.

Ïû•ÎåÄÌëúÎãòÍªòÏÑúÎäî Ïã§Ï†úÎ°ú Ïù¥Îü∞ ÏùòÏã¨ÏÉÅÏùÑ Ìï¥Î≥¥Îã§ Í∑∏ ÏùòÎØ∏Î•º Í∞ÄÎìùÏùÑ Ìï† Îïå Ïù¥Ï†ú Ïã§ÌóòÏã§ÏóêÏÑú Ïù¥Î†áÍ≤å Ïñ¥ÎäêÎ∂ÑÍªòÏÑú Ïù¥ Í≤∞Í≥ºÎ¨ºÏùÑ Í∞ÄÏßà Îïå Ïñ¥Îñ§ ÌåÅÎì§ÏùÑ ÎßêÏîÄ ÎìúÎ†∏ÎäîÎç∞Ïöî. ÍµâÏû•Ìûà Ï¢ãÏùÄ ÏÇ¨ÎûåÏù¥ Îê©ÎãàÎã§. ÏÇ¨Ïã§ Í∑∏Îü∞ Í≤ÉÎì§Ïù¥ ÍµêÍ≥ºÏÑúÏóê Ïïà ÎÇòÏôÄ ÏûàÎäî Í±∞Îùº ÏàòÏö© ÏïàÏ†ïÏ†ÅÏù¥ÎùºÍ≥† Í∞ÄÎ•¥Ïπ† Ïàò ÏóÜÎäî Í≤É Í∞ôÏïÑÏöî. ÎÑ§, Í∑∏Îü∞ ÌåÅÎì§Í≥º ÎçîÎ∂àÏñ¥ÏÑú FDAÍ∞Ä Î∞îÎùºÎ≥¥Îäî Í¥ÄÏ†êÏóê Ïö∞Î¶¨Í∞Ä

ÏãúÏû•ÏóêÏÑú Ïñ¥ÎñªÍ≤å Ï†ëÍ∑ºÌï¥Ïïº ÎêòÎäêÎÉêÎ•º Ï¢Ä Í∞úÏ≤ôÏùÑ ÌïòÍ≥†Ïöî. Í∑∏Î¶¨Í≥† Ïã§Ï†úÎ°ú Ïª§ÎÆ§ÎãàÏºÄÏù¥ÏÖòÏù¥ Í∞ÄÏû• ÌÅ∞ Ïù¥ÏäàÏûñÏïÑÏöî. Î™á Í∞úÎ•º Í∞ÄÎ©¥ Í∑∏ Îã§ÏùåÏóî Ïñ¥ÎñªÍ≤å Ìï† Í≤ÉÏù∏Í∞Ä, Í∑∏ Îã§ÏùåÏóî Ïñ¥ÎñªÍ≤å Ìï† Í≤ÉÏù∏Í∞Ä Í∑∏Îü∞ Í≤ÉÎì§ÏùÄ Ïò§ÌõÑ ÏÑ∏ÏÖòÏóê Í≥ÑÏÜç ÎÇòÏò¨ ÏòàÏ†ïÏù∏Îç∞ Í∑∏Îü∞ Í≤ÉÎì§ÏùÑ Ï¢Ä Îçî ÏÉùÍ∞ÅÌï¥ Î≥º Ïàò ÏûàÎäî ÏãúÍ∞ÑÏùÑ

Í∑∏ÎûòÏÑú Ïò§Îäò Ïª§Î≤ÑÎ•º Ìï†Í∫ºÎäî Ï≤´Î≤àÏß∏, Ïôú ÎØ∏Íµ≠ ÎßàÏºìÏù∏Í∞Ä, ÎØ∏Íµ≠Ïù¥ Í∞úÏù∏ ÎïÖÏù¥Í≥†

FDAÍ∞Ä Ïö∞Î¶¨ ÏùòÎ£åÍ∏∞Íµ¨Î•º Î∞îÎùºÎ≥¥Îäî Í¥ÄÏ†êÏù¥ Î≠°ÎãàÍπå?

Îã§Ïãú ÌïúÎ≤à ÏÑ§Î™ÖÏùÑ ÎìúÎ¶¨Í≥† Ïã§Ï†úÎ°ú Ïö∞Î¶¨Í∞Ä Í∑∏ Î¶¨ÌååÎÖ∏Î•º Î∞ãÌïòÍ∏∞ ÏúÑÌï¥ÏÑúÎäî Î≠ò Ìï¥Ïïº Îê©ÎãàÍπå Ïù¥Îü∞ Í≤ÉÎì§ÏùÑ Ï¢Ä Îçî ÎåÄÌôîÏùò Ï™ΩÏúºÎ°ú ÎßêÏîÄÏùÑ ÎìúÎ¶¨Í≤†ÏäµÎãàÎã§.

ÎãπÏó∞Ìûà Ïö∞Î¶¨ Î≥¥Ìò∏Î≥ëÏõêÏùÄ Ïã§Ï†úÎ°ú US ÎßàÏºìÏóê Îì§Ïñ¥Í∞ÄÍ∏∞ ÏúÑÌï¥ÏÑú FTAÍ∞Ä Ï≤´Î≤àÏß∏ Î∞òÏùëÏù¥ Îê†ÌÖêÎç∞ Í∑∏Í±∏ Ïñ¥ÎñªÍ≤å Îã¨Î†§Îì§ Ïàò ÏûàÏùÑÏßÄ Ïã§Ï†úÎ°ú... ÌîÑÎ†àÏûÑÏõåÌÅ¨Î•º ÎßåÎì§Ïñ¥ÏÑú Í±∞Í∏∞Ïóê ÌïòÎÇòÏùò Ï≤¥ÌÅ¨Î¶¨Ïä§Ìä∏Ï≤òÎüº Í∑∏Î†áÍ≤å ÎêòÍ≤å Ï¢ãÍ≤†Îã§ÎäîÍ≤å Ï†ú Î∞òÏùëÏûÖÎãàÎã§. Ïù¥Î†áÍ≤å ÏóºÎëêÏóê Í¥ÄÎ†®Ìï¥Í∞ÄÏßÄÍ≥† ÌïòÎ©¥ Ïù¥Ï†ú ÌöåÏÇ¨Ïóê Í∞ÄÎ©¥ ÌÜ°ÏùÑ ÌïòÎäî 4ÏãúÍ∞ÑÏßúÎ¶¨ ÌîÑÎ°úÍ∑∏Îû®ÏùÑ ÎßåÎì§Í∏∞ÎèÑ ÌïòÍ≥† Ìïú 8ÏãúÍ∞Ñ Ï†ïÎèÑ Ïù¥ÌãÄÏóê Í±∏Ï≥êÏÑú Ïù¥Î†áÍ≤å ÌñàÎäîÎç∞ Ïò§ÎäòÏùÄ 20Î∂Ñ ÎÇ¥Ïóê ÍµâÏû•Ìûà Îπ†Î•¥Í≤å Ï£ºÎßê ÌôòÏÉÅÏãùÏúºÎ°ú ÏßÄÎÇ¥ÎèÑÎ°ù ÌïòÍ≤†ÏäµÎãàÎã§.

</details>

#### Slide 4-6
![page_004](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_004_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_005](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_005_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_006](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_006_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

**ÏöîÏïΩ**
> Í∏ÄÎ°úÎ≤å ÎßàÏºìÏùÄ Ìïú 5Î∞± ÎπåÎ¶¨Ïñ∏ Ï†ïÎèÑ ÎêòÎäîÎç∞ ÎØ∏Íµ≠Ïù¥ 40-45%Î•º Ï∞®ÏßÄÌï©ÎãàÎã§. ÎØ∏Íµ≠ÏùÄ Í∞ÄÏû• ÌÅ∞ Ïã±Í∏Ä ÎßàÏºìÏûÖÎãàÎã§. FDAÎ•º ÌÜµÍ≥ºÌïòÎ©¥ Ï†ÑÏÑ∏Í≥Ñ Î∞îÏù¥Ïñ¥Îì§Ïù¥ Ïã±Í∏Ä Ïï°ÏÑ∏Ïä§Î°ú Î≥º Ïàò ÏûàÏäµÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

ÎãπÏó∞Ìûà Ïª§Î∏åÏÖÄÎü¨Ïùò ÌÇ§Ï£†. Í∏ÄÎ°úÎ≤å ÎßàÏºìÏùÄ Ìïú 5Î∞±.. Í∑∏.. 120Î∞∞Î¶¨ÏïÑ Ï†ïÎèÑ ÎêòÎäî ÎßàÏºìÏù∏Îç∞ Ï†ÑÏ≤¥ Í∑∏..

Í≥ÑÏÜç ÎäòÏñ¥ÎÇòÍ≥† Ìà¨Îü∞Ïù¥ Îñ†Ïò§Î•¥Îäî Í≤É Í∞ôÍ≥†, Ìà¨Î¶¨Î¶¨Ïñ∏ÏùÑ Î¥êÏïº ÎêòÎäî Í≤É Í∞ôÏïÑÏöî. Í∑∏ Ï§ëÏóê Îß•Îçî ÎîîÎ∞îÏù¥Ïä§Îäî Ï†ÑÏ≤¥Ï†ÅÏúºÎ°ú Ìïú 6%Ïùò ÏßÄÏó∞ÏùÑ Í∞ÄÏßÄÍ≥† ÏûàÏäµÎãàÎã§. Í∑∏Ï§ëÏóê Ïö∞Î¶¨ÎÇòÎùº ÎßàÏºìÏù¥ Ìïú 1.6% Îê©ÎãàÎã§. Í∑∏ÎûòÎèÑ ÎßéÏù¥ ÎäòÏñ¥ÎÇúÍ±∞Ï£†. 5ÎÖÑÏ†ïÎèÑÎßå 1%Í∞Ä ÎêêÏäµÎãàÎã§. ÏßÄÏó≠Ï†ÅÏù¥Í±∞ÎÇò ÎßàÏºìÏÇ¨Ïù¥Ï¶à ÎïåÎ¨∏Ïóê Ïö∞Î¶¨ÎÇòÎùºÏóêÏÑúÎßå Í∑∏ ÎîîÎ∞îÏù¥Ïä§Í∞Ä ÌÉàÎùΩÌïòÍ∏∞ÏóêÎäî ÏÑúÏä§ÌÖåÏù∏ ÌïòÎèÑÎ°ù ÌïòÏûê. Í∑∏ÎûòÏÑú ÎãπÏó∞Ìûà ÎØ∏Íµ≠ÏãúÏû•ÏúºÎ°ú Í∞ÄÏïº Îê©ÎãàÎã§. ÎØ∏Íµ≠ÏãúÏû•ÏùÄ Í±∞Ïùò Ï†Ñ Ïù∏ÎçîÏä§Ìä∏Î¶¨Ìä∏ Î∂ÑÏïºÏóêÏÑú 40%Îäî 45% Ï†ïÎèÑÏùò Ïâ¨Î£åÎ•º Í∞ÄÏßÄÍ≥† ÏûàÍ≥†Ïöî. Í∑∏Î¶¨Í≥† Í∞ÄÏû• ÌÅ∞, Ïù¥Í≤å ÍΩ§ Ï§ëÏöîÌïúÎç∞ Ïã±Í∏Ä ÎßàÏºìÏûÖÎãàÎã§. Ïã±Í∏Ä ÎßàÏºì. Ï†ÄÍ≤å Í∞ÄÏû• ÌÅ∞ Í±¥Îç∞.

Ïã±Í∏Ä ÎßàÏºìÏù¥ÎùºÎäî ÏùòÎ£åÍ∏∞Í∏∞ÎäîÏöî. ÏùòÎ£åÍ∏∞Í∏∞Îäî Ïñ¥Îñ§ ÎπÑÏ¶àÎãàÏä§ÎÉê. Ïö∞Î¶¨Í∞Ä ÌòÅÏã† ÎπÑÏ¶àÎãàÏä§. Ïù¥ FDAÎ•º ÌÜµÍ≥ºÌïòÎ©¥ Ï†ÑÏÑ∏Í≥ÑÏùò Î∞îÎãàÏãúÏû•ÏùÑ Í∑∏ÎÉ• Ïã±Í∏Ä Ïï°ÏÑ∏ÏÑúÎ¶¨Î°ú Î≥¥Îäî Í±∞ÏòàÏöî. ÌïúÍµ≠Îßå ÌÜµÍ≥ºÌïòÎ©¥ Ï†ÑÏÑ∏Í≥Ñ Î∞îÎãàÏãúÏû•Ïóê Ïï°ÏÑ∏ÏÑúÎ¶¨.

Ïù¥Î†áÍ≤å ÎßéÏù¥ Îì§Ïñ¥Í∞ëÎãàÎã§. ÏÇ¨ÎπÑÏóêÏù¥ÏÖò ÎßûÏ∂∞Í∞ÄÏßÄÍ≥† Í∑∏Îü∞ÏãùÏúºÎ°ú ÎßéÏù¥ Îì§Ïñ¥Í∞ÄÏ£†. Í∑∏ÎûòÏÑú Ïù¥ Îã®ÏùºÏãúÏû•Ïóê Îì§Ïñ¥Í∞ÄÎäî Í∞ÄÏû• ÌÅ∞ Îã®ÏùºÏãúÏû•Ïóê Îì§Ïñ¥Í∞ÄÎäî Í∑∏ÎÉ• ÏÑúÎ°ú ÏßÑÍ≤ÄÏäπÎ∂ÄÎ•º ÌïòÍ∏∞ ÎïåÎ¨∏Ïóê Í∏ÄÎ°úÎ≤å Ïä§ÌÉ†Îã§ÎìúÎßå ÏÇ¨ÎäîÍ≤å ÌïµÏù¥ Í∏∞Ïö∏Ïñ¥Í∏∞ ÏãúÏûëÌï¥Ïöî Í∑∏ Ïó¨Îü¨Î∂ÑÎì§Ïù¥ ÎßêÏîÄÌïòÏÖ®ÏßÄÎßå Ïã§Ï†úÎ°ú ÎØ∏Íµ≠ÏùÄ Ïñ¥ Î†àÎπåÎ†àÌÜ†Î¶¨ÎèÑ Í∑∏Î†áÏßÄÎßå ÎßàÏºì ÏûêÏ≤¥ÎèÑ Ïñ¥Îîî Í∑∏Îü¨ÎãàÍπå Ï£ºÎßêÏù¥Îûë Îã§Î•¥Íµ¨Ïöî. Î†àÎπåÎ†à, Í∑∏ Îç§Ïù¥ Îã§Î•¥Ï£†. Í∑∏ÎûòÏÑú Ïñ¥ÎîîÎ°ú Îì§Ïñ¥Í∞àÍ±∞ÎÉê Ïù¥Î†áÍ≤å.

ÏóêÏÑú ÎØ∏Íµ≠ÏùÑ ÌéòÎÑ∑Ìä∏Î¶≠ ÌïòÏãúÎäî ÌöåÏÇ¨Îì§Ïù¥ ÎØ∏Íµ≠ Ï†ÑÏ≤¥Î•º Î≥¥Í≥† Ïó¨Í∏∞ Ïó¨Í∏∞ Ïó¨Í∏∞ Ïù¥Î†áÍ≤å ÌïòÎäîÍ±∞ÏóêÏöî.

Ïù∏ÌÑ∞ÌéòÏù¥Ïä§Í∞Ä ÏûàÎã§ÎçòÏßÄ, Ïï±Ïù¥ ÏûàÏúºÎ©¥ Ïù¥Î†áÍ≤å ÎêúÎã§ÎçòÏßÄ, Ïó¨Í∏∞ Î°úÏª¨Ïóê ÏôÄÏÑúÎäî Ïó¨Í∏∞ Î°úÏª¨ÏóêÎßå Î∞îÍøîÏïº ÎêòÏ£†. Í∑∏Îü∞ Í≤ÉÎì§Ïù¥ ÎßéÏù¥ Ï§ëÏöîÌï©ÎãàÎã§. ÎãπÏó∞Ìûà ÌÅ¥Î¶¨Î≤ÑÎ†àÏù¥ÌÑ∞ÌïòÍ≥† ÌååÌä∏ÎÑàÏã≠Ïù¥ Ïó¨Í∏∞ÏÑú Ï∞æÎäîÍ≤å ÎÑàÎ¨¥ Ï§ëÏöîÌïòÏ£†. ÎØ∏Íµ≠ÏùÄ Í∞úÎ≥Ñ Ïã†Ïû•, ÎÇ¥Í∞Ä ÎîîÎ∞îÏù¥Ïä§ÎùºÎãàÍπå, ÎÇ¥Í∞Ä Î∞õÏùÄ ÎîîÎ∞îÏù¥Ïä§ÎùºÎãàÍπå Ïñ¥ÎîîÍ∞ÄÏÑú ÏßÅÏ†ë ÏòÅÏóÖÏùÑ ÌïòÎäî Í≤ÉÏùÄ Í±∞Ïùò Ïñ¥Î†µÏ£†. ÌÉë5ÎÇò ÌÉë10 ÎîîÏä§Ìä∏Î¶¨Î∞çÏù¥ Í∑∏ Ï†ÑÏ≤¥Î•º Í∞ÄÏßÄÍ≥†

</details>

#### Slide 7-12
![page_007](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_007_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_008](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_008_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_009](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_009_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_010](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_010_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_011](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_011_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_012](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_012_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

**ÏöîÏïΩ**
> Ïª§Î®∏ÏÖúÎùºÏù¥Ï†úÏù¥ÏÖòÏùÑ ÏúÑÌï¥ÏÑúÎäî Technology & InnovationÏù¥ Í∏∞Î≥∏Ïù¥Í≥†, Îëê Í∞ÄÏßÄ ÌïÑÎü¨Í∞Ä ÏûàÏäµÎãàÎã§: Manufacturing(Quality)Í≥º Regulation(Compliance). Î¨∏ÏÑúÌôîÍ∞Ä ÏóÜÏúºÎ©¥ Í∑∏ ÏùºÏùÄ Ïïà ÏùºÏñ¥ÎÇú Í≤ÅÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Ïù¥Í≤å Í∑∏ ÏÇ¨ÏóÖÏûêÎì§ÌïòÍ≥† Î≥ëÏõêÏÇ¨ÏóÖÏûêÎì§ÌïòÍ≥† ÏûàÎäî

Ïú†Ïä§Ìè∞ÏÖÄÎùºÏù¥Ï†úÏù¥ÏÖòÏùÄ Í∞ÄÏû• Ï§ëÏöîÌïúÍ≤å ÎãπÏó∞Ìûà ÌÖåÌÅ¨ÎÜÄÎ°úÏßÄÍ∞Ä Îê† Ïàò ÏûàÎã§Í≥† ÏÉùÍ∞ÅÌï©ÎãàÎã§. ÏôúÎÉêÎ©¥ ÌÉùÏ°∞ÏûÖÏùÄ ÎßàÏºìÏù¥ÎãàÍπåÏöî. Í∑∏Î¶¨Í≥† Ï≤´Î≤àÏß∏ Î∞©Ìñ•Ïù¥ Î†àÍ∑§Î†àÌÜ†Î¶¨Ïù¥Í∏∞ ÎïåÎ¨∏Ïóê Ïù¥ ÏãúÏûÖÎãàÎã§.

ÎßêÏîÄÌïòÏãúÎäî Í≤ΩÏö∞Í∞Ä ÎßéÏïÑÏöî. Í∑ºÎç∞ Î¨ºÎ°† Í∑∏Îü∞ Î©¥ÎèÑ ÏûàÏäµÎãàÎã§. ÏûàÎäîÎç∞ ÏÇ¨Ïã§ Ïù¥ Î†àÍ∑§Î†àÏù¥ÏÖòÏù¥ÎùºÎäî Í≤ÉÏùÄ Ïñ¥Îñ§ ÌïòÎÇòÏùò Î≤ΩÎèÑ Îê† Ïàò ÏûàÏßÄÎßå Í∏∞ÌöåÎèÑ Îê† Ïàò ÏûàÏñ¥Ïöî. Ï≤´Î≤àÏß∏Îäî Í∑∏ Î≤ΩÏù¥ ÏûàÎäîÎç∞ Î≤ΩÏùÑ ÎÑòÍ∏∞Îßå ÌïòÎ©¥ ÏïÑÍπå ÎßêÏîÄÎìúÎ¶∞ÎåÄÎ°ú 40% 50% Ï†ïÎèÑ Ï†ÑÏÑ∏Í≥Ñ ÏãúÏû•Ïóê ÎêòÎäî Îã®Ïùº ÎßàÏºìÏóê Ï†êÌïëÌï† Ïàò ÏûàÎã§Îäî Í≤É, Ïù¥Í≤å Ï≤´Î≤àÏß∏Í≥†Ïöî. ÎëêÎ≤àÏß∏Îäî ÏÇ¨Ïã§ÏùÄ FDAÍ∞Ä ÏûêÏÑ∏Ìûà Î≥¥Î©¥ Ïö∞Î¶¨ÌïúÌÖå, Îß•Ïª§Îãà ÏôÄÏù¥Ïä§ Îß§ÎãàÌéúÏÖòÌïúÌÖå Í∞à Í∏∏ÏùÑ ÏïåÎ†§Ï£ºÍ≥† ÏûàÎäî Í≤ÅÎãàÎã§. Í∑∏ÎãàÍπå Î™®Ï∞ΩÏö∞ ÏÑ†ÏÉùÎãòÏù¥ ÏñòÍ∏∞ÌïòÏÖ®ÏßÄÎßå Í∑∏Îü∞ Í∏∏Îì§ÏùÑ Í∞ÄÏù¥ÎìúÎùºÏù∏Ïóê ÎêòÍ≤å ÏûêÏÑ∏Ìïú Í≤å Ï£ºÍ≥† ÏûàÏñ¥Ïöî.

Í∑∏Î¶¨Í≥† Í∑∏ Îã§ÏùåÏóê Ïñ¥ Ïò§ÏºÄÏù¥ ÎÇ¥Í∞Ä Ïñ¥ Ï†ÄÍ∏∞

Í∑∏Î†áÍ≤å ÌïòÎäî Í≤ÉÎ≥¥Îã§ Ïù¥Í≤å Í±∞Ïùò ÌéòÎ°úÎ¶¨ÏïàÏù¥ ÌïòÎäîÍ≤å ÎßûÏäµÎãàÎã§ Ï≤òÏùåÏóê Ïõ®Ïù¥ÌÅ¥ ÎîîÎ∞îÏù¥Ïä§Î•º ÎîîÏûêÏù∏ÌïòÎäî Í≤ÉÎ∂ÄÌÑ∞ ÎÇ¥Í∞Ä Ïù¥Í±∏ Í∞ÄÏßÄÍ≥† Ïñ¥Îñ§ ÏóêÏñ¥Î¶¨Ìä∏ÎßÅÏùÑ Ìï† Í±∞ÏòàÏöî?

Ï∞∞ Ïàò ÏûàÍ≤†ÎäîÍ∞Ä? Í∑∏Îü¨Î©¥ Ïù¥Í≤å Ïñ¥Îñ§ ÏãùÏúºÎ°ú ÏûÑÌîåÎ°úÏä§Î•º Í∞ÄÍ≥† ÎÇ¥Í∞Ä Ïñ¥ÎñªÍ≤å ÏàòÏùµÏùÑ Í∞ÄÏßÄÍ≥† ÏûàÍ≤†ÎäîÍ∞Ä? Ïù¥Îü∞ Í≤ÉÎì§ÏùÑ Ïù¥Ï†ú Í∞ñÍ≤å ÎêòÎÑ§Ïöî. Í∑∏Îü∞ Í≤ÉÎì§ÏùÑ ÎØ∏Î¶¨ ÏÉùÍ∞ÅÏùÑ Ìï¥Ïïº Îê©ÎãàÎã§. Î¶¨Î≤ÑÏä§ Î®∏ÎãàÍ∞Ä Ïôú Ï§ëÏöîÌïòÏ£†? ÎãπÏó∞Ìûà Ï§ëÏöîÌïòÏ£† Î¶¨Î≤ÑÏä§ Î®∏Îãà Í∑∏Îüº Í±∞Í∏∞ÏÑú ÎèàÏù¥ ÎÇòÏò§ÎãàÍπå

Í∑ºÎç∞ Î≥¥Î©¥ Ïù¥ Î©îÎîîÏπ¥Îìú ÎîîÎ∞îÏù¥Ïä§ ÏãúÏû•ÏùÄ Îã§Î•∏ ÌÅ¨Î£®Ïä§Î©î ÏãúÏû•Í≥º Îã§Î•¥Í≤å Ïù¥ Ïä§ÌÖåÏù¥ Í≥®ÎìúÎì§Ïù¥ ÏóÑÏ≤≠ ÎßéÏäµÎãàÎã§. ÎãπÏó∞Ìûà Î≠ê..

Ïä§ÌÖåÏù∏Î∂àÎìúÎ•òÎäî Ïã§Ï†úÎ°ú Í∑∏ ÎîîÎ∞îÏù¥Ïä§Î•º TVÎÇò Ï∞®Î•º ÏÇ∞Îã§. ÎÇ¥Í∞Ä ÌùâÎÇ¥Í≥† ÎÇ¥Í∞Ä Î°úÎ¥áÏùÑ Î∞õÏïÑÏÑú Ïò§Í±∞Îì†Ïöî.

Î≠ê Í∑∏Îü∞Í±∞Ï£†. Í∑ºÎç∞ Ïù¥ ÎîîÎ∞îÏù¥Ïä§ Î∂ÄÎ∂ÑÏùÄ Ïù¥ Ï°∞Ìï© Ïù¥Îü¨Î©¥ÏùÄ

Ïù¥ ÎîîÎ∞îÏù¥Ïä§Ïùò ÏÇ¨Ïö©Ïûê, ÎîîÎ∞îÏù¥Ïä§Î•º ÌÖåÏä§Ìä∏ÌïòÎäî ÎåÄÏÉÅÏûê, ÎîîÎ∞îÏù¥Ïä§Î•º Ïã§Ï†úÎ°ú Í∞ÄÎ∂ÄÎäî, ÌÖåÏä§Ìä∏ÌïòÎäî Í∑∏ Ï†úÌíàÏóê Ïù¥ Ï†úÌíàÏù¥ÎùºÎì†ÏßÄ Î∞îÎÄêÎã§Îì†ÏßÄ Í≤∞Ï†ïÌïòÎäî ÏÇ¨Îûå Í∑∏ Îã§ÏùåÏóê Í∑∏ Ï†úÌíàÏù¥ ÏÇ¨Ïö©ÎêòÎäî Í≥≥ Í∑∏Î¶¨Í≥† Í∑∏Í±∞Î•º Ìè¨Í¥ÑÌïòÎäî Í∞ÄÎ∞úÎûÄÏä§ Ïù¥Î†áÍ≤å Îã§ Îã§Î¶ÖÎãàÎã§. Í∑∏ÎûòÏÑú ÎàÑÍµ¨Ïùò ÎàÑÍµ¨Ïùò Í≤∞Ï†ïÎèÑ ÏôÑÏ†ÑÌïòÎã§Í≥† Ìï† ÏàòÎäî ÏóÜÏßÄÎßå ÎàÑÍµ¨Ïùò Í≤∞Ï†ïÎèÑ Î¨¥ÏãúÌïúÎã§Í≥† Ìï† ÏàòÍ∞Ä ÏóÜÏñ¥Ïöî. Ïä§ÌÖåÏù¥ Í≥®ÎìúÍ∞Ä ÎÇ´Îã§, Ïä§ÌÖåÏù¥ Í≥®ÎìúÍ∞Ä. Ïù¥Í±∏ Î∞òÎìúÏãú Ìï¥Ïïº ÎêòÏûñÏïÑÏöî. Í∑∏ÎûòÏÑú ÎÇ¥Í∞Ä Ï†úÌíà ÎîîÏûêÏù∏ Ìï† ÎïåÎèÑ ÏïÑ, Ïù¥ Ï†úÌíàÏùÄ Îû© Ï†úÌíàÏù¥Í≥†, ÎîîÎ∞îÏù¥Ïä§Í≥†, Ïö∞Î¶¨ Îû©ÏóêÏÑú Ïì∞ÎãàÍπå ÎàÑÍµ¨ÌïúÌÖå Ï¢ãÍ≤å ÎîîÏûêÏù∏ÏúºÎ°ú, ÏÑ§Î™ÖÏÑúÎèÑ

Í∑∏ Îã§ÏùåÏóê Í∞ÄÍ≤©ÎèÑ Ïù¥Î†áÍ≤å Î¥êÎèÑ ÎêòÏßÄÎßå Îòê Îã§Î•¥Í≤å Ïã§Ï†úÎ°ú Íµ¨Îß§ÌïòÎ†§Îäî Î≥ëÏõê Î∞ñÏóê ÏûàÏûñÏïÑÏöî. Í∑∏ Ïä§ÌÖåÏù¥ÌîåÎì§Ïùò Ïù¥ÏïºÍ∏∞Îì§ÏùÑ ÎßéÏù¥ Îì§Ïñ¥Ïïº Ìï©ÎãàÎã§. Í∑∏ÎûòÏÑú ÎîîÏûêÏù∏Ìï† ÎïåÎ∂ÄÌÑ∞ Ïù¥Í±∞Î•º ÏÉùÍ∞ÅÌï¥Ïïº ÎêúÎã§ÎùºÎäî Í±∏ Íº≠ ÎßêÏîÄÎìúÎ¶¨Ï£†. Í∑∏Î†áÏßÄ ÏïäÏúºÎ©¥ Îã§ ÎßåÎì§Í≥† ÎÇòÏÑú Îòê Îã§Ïãú Ìï¥ÏïºÎêòÎäî Í≤ΩÏö∞Í∞Ä Ï†úÍ∞Ä Ïó¨Îü¨ Î≤à Î≥∏ Ï†ÅÏù¥ ÏûàÏäµÎãàÎã§. Í∑∏ÎûòÏÑú Ïù¥Í≤å Ïù¥Î†áÍ≤å ÎßêÌï† Ïàò ÏûàÎäîÎç∞ FDAÏùò Ïä§Ìä∏Î†àÏ†ÄÎ•º Ï≤òÏùåÎ∂ÄÌÑ∞ ÏÉùÍ∞ÅÌïòÎäî Í≤É, Ïù¥Í≤å Í∞ÄÏû• Ï§ëÏöîÌïòÎã§. Ïù¥Î†áÍ≤å ÎßêÏîÄÎìúÎ†∏Ï£†. Î¶¨Î≤ÑÏä§, Î¶¨Î≤ÑÏä§Îûë Ïª¥Ìì®ÌÑ∞Í∞Ä Ïñ¥ÎñªÍ≤å ÏõÄÏßÅÏù¥ÎäîÍ∞ÄÎ•º Î≥¥ÏïòÏäµÎãàÎã§.

Í∑∏Î†áÍ≤å ÎßêÏîÄ ÎìúÎ†∏ÏäµÎãàÎã§. Ïûê Í∑∏Îü¨Î©¥ FDA preparation approval Ìï† Îïå Ïã§Ï†úÏ†ÅÏúºÎ°ú Î≠êÍ∞Ä Ï§ëÏöîÌïòÍ≥† Ïôú Ïù¥Í±∏ Ìï¥Ïïº ÎêúÎã§ Ïù¥Îü∞ Í≤ÉÎì§ÏùÑ Ïû†Íπê Ïù¥Ï†ú Ï£ºÌô©ÏÉâ

ÎãπÏó∞Ìûà Ï†ÄÌù¨Ïùò Î™©ÌëúÎäî Í∏ÄÎ°úÎ≤å Ïª§Î®∏ÏÖúÎùºÏù¥Ï†ÄÏù¥ÏÖòÏûÖÎãàÎã§. Ïª§Î®∏ÏÖúÎùºÏù¥Ï†ÄÏù¥ÏÖòÏùÑ ÌïòÍ∏∞ ÏúÑÌï¥ÏÑúÎäî Î™®Îì† Í∏∞Ïà†Îì§ÏùÄ Í∏∞Î≥∏Ïù¥ ÌÖåÌÅ¨ÎÜÄÎ°úÏ¶àÏôÄ Ïù¥ÎÖ∏Î≤†Ïù¥ÏÖòÏù¥ Í∏∞Î≥∏Ïù¥ Îê©ÎãàÎã§. Î™®Îì† Í∏∞Î∞òÏóêÏÑú ÌÖåÌÅ¨ÎÜÄÎ°úÏ¶à. Í∑∏Î†áÏ£†. ÎÇ¥ Ï†úÌíàÏù¥ ÎîîÌçºÎü∞Ïã±, ÌÖåÌÅ¨ÎÜÄÎ¶¨ÏßÄ ÏôÄÏù¥Ïä§ ÎîîÌçºÎü∞Ïã±ÏùÑ Ìï©ÎãàÎã§. Ïó¨Í∏∞ÏÑú Ïª§Î®∏ÏÖúÎùºÏù¥Ï†úÏù¥ÏÖòÏúºÎ°ú Ïó∞Í≤∞Ìï† Îïå Ïù¥Í±∏ Ïñ¥ÎñªÍ≤å ÌïòÎäêÎÉê, Ïù¥Í≤å Ïù¥Ï†ú ÌÇπÏù∏Îç∞Ïöî. Îëê Í∞ÄÏßÄ ÌïÑÎü¨Í∞Ä ÏûàÏäµÎãàÎã§. ÌïòÎÇòÎäî Îß§ÎãàÌå®ÌÇπ ÌïÑÎü¨, ÌïòÎÇòÎäî Î†àÍ∑§Î†àÏù¥ÏÖò ÌïÑÎü¨Í∞Ä ÏûàÏäµÎãàÎã§. Îß§ÎãàÌå®ÌÇπÏùÑ ÌÜµÌï¥ÏÑú ÌÄÑÎ¶¨Ìã∞Î•º Ìà¨ÏûÖÌïòÍ≥†Ïöî. Î†àÍ∑§Îü¨ÏÖòÏùÑ ÌÜµÌï¥ÏÑú Í∑∏ ÎÇòÎùº, Í∑∏ Ï†ïÏ±Ö, ÌòπÏùÄ Í∑∏ Ïù∏ÎçîÏä§Ìä∏Î¶¨Ïóê Í∞êÏóºÎêú Ïª¥ÌîåÎùºÏù¥Ïñ∏Ïä§Î•º ÌïÑÏöîÎ°ú Ìï©ÎãàÎã§.

Ïù¥ ÎëêÍ∞ÄÏßÄÍ∞Ä Í∏∞Îä• Ïû†ÏãúÎßåÏöî Ïù¥ ÎëêÍ∞ÄÏßÄÎ•º Ïñ¥ÎñªÍ≤å Ìï† Í≤ÉÏù¥ÎÉê Ïù¥Í≤å Ïù¥Ï†ú Ï†ÄÌù¨Îì§Ïùò Í≥µÏù∏Ïù¥ ÎêòÎäîÍ±∞Ï£†

Ï≤òÏùåÏóê ÎßàÎ£®ÌÖçÏù¥ÎÇò Ïä§ÌÉÄÎìúÏóÖÏù¥ÎÇò Ï†ÑÎ∂Ä Îã§ Ïù¥ÎÖ∏Î≤†Ïù¥ÏÖòÏù¥ ÏûàÍ≥† ÌÖåÌÅ¨ÎÖ∏ÎèÑ ÏûàÍ≥† Ï†ÄÎèÑ Ïä§ÌÉÄÎìúÏóÖÏùÑ ÏòàÏ†ÑÏóê

ÏóëÏãúÏä§ Ìï† Í≤ΩÌóòÏù¥ ÏûàÎäîÎç∞ Í∑∏ÎïåÎäî Ïûò Î™∞ÎûêÎçò Í≤É Í∞ôÏïÑÏöî. ÌÖåÌÅ¨ÎÖ∏Î≤†Ïä§ÏôÄ SMÎèÑ Ïù¥Í±∞ ÎßåÎì§Î©¥ ÎÑàÎ¨¥ Ï¢ãÏùÄÎç∞ Ïù¥Í±∏ Ïôú Ïïà ÏÇ¥Íπå Ïù¥ ÏÉùÍ∞ÅÏùÑ ÌïòÎäîÍ±∞ÏóêÏöî. ÏÇ¨Ïã§ÏùÄ Ïù¥Ï†ú ÎßàÏºìÏù¥ Í∑∏Î†áÍ≤å ÎèåÏïÑÍ∞ÄÏßÑ ÏïäÍ≥† Í∑∏Í±∞Îäî ÎÇ¥Í∞Ä ÎÇ¥Í∞Ä ÎÇò Ï¢ãÏúºÎùºÍ≥† ÌïòÎäî Í±¥Îç∞ Í∑∏Í≤å ÏïÑÎãàÎùº Ïö∞Î¶¨Í∞Ä Ïª§Î®∏ÏäêÎùºÏù¥Ï¶àÎ•º ÏÉùÍ∞ÅÌïòÎ†§Í≥† ÌïòÎ©¥ ÎëêÍ∞ÄÏßÄÎ•º ÏôÑÏÑ±Ìï¥ÏïºÌï©ÎãàÎã§. Í∑∏Í≤å ÌÄÑÎ¶¨Ìã∞ÎùºÎäî Í≤ÉÏûÖÎãàÎã§. ÌÄÑÎ¶¨Ìã∞Îäî ÌçºÌè¨Î®ºÏä§ÏûÖÎãàÎã§. ÎãπÏó∞Ìûà ÏûàÏñ¥Ïïº Ìï©ÎãàÎã§.

ÎßéÏù¥ ÏûàÎäîÎç∞Ïöî? ÌïòÏó¨Ìäº Ïó¨Í∏∞ Ïù¥Í≤å ÏûàÏäµÎãàÎã§. Í∑∏Îü¨Î©¥ ÏöîÍµ¨Î•º ÌïòÍ∏∞ ÏúÑÌï¥ÏÑú

Ï†úÍ∞Ä ÎßêÏîÄ ÎìúÎ¶∞ Ïù¥Ïú†Îäî FAAÎäî Îß•ÎèÖ Î¶¨Î∞îÏù¥Ïä§Îäî ÌäπÎ≥ÑÌûà 21 CFR 820, 800 Ïù¥Í≤ÉÏùò Í∞íÏùÑ ÎåÄÏÉÅÏúºÎ°ú 21Ïù¥ ÏΩîÎìú Ïò§Î∏å Ìå®Îü¨Îîî Î†àÍ∑§Î†àÏù¥ÏÖò Ïù¥ÎùºÎ©¥ ÌóåÎ≤ïÏóêÏÑúÎ∂ÄÌÑ∞ Ï†ïÎ∂ÄÍ∞Ä Ï°∞ÏßÅÏù¥ Ïñ¥ÎñªÍ≤å ÎêúÎã§Í≥† ÏãúÏûëÏùÑ Ìï¥ÏÑú 21Î≤àÏß∏ ÌååÏù¥Îì§Ïóê ÌõàÏï§ÎìúÎ°úÍ∑∏ÎùºÎäî Î≤ïÏù¥ Í∑∏Ï§ëÏóê Ïó¨Îü¨Í∞ÄÏßÄ Í≤ÉÎì§Ïù¥ ÏûàÎäîÎç∞ 800Î≤àÏ†ïÎèÑ ÎêòÎ©¥ 800Î≤àÏóê HÎùºÍ≥† ÎêòÏñ¥ÏûàÎäîÎç∞ Í±∞Í∏∞Ïóê medical deviceÍ∞Ä ÏûàÎã§.

ÏïÑ Í∑∏ÎûòÏÑú Ïù¥Ï†ú Í∑∏ 800Î≤àÏù¥ Î©îÎîîÏª¨ ÎîîÎ∞îÏù¥Ïä§ÏòÄÍ∏∞ ÎïåÎ¨∏Ïóê 800Î≤àÏóêÏÑúÎèÑ 820Î≤àÏù¥ ÌÄÑÎ¶¨Ìã∞ ÏãúÏä§ÌÖú Î†àÍ∑§Î†àÏù¥ÏÖò QSRÏù¥ÎùºÍ≥† ÌïòÎäîÍ±∞Ï£†. Ïù¥Î†áÍ≤å Îê©ÎãàÎã§. Ï†úÍ∞Ä Ïù¥ ÎßêÏîÄÏùÑ ÎìúÎ¶¨ÏûêÎ©¥ Î©îÎîîÌÅ¥ ÎîîÎ∞îÏù¥Ïä§Î•º Í∞êÏïàÌïòÎäî Í≤ÉÏùÄ Î≤ïÏù¥ÎùºÎäî Í≤ÅÎãàÎã§.

Ïù¥Í≤å Î≠îÍ∞Ä Í±∞Î¶¨ÎùºÎäî Í±¥ ÎùΩÏÇ¨Ïù¥Ïä§Í∞Ä ÏïÑÎãàÏûñÏïÑÏöî. Ïù¥Í≤å Í∑∏ÎÉ• ÏûàÎäî Í∑∏ÎåÄÎ°ú Îî∞ÎùºÍ∞ÄÏÑú Ïù¥Í±∞Î•º Î∞ë ÌïòÎ©¥ÏÑú Îã§Í∞ÄÍ∞ÄÎäî Í±∞ÏòàÏöî.

Í∑∏ÎûòÏÑú ÎîîÏûêÏù∏ Ïª®Ìä∏Î°§ÏùÑ Ïñ¥ÎñªÍ≤å ÌïòÎäîÍ∞ÄÍ∞Ä ÌÅ¨Í≤å, ÌäπÌûà Ïö∞Î¶¨Í∞ôÏùÄ Î©îÌÉà ÎîîÎ∞îÏù¥ÏÑ†ÏóêÏÑú ÍµâÏû•Ìûà Ï§ëÏöîÌï©ÎãàÎã§. QnAÌïòÍ≥† ÎîîÏûêÏù∏ÌïòÍ≥† ÎîîÏûêÏù¥ÎÑàÌïòÍ≥† ÎîîÏûêÏù∏ Î¶¨Î∑∞, Ïï†ÌîåÎ¶¨ÏºÄÏù¥ÏÖò, Î≤†Î¶¨ÎÑ§Ïù¥ÏÖò, Ìä∏ÎûúÏä§ÌååÏõå Ï≤¥Ïù∏ÏßÄÌïòÍ≥† DHF Ïù¥Îü∞Í≤ÉÎì§ÏùÄ Í∑∏ ÏïÑÎ©îÎ¶¨Ïπº Ïä§ÌÑ∞Îîî, IDEÍ∞ôÏùÄ Í≤ΩÏö∞Îäî Ïù¥Í≤ÉÏùÄ Ìï∏ÎìúÏª®ÏÖâÏ∏°Ïù¥ÎûÄ, Ïù¥Í±∏ Ïã§Ï†úÎ°ú ÏûÑÌîåÎ¶¨Î©òÌä∏Î°ú Ìï¥ÏïºÎêòÎäî Í≤ÉÏûÖÎãàÎã§.

</details>

#### Slide 13-20
![page_013](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_013_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_014](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_014_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_015](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_015_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_016](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_016_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_017](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_017_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_018](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_018_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_019](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_019_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_020](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_020_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

**ÏöîÏïΩ**
> Pre-submissionÏù¥ Ï†ïÎßê Ï†ïÎßê Ï§ëÏöîÌï©ÎãàÎã§. ÍµâÏû•Ìûà ÌååÏõåÌíÄÌïòÍ≥† Ïù∏ÏÉÅÏ†ÅÏù∏ Î∞©Î≤ïÏûÖÎãàÎã§. Gap AnalysisÎ•º ÌÜµÌï¥ ÌöåÏÇ¨ Î¨∏ÏÑúÏôÄ FDA ÏöîÍµ¨ Î¨∏ÏÑú Í∞ÑÏùò Í∞ÑÍ≤©ÏùÑ Î¥êÏïº Ìï©ÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

FDÏóêÏÑú ÏñòÍ∏∞ÌïòÎäî Í≤ÉÏùÄ Î¶¨ÏÑúÏπòÍ∞Ä Ï§ëÍ∞ÑÏóê Í∞ÄÍ≥† ÎîîÎ≤®Î°≠Ïù¥ ÏãúÏûëÌï† Îïå, Í∑∏Îïå, Í∑∏ÎïåÍ∞Ä DHCFÍ∞Ä ÏãúÏûëÌïòÎäî Í±∞ÏóêÏöî. ÎîîÎ≤®Î°≠Ïù¥ÎùºÎäî Í≤å Î∞òÎìúÏãú. Í∑∏ÎûòÏÑú Î¶¨ÏÑúÏπòÎ•º Ìïú Îã§ÏùåÏóê ÎîîÎ≤®Î°≠Ïù¥ Îì§Ïñ¥Í∞ÑÎã§Îäî Ïù¥ÏïºÍ∏∞ ÏûêÏ≤¥Í∞Ä ÎîîÏûêÏù∏ Ïù∏ÌíãÏù¥ ÎÇòÏò§Í≥†Ïöî, ÎîîÏûêÏù∏ ÌîÑÎ°úÌÜ†ÏΩúÏù¥ ÎÇòÏò§Í≥†, ÎîîÏûêÏù∏ Í≤∞Í≥ºÍ∞Ä ÎÇòÏòµÎãàÎã§. Í∑∏ ÏñòÍ∏∞ÎãàÍπå, Í∑∏ ÎïåÎ∂ÄÌÑ∞ Î∞òÎìúÏãú ÎßåÎì§Ïñ¥Ïïº ÎêúÎã§.

Í∑∏ÎûòÏÑú Î≠ê Ïù¥Îü∞ Ïó¨Îü¨Í∞ÄÏßÄ Í≤ÉÎì§Ïù¥ÎÇò Ïù¥Îü∞ Îã§ÌÅêÎ©òÌÑ∞Î¶¨ÎèÑ ÎßåÎì§Í≥†

Ï†úÍ∞Ä ÌïòÎ©¥ 4ÏãúÍ∞ÑÏóêÏÑú 8ÏãúÍ∞ÑÏßúÎ¶¨ ÌîÑÎ°úÍ∑∏Îû®ÏùÑ Ïù¥Î†áÍ≤å ÎßåÎì§ÏóàÎäîÎç∞Ïöî. Í∑∏ÎûòÏÑú, Í∑∏ÎûòÏÑú Ï≤òÏùåÏóê ÌïòÍ∏∞ Ï†ÑÏóê Ïù¥Îü∞ Í±∞Î•º Îã§... Í±∞ÏπòÍ≥† Ïù¥Í±∞Îäî Ïù¥Ï†ú ÎÇ¥Í∞Ä ÌïòÎäî Í±∞Ïïº. Í∑∏Îü¨ÎãàÍπå Ïö∞Î¶¨ ÌöåÏÇ¨Í∞Ä ÌïòÎäî Í±∞Ïïº, ÌöåÏÇ¨Í∞Ä. Í∑∏ÎûòÏÑú Ìå®Ïä§Í∞Ä ÏûàÎäêÎÉê, Ï£ºÎäêÎÉê, Îì§ÎäêÎÉêÎ•º Î®ºÏ†Ä Í≤∞Ï†ïÌï† Îïå ÎåÄÎ∂ÄÎ∂ÑÏùÄ ÏïÑÎßà Ï£ºÍ≤†Ï£†, ÏÜåÏõêÎìúÎ¶¨Î©¥.

Ïù¥Í±∞Îäî Í∑∏ÎÉ• Îî± Í∞ÄÏù¥Îìú ÎùºÏù∏Ïóê Îã§ ÎÇòÏôÄÏûàÏäµÎãàÎã§. ÌååÏù¥ÌåÖÏùò Í∏∞ÌöåÎ•º Í∞ñÎäêÎÉê, ÌîºÌï¥Ïùò Í∏∞ÌöåÎ•º Í∞ñÎäêÎÉê, ÌååÏù¥ÌåÖÏùò Í∏∞ÌöåÎ•º Í∞ñÎäêÎÉê. ÏïÑÏù¥ÎîîÏñ¥ Í∞ôÏùÄ Í≤ÉÎèÑ ÎêòÍ≤å ÎßéÏù¥ Í∞ÄÍ≥†Ïöî.

Í∑∏ÎûòÏÑú ÏïÑÍπåÎèÑ Ïä§ÎãòÏù¥ ÌîÑÎ¶¨ÏÑúÎØ∏ÏÖò ÏùºÏù¥ ÎêòÍ≤å Ï§ëÏöîÌïòÎã§Í≥† ÌïòÏÖ®ÎäîÎç∞ Ï†ïÎßê Ï†ïÎßê ÌîÑÎ¶¨ÏÑúÎØ∏ÏÖò ÏùºÏù¥ ÎêòÍ≤å Ï§ëÏöîÌï©ÎãàÎã§. ÍµâÏû•Ìûà ÌååÏõåÌíÄÌïòÍ≥† Ïù∏ÏÉÅ ÍπäÏùÄ Î∞©Î≤ïÏù¥ÏóêÏöî.

Ìè¨Î©ÄÌïòÍ∏∞ÎèÑ ÌïòÍ≥†Ïöî. ÌïòÏßÄÎßå Ïù¥Í±∞ Ìï† Îïå ÎÇ¥Í∞Ä Í∞úÎ∞úÏùÑ ÌñàÏùÑ Îïå Ïñ¥Îñ§ ÌöåÏÇ¨Îûë Ïª®Ìä∏Î°§ÏùÑ Ìï¥ÏÑú Í∑∏ ÌöåÏÇ¨Î•º FDÎ°ú Í∞ÄÏ†∏Í∞ÄÍ≤†Îã§Í≥† ÌïòÎ©¥ Í∑∏ ÌöåÏÇ¨Í∞Ä ÏïÑÍπå ÎßêÏîÄÎìúÎ†∏Îçò ÎîîÏûêÏù∏ Ïª®Ìä∏Î°§Ïù¥ Îã§ ÎêêÏùÑÎïå Îã§ÌÅêÎ©òÌä∏Í∞Ä ÎßéÏù¥ ÎÇòÏôîÎäîÎç∞Ïöî, Í∑∏ Îã§ÌÅêÎ©òÌä∏ÏôÄ FDAÍ∞Ä Ïú†ÏùºÌïòÍ≤å ÎßåÎÇ¨ÏùÑÎïåÍ∞Ä ÏûàÏäµÎãàÎã§. ÏöîÍµ¨ÌïòÎäî Îã§ÌÅêÎ©òÌÑ∞Î¶¨ Í∞ÑÏùò Í∞ÑÍ≤©ÏùÑ Î¥ÖÎãàÎã§. Í∑∏ Í∞≠ Î∂ÑÏÑùÏù¥ÎùºÍ≥† ÌïòÎäîÎç∞, Í∑∏ Í∞≠ Î∂ÑÏÑùÏùÑ ÌïÑÎûòÏöî. Í∑∏ Îã§ÏùåÏóê ÌîÑÎ¶∞ÏºìÏùÑ Ï∞æÍ≥†Ïöî. ÌîÑÎ¶∞ÏºìÏùÑ Ï°∞Í∏à Ïù¥Îî∞ ÎßêÏîÄ ÎìúÎ¶¥Í≤åÏöî. ÌîÑÎ¶∞ÏºìÏùÑ Ï∞æÍ≥†, Í∑∏ Îã§ÏùåÏóê ÌÅ¥Î¶¨ÎãàÏª¨ ÌîÑÎ°úÌÜ†ÏΩúÏùÑ

Í∑∏ÎûòÏÑú ÏïÑÍπå Ï†ïÏàòÌñ•Ïù¥ ÌïèÎ≥º ÌååÏù¥ÎÑàÎ°ú Ïó¨Îü¨Í∞ÄÏßÄ ÏºÄÏù¥Ïä§Î•º ÎßêÌñàÎäîÎç∞ Í∑∏Í≤ÉÎì§ÏùÑ ÎØ∏Î¶¨ Îã§ Î∂àÎü¨Îã§ÎÖÄÏöî. Í∑∏ÎûòÏÑú Í∑∏Í≤å Ïù∏ÌÅ¥Î£®ÏÖò ÌÅ¨ÎùºÏù¥ÌÜ†Î¶¨ÌïòÍ≥† ÏùµÏä§ÌÅ¥Î£®ÏÖò ÌÅ¨ÎùºÏù¥ÌÜ†Î¶¨Î•º ÎØ∏Î¶¨ ÎßåÎì§Ïñ¥ ÎÜìÏùÄÍ±∞ÏóêÏöî. Í∑∏Í≤å Ïù¥Ï†ú Ï§ëÏöîÌï©ÎãàÎã§. ÎØ∏Î¶¨ÎØ∏Î¶¨ ÌïúÎã§ÎäîÍ≤å ÏïÑÏ£º Ï§ëÏöîÌïòÏ£†. ÏôúÎÉêÎ©¥ FK Ïä§ÌÑ∞ÎîîÍ∞Ä ÏãúÏûëÏù¥ ÎêòÎ©¥ ÌéòÏù¥ÌÅ¨ ÌïòÎ©¥ Ï†àÎåÄ ÏïàÎê©ÎãàÎã§. Ï†àÎåÄ ÏïàÎèºÏöî. Ï∞®ÎùºÎ¶¨ Î¶¨Ìä∏ÎûôÏùÑ ÌïòÎäîÍ≤å ÎÇ´ÏßÄ. Ìó§ÎìúÎùºÎ©¥ ÍµâÏû•Ìûà ÌÉÄÍ≤©Ïù¥ ÏûàÏñ¥. ÌäπÌûà Ïã∏ÎçïÍ∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî Î∂ÄÏ°±ÌñàÏ£†.

Í∑∏Î¶¨Í≥† ÌïÑÏÇ¥ÏùÄ Î≠ê ÌïòÏó¨Ìäº Ïó¨Í∏∞ÎûëÏùÄ Îπ®Î¶¨ Ïª§ÎÆ§ÎãàÏºÄÏù¥ÏÖò ÌïòÎäîÍ≤å ÏµúÍ≥†Îã§ ÌïòÏßÄÎßå Ïù¥Î†áÍ≤å ÎûúÎç§ ÏßàÎ¨∏ÏùÑ ÎçòÏßÄÎ©¥ Ï†àÎåÄ ÏïàÎêòÍ≥† Í∞ÄÏù¥Îìú ÎùºÏù∏Ïóê Îî∞ÎùºÏÑú ÏûòÌï¥Ïïº Îê©ÎãàÎã§. Í∑∏Î¶¨Í≥† Ïù¥Îü∞Í≤ÉÎì§ÏùÄ ÎãπÏó∞Ìûà Ï§ÄÎπÑÍ∞Ä ÎêòÏñ¥Ïïº ÎêòÍµ¨Ïöî. ÏÇ¨Ïã§ Ïù¥ ÏñòÍ∏∞Î•º Ï¢Ä ÎßéÏù¥ ÎìúÎ¶¨Í≥† Ïã∂ÏùÄÎç∞, ÌîºÌï¥Ïïº Ìï† Î™á Í∞ÄÏßÄÏùò ÎØ∏Ïä§ÌÖåÎ¶¨Í∞Ä ÏûàÏäµÎãàÎã§.

Ï≤òÏùåÏóê ÎîîÎ∞îÏù¥Ïä§Î•º ÎßåÎì§Îïå Ïò§Ï†ÑÏóê ÏµúÏö∞Ï¢Ö ÍµêÏàòÎãòÏù¥ ÎßêÏîÄÌïòÏÖ®ÏßÄÎßå Ï∫îÏÑú Îã§Ïù¥Î≤ÑÎÇòÏä§Ìã±ÏùÑ ÌôàÏºÄÏñ¥Î°ú ÌïúÎã§Í≥†

Í∏∞Ïà†ÏùÄ ÎêòÍ≤†Ï£†. Í∏∞Ïà†ÏùÄ Îê©ÎãàÎã§. ÌïòÏßÄÎßå ÌíÄÎπÑÏºìÏù¥ ÏùºÎã® ÏóÜÍ≥† Ìå®Ìä∏Ïõ®Ïù¥Í∞Ä Ïû°ÌûàÏßÄ ÏïäÏïÑÏöî. Ìå®Ìä∏Ïõ®Ïù¥Í∞Ä ÏóÜÏúºÎ©¥ Í∞à ÏàòÍ∞Ä ÏóÜÏ£†. ÎãπÏó∞Ìûà. Í∏∏Ïù¥ ÏóÜÎäîÎç∞. Í∑∏ÎûòÏÑú Í∏∏ÏùÑ Îßâ ÎàÑÎ†§Ïïº ÎèºÏöî. Í∏∏ÏùÑ ÎßåÎìúÎäî Í∏∏ÎèÑ Ïó¨Îü¨ Í∞ÄÏßÄÍ∞Ä ÏûàÏßÄÎßå ÎÇ®Îì§Ïù¥ Í∞ÄÏßÄ ÏïäÎäî Í∏∏ÏùÑ Íµ≥Ïù¥ Í∞ÄÎ†§Í≥† ÌïòÎäî Í±¥ ÏÉÅÎãπÌûà ÌûòÎì§Ï£†.

Í∑∏ ÎîîÏûêÏù∏Ìï† Í∑∏ ÎîîÎ∞îÏù¥Ïä§Î•º ÎîîÏûêÏù∏Ìï†Í±∞Îã§ Ïù¥Îü¥Îïå ÎßéÏù¥ ÏÉùÍ∞ÅÎÇòÏöî Í∑∏Î†áÍ≤å Ìï¥ÏÑú ÌíÄÏ∫°Ïù¥ Î∞òÎìúÏãú ÏûàÏñ¥ÏïºÎê©ÎãàÎã§. Í∑∏ ÏïÑÍπåÎèÑ ÎßêÏîÄÎìúÎ†∏ÏßÄÎßå

Í∑∏ Î©ÄÌã∞Ìîå Ïª¥ÌîåÎ†âÌÑ∞ÎÇò Î©ÄÌã∞Ìîå ÌîÑÎ†àÎîîÏºìÏù¥ ÌïúÍµ≠ÏùÄ ÎêúÎã§Í≥† Ìï¥Ïöî. Í∑ºÎç∞ ÎØ∏Íµ≠ÏùÄ Ï¢Ä Ïñ¥Î†µÏäµÎãàÎã§. Í∑∏Î¶¨Í≥† ÏÑúÎ∏êÏÖò Îç∞Ïù¥ÌÑ∞Í∞Ä ÎîîÏûêÏù∏ Ïª®Ìä∏Î°§Îü¨Î•º Îî∞Î•¥ÏßÄ ÏïäÎäî Í≤ΩÏö∞Í∞Ä ÎßéÏïÑÏöî. Ï†ÄÎèÑ Í∑∏Îü∞ Í≤ΩÏö∞Í∞Ä ÎßéÏùÄÎç∞, Í∞≠ Î∂ÑÏÑùÏùÑ Ìï† Îïå Í∞ÄÏ†∏Ïò® ÏïÑÎÇ†Î°úÍ∑∏ ÌÅ¨ÎûòÏä§Ìã∞Ïïà Í≤åÏù¥Î∞çÏù¥ ÎêòÍ≤å Ï¢ãÏïòÏñ¥Ïöî.

Í∑∏ÎûòÏÑú Í∑∏Í±∏ Îπ®Î¶¨ ÎßåÎì§Í≥† Ìï¥ÏÑú ÏßÄÎÇòÍ∞ÄÎäîÎç∞ Í≤∞Íµ≠ FDAÍ∞Ä Î≠ò ÏöîÍµ¨ÌñàÎÉêÎ©¥ Í∑∏ Model Comparison, Method Comparison Îç∞Ïù¥ÌÑ∞Í∞Ä Í∑∏Í≤ÉÏùò Ïõê ÏÜåÏä§, Í∑∏Îü¨ÎãàÍπå Î°úÎç∞Ïù¥ÌÑ∞Î•º Îã¨ÎùºÍ≥† ÌïòÎäîÍ±∞Ï£†. Í≤∞Íµ≠ÏóêÎäî Í∑∏ Î©îÏÜåÎìú Ïª¥Ìì®ÌÑ∞Î•º ÌïòÎäî Í∑∏ ÏÉòÌîåÏùò Ìä∏ÎûôÏÑúÎπåÎ¶¨Ìã∞Í∞Ä ÏóÜÏóàÏñ¥Ïöî. ÏôúÎÉê? Í∑∏ Îç∞Ïù¥ÌÑ∞Í∞Ä ÌïúÍµ≠ÏóêÏÑú ÏóÜÏóàÏñ¥Ïöî. ÌïúÍµ≠ÏóêÏÑú ÍµâÏû•Ìûà Ï¢ãÏùÄ Î≥ëÏõêÏóêÏÑú ÌïúÍ±∞ÏóêÏöî ÌïòÏßÄÎßå Í∑∏ Îç∞Ïù¥ÌÑ∞Í∞Ä ÏóÜÏóàÏñ¥Ïöî Ïù¥Í≤å ÏûàÎäîÎç∞ ÎÇº Ïàò ÏóÜÏùÑ Ï†ïÎèÑÏòÄÏñ¥Ïöî.

Í∑∏Î†áÍ≤å ÌñàÏúºÎãàÍπå Í∑∏Î¶¨Í≥† Ïä§ÌÑ∞ÎîîÎ•º ÏãúÏûëÌï†Îïå Î†àÏù¥Ïä§Ïùò Î†àÌîÑÎ¶¨ÏÑºÌã∞Î∏åÌïú Í±∏ Í≥®ÎùºÏïº ÎêòÍ∏∞ ÎïåÎ¨∏Ïóê Ïù¥Í≤å Ïã§Ï†úÏ†ÅÏúºÎ°ú ÏâΩÏßÄÍ∞Ä ÏïäÏïÑÏöî. ÏóÜÎã§Í≥†Îäî ÎßêÌï† ÏàòÎäî ÏóÜÏßÄÎßå Í∑∏Î¶¨Í≥† Ïö∞Î¶¨Í∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî Ìú¥Î®∏Î∞±ÌÑ∞Ïä§ÌÑ∞Î¶¨ÎÇò Ïù¥Îü∞ Í≤ÉÎì§ÎèÑ Í∑∏ÎûòÏÑú Ïù¥Î†áÍ≤å ÌîºÎìúÎ∞±ÏùÑ ÌîÑÎ°úÏï°Ìã∞Î∏îÎ¶¨ Ï§ÄÎπÑÎ•º ÌïòÎäîÍ≤å ÎêòÍ≤å Ï§ëÏöîÌï©ÎãàÎã§. Ï≤òÏùåÎ∂ÄÌÑ∞. Í∑∏ Îã§ÏùåÏóê Îã§ÌÅêÎ©òÌä∏ÎèÑ ÏãúÏä§ÌÖúÏóê Îì§Ïñ¥Í∞ÄÍ≤å. Î™®Îì† Îã§ÌÅêÎ©òÌä∏Í∞Ä Ï†ïÎßê ÎÑàÎ¨¥ Ï§ëÏöîÌï©ÎãàÎã§.

</details>

#### Slide 21-31
![page_021](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_021_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_022](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_022_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_023](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_023_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_024](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_024_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_025](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_025_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_026](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_026_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_027](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_027_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_028](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_028_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_029](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_029_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_030](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_030_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

![page_031](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_031_5._KAMDA_25_Conference_Deck_-_Jay_Han_Deck_25-10-23.jpg)

**ÏöîÏïΩ**
> Í∞ÄÏû• Ï§ëÏöîÌïú ÏÑ±Í≥µ ÏöîÏù∏ÏùÄ Early Stage PlanningÏûÖÎãàÎã§. CommercializationÎ∂ÄÌÑ∞ Ïó≠ÏàúÏúºÎ°ú ÏÉùÍ∞ÅÌïòÎ©¥ÏÑú Ï†úÌíàÏùÑ ÎßåÎìúÎäî Í≤å Î≤†Ïä§Ìä∏ÏûÖÎãàÎã§. Î°úÎìúÎßµÏùÑ Ïû°Îäî Í≤å ÏïÑÏ£º Ï§ëÏöîÌï©ÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Í∑∏Í±∞Ïóê ÏöîÍµ¨Ï°∞Í±¥Ïù¥ Ï≤´Î≤àÏß∏Í∞Ä Early Stage Planning Ïù¥Í±∞Îäî ÏïÑÏòà Îí§ÏóêÏÑúÎ∂ÄÌÑ∞ ÏÉùÍ∞ÅÌïòÎäîÍ≤å Ï¢ãÏ£†. CommercializationÏùÑ ÏúÑÌï¥ÏÑúÎäî Ïñ¥Îñ§ InverseÎ•º ÌïòÍ≥† Í∑∏Îü¨Î©¥ Ïñ¥Îñ§ ÎÑå Ìï¥ÏÑùÏùÑ Ìï†Í±∞ÎÉê?

ÎØ∏Î¶¨ ÏÉùÍ∞ÅÌïòÎ©¥ÏÑú Îß§ Ï†úÌíàÏùÑ Îã§Î£®Í≥† ÎÇòÍ∞ÄÎäîÍ≤å Î≤†Ïä§Ìä∏ÏûÖÎãàÎã§.

FD ÏóêÏñ¥ÌîåÎ°úÍ∑∏Ïùò Î∞òÏùÄ ÏïÑÎãàÏßÄÎßå ÍµâÏû•Ìûà ÌÅ¨Îã§. Ïù¥Í≤ÉÎßå Ï§ÄÎπÑÎ•º ÏûòÌïòÎ©¥ Í∑∏ Îã§ÏùåÏùò Î¶¨Î≤ÑÏä§Í±¥, Ïª®Ïã§Îü¨ÏóêÏù¥Ï†ÄÏÖòÎèÑ ÏïÑÏ£º ÏâΩÍ≤å Í∞à Ïàò ÏûàÎã§. FDI Ïª§ÎÆ§ÎãàÏºÄÏù¥ÏÖò, ÎîîÏä§ÌîåÎ†àÏù¥ÏÖò Ï∞æÎäî Í≤ÉÎèÑ FDIÍ∞Ä ÎÇòÏò¨ Îïå Ï∞æÎäî Í≤å ÏïÑÎãàÎùº Ìõ®Ïî¨ Ï†ÑÎ∂Ä Îã§ Ï∞æÎäî Í≤ÅÎãàÎã§. Í∑∏Î¶¨Í≥† Î¶¨Ïù∏Î≥¥Ïä§ ÎßàÏ∞¨Í∞ÄÏßÄÎ°ú. Í∑∏Îü∞ Í≤ÉÎì§ÏùÑ ÏûêÏú†ÎÇò ÏãúÍ∞ÑÎèÑ ÏûÉÏñ¥Î≤ÑÎ¶¨ÏßÄ ÏïäÍ≥†Ïöî. Í∑∏ Îã§ÏùåÏóê Î©îÏä§ÌÑ∞ ÌéÄÎî©ÎùºÏö¥ÎìúÏóêÏÑúÎèÑ Ïûò Í¥úÏ∞ÆÏùÑ ÏàòÍ∞Ä ÏûàÏäµÎãàÎã§. ÏäπÎ∂ÄÏûëÏù¥ Ïù¥Ïñ¥Ïßà ÏàòÍ∞Ä ÏûàÏ£†. Í∑∏ÎûòÏÑú ÎßàÏºìÌïòÍ≥† Í∞ÄÎäîÍ±∞Îã§.

ÌéúÏùÑ ÏùºÏßÅÌïòÍ≥†, ÏóëÏä§ÌçºÌä∏Î•º ÏÇ¨Ïö©Ìï¥ÏïºÌïòÍ≥†, Ïª§ÎÆ§ÎãàÏºÄÏù¥ÏÖò ÌîÑÎ°úÏï°Ìã∞Î∏åÎ•º Ìï¥ÏïºÌï©ÎãàÎã§. Î¨ºÎ°† Îã§ Í∏∞Î°ùÏùÄ ÎêòÏßÄÎßå, Í∑∏Î¶¨Í≥† Îç∞Ïù¥ÌÑ∞Î•º ÏïÑÏ£º Ï§ëÏöîÏãúÌï¥ÏïºÌï©ÎãàÎã§. Í∑∏ÎûòÏÑú at least in the deep, systematical Ïù¥ÎùºÎäîÍ≤å Ï≤òÏùåÏóê Î°úÎìúÎßµÏùÑ Ïû°ÎäîÍ≤å ÏïÑÏ£º Ï§ëÏöîÌïòÎã§. Í∑∏ ÎßêÏîÄÏùÑ Í∞ïÏ°∞ÎìúÎ¶ΩÎãàÎã§.

ÏïÑ Ïù¥Í≤å Ïù¥Ï†ú ÏµúÍ∑ºÏóê ÏóÖÎç∞Ïù¥Ìä∏Ïù∏Îç∞ Ïó¨Í∏∞ ÏûàÎã§ Í∑∏Î¶¨Í≥†

Í∑∏ ÌÅ∞ Ïú†ÏÑ∏Î®ºÌä∏Îäî LEDÏòÄÏ£†. Í∑∏ Îã§ÏùåÏóê ÏßÄÍ∏àÏùÄ Cybersky LEDÎùºÍ≥† SAMD ÏôÑÏ†ÑÌûà ÏûàÏäµÎãàÎã§.

ÌÉÄÎâ¥Îç∏Ïä§Îäî Ï†ÄÌù¨Îäî Ïù∏ÏÇ¨Î•º Ï£ºÎ°ú ÌïòÎäîÎç∞Ïöî. Ï†ÄÌù¨Îäî Ïù∏Ïñ¥ ÏûÑÏÉÅÏùÑ Ìï† Îïå ÌïÑÏöîÌïú ÏÜåÌîÑÌä∏Ïõ®Ïñ¥Í∞Ä Îî∞Î°ú ÏûàÏäµÎãàÎã§. Í∑∏Í≤å ÏùºÎ†âÌä∏Î°úÎãâ Îç∞Ïù¥ÌÑ∞ Ï∫°ÏäêÏûÖÎãàÎã§.

ÏùºÎ†âÌä∏Î°úÎãâ Îç∞Ïù¥ÌÑ∞ Ï∫°Ï≤ò ÏÜåÌîÑÌä∏Ïõ®Ïñ¥Í∞Ä ÏûàÏäµÎãàÎã§. Îç∞Ïù¥ÌÑ∞Î•º Î≥¥Î©¥ Îç∞Ïù¥ÌÑ∞ÎèÑ ÎßéÏù¥ Îã§Î¶ÖÎãàÎã§. ÎπÑÏ¶àÎãàÏä§ÎèÑ ÌïòÍ≥† Ï†úÏùº Ï§ëÏöîÌïú Í≤ÉÏùÄ ÏñºÎ∞îÏù¥Ìä∏Î¶¨ ÏÑúÎπÑÏä§ÏóêÏÑú ÌïúÍµ≠ÏóêÏÑú ÌòπÏùÄ Îã§Î•∏ ÎÇòÎùºÏóêÏÑú ÎØ∏Íµ≠ÏúºÎ°ú Í∑∏Í±∞ ÏûàÏûñÏïÑÏöî, Ïù¥Ï†ú ÏÖîÎàÑÏùò Í∑∏...

Ìï† Îïå ÌòπÏùÄ ÌöåÏÇ¨Î•º ÏùºÏàòÎåÄÎ°ú Ïú†ÏßÄÌï† Îïå Ï†ÄÎäî ÏùΩÏóàÍ≥†, Í∑∏Î¶¨Í≥† ÎßàÏºÄÌåÖ.

Í∑∏ Îã§ÏùåÏóê Î†àÏù∏Î≥¥Ïö∞Ïä§ÌïòÍ≥† Ïù¥Îü∞ Í≤ÉÎì§ Í≥ÑÏÜç ÏÑ§Î™ÖÌï¥ Ï£ºÏãúÎ©¥ ÏïÑÏ£º Ï¢ãÏùÄ ÌôúÏïΩÏùÑ Í∞ÄÏ†∏Í∞à Ïàò ÏûàÏùÑ Í≤É Í∞ôÏäµÎãàÎã§. Í∞êÏÇ¨Ìï©ÎãàÎã§.

</details>

---

<details>
<summary>üìù Full Transcript</summary>

ÎÑàÎ¨¥ Ïûò Ï§ÄÎπÑÌï¥ Ï£ºÏÖîÍ∞ÄÏßÄÍ≥† Ïñ¥ÎñªÍ≤å Ìï¥Ïïº Îê†ÏßÄ Î™®Î•¥Í≤†ÎÑ§Ïöî.

Ï†úÎ™©ÏùÄ FDA ÌîÑÎûúÏª§Î¶¨ÏÖò Í∏ÄÎ°úÎ≤å Ïä§ÌÖåÏù¥ÎçîÏßÄ ÎØ∏Íµ≠ ÎßàÏºìÏùÑ ÏúÑÌï¥ÏÑú Ïù¥Î†áÍ≤å ÏûëÏÑ±ÌñàÏäµÎãàÎã§.

Ïû•ÎåÄÌëúÎãòÍªòÏÑúÎäî Ïã§Ï†úÎ°ú Ïù¥Îü∞ ÏùòÏã¨ÏÉÅÏùÑ Ìï¥Î≥¥Îã§ Í∑∏ ÏùòÎØ∏Î•º Í∞ÄÎìùÏùÑ Ìï† Îïå Ïù¥Ï†ú Ïã§ÌóòÏã§ÏóêÏÑú Ïù¥Î†áÍ≤å Ïñ¥ÎäêÎ∂ÑÍªòÏÑú Ïù¥ Í≤∞Í≥ºÎ¨ºÏùÑ Í∞ÄÏßà Îïå Ïñ¥Îñ§ ÌåÅÎì§ÏùÑ ÎßêÏîÄ ÎìúÎ†∏ÎäîÎç∞Ïöî. ÍµâÏû•Ìûà Ï¢ãÏùÄ ÏÇ¨ÎûåÏù¥ Îê©ÎãàÎã§. ÏÇ¨Ïã§ Í∑∏Îü∞ Í≤ÉÎì§Ïù¥ ÍµêÍ≥ºÏÑúÏóê Ïïà ÎÇòÏôÄ ÏûàÎäî Í±∞Îùº ÏàòÏö© ÏïàÏ†ïÏ†ÅÏù¥ÎùºÍ≥† Í∞ÄÎ•¥Ïπ† Ïàò ÏóÜÎäî Í≤É Í∞ôÏïÑÏöî. ÎÑ§, Í∑∏Îü∞ ÌåÅÎì§Í≥º ÎçîÎ∂àÏñ¥ÏÑú FDAÍ∞Ä Î∞îÎùºÎ≥¥Îäî Í¥ÄÏ†êÏóê Ïö∞Î¶¨Í∞Ä

ÏãúÏû•ÏóêÏÑú Ïñ¥ÎñªÍ≤å Ï†ëÍ∑ºÌï¥Ïïº ÎêòÎäêÎÉêÎ•º Ï¢Ä Í∞úÏ≤ôÏùÑ ÌïòÍ≥†Ïöî. Í∑∏Î¶¨Í≥† Ïã§Ï†úÎ°ú Ïª§ÎÆ§ÎãàÏºÄÏù¥ÏÖòÏù¥ Í∞ÄÏû• ÌÅ∞ Ïù¥ÏäàÏûñÏïÑÏöî. Î™á Í∞úÎ•º Í∞ÄÎ©¥ Í∑∏ Îã§ÏùåÏóî Ïñ¥ÎñªÍ≤å Ìï† Í≤ÉÏù∏Í∞Ä, Í∑∏ Îã§ÏùåÏóî Ïñ¥ÎñªÍ≤å Ìï† Í≤ÉÏù∏Í∞Ä Í∑∏Îü∞ Í≤ÉÎì§ÏùÄ Ïò§ÌõÑ ÏÑ∏ÏÖòÏóê Í≥ÑÏÜç ÎÇòÏò¨ ÏòàÏ†ïÏù∏Îç∞ Í∑∏Îü∞ Í≤ÉÎì§ÏùÑ Ï¢Ä Îçî ÏÉùÍ∞ÅÌï¥ Î≥º Ïàò ÏûàÎäî ÏãúÍ∞ÑÏùÑ

Í∑∏ÎûòÏÑú Ïò§Îäò Ïª§Î≤ÑÎ•º Ìï†Í∫ºÎäî Ï≤´Î≤àÏß∏, Ïôú ÎØ∏Íµ≠ ÎßàÏºìÏù∏Í∞Ä, ÎØ∏Íµ≠Ïù¥ Í∞úÏù∏ ÎïÖÏù¥Í≥†

FDAÍ∞Ä Ïö∞Î¶¨ ÏùòÎ£åÍ∏∞Íµ¨Î•º Î∞îÎùºÎ≥¥Îäî Í¥ÄÏ†êÏù¥ Î≠°ÎãàÍπå?

Îã§Ïãú ÌïúÎ≤à ÏÑ§Î™ÖÏùÑ ÎìúÎ¶¨Í≥† Ïã§Ï†úÎ°ú Ïö∞Î¶¨Í∞Ä Í∑∏ Î¶¨ÌååÎÖ∏Î•º Î∞ãÌïòÍ∏∞ ÏúÑÌï¥ÏÑúÎäî Î≠ò Ìï¥Ïïº Îê©ÎãàÍπå Ïù¥Îü∞ Í≤ÉÎì§ÏùÑ Ï¢Ä Îçî ÎåÄÌôîÏùò Ï™ΩÏúºÎ°ú ÎßêÏîÄÏùÑ ÎìúÎ¶¨Í≤†ÏäµÎãàÎã§.

ÎãπÏó∞Ìûà Ïö∞Î¶¨ Î≥¥Ìò∏Î≥ëÏõêÏùÄ Ïã§Ï†úÎ°ú US ÎßàÏºìÏóê Îì§Ïñ¥Í∞ÄÍ∏∞ ÏúÑÌï¥ÏÑú FTAÍ∞Ä Ï≤´Î≤àÏß∏ Î∞òÏùëÏù¥ Îê†ÌÖêÎç∞ Í∑∏Í±∏ Ïñ¥ÎñªÍ≤å Îã¨Î†§Îì§ Ïàò ÏûàÏùÑÏßÄ Ïã§Ï†úÎ°ú... ÌîÑÎ†àÏûÑÏõåÌÅ¨Î•º ÎßåÎì§Ïñ¥ÏÑú Í±∞Í∏∞Ïóê ÌïòÎÇòÏùò Ï≤¥ÌÅ¨Î¶¨Ïä§Ìä∏Ï≤òÎüº Í∑∏Î†áÍ≤å ÎêòÍ≤å Ï¢ãÍ≤†Îã§ÎäîÍ≤å Ï†ú Î∞òÏùëÏûÖÎãàÎã§. Ïù¥Î†áÍ≤å ÏóºÎëêÏóê Í¥ÄÎ†®Ìï¥Í∞ÄÏßÄÍ≥† ÌïòÎ©¥ Ïù¥Ï†ú ÌöåÏÇ¨Ïóê Í∞ÄÎ©¥ ÌÜ°ÏùÑ ÌïòÎäî 4ÏãúÍ∞ÑÏßúÎ¶¨ ÌîÑÎ°úÍ∑∏Îû®ÏùÑ ÎßåÎì§Í∏∞ÎèÑ ÌïòÍ≥† Ìïú 8ÏãúÍ∞Ñ Ï†ïÎèÑ Ïù¥ÌãÄÏóê Í±∏Ï≥êÏÑú Ïù¥Î†áÍ≤å ÌñàÎäîÎç∞ Ïò§ÎäòÏùÄ 20Î∂Ñ ÎÇ¥Ïóê ÍµâÏû•Ìûà Îπ†Î•¥Í≤å Ï£ºÎßê ÌôòÏÉÅÏãùÏúºÎ°ú ÏßÄÎÇ¥ÎèÑÎ°ù ÌïòÍ≤†ÏäµÎãàÎã§.

ÎãπÏó∞Ìûà Ïª§Î∏åÏÖÄÎü¨Ïùò ÌÇ§Ï£†. Í∏ÄÎ°úÎ≤å ÎßàÏºìÏùÄ Ìïú 5Î∞±.. Í∑∏.. 120Î∞∞Î¶¨ÏïÑ Ï†ïÎèÑ ÎêòÎäî ÎßàÏºìÏù∏Îç∞ Ï†ÑÏ≤¥ Í∑∏..

Í≥ÑÏÜç ÎäòÏñ¥ÎÇòÍ≥† Ìà¨Îü∞Ïù¥ Îñ†Ïò§Î•¥Îäî Í≤É Í∞ôÍ≥†, Ìà¨Î¶¨Î¶¨Ïñ∏ÏùÑ Î¥êÏïº ÎêòÎäî Í≤É Í∞ôÏïÑÏöî. Í∑∏ Ï§ëÏóê Îß•Îçî ÎîîÎ∞îÏù¥Ïä§Îäî Ï†ÑÏ≤¥Ï†ÅÏúºÎ°ú Ìïú 6%Ïùò ÏßÄÏó∞ÏùÑ Í∞ÄÏßÄÍ≥† ÏûàÏäµÎãàÎã§. Í∑∏Ï§ëÏóê Ïö∞Î¶¨ÎÇòÎùº ÎßàÏºìÏù¥ Ìïú 1.6% Îê©ÎãàÎã§. Í∑∏ÎûòÎèÑ ÎßéÏù¥ ÎäòÏñ¥ÎÇúÍ±∞Ï£†. 5ÎÖÑÏ†ïÎèÑÎßå 1%Í∞Ä ÎêêÏäµÎãàÎã§. ÏßÄÏó≠Ï†ÅÏù¥Í±∞ÎÇò ÎßàÏºìÏÇ¨Ïù¥Ï¶à ÎïåÎ¨∏Ïóê Ïö∞Î¶¨ÎÇòÎùºÏóêÏÑúÎßå Í∑∏ ÎîîÎ∞îÏù¥Ïä§Í∞Ä ÌÉàÎùΩÌïòÍ∏∞ÏóêÎäî ÏÑúÏä§ÌÖåÏù∏ ÌïòÎèÑÎ°ù ÌïòÏûê. Í∑∏ÎûòÏÑú ÎãπÏó∞Ìûà ÎØ∏Íµ≠ÏãúÏû•ÏúºÎ°ú Í∞ÄÏïº Îê©ÎãàÎã§. ÎØ∏Íµ≠ÏãúÏû•ÏùÄ Í±∞Ïùò Ï†Ñ Ïù∏ÎçîÏä§Ìä∏Î¶¨Ìä∏ Î∂ÑÏïºÏóêÏÑú 40%Îäî 45% Ï†ïÎèÑÏùò Ïâ¨Î£åÎ•º Í∞ÄÏßÄÍ≥† ÏûàÍ≥†Ïöî. Í∑∏Î¶¨Í≥† Í∞ÄÏû• ÌÅ∞, Ïù¥Í≤å ÍΩ§ Ï§ëÏöîÌïúÎç∞ Ïã±Í∏Ä ÎßàÏºìÏûÖÎãàÎã§. Ïã±Í∏Ä ÎßàÏºì. Ï†ÄÍ≤å Í∞ÄÏû• ÌÅ∞ Í±¥Îç∞.

Ïã±Í∏Ä ÎßàÏºìÏù¥ÎùºÎäî ÏùòÎ£åÍ∏∞Í∏∞ÎäîÏöî. ÏùòÎ£åÍ∏∞Í∏∞Îäî Ïñ¥Îñ§ ÎπÑÏ¶àÎãàÏä§ÎÉê. Ïö∞Î¶¨Í∞Ä ÌòÅÏã† ÎπÑÏ¶àÎãàÏä§. Ïù¥ FDAÎ•º ÌÜµÍ≥ºÌïòÎ©¥ Ï†ÑÏÑ∏Í≥ÑÏùò Î∞îÎãàÏãúÏû•ÏùÑ Í∑∏ÎÉ• Ïã±Í∏Ä Ïï°ÏÑ∏ÏÑúÎ¶¨Î°ú Î≥¥Îäî Í±∞ÏòàÏöî. ÌïúÍµ≠Îßå ÌÜµÍ≥ºÌïòÎ©¥ Ï†ÑÏÑ∏Í≥Ñ Î∞îÎãàÏãúÏû•Ïóê Ïï°ÏÑ∏ÏÑúÎ¶¨.

Ïù¥Î†áÍ≤å ÎßéÏù¥ Îì§Ïñ¥Í∞ëÎãàÎã§. ÏÇ¨ÎπÑÏóêÏù¥ÏÖò ÎßûÏ∂∞Í∞ÄÏßÄÍ≥† Í∑∏Îü∞ÏãùÏúºÎ°ú ÎßéÏù¥ Îì§Ïñ¥Í∞ÄÏ£†. Í∑∏ÎûòÏÑú Ïù¥ Îã®ÏùºÏãúÏû•Ïóê Îì§Ïñ¥Í∞ÄÎäî Í∞ÄÏû• ÌÅ∞ Îã®ÏùºÏãúÏû•Ïóê Îì§Ïñ¥Í∞ÄÎäî Í∑∏ÎÉ• ÏÑúÎ°ú ÏßÑÍ≤ÄÏäπÎ∂ÄÎ•º ÌïòÍ∏∞ ÎïåÎ¨∏Ïóê Í∏ÄÎ°úÎ≤å Ïä§ÌÉ†Îã§ÎìúÎßå ÏÇ¨ÎäîÍ≤å ÌïµÏù¥ Í∏∞Ïö∏Ïñ¥Í∏∞ ÏãúÏûëÌï¥Ïöî Í∑∏ Ïó¨Îü¨Î∂ÑÎì§Ïù¥ ÎßêÏîÄÌïòÏÖ®ÏßÄÎßå Ïã§Ï†úÎ°ú ÎØ∏Íµ≠ÏùÄ Ïñ¥ Î†àÎπåÎ†àÌÜ†Î¶¨ÎèÑ Í∑∏Î†áÏßÄÎßå ÎßàÏºì ÏûêÏ≤¥ÎèÑ Ïñ¥Îîî Í∑∏Îü¨ÎãàÍπå Ï£ºÎßêÏù¥Îûë Îã§Î•¥Íµ¨Ïöî. Î†àÎπåÎ†à, Í∑∏ Îç§Ïù¥ Îã§Î•¥Ï£†. Í∑∏ÎûòÏÑú Ïñ¥ÎîîÎ°ú Îì§Ïñ¥Í∞àÍ±∞ÎÉê Ïù¥Î†áÍ≤å.

ÏóêÏÑú ÎØ∏Íµ≠ÏùÑ ÌéòÎÑ∑Ìä∏Î¶≠ ÌïòÏãúÎäî ÌöåÏÇ¨Îì§Ïù¥ ÎØ∏Íµ≠ Ï†ÑÏ≤¥Î•º Î≥¥Í≥† Ïó¨Í∏∞ Ïó¨Í∏∞ Ïó¨Í∏∞ Ïù¥Î†áÍ≤å ÌïòÎäîÍ±∞ÏóêÏöî.

Ïù∏ÌÑ∞ÌéòÏù¥Ïä§Í∞Ä ÏûàÎã§ÎçòÏßÄ, Ïï±Ïù¥ ÏûàÏúºÎ©¥ Ïù¥Î†áÍ≤å ÎêúÎã§ÎçòÏßÄ, Ïó¨Í∏∞ Î°úÏª¨Ïóê ÏôÄÏÑúÎäî Ïó¨Í∏∞ Î°úÏª¨ÏóêÎßå Î∞îÍøîÏïº ÎêòÏ£†. Í∑∏Îü∞ Í≤ÉÎì§Ïù¥ ÎßéÏù¥ Ï§ëÏöîÌï©ÎãàÎã§. ÎãπÏó∞Ìûà ÌÅ¥Î¶¨Î≤ÑÎ†àÏù¥ÌÑ∞ÌïòÍ≥† ÌååÌä∏ÎÑàÏã≠Ïù¥ Ïó¨Í∏∞ÏÑú Ï∞æÎäîÍ≤å ÎÑàÎ¨¥ Ï§ëÏöîÌïòÏ£†. ÎØ∏Íµ≠ÏùÄ Í∞úÎ≥Ñ Ïã†Ïû•, ÎÇ¥Í∞Ä ÎîîÎ∞îÏù¥Ïä§ÎùºÎãàÍπå, ÎÇ¥Í∞Ä Î∞õÏùÄ ÎîîÎ∞îÏù¥Ïä§ÎùºÎãàÍπå Ïñ¥ÎîîÍ∞ÄÏÑú ÏßÅÏ†ë ÏòÅÏóÖÏùÑ ÌïòÎäî Í≤ÉÏùÄ Í±∞Ïùò Ïñ¥Î†µÏ£†. ÌÉë5ÎÇò ÌÉë10 ÎîîÏä§Ìä∏Î¶¨Î∞çÏù¥ Í∑∏ Ï†ÑÏ≤¥Î•º Í∞ÄÏßÄÍ≥†

Ïù¥Í≤å Í∑∏ ÏÇ¨ÏóÖÏûêÎì§ÌïòÍ≥† Î≥ëÏõêÏÇ¨ÏóÖÏûêÎì§ÌïòÍ≥† ÏûàÎäî

Ïú†Ïä§Ìè∞ÏÖÄÎùºÏù¥Ï†úÏù¥ÏÖòÏùÄ Í∞ÄÏû• Ï§ëÏöîÌïúÍ≤å ÎãπÏó∞Ìûà ÌÖåÌÅ¨ÎÜÄÎ°úÏßÄÍ∞Ä Îê† Ïàò ÏûàÎã§Í≥† ÏÉùÍ∞ÅÌï©ÎãàÎã§. ÏôúÎÉêÎ©¥ ÌÉùÏ°∞ÏûÖÏùÄ ÎßàÏºìÏù¥ÎãàÍπåÏöî. Í∑∏Î¶¨Í≥† Ï≤´Î≤àÏß∏ Î∞©Ìñ•Ïù¥ Î†àÍ∑§Î†àÌÜ†Î¶¨Ïù¥Í∏∞ ÎïåÎ¨∏Ïóê Ïù¥ ÏãúÏûÖÎãàÎã§.

ÎßêÏîÄÌïòÏãúÎäî Í≤ΩÏö∞Í∞Ä ÎßéÏïÑÏöî. Í∑ºÎç∞ Î¨ºÎ°† Í∑∏Îü∞ Î©¥ÎèÑ ÏûàÏäµÎãàÎã§. ÏûàÎäîÎç∞ ÏÇ¨Ïã§ Ïù¥ Î†àÍ∑§Î†àÏù¥ÏÖòÏù¥ÎùºÎäî Í≤ÉÏùÄ Ïñ¥Îñ§ ÌïòÎÇòÏùò Î≤ΩÎèÑ Îê† Ïàò ÏûàÏßÄÎßå Í∏∞ÌöåÎèÑ Îê† Ïàò ÏûàÏñ¥Ïöî. Ï≤´Î≤àÏß∏Îäî Í∑∏ Î≤ΩÏù¥ ÏûàÎäîÎç∞ Î≤ΩÏùÑ ÎÑòÍ∏∞Îßå ÌïòÎ©¥ ÏïÑÍπå ÎßêÏîÄÎìúÎ¶∞ÎåÄÎ°ú 40% 50% Ï†ïÎèÑ Ï†ÑÏÑ∏Í≥Ñ ÏãúÏû•Ïóê ÎêòÎäî Îã®Ïùº ÎßàÏºìÏóê Ï†êÌïëÌï† Ïàò ÏûàÎã§Îäî Í≤É, Ïù¥Í≤å Ï≤´Î≤àÏß∏Í≥†Ïöî. ÎëêÎ≤àÏß∏Îäî ÏÇ¨Ïã§ÏùÄ FDAÍ∞Ä ÏûêÏÑ∏Ìûà Î≥¥Î©¥ Ïö∞Î¶¨ÌïúÌÖå, Îß•Ïª§Îãà ÏôÄÏù¥Ïä§ Îß§ÎãàÌéúÏÖòÌïúÌÖå Í∞à Í∏∏ÏùÑ ÏïåÎ†§Ï£ºÍ≥† ÏûàÎäî Í≤ÅÎãàÎã§. Í∑∏ÎãàÍπå Î™®Ï∞ΩÏö∞ ÏÑ†ÏÉùÎãòÏù¥ ÏñòÍ∏∞ÌïòÏÖ®ÏßÄÎßå Í∑∏Îü∞ Í∏∏Îì§ÏùÑ Í∞ÄÏù¥ÎìúÎùºÏù∏Ïóê ÎêòÍ≤å ÏûêÏÑ∏Ìïú Í≤å Ï£ºÍ≥† ÏûàÏñ¥Ïöî. Ï°∞Í∏à ÏûàÎã§Í∞Ä Í∑∏Îü∞ ÏñòÍ∏∞Î•º ÌïúÎ≤à Ìï¥Î≥¥Í≤†ÏäµÎãàÎã§. Í∑∏Î¶¨Í≥† Î†àÍ∑§Îü¨ Ìä∏Î†àÏù¥ÎÑà ÏõåÎ¶¨ÎèÑ ÌïòÏßÄÎßå Í∏∞ÌöçÍ∞Ä.

Í∑∏Î¶¨Í≥† Í∑∏ Îã§ÏùåÏóê Ïñ¥ Ïò§ÏºÄÏù¥ ÎÇ¥Í∞Ä Ïñ¥ Ï†ÄÍ∏∞

Í∑∏Î†áÍ≤å ÌïòÎäî Í≤ÉÎ≥¥Îã§ Ïù¥Í≤å Í±∞Ïùò ÌéòÎ°úÎ¶¨ÏïàÏù¥ ÌïòÎäîÍ≤å ÎßûÏäµÎãàÎã§ Ï≤òÏùåÏóê Ïõ®Ïù¥ÌÅ¥ ÎîîÎ∞îÏù¥Ïä§Î•º ÎîîÏûêÏù∏ÌïòÎäî Í≤ÉÎ∂ÄÌÑ∞ ÎÇ¥Í∞Ä Ïù¥Í±∏ Í∞ÄÏßÄÍ≥† Ïñ¥Îñ§ ÏóêÏñ¥Î¶¨Ìä∏ÎßÅÏùÑ Ìï† Í±∞ÏòàÏöî?

Ï∞∞ Ïàò ÏûàÍ≤†ÎäîÍ∞Ä? Í∑∏Îü¨Î©¥ Ïù¥Í≤å Ïñ¥Îñ§ ÏãùÏúºÎ°ú ÏûÑÌîåÎ°úÏä§Î•º Í∞ÄÍ≥† ÎÇ¥Í∞Ä Ïñ¥ÎñªÍ≤å ÏàòÏùµÏùÑ Í∞ÄÏßÄÍ≥† ÏûàÍ≤†ÎäîÍ∞Ä? Ïù¥Îü∞ Í≤ÉÎì§ÏùÑ Ïù¥Ï†ú Í∞ñÍ≤å ÎêòÎÑ§Ïöî. Í∑∏Îü∞ Í≤ÉÎì§ÏùÑ ÎØ∏Î¶¨ ÏÉùÍ∞ÅÏùÑ Ìï¥Ïïº Îê©ÎãàÎã§. Î¶¨Î≤ÑÏä§ Î®∏ÎãàÍ∞Ä Ïôú Ï§ëÏöîÌïòÏ£†? ÎãπÏó∞Ìûà Ï§ëÏöîÌïòÏ£† Î¶¨Î≤ÑÏä§ Î®∏Îãà Í∑∏Îüº Í±∞Í∏∞ÏÑú ÎèàÏù¥ ÎÇòÏò§ÎãàÍπå

Í∑ºÎç∞ Î≥¥Î©¥ Ïù¥ Î©îÎîîÏπ¥Îìú ÎîîÎ∞îÏù¥Ïä§ ÏãúÏû•ÏùÄ Îã§Î•∏ ÌÅ¨Î£®Ïä§Î©î ÏãúÏû•Í≥º Îã§Î•¥Í≤å Ïù¥ Ïä§ÌÖåÏù¥ Í≥®ÎìúÎì§Ïù¥ ÏóÑÏ≤≠ ÎßéÏäµÎãàÎã§. ÎãπÏó∞Ìûà Î≠ê..

Ïä§ÌÖåÏù∏Î∂àÎìúÎ•òÎäî Ïã§Ï†úÎ°ú Í∑∏ ÎîîÎ∞îÏù¥Ïä§Î•º TVÎÇò Ï∞®Î•º ÏÇ∞Îã§. ÎÇ¥Í∞Ä ÌùâÎÇ¥Í≥† ÎÇ¥Í∞Ä Î°úÎ¥áÏùÑ Î∞õÏïÑÏÑú Ïò§Í±∞Îì†Ïöî.

Î≠ê Í∑∏Îü∞Í±∞Ï£†. Í∑ºÎç∞ Ïù¥ ÎîîÎ∞îÏù¥Ïä§ Î∂ÄÎ∂ÑÏùÄ Ïù¥ Ï°∞Ìï© Ïù¥Îü¨Î©¥ÏùÄ

Ïù¥ ÎîîÎ∞îÏù¥Ïä§Ïùò ÏÇ¨Ïö©Ïûê, ÎîîÎ∞îÏù¥Ïä§Î•º ÌÖåÏä§Ìä∏ÌïòÎäî ÎåÄÏÉÅÏûê, ÎîîÎ∞îÏù¥Ïä§Î•º Ïã§Ï†úÎ°ú Í∞ÄÎ∂ÄÎäî, ÌÖåÏä§Ìä∏ÌïòÎäî Í∑∏ Ï†úÌíàÏóê Ïù¥ Ï†úÌíàÏù¥ÎùºÎì†ÏßÄ Î∞îÎÄêÎã§Îì†ÏßÄ Í≤∞Ï†ïÌïòÎäî ÏÇ¨Îûå Í∑∏ Îã§ÏùåÏóê Í∑∏ Ï†úÌíàÏù¥ ÏÇ¨Ïö©ÎêòÎäî Í≥≥ Í∑∏Î¶¨Í≥† Í∑∏Í±∞Î•º Ìè¨Í¥ÑÌïòÎäî Í∞ÄÎ∞úÎûÄÏä§ Ïù¥Î†áÍ≤å Îã§ Îã§Î¶ÖÎãàÎã§. Í∑∏ÎûòÏÑú ÎàÑÍµ¨Ïùò ÎàÑÍµ¨Ïùò Í≤∞Ï†ïÎèÑ ÏôÑÏ†ÑÌïòÎã§Í≥† Ìï† ÏàòÎäî ÏóÜÏßÄÎßå ÎàÑÍµ¨Ïùò Í≤∞Ï†ïÎèÑ Î¨¥ÏãúÌïúÎã§Í≥† Ìï† ÏàòÍ∞Ä ÏóÜÏñ¥Ïöî. Ïä§ÌÖåÏù¥ Í≥®ÎìúÍ∞Ä ÎÇ´Îã§, Ïä§ÌÖåÏù¥ Í≥®ÎìúÍ∞Ä. Ïù¥Í±∏ Î∞òÎìúÏãú Ìï¥Ïïº ÎêòÏûñÏïÑÏöî. Í∑∏ÎûòÏÑú ÎÇ¥Í∞Ä Ï†úÌíà ÎîîÏûêÏù∏ Ìï† ÎïåÎèÑ ÏïÑ, Ïù¥ Ï†úÌíàÏùÄ Îû© Ï†úÌíàÏù¥Í≥†, ÎîîÎ∞îÏù¥Ïä§Í≥†, Ïö∞Î¶¨ Îû©ÏóêÏÑú Ïì∞ÎãàÍπå ÎàÑÍµ¨ÌïúÌÖå Ï¢ãÍ≤å ÎîîÏûêÏù∏ÏúºÎ°ú, ÏÑ§Î™ÖÏÑúÎèÑ

Í∑∏ Îã§ÏùåÏóê Í∞ÄÍ≤©ÎèÑ Ïù¥Î†áÍ≤å Î¥êÎèÑ ÎêòÏßÄÎßå Îòê Îã§Î•¥Í≤å Ïã§Ï†úÎ°ú Íµ¨Îß§ÌïòÎ†§Îäî Î≥ëÏõê Î∞ñÏóê ÏûàÏûñÏïÑÏöî. Í∑∏ Ïä§ÌÖåÏù¥ÌîåÎì§Ïùò Ïù¥ÏïºÍ∏∞Îì§ÏùÑ ÎßéÏù¥ Îì§Ïñ¥Ïïº Ìï©ÎãàÎã§. Í∑∏ÎûòÏÑú ÎîîÏûêÏù∏Ìï† ÎïåÎ∂ÄÌÑ∞ Ïù¥Í±∞Î•º ÏÉùÍ∞ÅÌï¥Ïïº ÎêúÎã§ÎùºÎäî Í±∏ Íº≠ ÎßêÏîÄÎìúÎ¶¨Ï£†. Í∑∏Î†áÏßÄ ÏïäÏúºÎ©¥ Îã§ ÎßåÎì§Í≥† ÎÇòÏÑú Îòê Îã§Ïãú Ìï¥ÏïºÎêòÎäî Í≤ΩÏö∞Í∞Ä Ï†úÍ∞Ä Ïó¨Îü¨ Î≤à Î≥∏ Ï†ÅÏù¥ ÏûàÏäµÎãàÎã§. Í∑∏ÎûòÏÑú Ïù¥Í≤å Ïù¥Î†áÍ≤å ÎßêÌï† Ïàò ÏûàÎäîÎç∞ FDAÏùò Ïä§Ìä∏Î†àÏ†ÄÎ•º Ï≤òÏùåÎ∂ÄÌÑ∞ ÏÉùÍ∞ÅÌïòÎäî Í≤É, Ïù¥Í≤å Í∞ÄÏû• Ï§ëÏöîÌïòÎã§. Ïù¥Î†áÍ≤å ÎßêÏîÄÎìúÎ†∏Ï£†. Î¶¨Î≤ÑÏä§, Î¶¨Î≤ÑÏä§Îûë Ïª¥Ìì®ÌÑ∞Í∞Ä Ïñ¥ÎñªÍ≤å ÏõÄÏßÅÏù¥ÎäîÍ∞ÄÎ•º Î≥¥ÏïòÏäµÎãàÎã§.

Í∑∏Î†áÍ≤å ÎßêÏîÄ ÎìúÎ†∏ÏäµÎãàÎã§. Ïûê Í∑∏Îü¨Î©¥ FDA preparation approval Ìï† Îïå Ïã§Ï†úÏ†ÅÏúºÎ°ú Î≠êÍ∞Ä Ï§ëÏöîÌïòÍ≥† Ïôú Ïù¥Í±∏ Ìï¥Ïïº ÎêúÎã§ Ïù¥Îü∞ Í≤ÉÎì§ÏùÑ Ïû†Íπê Ïù¥Ï†ú Ï£ºÌô©ÏÉâ

ÎãπÏó∞Ìûà Ï†ÄÌù¨Ïùò Î™©ÌëúÎäî Í∏ÄÎ°úÎ≤å Ïª§Î®∏ÏÖúÎùºÏù¥Ï†ÄÏù¥ÏÖòÏûÖÎãàÎã§. Ïª§Î®∏ÏÖúÎùºÏù¥Ï†ÄÏù¥ÏÖòÏùÑ ÌïòÍ∏∞ ÏúÑÌï¥ÏÑúÎäî Î™®Îì† Í∏∞Ïà†Îì§ÏùÄ Í∏∞Î≥∏Ïù¥ ÌÖåÌÅ¨ÎÜÄÎ°úÏ¶àÏôÄ Ïù¥ÎÖ∏Î≤†Ïù¥ÏÖòÏù¥ Í∏∞Î≥∏Ïù¥ Îê©ÎãàÎã§. Î™®Îì† Í∏∞Î∞òÏóêÏÑú ÌÖåÌÅ¨ÎÜÄÎ°úÏ¶à. Í∑∏Î†áÏ£†. ÎÇ¥ Ï†úÌíàÏù¥ ÎîîÌçºÎü∞Ïã±, ÌÖåÌÅ¨ÎÜÄÎ¶¨ÏßÄ ÏôÄÏù¥Ïä§ ÎîîÌçºÎü∞Ïã±ÏùÑ Ìï©ÎãàÎã§. Ïó¨Í∏∞ÏÑú Ïª§Î®∏ÏÖúÎùºÏù¥Ï†úÏù¥ÏÖòÏúºÎ°ú Ïó∞Í≤∞Ìï† Îïå Ïù¥Í±∏ Ïñ¥ÎñªÍ≤å ÌïòÎäêÎÉê, Ïù¥Í≤å Ïù¥Ï†ú ÌÇπÏù∏Îç∞Ïöî. Îëê Í∞ÄÏßÄ ÌïÑÎü¨Í∞Ä ÏûàÏäµÎãàÎã§. ÌïòÎÇòÎäî Îß§ÎãàÌå®ÌÇπ ÌïÑÎü¨, ÌïòÎÇòÎäî Î†àÍ∑§Î†àÏù¥ÏÖò ÌïÑÎü¨Í∞Ä ÏûàÏäµÎãàÎã§. Îß§ÎãàÌå®ÌÇπÏùÑ ÌÜµÌï¥ÏÑú ÌÄÑÎ¶¨Ìã∞Î•º Ìà¨ÏûÖÌïòÍ≥†Ïöî. Î†àÍ∑§Îü¨ÏÖòÏùÑ ÌÜµÌï¥ÏÑú Í∑∏ ÎÇòÎùº, Í∑∏ Ï†ïÏ±Ö, ÌòπÏùÄ Í∑∏ Ïù∏ÎçîÏä§Ìä∏Î¶¨Ïóê Í∞êÏóºÎêú Ïª¥ÌîåÎùºÏù¥Ïñ∏Ïä§Î•º ÌïÑÏöîÎ°ú Ìï©ÎãàÎã§.

Ïù¥ ÎëêÍ∞ÄÏßÄÍ∞Ä Í∏∞Îä• Ïû†ÏãúÎßåÏöî Ïù¥ ÎëêÍ∞ÄÏßÄÎ•º Ïñ¥ÎñªÍ≤å Ìï† Í≤ÉÏù¥ÎÉê Ïù¥Í≤å Ïù¥Ï†ú Ï†ÄÌù¨Îì§Ïùò Í≥µÏù∏Ïù¥ ÎêòÎäîÍ±∞Ï£†

Ï≤òÏùåÏóê ÎßàÎ£®ÌÖçÏù¥ÎÇò Ïä§ÌÉÄÎìúÏóÖÏù¥ÎÇò Ï†ÑÎ∂Ä Îã§ Ïù¥ÎÖ∏Î≤†Ïù¥ÏÖòÏù¥ ÏûàÍ≥† ÌÖåÌÅ¨ÎÖ∏ÎèÑ ÏûàÍ≥† Ï†ÄÎèÑ Ïä§ÌÉÄÎìúÏóÖÏùÑ ÏòàÏ†ÑÏóê

ÏóëÏãúÏä§ Ìï† Í≤ΩÌóòÏù¥ ÏûàÎäîÎç∞ Í∑∏ÎïåÎäî Ïûò Î™∞ÎûêÎçò Í≤É Í∞ôÏïÑÏöî. ÌÖåÌÅ¨ÎÖ∏Î≤†Ïä§ÏôÄ SMÎèÑ Ïù¥Í±∞ ÎßåÎì§Î©¥ ÎÑàÎ¨¥ Ï¢ãÏùÄÎç∞ Ïù¥Í±∏ Ïôú Ïïà ÏÇ¥Íπå Ïù¥ ÏÉùÍ∞ÅÏùÑ ÌïòÎäîÍ±∞ÏóêÏöî. ÏÇ¨Ïã§ÏùÄ Ïù¥Ï†ú ÎßàÏºìÏù¥ Í∑∏Î†áÍ≤å ÎèåÏïÑÍ∞ÄÏßÑ ÏïäÍ≥† Í∑∏Í±∞Îäî ÎÇ¥Í∞Ä ÎÇ¥Í∞Ä ÎÇò Ï¢ãÏúºÎùºÍ≥† ÌïòÎäî Í±¥Îç∞ Í∑∏Í≤å ÏïÑÎãàÎùº Ïö∞Î¶¨Í∞Ä Ïª§Î®∏ÏäêÎùºÏù¥Ï¶àÎ•º ÏÉùÍ∞ÅÌïòÎ†§Í≥† ÌïòÎ©¥ ÎëêÍ∞ÄÏßÄÎ•º ÏôÑÏÑ±Ìï¥ÏïºÌï©ÎãàÎã§. Í∑∏Í≤å ÌÄÑÎ¶¨Ìã∞ÎùºÎäî Í≤ÉÏûÖÎãàÎã§. ÌÄÑÎ¶¨Ìã∞Îäî ÌçºÌè¨Î®ºÏä§ÏûÖÎãàÎã§. ÎãπÏó∞Ìûà ÏûàÏñ¥Ïïº Ìï©ÎãàÎã§. 5Î∂Ñ ÎÇ®ÏïòÏñ¥Ïöî.

ÎßéÏù¥ ÏûàÎäîÎç∞Ïöî? ÌïòÏó¨Ìäº Ïó¨Í∏∞ Ïù¥Í≤å ÏûàÏäµÎãàÎã§. Í∑∏Îü¨Î©¥ ÏöîÍµ¨Î•º ÌïòÍ∏∞ ÏúÑÌï¥ÏÑú

Ï†úÍ∞Ä ÎßêÏîÄ ÎìúÎ¶∞ Ïù¥Ïú†Îäî FAAÎäî Îß•ÎèÖ Î¶¨Î∞îÏù¥Ïä§Îäî ÌäπÎ≥ÑÌûà 21 CFR 820, 800 Ïù¥Í≤ÉÏùò Í∞íÏùÑ ÎåÄÏÉÅÏúºÎ°ú 21Ïù¥ ÏΩîÎìú Ïò§Î∏å Ìå®Îü¨Îîî Î†àÍ∑§Î†àÏù¥ÏÖò Ïù¥ÎùºÎ©¥ ÌóåÎ≤ïÏóêÏÑúÎ∂ÄÌÑ∞ Ï†ïÎ∂ÄÍ∞Ä Ï°∞ÏßÅÏù¥ Ïñ¥ÎñªÍ≤å ÎêúÎã§Í≥† ÏãúÏûëÏùÑ Ìï¥ÏÑú 21Î≤àÏß∏ ÌååÏù¥Îì§Ïóê ÌõàÏï§ÎìúÎ°úÍ∑∏ÎùºÎäî Î≤ïÏù¥ Í∑∏Ï§ëÏóê Ïó¨Îü¨Í∞ÄÏßÄ Í≤ÉÎì§Ïù¥ ÏûàÎäîÎç∞ 800Î≤àÏ†ïÎèÑ ÎêòÎ©¥ 800Î≤àÏóê HÎùºÍ≥† ÎêòÏñ¥ÏûàÎäîÎç∞ Í±∞Í∏∞Ïóê medical deviceÍ∞Ä ÏûàÎã§. Í∑∏ Ïô∏Ïóê Îã§Î•∏Í≤ÉÎì§Ïù¥ ÎßéÏù¥ ÏûàÏñ¥Ïöî. Í∑∏Îü¨ÎãàÍπå Ïä§ÌÜ†Î¶¨ÌïúÌÖåÎäî Ïñ¥ÎñªÍ≤å Ìï¥Ïïº ÎêúÎã§, Í∞ÅÎèÑÎ•º ÎîîÌååÌï¥Ïïº ÎêúÎã§, ÌîÑÎ†âÌã∞Ïä§ÌïúÌÖåÎäî Ïñ¥ÎñªÍ≤å Ìï¥Ïïº ÎêúÎã§, Î≠êÎùºÍ≥† ÏñòÍ∏∞Ìï¥Ïïº ÎêúÎã§, Í∑∏Î†áÏäµÎãàÎã§.

ÏïÑ Í∑∏ÎûòÏÑú Ïù¥Ï†ú Í∑∏ 800Î≤àÏù¥ Î©îÎîîÏª¨ ÎîîÎ∞îÏù¥Ïä§ÏòÄÍ∏∞ ÎïåÎ¨∏Ïóê 800Î≤àÏóêÏÑúÎèÑ 820Î≤àÏù¥ ÌÄÑÎ¶¨Ìã∞ ÏãúÏä§ÌÖú Î†àÍ∑§Î†àÏù¥ÏÖò QSRÏù¥ÎùºÍ≥† ÌïòÎäîÍ±∞Ï£†. ÏßÄÍ∏àÏùÄ ÏïÑÎßà ÎÇ¥ÎÖÑÎ∂ÄÌÑ∞Îäî ÌïòÎ™®ÎÇòÏù¥Ï¶àÍ∞Ä ÎêòÍ∞ÄÏßÄÍ≥† ÎëêÍ∞úÍ∞Ä Í∞ôÏù¥ ÏùºÏÇ∞ ÏÇ¨Ìè¨Î°ú Ïó∞Í≤∞ÎêòÎäî ÏßÄÏ†êÏù¥ ÏûàÏäµÎãàÎã§. Ï≤òÏùåÏóê FDAÎ•º ÍµêÏú°ÏùÑ Î∞õÏúºÎ©¥ Ïö∞Î¶¨ QSRÌïòÍ≥† 134 Î∞îÏù¥Îü¨Ïä§ÌïòÍ≥† ÌïòÍ≥† Îã§ÎãàÏßÄ ÏïäÏùÄ Í±∞Î•º Ï†ëÌñàÎäîÎç∞ ÌïòÏó¨Ìäº Í∑∏ÎûòÏöî. Ïù¥Î†áÍ≤å Îê©ÎãàÎã§. Ï†úÍ∞Ä Ïù¥ ÎßêÏîÄÏùÑ ÎìúÎ¶¨ÏûêÎ©¥ Î©îÎîîÌÅ¥ ÎîîÎ∞îÏù¥Ïä§Î•º Í∞êÏïàÌïòÎäî Í≤ÉÏùÄ Î≤ïÏù¥ÎùºÎäî Í≤ÅÎãàÎã§.

Ïù¥Í≤å Î≠îÍ∞Ä Í±∞Î¶¨ÎùºÎäî Í±¥ ÎùΩÏÇ¨Ïù¥Ïä§Í∞Ä ÏïÑÎãàÏûñÏïÑÏöî. Ïù¥Í≤å Í∑∏ÎÉ• ÏûàÎäî Í∑∏ÎåÄÎ°ú Îî∞ÎùºÍ∞ÄÏÑú Ïù¥Í±∞Î•º Î∞ë ÌïòÎ©¥ÏÑú Îã§Í∞ÄÍ∞ÄÎäî Í±∞ÏòàÏöî.

Í∑∏ÎûòÏÑú ÎîîÏûêÏù∏ Ïª®Ìä∏Î°§ÏùÑ Ïñ¥ÎñªÍ≤å ÌïòÎäîÍ∞ÄÍ∞Ä ÌÅ¨Í≤å, ÌäπÌûà Ïö∞Î¶¨Í∞ôÏùÄ Î©îÌÉà ÎîîÎ∞îÏù¥ÏÑ†ÏóêÏÑú ÍµâÏû•Ìûà Ï§ëÏöîÌï©ÎãàÎã§. QnAÌïòÍ≥† ÎîîÏûêÏù∏ÌïòÍ≥† ÎîîÏûêÏù¥ÎÑàÌïòÍ≥† ÎîîÏûêÏù∏ Î¶¨Î∑∞, Ïï†ÌîåÎ¶¨ÏºÄÏù¥ÏÖò, Î≤†Î¶¨ÎÑ§Ïù¥ÏÖò, Ìä∏ÎûúÏä§ÌååÏõå Ï≤¥Ïù∏ÏßÄÌïòÍ≥† DHF Ïù¥Îü∞Í≤ÉÎì§ÏùÄ Í∑∏ ÏïÑÎ©îÎ¶¨Ïπº Ïä§ÌÑ∞Îîî, IDEÍ∞ôÏùÄ Í≤ΩÏö∞Îäî Ïù¥Í≤ÉÏùÄ Ìï∏ÎìúÏª®ÏÖâÏ∏°Ïù¥ÎûÄ, Ïù¥Í±∏ Ïã§Ï†úÎ°ú ÏûÑÌîåÎ¶¨Î©òÌä∏Î°ú Ìï¥ÏïºÎêòÎäî Í≤ÉÏûÖÎãàÎã§. Ï§ëÏöîÌïòÏ£†. Ïù∏ÌîåÎ£®ÏóîÌÑ∞ Ìï† Îïå ÌîÑÎ°úÏ†ùÌä∏ ÌîåÎûúÏùÑ Ïñ¥ÎñªÍ≤å Ïì∏ Í≤ÉÏù∏Í∞Ä? Î≠ò Î≥¥Í≥† Ïì∏ Í≤ÉÏù∏Í∞Ä? Ïú†Ï†ÄÏôÄ ÎØ∏ÎîîÏñ¥ÏóêÏÑú ÎîîÏûêÏù∏ ÏΩîÏä§ ÎÑòÏñ¥ Ïò§Í∏∞ ÏúÑÌï¥ÏÑúÎäî Ïñ¥ÎñªÍ≤å Ìï¥Ïïº ÎêòÎäîÍ∞Ä? DPPÎ•º Î≠ê...

ÎÇ®Í≤®Ïïº ÎêòÍ≥†, ÌîºÎîîÏñ∏Ïù¥ ÏûàÏñ¥Ïïº ÎêòÍ≥†, ÌîºÎîîÏñ∏ÏùÄ ÌîÑÎ¶¨ÎØ∏Ïñ¥ ÎîîÏûêÏù∏ Î¶¨Î∑∞, Î¶¨Î∑∞Î•º Ìïú Î≤à Í±∞Ï≥êÏïº ÎêòÍ≥†, Ïù¥ Ïª§ÎÑêÏùÑ ÎßåÎì§Ïñ¥Ï£ºÎ©¥ ÌîÑÎ¶¨Ìã∞Ïª¨ ÎîîÏûêÏù∏ Î¶¨Î∑∞Î•º Í±∞ÏπòÍ≥†, Ìä∏ÎûúÏä§Ìè¨Ïñ¥ÏóêÏÑú ÌîÑÎ¶¨Ìã∞Ïª¨ Ïä§ÌÑ∞Îîî, ÌÅ¥Î¶∞Ïπ¥Ïä§ÌÑ∞ÎîîÏôÄ ÌÅ¥Î¶∞Ïπ¥Ïä§ÌÑ∞ÎîîÏùò Í≤ΩÏö∞ÏóêÎäî ÌÅ¥Î¶∞Ïπ¥Ïä§ÌÑ∞Îîî ÌîÑÎ°úÌÜ†ÏΩú Ïä§ÌÉë ÏãúÏä§ÌÖúÏùÑ Ïù¥Ïö©ÌïòÎ©¥ ÏïàÎê†ÍπåÏöî? ÏïÑÍπåÎäî Ï†úÍ∞Ä Î≤ïÏùÑ ÎßêÏîÄÎìúÎ†∏ÎäîÎç∞ Îëê Î≤àÏß∏Îäî Îã§ÌÅêÎ©òÌä∏Ïùò ÎßêÏîÄÏûÖÎãàÎã§. Îã§ÌÅêÎ©òÌä∏Í∞Ä ÏóÜÏúºÎ©¥ Í∑∏ ÏùºÏùÄ Ïïà ÏùºÏñ¥ÎÇòÎäî Í±∞Í≥†Ïöî. Îã§ÌÅêÎ©òÌä∏Í∞Ä ÏóÜÏúºÎ©¥ Í∑∏Í±¥ ÏóÜÎäî Í≤ÅÎãàÎã§. Ïù¥ÎÇò Í∑∏ ÏûÖÏû•ÏóêÏÑú Î∞òÎìúÏãú Î∞îÍæ∏Î©¥ Îê† Í≤É Í∞ôÏäµÎãàÎã§. Ïã§Ï†úÎ°ú ÏóëÏä§ÌÖåÏù¥ Î¶¨Î∑∞Ìï† Îïå, Ïä§ÌÅ¨Î¶∞ Ï∫°Ï≥êÌï† Îïå ÍµâÏû•Ìûà Í∑∏...

Ïö∞Î¶¨ Îß§ÎãàÏ†ÄÎãòÎì§Ïù¥ Í∞ïÍµ¨ÌïòÎäî Î∂ÄÎ∂Ñ Ï§ëÏóê ÌïòÎÇòÏóêÏöî. Îã§ÌÅêÎ©òÌÑ∞Î¶¨ Ïñ∏Ï†úÎ∂ÄÌÑ∞ Í∏∞ÏñµÌï¥Ïïº ÎêòÎäêÎÉê.

FDÏóêÏÑú ÏñòÍ∏∞ÌïòÎäî Í≤ÉÏùÄ Î¶¨ÏÑúÏπòÍ∞Ä Ï§ëÍ∞ÑÏóê Í∞ÄÍ≥† ÎîîÎ≤®Î°≠Ïù¥ ÏãúÏûëÌï† Îïå, Í∑∏Îïå, Í∑∏ÎïåÍ∞Ä DHCFÍ∞Ä ÏãúÏûëÌïòÎäî Í±∞ÏóêÏöî. ÎîîÎ≤®Î°≠Ïù¥ÎùºÎäî Í≤å Î∞òÎìúÏãú. Í∑∏ÎûòÏÑú Î¶¨ÏÑúÏπòÎ•º Ìïú Îã§ÏùåÏóê ÎîîÎ≤®Î°≠Ïù¥ Îì§Ïñ¥Í∞ÑÎã§Îäî Ïù¥ÏïºÍ∏∞ ÏûêÏ≤¥Í∞Ä ÎîîÏûêÏù∏ Ïù∏ÌíãÏù¥ ÎÇòÏò§Í≥†Ïöî, ÎîîÏûêÏù∏ ÌîÑÎ°úÌÜ†ÏΩúÏù¥ ÎÇòÏò§Í≥†, ÎîîÏûêÏù∏ Í≤∞Í≥ºÍ∞Ä ÎÇòÏòµÎãàÎã§. Í∑∏ ÏñòÍ∏∞ÎãàÍπå, Í∑∏ ÎïåÎ∂ÄÌÑ∞ Î∞òÎìúÏãú ÎßåÎì§Ïñ¥Ïïº ÎêúÎã§.

Í∑∏ÎûòÏÑú Î≠ê Ïù¥Îü∞ Ïó¨Îü¨Í∞ÄÏßÄ Í≤ÉÎì§Ïù¥ÎÇò Ïù¥Îü∞ Îã§ÌÅêÎ©òÌÑ∞Î¶¨ÎèÑ ÎßåÎì§Í≥†

Ï†úÍ∞Ä ÌïòÎ©¥ 4ÏãúÍ∞ÑÏóêÏÑú 8ÏãúÍ∞ÑÏßúÎ¶¨ ÌîÑÎ°úÍ∑∏Îû®ÏùÑ Ïù¥Î†áÍ≤å ÎßåÎì§ÏóàÎäîÎç∞Ïöî. Í∑∏ÎûòÏÑú, Í∑∏ÎûòÏÑú Ï≤òÏùåÏóê ÌïòÍ∏∞ Ï†ÑÏóê Ïù¥Îü∞ Í±∞Î•º Îã§... Í±∞ÏπòÍ≥† Ïù¥Í±∞Îäî Ïù¥Ï†ú ÎÇ¥Í∞Ä ÌïòÎäî Í±∞Ïïº. Í∑∏Îü¨ÎãàÍπå Ïö∞Î¶¨ ÌöåÏÇ¨Í∞Ä ÌïòÎäî Í±∞Ïïº, ÌöåÏÇ¨Í∞Ä. Í∑∏ÎûòÏÑú Ìå®Ïä§Í∞Ä ÏûàÎäêÎÉê, Ï£ºÎäêÎÉê, Îì§ÎäêÎÉêÎ•º Î®ºÏ†Ä Í≤∞Ï†ïÌï† Îïå ÎåÄÎ∂ÄÎ∂ÑÏùÄ ÏïÑÎßà Ï£ºÍ≤†Ï£†, ÏÜåÏõêÎìúÎ¶¨Î©¥.

Ïù¥Í±∞Îäî Í∑∏ÎÉ• Îî± Í∞ÄÏù¥Îìú ÎùºÏù∏Ïóê Îã§ ÎÇòÏôÄÏûàÏäµÎãàÎã§. ÌååÏù¥ÌåÖÏùò Í∏∞ÌöåÎ•º Í∞ñÎäêÎÉê, ÌîºÌï¥Ïùò Í∏∞ÌöåÎ•º Í∞ñÎäêÎÉê, ÌååÏù¥ÌåÖÏùò Í∏∞ÌöåÎ•º Í∞ñÎäêÎÉê. ÏïÑÏù¥ÎîîÏñ¥ Í∞ôÏùÄ Í≤ÉÎèÑ ÎêòÍ≤å ÎßéÏù¥ Í∞ÄÍ≥†Ïöî.

Í∑∏ÎûòÏÑú ÏïÑÍπåÎèÑ Ïä§ÎãòÏù¥ ÌîÑÎ¶¨ÏÑúÎØ∏ÏÖò ÏùºÏù¥ ÎêòÍ≤å Ï§ëÏöîÌïòÎã§Í≥† ÌïòÏÖ®ÎäîÎç∞ Ï†ïÎßê Ï†ïÎßê ÌîÑÎ¶¨ÏÑúÎØ∏ÏÖò ÏùºÏù¥ ÎêòÍ≤å Ï§ëÏöîÌï©ÎãàÎã§. ÍµâÏû•Ìûà ÌååÏõåÌíÄÌïòÍ≥† Ïù∏ÏÉÅ ÍπäÏùÄ Î∞©Î≤ïÏù¥ÏóêÏöî.

Ìè¨Î©ÄÌïòÍ∏∞ÎèÑ ÌïòÍ≥†Ïöî. ÌïòÏßÄÎßå Ïù¥Í±∞ Ìï† Îïå ÎÇ¥Í∞Ä Í∞úÎ∞úÏùÑ ÌñàÏùÑ Îïå Ïñ¥Îñ§ ÌöåÏÇ¨Îûë Ïª®Ìä∏Î°§ÏùÑ Ìï¥ÏÑú Í∑∏ ÌöåÏÇ¨Î•º FDÎ°ú Í∞ÄÏ†∏Í∞ÄÍ≤†Îã§Í≥† ÌïòÎ©¥ Í∑∏ ÌöåÏÇ¨Í∞Ä ÏïÑÍπå ÎßêÏîÄÎìúÎ†∏Îçò ÎîîÏûêÏù∏ Ïª®Ìä∏Î°§Ïù¥ Îã§ ÎêêÏùÑÎïå Îã§ÌÅêÎ©òÌä∏Í∞Ä ÎßéÏù¥ ÎÇòÏôîÎäîÎç∞Ïöî, Í∑∏ Îã§ÌÅêÎ©òÌä∏ÏôÄ FDAÍ∞Ä Ïú†ÏùºÌïòÍ≤å ÎßåÎÇ¨ÏùÑÎïåÍ∞Ä ÏûàÏäµÎãàÎã§. ÏöîÍµ¨ÌïòÎäî Îã§ÌÅêÎ©òÌÑ∞Î¶¨ Í∞ÑÏùò Í∞ÑÍ≤©ÏùÑ Î¥ÖÎãàÎã§. Í∑∏ Í∞≠ Î∂ÑÏÑùÏù¥ÎùºÍ≥† ÌïòÎäîÎç∞, Í∑∏ Í∞≠ Î∂ÑÏÑùÏùÑ ÌïÑÎûòÏöî. Í∑∏ Îã§ÏùåÏóê ÌîÑÎ¶∞ÏºìÏùÑ Ï∞æÍ≥†Ïöî. ÌîÑÎ¶∞ÏºìÏùÑ Ï°∞Í∏à Ïù¥Îî∞ ÎßêÏîÄ ÎìúÎ¶¥Í≤åÏöî. ÌîÑÎ¶∞ÏºìÏùÑ Ï∞æÍ≥†, Í∑∏ Îã§ÏùåÏóê ÌÅ¥Î¶¨ÎãàÏª¨ ÌîÑÎ°úÌÜ†ÏΩúÏùÑ

Í∑∏ÎûòÏÑú ÏïÑÍπå Ï†ïÏàòÌñ•Ïù¥ ÌïèÎ≥º ÌååÏù¥ÎÑàÎ°ú Ïó¨Îü¨Í∞ÄÏßÄ ÏºÄÏù¥Ïä§Î•º ÎßêÌñàÎäîÎç∞ Í∑∏Í≤ÉÎì§ÏùÑ ÎØ∏Î¶¨ Îã§ Î∂àÎü¨Îã§ÎÖÄÏöî. Í∑∏ÎûòÏÑú Í∑∏Í≤å Ïù∏ÌÅ¥Î£®ÏÖò ÌÅ¨ÎùºÏù¥ÌÜ†Î¶¨ÌïòÍ≥† ÏùµÏä§ÌÅ¥Î£®ÏÖò ÌÅ¨ÎùºÏù¥ÌÜ†Î¶¨Î•º ÎØ∏Î¶¨ ÎßåÎì§Ïñ¥ ÎÜìÏùÄÍ±∞ÏóêÏöî. Í∑∏Í≤å Ïù¥Ï†ú Ï§ëÏöîÌï©ÎãàÎã§. ÎØ∏Î¶¨ÎØ∏Î¶¨ ÌïúÎã§ÎäîÍ≤å ÏïÑÏ£º Ï§ëÏöîÌïòÏ£†. ÏôúÎÉêÎ©¥ FK Ïä§ÌÑ∞ÎîîÍ∞Ä ÏãúÏûëÏù¥ ÎêòÎ©¥ ÌéòÏù¥ÌÅ¨ ÌïòÎ©¥ Ï†àÎåÄ ÏïàÎê©ÎãàÎã§. Ï†àÎåÄ ÏïàÎèºÏöî. Ï∞®ÎùºÎ¶¨ Î¶¨Ìä∏ÎûôÏùÑ ÌïòÎäîÍ≤å ÎÇ´ÏßÄ. Ìó§ÎìúÎùºÎ©¥ ÍµâÏû•Ìûà ÌÉÄÍ≤©Ïù¥ ÏûàÏñ¥. ÌäπÌûà Ïã∏ÎçïÍ∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî Î∂ÄÏ°±ÌñàÏ£†.

Í∑∏Î¶¨Í≥† ÌïÑÏÇ¥ÏùÄ Î≠ê ÌïòÏó¨Ìäº Ïó¨Í∏∞ÎûëÏùÄ Îπ®Î¶¨ Ïª§ÎÆ§ÎãàÏºÄÏù¥ÏÖò ÌïòÎäîÍ≤å ÏµúÍ≥†Îã§ ÌïòÏßÄÎßå Ïù¥Î†áÍ≤å ÎûúÎç§ ÏßàÎ¨∏ÏùÑ ÎçòÏßÄÎ©¥ Ï†àÎåÄ ÏïàÎêòÍ≥† Í∞ÄÏù¥Îìú ÎùºÏù∏Ïóê Îî∞ÎùºÏÑú ÏûòÌï¥Ïïº Îê©ÎãàÎã§. Í∑∏Î¶¨Í≥† Ïù¥Îü∞Í≤ÉÎì§ÏùÄ ÎãπÏó∞Ìûà Ï§ÄÎπÑÍ∞Ä ÎêòÏñ¥Ïïº ÎêòÍµ¨Ïöî. ÏÇ¨Ïã§ Ïù¥ ÏñòÍ∏∞Î•º Ï¢Ä ÎßéÏù¥ ÎìúÎ¶¨Í≥† Ïã∂ÏùÄÎç∞, ÌîºÌï¥Ïïº Ìï† Î™á Í∞ÄÏßÄÏùò ÎØ∏Ïä§ÌÖåÎ¶¨Í∞Ä ÏûàÏäµÎãàÎã§.

Ï≤òÏùåÏóê ÎîîÎ∞îÏù¥Ïä§Î•º ÎßåÎì§Îïå Ïò§Ï†ÑÏóê ÏµúÏö∞Ï¢Ö ÍµêÏàòÎãòÏù¥ ÎßêÏîÄÌïòÏÖ®ÏßÄÎßå Ï∫îÏÑú Îã§Ïù¥Î≤ÑÎÇòÏä§Ìã±ÏùÑ ÌôàÏºÄÏñ¥Î°ú ÌïúÎã§Í≥†

Í∏∞Ïà†ÏùÄ ÎêòÍ≤†Ï£†. Í∏∞Ïà†ÏùÄ Îê©ÎãàÎã§. ÌïòÏßÄÎßå ÌíÄÎπÑÏºìÏù¥ ÏùºÎã® ÏóÜÍ≥† Ìå®Ìä∏Ïõ®Ïù¥Í∞Ä Ïû°ÌûàÏßÄ ÏïäÏïÑÏöî. Ìå®Ìä∏Ïõ®Ïù¥Í∞Ä ÏóÜÏúºÎ©¥ Í∞à ÏàòÍ∞Ä ÏóÜÏ£†. ÎãπÏó∞Ìûà. Í∏∏Ïù¥ ÏóÜÎäîÎç∞. Í∑∏ÎûòÏÑú Í∏∏ÏùÑ Îßâ ÎàÑÎ†§Ïïº ÎèºÏöî. Í∏∏ÏùÑ ÎßåÎìúÎäî Í∏∏ÎèÑ Ïó¨Îü¨ Í∞ÄÏßÄÍ∞Ä ÏûàÏßÄÎßå ÎÇ®Îì§Ïù¥ Í∞ÄÏßÄ ÏïäÎäî Í∏∏ÏùÑ Íµ≥Ïù¥ Í∞ÄÎ†§Í≥† ÌïòÎäî Í±¥ ÏÉÅÎãπÌûà ÌûòÎì§Ï£†.

Í∑∏ ÎîîÏûêÏù∏Ìï† Í∑∏ ÎîîÎ∞îÏù¥Ïä§Î•º ÎîîÏûêÏù∏Ìï†Í±∞Îã§ Ïù¥Îü¥Îïå ÎßéÏù¥ ÏÉùÍ∞ÅÎÇòÏöî Í∑∏Î†áÍ≤å Ìï¥ÏÑú ÌíÄÏ∫°Ïù¥ Î∞òÎìúÏãú ÏûàÏñ¥ÏïºÎê©ÎãàÎã§. Í∑∏ ÏïÑÍπåÎèÑ ÎßêÏîÄÎìúÎ†∏ÏßÄÎßå

Í∑∏ Î©ÄÌã∞Ìîå Ïª¥ÌîåÎ†âÌÑ∞ÎÇò Î©ÄÌã∞Ìîå ÌîÑÎ†àÎîîÏºìÏù¥ ÌïúÍµ≠ÏùÄ ÎêúÎã§Í≥† Ìï¥Ïöî. Í∑ºÎç∞ ÎØ∏Íµ≠ÏùÄ Ï¢Ä Ïñ¥Î†µÏäµÎãàÎã§. Î©ÄÌã∞ÌîåÌïòÍ≤å Ï∞®ÎùºÎ¶¨ ÎÇ¥ Ï†úÌíàÏùÑ ÎÇ®Í±∞ÎÇò Í∑∏ÎûòÏÑú ÎÇ®ÏïòÎã§Îì†ÏßÄ Í∑∏Î†áÍ≤å ÌïòÎäî. Í∑∏Î¶¨Í≥† ÏÑúÎ∏êÏÖò Îç∞Ïù¥ÌÑ∞Í∞Ä ÎîîÏûêÏù∏ Ïª®Ìä∏Î°§Îü¨Î•º Îî∞Î•¥ÏßÄ ÏïäÎäî Í≤ΩÏö∞Í∞Ä ÎßéÏïÑÏöî. Ï†ÄÎèÑ Í∑∏Îü∞ Í≤ΩÏö∞Í∞Ä ÎßéÏùÄÎç∞, Í∞≠ Î∂ÑÏÑùÏùÑ Ìï† Îïå Í∞ÄÏ†∏Ïò® ÏïÑÎÇ†Î°úÍ∑∏ ÌÅ¨ÎûòÏä§Ìã∞Ïïà Í≤åÏù¥Î∞çÏù¥ ÎêòÍ≤å Ï¢ãÏïòÏñ¥Ïöî. ÎêòÍ≤å Ï¢ãÏïÑÏÑú 5Ïõî Ï§ëÎèÑÎäî Ï∂©Î∂ÑÌï©ÎãàÎã§. ÌïòÍ≥†, Î≠ê ÌïÑÏöîÌï† Í≤ÉÎèÑ...

Í∑∏ÎûòÏÑú Í∑∏Í±∏ Îπ®Î¶¨ ÎßåÎì§Í≥† Ìï¥ÏÑú ÏßÄÎÇòÍ∞ÄÎäîÎç∞ Í≤∞Íµ≠ FDAÍ∞Ä Î≠ò ÏöîÍµ¨ÌñàÎÉêÎ©¥ Í∑∏ Model Comparison, Method Comparison Îç∞Ïù¥ÌÑ∞Í∞Ä Í∑∏Í≤ÉÏùò Ïõê ÏÜåÏä§, Í∑∏Îü¨ÎãàÍπå Î°úÎç∞Ïù¥ÌÑ∞Î•º Îã¨ÎùºÍ≥† ÌïòÎäîÍ±∞Ï£†. Í≤∞Íµ≠ÏóêÎäî Í∑∏ Î©îÏÜåÎìú Ïª¥Ìì®ÌÑ∞Î•º ÌïòÎäî Í∑∏ ÏÉòÌîåÏùò Ìä∏ÎûôÏÑúÎπåÎ¶¨Ìã∞Í∞Ä ÏóÜÏóàÏñ¥Ïöî. ÏôúÎÉê? Í∑∏ Îç∞Ïù¥ÌÑ∞Í∞Ä ÌïúÍµ≠ÏóêÏÑú ÏóÜÏóàÏñ¥Ïöî. ÌïúÍµ≠ÏóêÏÑú ÍµâÏû•Ìûà Ï¢ãÏùÄ Î≥ëÏõêÏóêÏÑú ÌïúÍ±∞ÏóêÏöî ÌïòÏßÄÎßå Í∑∏ Îç∞Ïù¥ÌÑ∞Í∞Ä ÏóÜÏóàÏñ¥Ïöî Ïù¥Í≤å ÏûàÎäîÎç∞ ÎÇº Ïàò ÏóÜÏùÑ Ï†ïÎèÑÏòÄÏñ¥Ïöî. ÎÇ¥Í∏∞Í∞Ä Ï¢Ä ÌûòÎì†...

Í∑∏Î†áÍ≤å ÌñàÏúºÎãàÍπå Í∑∏Î¶¨Í≥† Ïä§ÌÑ∞ÎîîÎ•º ÏãúÏûëÌï†Îïå Î†àÏù¥Ïä§Ïùò Î†àÌîÑÎ¶¨ÏÑºÌã∞Î∏åÌïú Í±∏ Í≥®ÎùºÏïº ÎêòÍ∏∞ ÎïåÎ¨∏Ïóê Ïù¥Í≤å Ïã§Ï†úÏ†ÅÏúºÎ°ú ÏâΩÏßÄÍ∞Ä ÏïäÏïÑÏöî. ÏóÜÎã§Í≥†Îäî ÎßêÌï† ÏàòÎäî ÏóÜÏßÄÎßå Í∑∏Î¶¨Í≥† Ïö∞Î¶¨Í∞ôÏùÄ Í≤ΩÏö∞ÏóêÎäî Ìú¥Î®∏Î∞±ÌÑ∞Ïä§ÌÑ∞Î¶¨ÎÇò Ïù¥Îü∞ Í≤ÉÎì§ÎèÑ Í∑∏ÎûòÏÑú Ïù¥Î†áÍ≤å ÌîºÎìúÎ∞±ÏùÑ ÌîÑÎ°úÏï°Ìã∞Î∏îÎ¶¨ Ï§ÄÎπÑÎ•º ÌïòÎäîÍ≤å ÎêòÍ≤å Ï§ëÏöîÌï©ÎãàÎã§. Ï≤òÏùåÎ∂ÄÌÑ∞. Í∑∏ Îã§ÏùåÏóê Îã§ÌÅêÎ©òÌä∏ÎèÑ ÏãúÏä§ÌÖúÏóê Îì§Ïñ¥Í∞ÄÍ≤å. Î™®Îì† Îã§ÌÅêÎ©òÌä∏Í∞Ä Ï†ïÎßê ÎÑàÎ¨¥ Ï§ëÏöîÌï©ÎãàÎã§. Í∑∏ÎûòÏÑú ÏïÑÍπå Í∑∏ ÎîîÏûêÏù∏ Ïª®Ìä∏Î°§ÏùÑ Îã§ Îî∞ÎùºÏïº ÎêúÎã§Îäî Í±∏ ÎßêÏîÄÎìúÎ¶¨Í≥†Ïöî. Í∞ÄÏû• Í∑∏ ÏÑùÏÑ∏Ïä§...

Í∑∏Í±∞Ïóê ÏöîÍµ¨Ï°∞Í±¥Ïù¥ Ï≤´Î≤àÏß∏Í∞Ä Early Stage Planning Ïù¥Í±∞Îäî ÏïÑÏòà Îí§ÏóêÏÑúÎ∂ÄÌÑ∞ ÏÉùÍ∞ÅÌïòÎäîÍ≤å Ï¢ãÏ£†. CommercializationÏùÑ ÏúÑÌï¥ÏÑúÎäî Ïñ¥Îñ§ InverseÎ•º ÌïòÍ≥† Í∑∏Îü¨Î©¥ Ïñ¥Îñ§ ÎÑå Ìï¥ÏÑùÏùÑ Ìï†Í±∞ÎÉê?

ÎØ∏Î¶¨ ÏÉùÍ∞ÅÌïòÎ©¥ÏÑú Îß§ Ï†úÌíàÏùÑ Îã§Î£®Í≥† ÎÇòÍ∞ÄÎäîÍ≤å Î≤†Ïä§Ìä∏ÏûÖÎãàÎã§.

FD ÏóêÏñ¥ÌîåÎ°úÍ∑∏Ïùò Î∞òÏùÄ ÏïÑÎãàÏßÄÎßå ÍµâÏû•Ìûà ÌÅ¨Îã§. Ïù¥Í≤ÉÎßå Ï§ÄÎπÑÎ•º ÏûòÌïòÎ©¥ Í∑∏ Îã§ÏùåÏùò Î¶¨Î≤ÑÏä§Í±¥, Ïª®Ïã§Îü¨ÏóêÏù¥Ï†ÄÏÖòÎèÑ ÏïÑÏ£º ÏâΩÍ≤å Í∞à Ïàò ÏûàÎã§. FDI Ïª§ÎÆ§ÎãàÏºÄÏù¥ÏÖò, ÎîîÏä§ÌîåÎ†àÏù¥ÏÖò Ï∞æÎäî Í≤ÉÎèÑ FDIÍ∞Ä ÎÇòÏò¨ Îïå Ï∞æÎäî Í≤å ÏïÑÎãàÎùº Ìõ®Ïî¨ Ï†ÑÎ∂Ä Îã§ Ï∞æÎäî Í≤ÅÎãàÎã§. Í∑∏Î¶¨Í≥† Î¶¨Ïù∏Î≥¥Ïä§ ÎßàÏ∞¨Í∞ÄÏßÄÎ°ú. Í∑∏Îü∞ Í≤ÉÎì§ÏùÑ ÏûêÏú†ÎÇò ÏãúÍ∞ÑÎèÑ ÏûÉÏñ¥Î≤ÑÎ¶¨ÏßÄ ÏïäÍ≥†Ïöî. Í∑∏ Îã§ÏùåÏóê Î©îÏä§ÌÑ∞ ÌéÄÎî©ÎùºÏö¥ÎìúÏóêÏÑúÎèÑ Ïûò Í¥úÏ∞ÆÏùÑ ÏàòÍ∞Ä ÏûàÏäµÎãàÎã§. ÏäπÎ∂ÄÏûëÏù¥ Ïù¥Ïñ¥Ïßà ÏàòÍ∞Ä ÏûàÏ£†. Í∑∏ÎûòÏÑú ÎßàÏºìÌïòÍ≥† Í∞ÄÎäîÍ±∞Îã§.

ÌéúÏùÑ ÏùºÏßÅÌïòÍ≥†, ÏóëÏä§ÌçºÌä∏Î•º ÏÇ¨Ïö©Ìï¥ÏïºÌïòÍ≥†, Ïª§ÎÆ§ÎãàÏºÄÏù¥ÏÖò ÌîÑÎ°úÏï°Ìã∞Î∏åÎ•º Ìï¥ÏïºÌï©ÎãàÎã§. Î¨ºÎ°† Îã§ Í∏∞Î°ùÏùÄ ÎêòÏßÄÎßå, Í∑∏Î¶¨Í≥† Îç∞Ïù¥ÌÑ∞Î•º ÏïÑÏ£º Ï§ëÏöîÏãúÌï¥ÏïºÌï©ÎãàÎã§. Í∑∏ÎûòÏÑú at least in the deep, systematical Ïù¥ÎùºÎäîÍ≤å Ï≤òÏùåÏóê Î°úÎìúÎßµÏùÑ Ïû°ÎäîÍ≤å ÏïÑÏ£º Ï§ëÏöîÌïòÎã§. Í∑∏ ÎßêÏîÄÏùÑ Í∞ïÏ°∞ÎìúÎ¶ΩÎãàÎã§.

ÏïÑ Ïù¥Í≤å Ïù¥Ï†ú ÏµúÍ∑ºÏóê ÏóÖÎç∞Ïù¥Ìä∏Ïù∏Îç∞ Ïó¨Í∏∞ ÏûàÎã§ Í∑∏Î¶¨Í≥†

Í∑∏ ÌÅ∞ Ïú†ÏÑ∏Î®ºÌä∏Îäî LEDÏòÄÏ£†. Í∑∏ Îã§ÏùåÏóê ÏßÄÍ∏àÏùÄ Cybersky LEDÎùºÍ≥† SAMD ÏôÑÏ†ÑÌûà ÏûàÏäµÎãàÎã§.

ÌÉÄÎâ¥Îç∏Ïä§Îäî Ï†ÄÌù¨Îäî Ïù∏ÏÇ¨Î•º Ï£ºÎ°ú ÌïòÎäîÎç∞Ïöî. Ï†ÄÌù¨Îäî Ïù∏Ïñ¥ ÏûÑÏÉÅÏùÑ Ìï† Îïå ÌïÑÏöîÌïú ÏÜåÌîÑÌä∏Ïõ®Ïñ¥Í∞Ä Îî∞Î°ú ÏûàÏäµÎãàÎã§. Í∑∏Í≤å ÏùºÎ†âÌä∏Î°úÎãâ Îç∞Ïù¥ÌÑ∞ Ï∫°ÏäêÏûÖÎãàÎã§.

ÏùºÎ†âÌä∏Î°úÎãâ Îç∞Ïù¥ÌÑ∞ Ï∫°Ï≤ò ÏÜåÌîÑÌä∏Ïõ®Ïñ¥Í∞Ä ÏûàÏäµÎãàÎã§. Îç∞Ïù¥ÌÑ∞Î•º Î≥¥Î©¥ Îç∞Ïù¥ÌÑ∞ÎèÑ ÎßéÏù¥ Îã§Î¶ÖÎãàÎã§. ÎπÑÏ¶àÎãàÏä§ÎèÑ ÌïòÍ≥† Ï†úÏùº Ï§ëÏöîÌïú Í≤ÉÏùÄ ÏñºÎ∞îÏù¥Ìä∏Î¶¨ ÏÑúÎπÑÏä§ÏóêÏÑú ÌïúÍµ≠ÏóêÏÑú ÌòπÏùÄ Îã§Î•∏ ÎÇòÎùºÏóêÏÑú ÎØ∏Íµ≠ÏúºÎ°ú Í∑∏Í±∞ ÏûàÏûñÏïÑÏöî, Ïù¥Ï†ú ÏÖîÎàÑÏùò Í∑∏...

Ìï† Îïå ÌòπÏùÄ ÌöåÏÇ¨Î•º ÏùºÏàòÎåÄÎ°ú Ïú†ÏßÄÌï† Îïå Ï†ÄÎäî ÏùΩÏóàÍ≥†, Í∑∏Î¶¨Í≥† ÎßàÏºÄÌåÖ.

Í∑∏ Îã§ÏùåÏóê Î†àÏù∏Î≥¥Ïö∞Ïä§ÌïòÍ≥† Ïù¥Îü∞ Í≤ÉÎì§ Í≥ÑÏÜç ÏÑ§Î™ÖÌï¥ Ï£ºÏãúÎ©¥ ÏïÑÏ£º Ï¢ãÏùÄ ÌôúÏïΩÏùÑ Í∞ÄÏ†∏Í∞à Ïàò ÏûàÏùÑ Í≤É Í∞ôÏäµÎãàÎã§. Í∞êÏÇ¨Ìï©ÎãàÎã§.

Ï†ÄÌù¨Í∞Ä ÏãúÍ∞ÑÏùÑ Ìïú 10Î∂ÑÏ†ïÎèÑ Îï°Í≤ºÏóàÎäîÎç∞Ïöî. Íµ≠Ïû•ÎãòÍªòÏÑú Í≥°ÏùÑ Ïì∞ÏÖîÏÑú Ï≤¥Í∞êÏù¥ Îã§Ïãú Ï†ïÏã†Ïù¥ ÏôîÏäµÎãàÎã§. Ïò§Îäò ÏßÄÍ∏à ÏÇ¨Ïã§ FDAÍ∞Ä ÏõåÎÇô Ï§ëÏöîÌïú Î∂ÑÎì§Ïù¥ ÎßéÎã§Î≥¥ÎãàÍπå

</details>

---

## 4. Sung Park

| | |
|---|---|
| ‚è∞ | **02:20 PM ~ 02:40 PM** |
| üè¢ | Reed Smith LLP |
| üìå | "Appropriate Risk Allocation in the FDA World" |
| üí° | FDAÎ≤ï Ï†ÑÎ¨∏ Î≥ÄÌò∏ÏÇ¨ - "ÌîåÎü¨Î®∏(Î¨∏Ï†ú ÏàòÎ¶¨)" & "ÌéòÏù∏ÌÑ∞(Ìà¨ÏûêÏûêÏóêÍ≤å FDA Î¶¨Ïä§ÌÅ¨ ÏÑ§Î™Ö)" |

---

### Summary

#### ÎîîÏßÄÌÑ∏Ìó¨Ïä§ ÏãúÏû• Í∞úÏöî
- FDA ÌóàÍ∞Ä AI ÏùòÎ£åÍ∏∞Í∏∞ ÏïΩ 1,250Í∞ú, 75%(956Í∞ú)Í∞Ä Î∞©ÏÇ¨ÏÑ† Í¥ÄÎ†®
- ÌïúÍµ≠ Í∏∞ÏóÖ Í≤ΩÏüÅÎ†•: ÏÉÅÎåÄÏ†ÅÏúºÎ°ú Ï†ÅÏùÄ Í∑úÏ†ú + ÌíçÎ∂ÄÌïú ÎîîÏßÄÌÑ∏ Ïù∏Ïû¨
- 2024ÎÖÑ Ìà¨Ïûê ÏÑ±Ïû•: $9.9B, ÌèâÍ∑† Îîú ÏÇ¨Ïù¥Ï¶à $20.4M ‚Üí $28.1M
- 19Í∞ú ÌöåÏÇ¨Í∞Ä $100M+ Î©îÍ∞ÄÎùºÏö¥Îìú Ïú†Ïπò

#### FDA Í∑úÏ†ú ÎèÑÏ†ÑÍ≥ºÏ†ú
- 1976ÎÖÑ ÏùòÎ£åÍ∏∞Í∏∞ Î≤ïÎ†πÏù¥ ÎîîÏßÄÌÑ∏Ìó¨Ïä§Ïóê ÏôÑÏ†ÑÌûà Ï†ÅÏö©ÎêòÏßÄ ÏïäÏùå
- FDAÍ∞Ä ÏÉàÎ°úÏö¥/Í∏∞Ï°¥ Í∑úÏ†úÎ•º Îß§Ïö∞ Í≥µÍ≤©Ï†ÅÏúºÎ°ú Ìï¥ÏÑù
- ÏÉÅÎãπÌïú Î¶¨ÏÜåÏä§Î•º Í∑úÏ†ú ÏßëÌñâÏóê ÏÇ¨Ïö©

#### ÏÇ¨Î°Ä Ïó∞Íµ¨ 1: WHOOP
- Ïõ®Ïñ¥Îü¨Î∏î Í∏∞Í∏∞ÏóêÏÑú ÌòàÏïï Îç∞Ïù¥ÌÑ∞ ÌëúÏãúÎßåÏúºÎ°ú ÏùòÎ£åÍ∏∞Í∏∞ Î∂ÑÎ•ò
- FDA: ÌòàÏïï Ï∏°Ï†ï ÏûêÏ≤¥Í∞Ä "inherently diagnostic"
- CEOÍ∞Ä Í≥µÍ∞úÏ†ÅÏúºÎ°ú FDAÏôÄ Ïã∏Ïö∞Í≤†Îã§Í≥† Î∞úÌëú
- "Bad facts make for bad precedents" - Ïã∏Ïö∞Í∏∞ Ï¢ãÏùÄ ÏÇ¨Î°Ä ÏïÑÎãò

#### ÏÇ¨Î°Ä Ïó∞Íµ¨ 2: Clinical Decision Support (CDS)
- ÏùòÎ£åÍ∏∞Í∏∞ Ìö®Îä• ÌëúÍ∏∞ÌïòÎ©¥ÏÑúÎèÑ Í∑úÏ†ú Î©¥Ï†ú Í∞ÄÎä•Ìïú Ïπ¥ÌÖåÍ≥†Î¶¨
- 4Í∞ÄÏßÄ Î©¥Ï†ú Í∏∞Ï§Ä:
  1. ÏùòÎ£å Ïù¥ÎØ∏ÏßÄ/ÏãúÍ∑∏ÎÑê ÏßÅÏ†ë Î∂ÑÏÑù Ïïà Ìï®
  2. ÏùòÎ£å Ï†ïÎ≥¥ ÎîîÏä§ÌîåÎ†àÏù¥
  3. ÏùòÎ£åÏßÑÏóêÍ≤å Í≤∞Ï†ï ÏïÑÎãå Ï∂îÏ≤úÎßå Ï†úÍ≥µ
  4. ÎèÖÎ¶ΩÏ†Å Í≤ÄÌÜ† Í∞ÄÎä•Ìïú Í∑ºÍ±∞ Ï†úÍ≥µ
- FDA Ï∂îÍ∞Ä Ï†úÌïú: ÏûêÎèôÌôî Í∏àÏßÄ, Í∏âÎ∞ïÌïú ÏÉÅÌô© ÏÇ¨Ïö© Ïãú ÏùòÎ£åÍ∏∞Í∏∞ Î∂ÑÎ•ò
- 2023ÎÖÑ 9Ïõî Ï§ëÌôòÏûê Î™®ÎãàÌÑ∞ÎßÅ Ï†úÌíàÏóê Í≤ΩÍ≥†Ïû• Î∞úÏÜ°

#### Ï†ÑÎûµÏ†Å Í≥†Î†§ÏÇ¨Ìï≠
- Î¶¨Ïä§ÌÅ¨ Í∞êÏàòÎäî Î∂àÍ∞ÄÌîºÌïòÏßÄÎßå Ï†àÎåÄ Í±¥ÎìúÎ¶¨Î©¥ Ïïà ÎêòÎäî ÏòÅÏó≠ ÌååÏïÖ ÌïÑÏöî
- FDA Í∑úÏ†úÎ•º Î∞õÏùÑ ÌïÑÏöîÍ∞Ä ÏûàÎäîÏßÄ Í≥†Î†§ - Í∏∞Îä• Ï°∞Ï†ïÏúºÎ°ú Í∑úÏ†ú ÌöåÌîº Í∞ÄÎä•
- Ìà¨ÏûêÏûêÎì§ÏùÄ ÏùºÎ∞òÏ†ÅÏúºÎ°ú Í∑úÏ†ú Î∞õÏßÄ ÏïäÎäî Ï†úÌíà ÏÑ†Ìò∏
- Ïó∞Î∞© + Ï£º Ï†ïÎ∂Ä Í∑úÏ†ú Î™®Îëê Î™®ÎãàÌÑ∞ÎßÅ ÌïÑÏöî
- ÌïúÍµ≠ ÌöåÏÇ¨Îì§ Ï†úÌíà Ïö∞ÏàòÌïòÏßÄÎßå ÎØ∏Íµ≠ ÏãúÏû• ÎÖ∏Ï∂ú Î∂ÄÏ°± - Ïª®ÌçºÎü∞Ïä§ Ï∞∏Í∞Ä Í∂åÏû•

#### Action Items
- [ ] ÎîîÏßÄÌÑ∏Ìó¨Ïä§ Í∑úÏ†ú "ÏßÄÎ¢∞Î∞≠" ÌååÏïÖ Î∞è ÌöåÌîº Ï†ÑÎûµ ÏàòÎ¶Ω
- [ ] FDA Í∑úÏ†ú Ïó¨Î∂ÄÏóê Îî∞Î•∏ Ï†úÌíà Í∏∞Îä• ÏÑ§Í≥Ñ Í≤ÄÌÜ†
- [ ] Ïó∞Î∞© Î∞è Ï£º Ï†ïÎ∂Ä Îç∞Ïù¥ÌÑ∞ ÌîÑÎùºÏù¥Î≤ÑÏãú Í∑úÏ†ú Î™®ÎãàÌÑ∞ÎßÅ
- [ ] ÎØ∏Íµ≠ Ïª®ÌçºÎü∞Ïä§ Ï∞∏Í∞Ä Îì± Ï†úÌíà ÌôçÎ≥¥ Í∏∞Ìöå ÌôïÎåÄ

---

### Slides

#### Slide 1
![page_001](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_001_6._KAMDA_Sung_Park_Reed_Smith_LLP.jpg)

**ÏöîÏïΩ**
> Ïù¥ ÌòëÌöå ÎßåÎìúÏã† Í±∞ Ï∂ïÌïòÎìúÎ¶ΩÎãàÎã§. ÌïúÍµ≠ ÌöåÏÇ¨Îì§ÏóêÍ≤å Î™©ÏÜåÎ¶¨Í∞Ä ÌïÑÏöîÌïòÎã§Í≥† ÏÉùÍ∞ÅÌñàÎäîÎç∞ Ïù¥Î†áÍ≤å ÎßåÎì§Ïñ¥Ï†∏ÏÑú Îã§ÌñâÏûÖÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Î®ºÏ†Ä Ïù¥ ÌòëÌöå ÎßåÎìúÏã† Í±∞ Ï∂ïÌïòÎìúÎ¶¨Í≥†Ïöî. Ï†úÍ∞Ä Îã§Î•∏ ÎïåÎèÑ ÏñòÍ∏∞ÌñàÏùÑ Îïå Ìï≠ÏÉÅ ÌïúÍµ≠ ÌöåÏÇ¨Îì§ÏóêÍ≤å Î™©ÏÜåÎ¶¨Í∞Ä ÌïÑÏöîÌïòÎã§Í≥† ÏÉùÍ∞ÅÌïòÍ≥† ÏûàÏóàÎäîÎç∞ Ïù¥Î†áÍ≤å ÎßåÎì§Ïñ¥Ï†∏ÏÑú Îã§ÌñâÏûÖÎãàÎã§. ÏòàÎ•º Îì§Ïñ¥ÏÑú FDAÍ∞ôÏùÄ ÏÉàÎ°úÏö¥ Í∑úÏ†ïÏù¥ÎÇò Î≤ïÏïàÏù¥ ÎÇòÏôîÏùÑ ÎïåÎäî ÎØ∏Íµ≠ ÌòëÌöåÎÇò ÌöåÏÇ¨Îì§Ïù¥ Ïª§Î©òÌä∏Î•º ÌÜµÌï¥ÏÑú Federal RegistryÎ•º ÏÑ†ÎØ∏Ïã†ÏùÑ Ìïú Í≤ΩÏö∞Í∞Ä ÎßéÏùÄÎç∞ Í∑∏Îü∞ Í±∏ Î≥¥Î©¥ÏÑú Ìï≠ÏÉÅ ÌïúÍµ≠ ÌöåÏÇ¨Îì§ÎèÑ... Îòê Ïù¥Í≤å ÏûàÏúºÎ©¥ Î≤†ÎÑ§ÌîºÏÖúÌïòÍ≤†Îã§Í≥† ÏÉùÍ∞ÅÌñàÎäîÎç∞ Ïù¥Î≤àÏóê Í∑∏Îü∞ Í∏∞Í¥ÄÏù¥ ÏÉùÍ∏¥ Í≤É Í∞ôÏäµÎãàÎã§. Ï†ÄÎäî Î∞ïÏÑ±ÏõêÏù¥ÎùºÍ≥† ÌïòÍ≥†Ïöî. Í∑∏ Îã§Ïùå Î¶¨Îìú Ïä§ÎØ∏Ïä§Ïùò FDAÎ≤ï Í¥ÄÎ†® Î≥ÄÌò∏ÏÇ¨ÏûÖÎãàÎã§.

</details>

#### Slide 2
![page_002](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_002_6._KAMDA_Sung_Park_Reed_Smith_LLP.jpg)

**ÏöîÏïΩ**
> Ï†ÄÎäî ÌïòÎäî ÏùºÏùÑ ÌîåÎü¨Î®∏ ÎòêÎäî ÌéòÏù∏ÌÑ∞ÎùºÍ≥† Ìï©ÎãàÎã§. ÌîåÎü¨Î®∏Îäî FDA Í¥ÄÎ†® Î¨∏Ï†úÎ•º Í≥†ÏπòÍ≥†, ÌéòÏù∏ÌÑ∞Îäî Ìà¨ÏûêÏûêÎì§ÏóêÍ≤å FDA Î¶¨Ïä§ÌÅ¨Î•º ÏÑ§Î™ÖÌï©ÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Ï†ÄÎäî Ï†úÍ∞Ä ÌïòÎäî ÏùºÏùÑ ÌîåÎü¨Î®∏ ÎòêÎäî ÌéòÏù∏ÌÑ∞ÎùºÍ≥† ÌïòÎäîÎç∞ ÌîåÎü¨Î®∏Îäî Î¨∏Ï†ú ÏÉùÍ≤ºÏùÑ Îïå FDA Í¥ÄÎ†® ÏùºÏùÑ Í≥†ÏπòÍ∏∞ ÎïåÎ¨∏Ïóê ÌîåÎü¨Î®∏Í≥†Ïöî. ÌéòÏù∏ÌÑ∞ Í∞ôÏùÄ Í≤ΩÏö∞Îäî Ìà¨ÏûêÏûêÎì§ÏóêÍ≤å FDA Í¥ÄÎ†® Î¶¨Ïä§ÌÅ¨Ïóê ÎåÄÌï¥ÏÑú ÏÑ§Î™ÖÏùÑ ÌïòÍ∏∞ ÎïåÎ¨∏Ïóê

Ïò§Îäò ÎÇòÎàà ÎÇ¥Ïö©Îì§Ïù¥ Î≥ÄÌò∏ÏÇ¨ ÌÅ¥ÎùºÏù¥Ïñ∏Ìä∏ Î¶¥Î†àÏù¥Ïã±Ïù¥ÎÇò Ïù¥Í±∏ ÎßêÏîÄÎìúÎ¶¨ÎùºÍ≥† Ï†ÄÎäî ÌöåÏÇ¨ÏóêÏÑú Í≥ÑÏÜç ÍµêÏú°Î∞õÍ≥† ÏûàÏäµÎãàÎã§.

Ïò§Îäò ÎÖºÏùòÌï† ÎÇ¥Ïö©ÏùÄ Ï≤´ Î≤àÏß∏Î°úÎäî ÏßÄÍ∏à ÎîîÏßÄÌÑ∏ ÏóëÏä§ ÏãúÏû•ÏóêÏÑú ÏñºÎßàÎÇò ÎßéÏùÄ ÌòÅÏã†Í∞êÏù¥ ÏùºÏñ¥ÎÇòÍ≥† ÏûàÎäîÏßÄ, Ìà¨Ïûê ÏãúÏû•ÎèÑ ÏñºÎßàÎÇò Ïª§ÏßÄÍ≥† ÏûàÎäîÏßÄ Í∑∏Ïóê Í¥ÄÌï¥ÏÑú Í∑úÏ†úÍ∞Ä Ïñ¥ÎñªÍ≤å Î∞úÎ™©ÏùÑ Ïû°Í≥† ÏûàÎäîÏßÄÏóê Í¥ÄÌïú Í±∞Í≥†Ïöî. ÌîåÎ†àÏù∏ÌïÑÎìúÎ°ú Î¥§ÏùÑ Îïå, Î¨ºÎ°† ÏïÑÍπå ÎßêÏîÄÎìúÎ¶∞ Í≤ÉÏ≤òÎüº Ïª§Î©òÌä∏Î•º ÏÑ†ÎØ∏ÏÖòÌïòÎäî Í∑∏Îü∞ Ïï°Ìã∞ÎπÑÌã∞Î•º ÌÜµÌï¥ÏÑú ÌîåÎ†àÏù∏ÌïÑÎìúÎ•º Î∞îÍæ∏Î†§Í≥† ÌïòÏã§ Ïàò ÏûàÍ≤†ÏßÄÎßå Î∞îÎÄåÏßÄ ÏïäÎäî Í≥ºÏ†ïÏóêÏÑú Ïù¥Îü∞ ÌîåÎ†àÏù∏ÌïÑÎìúÎäî Ïö∞Î¶¨ÏóêÍ≤å Ï£ºÏñ¥ÏßÑ Í±¥Îç∞ Ïù¥Í±∏ Ïñ¥ÎñªÍ≤å ÌôúÏö©Ìï¥ÏÑú ÏÑ±Í≥µÏùÑ ÏãúÌÇ¨ Ïàò ÏûàÏùÑÏßÄÏóê Í¥ÄÌïú ÎÇ¥Ïö©ÏûÖÎãàÎã§.

ÎîîÏßÄÌÑ∏Ïä§, Îã®Ïñ¥ ÎîîÏßÄÌÑ∏Ïä§Î•º Î¥§ÏùÑ Îïå Ïó¨Í∏∞Ïóê Î≤ïÏ†Å Îç∞ÌîºÎãàÏÖòÏùÄ ÏóÜÏßÄÎßå Ï£ºÏöî ÎîîÏßÄÌÑ∏ Í∏∞Ïà†ÏùÑ Ïù¥Ïö©Ìï¥ÏÑú Í±¥Í∞ïÏù¥ÎÇò ÏûÑÏÉÅ Í≤∞Í≥ºÎ•º Ìñ•ÏÉÅÏãúÌÇ§Îäî Í≤ÉÏù¥ÎùºÍ≥† Î≥¥Î©¥ Îê† Í≤É Í∞ôÏäµÎãàÎã§. Ïù¥ Îç∞ÌîºÎãàÏÖòÏù¥ ÍµâÏû•Ìûà Î∏åÎùºÎçîÏ£†. Í∑∏Îü∞Îç∞ ÏùºÎ∞òÏ†ÅÏúºÎ°ú Ïö∞Î¶¨Í∞Ä ÏÇ¨Ïö©ÌïòÎäî ÎîîÏßÄÌÑ∏Ìó¨Ïä§ Îã®Ïñ¥Ïùò ÏùòÎØ∏Îäî ÏïÑÍπå ÎßêÏîÄÌïòÏã† ÎåÄÎ°ú SAMT Í∑∏Îü¨ÎãàÍπå ÏòàÎ•º Îì§Ïñ¥ÏÑú AIÎ•º ÏÇ¨Ïö©Ìïú ÏÜåÌîÑÌä∏Ïõ®Ïñ¥ Ï†ïÎèÑÍ∞Ä Îê† Ïàò ÏûàÍ≤†Ï£†. Í∑∏Î¶¨Í≥† ÏÇ¨Ïã§ ÏöîÏ¶ò Í∑∏Îü∞ Í∏∞Îä•Îì§ÏùÄ ÏõåÎÇô Í±∞Ïùò Î™®Îì† ÏùòÎ£åÍ∏∞Í∏∞Ïóê ÎßéÏïÑÏ†∏ÏÑú ÎîîÏßÄÌÑ∏Ìó¨Ïä§ ÏùòÎ£åÍ∏∞Í∏∞ÎùºÍ≥† ÌïòÏßÄ ÏïäÏùÑ Ïàò ÏûàÎäî ÏùòÎ£åÍ∏∞Í∏∞Í∞Ä Ïò§ÌûàÎ†§ Ï†ÅÏùÑ Ï†ïÎèÑÏûÖÎãàÎã§. FDAÏóêÏÑú ÏßÄÍ∏à ÌòÑÏû¨ÍπåÏßÄ ÌóàÍ∞ÄÎ•º Î∞õÏùÄ Ï†ïÌôïÌûà ÎßêÌïòÎ©¥ 510 DifferenceÎ•º Î∞õÏùÄ G-SERVICE AI ÏùòÎ£åÍ∏∞Í∏∞Í∞Ä 1250Í∞ú Ï†ïÎèÑ ÎêòÍ≥†Ïöî. Í∑∏ Îã§ÏùåÏóê Í∑∏ Ï§ë Í±∞Ïùò Ï†ïÌôïÌïòÍ≤å 75%Ïù∏ 956Í∞ú Ï†ïÎèÑÍ∞Ä Radiology PhilatelyÏóêÏÑú ÌóàÍ∞ÄÎ•º Î∞õÏùÄ

Í∑∏Î¶¨Í≥† Ïù¥ Ï§ëÏóêÏÑúÎäî ÏÇ¨Ïã§ ÌïúÍµ≠ ÌöåÏÇ¨Îì§ÎèÑ ÍµâÏû•Ìûà ÎßéÏäµÎãàÎã§. Í∑∏ÎûòÏÑú Ï†úÍ∞Ä ÏÉùÍ∞ÅÌïòÍ∏∞ÏóêÎäî ÌïúÍµ≠ ÌöåÏÇ¨Îì§Ïù¥ ÏÉÅÎãπÌïú Ïù¥Ï†êÏùÑ Í∞ÄÏßÄÍ≥† Í≤ΩÏüÅÎ†•ÏùÑ Í∞ÄÏßà Ïàò ÏûàÎäî Î∂ÑÏïºÍ∞Ä ÎîîÏßÄÌÑ∏Ïä§ ÎùºÍ≥† ÏÉùÍ∞ÅÌïòÎäîÎç∞ Í∑∏ Ïù¥Ïú†Îäî Ï≤´ Î≤àÏß∏Î°úÎäî Î∞©Í∏à ÎßêÏîÄÌïòÏã† Î≤ïÏ†Å ÎòêÎäî regulatory Í∑úÏ†ú Ï†ÑÎûµÏù¥ Îã§Î•∏ ÌïÑÎìúÏóê ÎπÑÌï¥ÏÑúÎäî Ï¢Ä Îçî Ï†ÅÏùÄ Ìé∏Ïù¥Íµ¨Ïöî. ÎëêÎ≤àÏß∏Î°úÎäî ÌïúÍµ≠Ïóê ÏõåÎÇô Ïû¨Îä•Ïù¥ ÏûàÏúºÏã† Î∂ÑÎì§ÎèÑ Ïù¥Ï™ΩÏúºÎ°ú ÎßéÏïÑÏÑú ÎîîÏßÄÌÑ∏ ÏÇ¨ÏóÖÏù¥ ÏïûÏúºÎ°úÎèÑ ÌÅ¨ÏßÄ ÏïäÏùÑÍπå Í∞úÏù∏Ï†ÅÏúºÎ°ú ÏÉùÍ∞ÅÌïòÍ≥† ÏûàÍ≥† Îòê ÏßÄÎÇú Î™áÎÖÑÎßå Ï†úÍ∞Ä Í≤ΩÌóòÌï¥ ÏôîÎçò Î∂ÄÎ∂ÑÏûÖÎãàÎã§. Ìà¨Ïûê ÏãúÏû• Í∞ôÏùÄ Í≤ΩÏö∞Îäî 2024ÎÖÑÏóê ÎπÑÌï¥ÏÑú Ìà¨ÏûêÍ∞Ä Í∑∏ÎûòÎèÑ ÎßéÏù¥ ÎäòÏñ¥ÎÇú Ìé∏Ïù∏Îç∞Ïöî. ÏßÄÍ∏à 3Ïõî 3ÏùºÏóê ÎÅùÎÇ¨ÏùÑ Îïå 9.9Î∞ÄÎ†àÎãå Îã¨Îü¨

Average deal sizeÎèÑ ÏûëÎÖÑÏóê 20.4Î∞ÄÎ¶¨Ïñ∏ÏóêÏÑú 28.1Î∞ÄÎ¶¨Ïñ∏Ï†ïÎèÑ Ïò¨ÎûêÍ≥†, Ïó¨Í∏∞ÏÑú ÌïúÍ∞ÄÏßÄÎäî Ïù¥ Ïà´ÏûêÏùò ÏÉÅÎãπÎ∂ÄÎ∂ÑÏù¥ Î©îÍ∞ÄÎùºÏö¥ÎìúÎùºÍ≥† Î∂àÎ¶¨Îäî ÏÉÅÎãπÌûà ÌÅ∞ Ìä∏ÎûúÏÑπÏÖòÏùò ÌöåÏÇ¨Í∞Ä ÎßéÏäµÎãàÎã§. 19Í∞úÏ†ïÎèÑÏùò ÌöåÏÇ¨Îì§Ïù¥ 100Î∞ÄÎ¶¨Ïñ∏Ï†ïÎèÑ, ÎòêÎäî Îçî ÌÅ∞ Î©îÍ∞ÄÎùºÏö¥ÎìúÎùºÍ≥† Î∂àÎ¶ΩÎãàÎã§. Í∑∏ Îã§ÏùåÏóê Ïù¥Í±∞Îäî ÏïûÏúºÎ°ú ÏûàÏùÑ AURA, Í±∞Ïùò 900Î∞±ÎßåÏõê Îê†Í±∞ÎùºÍ≥† ÌïòÎäîÎç∞, AURAÎ•º Ïì∞Ïã† Î∂Ñ ÏûàÎÇòÏöî? Í∑∏ ÌéÄÎî©ÏùÄ ÏïÑÏßÅ Ïπ¥Ïö¥Ìä∏ÌïòÏßÄ ÏïäÏùÄ Í∑∏Îü∞ Ïà´ÏûêÏûÖÎãàÎã§. M&A Ïï°Ìã∞ÎπÑÌã∞ÎèÑ ÎäòÏñ¥ÎÇòÏÑú ÏûëÎÖÑ 120Í∞ú Ï†ïÎèÑÏóêÏÑú ÏßÄÍ∏à 165Í∞úÎ•º ÎÑòÏóàÎã§Í≥† Ìï©ÎãàÎã§.

Í∑∏Î†áÍ≤å ÏãúÏû•Ïù¥ Ïª§ÏßÄÍ≥† ÏûàÍ≥† ÌòÅÏã†ÎèÑ ÎßéÏïÑÏßÄÍ≥† ÏûàÎäî FDA Í∑úÏ†ú ÌóàÍ∞ÄÎ•º Î∞õÎäî Î∞òÎ©¥ÏóêÏÑú Î∞úÎ™©ÏùÑ Ïû°Í≥† ÏûàÎäî Î∂ÄÎ∂ÑÏùÄ Ï†ú ÏÉùÍ∞ÅÏóêÎäî FDA Í∑úÏ†ú Î∂ÄÎ∂ÑÏûÖÎãàÎã§. FDA ÏùòÎ£åÍ∏∞Í¥ÄÎ†® Î≤ïÎ†πÏùÄ 1976ÎÖÑÏóê Î®ºÏ†Ä ÎßåÎì§Ïñ¥Ï°åÍ≥† Í∑∏ÎûòÏÑú ÏùºÎã®ÏùÄ ÏÉÅÎãπÌûà ÏùòÌöåÏóêÏÑúÎèÑ Í∑∏Î†áÍ≥† FDA Î∂ÄÎ∂ÄÎèÑ Í∑∏Î†áÍ≥† Î≠ê Ïä§ÌÉúÏ∏ÑÎì§Í≥º Í∞ÄÏù¥Îì†Ïä§Îì§ ÌÜµÌï¥ÏÑú ÎßéÏùÄ Î≥ÄÌôîÎ•º ÏïÑÏßÅ ÏÉÅÎãπÎ∂ÄÎ∂ÑÏù¥ ÎîîÏßÄÌÑ∏Ïä§ÏóêÎäî Ï°∞Î™ÖÏù¥ ÎêòÏßÄ ÏïäÏäµÎãàÎã§. ÎëêÎ≤àÏß∏, Ïù¥Í±∞Î≥¥Îã§ Îçî Ï†úÍ∞Ä Ìï≠ÏÉÅ ÏïÑÏâ¨Ïö¥ Î∂ÄÎ∂ÑÏùÄ Î≠êÎÉêÎ©¥ FDAÏóêÏÑú Í≥ÑÏÜç Ïù¥ ÏÉàÎ°úÏö¥ Î≤îÏ£ÑÎì§Ïù¥ÎÇò Í∏∞Ï°¥ Î≤îÏ£ÑÎì§ÏùÑ ÍµâÏû•Ìûà aggressiveÌïòÍ≤å Ìï¥ÏÑùÏùÑ Ìï©ÎãàÎã§. Í∑∏Î¶¨Í≥† Í∑∏ aggressiveÌïú Ìï¥ÏÑùÏùÑ ÏßÄÌÇ§Í∏∞ ÏúÑÌï¥ÏÑú ÍµâÏû•Ìûà ÎßéÏùÄ Î¶¨ÏÜåÏä§Î•º Ï†ÄÎäî ÎÇ≠ÎπÑÌïòÍ≥† ÏûàÏäµÎãàÎã§.

ÏÉùÍ∞ÅÌï©ÎãàÎã§. Ïù¥Í±∞Ïóê ÎåÄÌï¥ÏÑú ÎëêÍ∞ÄÏßÄ ÏòàÏãúÎ•º ÏÉùÍ∞ÅÌï¥ Î≥ºÍ±∞Íµ¨Ïöî. Í∑∏ÎûòÏÑú Ï†úÍ∞Ä Ïù¥ ÏñòÍ∏∞Î•º ÌïòÎäîÍ±¥ Î¨¥ÏóáÏù¥ÎÉêÎ©¥, Í∑∏ Î¶¨ÏÜåÏä§Í∞Ä ÎÇ≠ÎπÑÍ∞Ä ÎêòÍ≥† ÏûàÎçò ÏïÑÎãàÎ©¥ Ïñ¥Îñ§ ÏóÖÍ∑∏Î†àÏù¥ÎìúÍ∞Ä Îê† Ïàò ÏûàÎçò Í∞ÑÏóê Ï†ÄÌù¨Í∞Ä Ìï† ÏùºÏùÄ Í∑∏ ÎÇòÏ§ëÏóê Î≥¥ÏãúÍ≤†ÏßÄÎßå ÏßÄÎ¢∞Ï∞æÍ∏∞Ï≤òÎüº Í∞ÄÏßÄ ÏïäÏùÑ ÎïåÎ•º ÏïåÎ©¥ ÎêòÎäîÍ±∞Í±∞Îì†Ïöî. Í±∞Í∏∞Îäî ÌîºÌï¥Í∞ÄÎ©¥ÏÑú Í∞ÄÏû• ÏãúÏû•Ïóê Îπ®Î¶¨ Ïª§Î®∏ÏÖúÎùºÏù¥Ï¶à Ìï† Ïàò ÏûàÎèÑÎ°ù Ï†úÍ∞Ä ÌîåÎûòÎãõ Î∂ÑÎì§Í≥º Ìï≠ÏÉÅ ÎÖºÏùòÌïòÎäî Î∂ÄÎ∂ÑÏù¥ Ïù¥Îü∞ Ï†êÏûÖÎãàÎã§. ÏïÑÍπå ÏºÄÏù¥Ïä§ ÎëêÍ∞úÎ•º ÎÖºÏùòÌïòÍ≤†Îã§Í≥† ÌñàÎäîÎç∞ ÌòπÏãú

</details>

#### Slide 3
![page_003](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_003_6._KAMDA_Sung_Park_Reed_Smith_LLP.jpg)

**ÏöîÏïΩ**
> WHOOP Í∏∞Í∏∞Ïùò Blood Pressure Í∏∞Îä•Ïù¥ ÎÖºÎûÄÏù¥ ÎêêÏäµÎãàÎã§. FDAÎäî ÌòàÏïïÏùÑ ÎÇòÌÉÄÎÇ¥Îäî Í≤É ÏûêÏ≤¥Í∞Ä "inherently diagnostic"Ïù¥ÎùºÍ≥† Ï£ºÏû•Ìï©ÎãàÎã§. CEOÍ∞Ä Í≥µÍ∞úÏ†ÅÏúºÎ°ú FDAÏôÄ Ïã∏Ïö∞Í≤†Îã§Í≥† ÌñàÏßÄÎßå, Ïù¥Í±¥ Ïã∏Ïö∞Í∏∞ Ï¢ãÏùÄ ÏÇ¨Î°ÄÍ∞Ä ÏïÑÎãôÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Ïó¨Í∏∞ WOOP!ÎùºÎäî Ï†úÌíà Ïì∞Ïã† Î∂Ñ ÏûàÏúºÏã†Í∞ÄÏöî? ÏïÑÎãà, Î≥¥Ïã† Î∂Ñ? ÏïÑ, Ïì∞Ïã† Î∂ÑÏù¥Ïöî? ÎÑ§, ÌòπÏãú Î™®Î•¥ÏãúÎäî Î∂ÑÎì§ÏùÄ...

Ïù¥ Ï†úÌíàÏù∏Îç∞Ïöî. Ïò§Î•∏Ï™ΩÏóê ÌåîÎ™©Ïóê Ï∞®Í≥† ÏûàÎäî Ï†úÌíàÏù¥ ÏûàÏ£†. Í∑∏Î¶¨Í≥† Ïó¨Í∏∞ Í∑∏ÎûòÌîΩ ÌïúÎ≤à Î¥êÏ£ºÏÑ∏Ïöî. 118, 78. Í∑∏ Îã§ÏùåÏóê Ï¥àÎ°ùÏÉâ, ÎÖ∏ÎûÄÏÉâ, Ï£ºÌô©ÏÉâ ÏûàÏ£†. Ïó¨Í∏∞ Ï¥àÎ°ùÏÉâ, ÎÖ∏ÎûÄÏÉâ, Ï£ºÌô©ÏÉâÎèÑ ÏòàÏ†ÑÏóê ÎπÑÌï¥ÏÑú Î∞îÏÅúÎç∞, Ïù¥Í≤å Ïôú Ï§ëÏöîÌïúÏßÄ Ï°∞Í∏à Ïù¥Îî∞Í∞Ä ÎßêÏîÄÎìúÎ¶¥Í≤åÏöî. Ï†úÍ∞Ä ÏßÄÍ∏à ÏñòÍ∏∞Ìï† Î∂ÄÎ∂ÑÏùÄ General WellnessÎùºÎäî Í≤ÉÏóê Í¥ÄÌïú Ïª®ÏÖâ, General WellnessÎùºÎäî regulatory pathwayÏóêÏöî. Í∏∞ÏóÖÏù¥ ÌÅ¨ÏßÄ ÏïäÏùÄ ÏùºÎ∞òÏ†ÅÏù∏ Ìó¨Ìã∞Ìïú ÎùºÏù¥ÌîÑÏä§ÌÉÄÏùºÏùÑ Î©îÏù∏ÌÖåÏù∏ÌïòÍ±∞ÎÇò Ïù∏ÏΩîÎ¶¨Ï¶àÌïòÎäî ÏÜåÌîÑÌä∏Ïõ®Ïñ¥ Ï†úÌíàÏóê ÎåÄÌï¥ÏÑúÎäî FDAÍ∞Ä ÏùòÎ£åÍ∏∞Í∏∞Î°ú Í∑úÏ†úÌïòÏßÄ ÏïäÎäîÎã§. Í∑úÏ†úÌïòÏßÄ ÏïäÏùÑ ÎøêÎßå ÏïÑÎãàÎùº Î≤ïÏ†ÅÏúºÎ°ú ÏùòÌöåÍ∞Ä Í∑úÏ†úÎ•º Î™ªÌïòÍ≤å Ìï¥ÎÜ®Ïñ¥Ïöî.

Ï†ïÌôïÌïú Î≤ïÏ†Å ÎÇ¥ÎπÑÏ£ºÏùòÏûÖÎãàÎã§. Í∑∏Î†áÍ≤å Ìï¥ÎÜ®Í≥†, Í∑ºÎç∞ ÏïÑÍπå Ï†úÍ∞Ä ÎßêÏîÄÎìúÎ†∏Îçò Í≤ÉÏ≤òÎüº FDAÏóêÏÑú Ïù¥Îü∞ Î∂ÄÎ∂ÑÏóê ÎåÄÌï¥ÏÑú ÍµâÏû•Ìûà ÏóÑÍ≤©ÌïòÍ≤å Ïù¥ Î≤ïÏïàÏùÑ Ìï¥ÏÑùÏùÑ ÌïòÍ≥† ÏûàÏäµÎãàÎã§.

FTAÏóê ÏÇ¨Îäî ÎßêÏùÄ, ÏßÄÍ∏à Ïó¨Í∏∞ Ïö∞Ìù°Í∏∞Í∏∞ ÏûàÏ£†? Ïö∞Ìù°Í∏∞Í∏∞ 5ÏõîÎã¨Ïóê ÏÉàÎ°ú ÎÇòÏò§Îäî Blood Pressure Insight ÌòàÏïï, ÌòàÏïï Ïù∏ÏÇ¨Ïù¥Ìä∏, ÌòàÏïï Î≠ê Ïù∏ÏÇ¨Ïù¥Ìä∏Î©¥ ÏïÑ, ÌïòÏó¨Ìäº ÌòàÏïïÏóê ÎåÄÌï¥ÏÑú Ïà´ÏûêÎ•º ÌëúÏãúÌï¥Ï£ºÎäî Ïù¥ ÌñâÏúÑ ÏûêÏ≤¥Í∞Ä Ïù¥ Í∏∞Í∏∞Î•º ÏùòÎ£åÍ∏∞Í∏∞Î°ú Î∞îÍæºÎã§ Ïù¥ ÎßêÏûÖÎãàÎã§. Í∑∏Î¶¨Í≥† Movi, FD ÌÅ¥Î¶¨Ïñ¥ÎßÅÏä§Í∞Ä ÏóÜÏóàÍ∏∞ ÎïåÎ¨∏Ïóê Ïù¥ Ïú†Î†•Ïù¥Í∏∞Îäî Î∂àÎ≤ï Ïú†Î†•Ïù¥Í∏∞Îã§.

Ïù¥Î†áÍ≤å ÌñàÎäîÎç∞, ÍµâÏû•Ìûà Ï¢Ä Ïù∏Ìä∏Î°úÏä§ÌåÖ ÌïúÍ±∞Îäî ÏÇ¨Ïã§ Ïö∞Î¶¨Í∞Ä Ïó¨Í∏∞ Ïò®ÎèÑÍ≥Ñ ÏûàÏûñÏïÑÏöî.

ÏùºÎ∞òÏ†ÅÏúºÎ°ú ÏâΩÍ≤å ÏÇ¨Ïö©Ìï† Ïàò ÏûàÎäî Ïò®ÎèÑÍ≥Ñ.

ÏùºÎ∞òÏ†ÅÏù∏, ÎòêÎäî Heart Rate Monitor, ÎòêÎäî Oxygen Saturation Monitor, Ïù¥Îü∞ Í≤ΩÏö∞Îäî ÏùòÎ£åÍ∏∞Í∏∞Î°ú ÏÇ¨Ïö©ÌïòÎäî Í≤ΩÏö∞ÎèÑ ÏûàÍ≥†, ÏïÑÎãàÎ©¥ ÏùòÎ£åÍ∏∞Í∏∞Í∞Ä ÏïÑÎãå Í≤ΩÏö∞Î•º ÏÇ¨Ïö©ÌïòÎäî Í≤ΩÏö∞ÎèÑ ÏûàÏñ¥Ïöî. ÏòàÎ•ºÎì§Ïñ¥ÏÑú Ï†úÍ∞Ä ÏûêÏ†ÑÍ±∞ Ïûò ÌÉÄÎäîÎç∞, ÏûêÏ†ÑÍ±∞ ÌÉà Îïå ÌóàÎ∏åÎ†àÏù¥Ìä∏ Î™®ÎãàÌÑ∞ÎßÅ ÌïòÎäîÍ±¥ ÏùòÎ£åÍ∏∞Í∏∞ Ïö©ÎèÑÎäî ÏïÑÎãàÍ≤†Ï£†? Í∑∏ Îã§ÏùåÏóê SPO2ÎèÑ FDAÎèÑ Ïù∏Ï†ïÌï©ÎãàÎã§. ÏùòÎ£åÍ∏∞Í∏∞Î°ú ÏÇ¨Ïö©ÌïòÎäî Í≤ΩÏö∞Í∞Ä ÏûàÍ≥†, ÏùòÎ£åÍ∏∞Í∏∞Î°ú ÏÇ¨Ïö©ÌïòÏßÄ ÏïäÎäî Í≤ΩÏö∞Í∞Ä ÏûàÎã§Í≥†. Ïã§Ï†ú ÌîÑÎ°úÌÜ†ÏΩúÏùÑ Îëê Í∞ú Îã§Î•¥Í≤å ÎßåÎì§Ïñ¥ÎÜ®Ïñ¥Ïöî. FDAÍ∞Ä Ïó¨Í∏∞ÏÑú ÏñòÍ∏∞ÌïòÎäîÍ±∞Îäî...

ÌôîÎ©¥Ïù¥ ÏûòÎ™ªÎì§Ïñ¥ÏôîÎÑ§Ïöî. FDAÍ∞Ä Ïó¨Í∏∞ÏÑú ÏñòÍ∏∞ÌïòÎäî Í≤ÉÏùÄ Î∏îÎ°Ø ÌîÑÎ†àÏÖîÎ•º ÎÇòÌÉÄÎÇ¥Í∏∞ ÎïåÎ¨∏Ïóê Î∏îÎ°Ø ÌîÑÎ†àÏÖîÎ•º ÎÇòÌÉÄÎÇ¥Í∏∞ ÎïåÎ¨∏Ïóê Ïñ¥, Ïù∏Ìó§Î•ºÎ¶¨ Í∑∏ ÏûêÏ≤¥Í∞Ä ÏùòÎ£åÍ∏∞Í∏∞Î°ú Íµ¨Î∂ÑÏù¥ Îê† ÏàòÎ∞ñÏóê, Í∑úÏ†úÍ∞Ä Îê† ÏàòÎ∞ñÏóê ÏóÜÎã§. Ïù¥Í±∞ÏòàÏöî. ÏòàÎ•º Îì§Ïñ¥ÏÑú Ï†úÍ∞Ä Ïò®ÎèÑÍ≥ÑÍ∞Ä ÏûàÏñ¥Ïöî. Ïò®ÎèÑÍ≥ÑÍ∞Ä ÏûàÎäîÎç∞ Ïò®ÎèÑÎ•º ÎÇòÌÉÄÎÇ¥Í∏∞ ÎïåÎ¨∏Ïóê Í∑∏ ÏûêÏ≤¥Í∞Ä ÏùòÎ£åÍ∏∞Ïù¥Îã§. ÏßàÎ≥ëÏùÑ ÏßÑÎã®ÌïòÎäî ÌñâÏúÑÎã§. ÎòêÎäî ÌóêÌéòÏù¥ Î™®ÎãàÌÑ∞Í∞Ä ÏûàÏñ¥Ïöî. Í∑ºÎç∞ Ï†úÍ∞Ä Î≠ê Îõ∞Í∏∞ÎèÑ ÌïòÍ≥† ÏûêÏ†ÑÍ±∞ÎèÑ ÌÉÄÎäîÎç∞ Í∑∏Îïå ÌóêÌéòÎ•º Ïû¨Í∏∞ ÏúÑÌï¥ÏÑú ÏÇ¨Ïö©Ìïú Í±¥Îç∞ Í∑∏ ÌñâÏúÑ ÏûêÏ≤¥Í∞Ä ÏùòÎ£åÏßÑÎã® ÌñâÏúÑÎã§. Ïù¥Î†áÍ≤å ÌåêÎã®Ìïú Í±∞ÏòàÏöî. Ïã§Ï†úÎ°ú Í∑∏ Î≠êÎû¨ÎäîÏßÄ Î≥¥Î©¥ inherently means diagnosis ÎùºÎäî Îã®Ïñ¥Îì§Ïù¥ ÎÇòÏòµÎãàÎã§.

Î≤ïÏ†ÅÏúºÎ°ú Î¥§ÏùÑÎïå ÍµâÏû•Ìûà ÍµâÏû•Ìûà Ïñ¥Í∑∏Î†àÏãúÎ∏åÌïú Ìï¥ÏÑùÏù¥Íµ¨Ïöî. Í∑ºÎç∞ Ï†úÍ∞Ä ÎÜÄÎûêÎçòÍ±∞Îäî Ïù¥ ÌöåÏÇ¨Ïóê ÎåÄÌï¥ÏÑú Îçî ÎÜÄÎûêÏäµÎãàÎã§. Ïù¥ ÌöåÏÇ¨Í∞Ä 5ÏõîÎã¨Ïóê Ï†úÌíà Ï∂úÏãúÌïòÍ≥† 7ÏõîÎã¨ FDAÎ∂ÄÌÑ∞ ÏõêÏù∏ÏùÑ Î∞õÏïòÏñ¥Ïöî. ÍµâÏû•Ìûà Îπ®Î¶¨ Î∞õÏùÄÍ±∞Í±∞Îì†Ïöî. Î∞õÏûêÎßàÏûê CNNÏùò Will AhmedÍ∞Ä LinkedInÏóê Ïä§ÌÖåÏù¥ÌÅ¨ÎßÅÏùÑ ÌÜµÌï¥ ÎßêÌñàÏäµÎãàÎã§. Í∑∏Îü¨Î©¥ÏÑú Ïö∞Î¶¨Îäî FDAÏóê ÎåÄÌï¥ Ï†ïÎ≥¥Î•º Ï†ÑÎã¨ÌñàÏäµÎãàÎã§. Ïö∞Î¶¨Îäî FDAÏùò Ïï±ÏóêÏÑú ÎØ∏Î™®Î•º Í≥ÑÏÇ∞ÌïòÏßÄ ÏïäÏùÑ Í≤ÉÏûÖÎãàÎã§. Ï£ºÎ°ú FDAÌïòÍ≥† Ïã∏Ïö∏ ÎïåÎäî Ï°∞Ïö©Ìûà Ïã∏Ïö∞ÎäîÎç∞ CEOÍ∞Ä ÌôàÌéòÏù¥ÏßÄÏôÄ Í∞úÏù∏ ÎßÅÎî©Ïóê Ïö∞Î¶¨Îäî FDA Í≥ÑÏÜç Ïã∏Ïö∞Í≤†Îã§ Ïù¥Î†áÍ≤å ÌëúÍ∏∞Î•º ÌïúÍ≤ÅÎãàÎã§. Í∑∏Îü¨Í≥†ÏÑúÎäî Ï†úÍ∞Ä Ïù¥Í≤å Ïò§Îäò ÏÇ¨ÏßÑÏù∏Îç∞ ÏïÑÏßÅÎèÑ Ïïà ÎÇ¥Î†∏Ïñ¥Ïöî. Í≥ÑÏÜç Ïã∏Ïö∞Í≤†Îã§ Ïù¥Í±∞Ï£†. Í∑ºÎç∞ ÌïúÍ∞ÄÏßÄ Î∞îÎÄê Ï†êÏùÄ ÏòàÏ†ÑÏóê Î≥¥Î©¥ÏùÄ Ïó¨Í∏∞Í∞Ä Ï¥àÎ°ùÏÉâ Ï£ºÌô©ÏÉâÏù¥ÏóàÎÇò Îπ®Í∞ÑÏÉâ Ïù¥Î†áÍ≤å Îèº ÏûàÏóàÎäîÎç∞ ÏßÄÍ∏à ÏÉâÏùÑ ÏÇ¥Ïßù Î∞îÍø®ÎçîÎùºÍµ¨Ïöî.

Í∑∏ÎûòÏÑú ÏïÑÏßÅ Î≠îÍ∞Ä Î∞∞ÌÅ¨Îüº ÎîîÏä§Ïª§Ïã±Ïù¥ ÏûàÏßÄ ÏïäÎÇò Í∑∏Îü∞ ÏÉùÍ∞ÅÏùÑ ÌïòÍ≤†ÏäµÎãàÎã§. Ïù¥Í±∞Îäî Ï†ú Î≤ïÏ†Å ÏÉùÍ∞ÅÏùÄ Í∑∏Î†áÎã§Í≥† ÌïòÏßÄÎßå ÌïòÏßÄÎßå Í∑∏Î†áÎã§Í≥† Ìï¥ÏÑú Ï†ú ÏÉùÍ∞ÅÏóêÎäî ÏïÑÎßà 5B Ïã∏Ïö∞Í∏∞Ïóê ÍµâÏû•Ìûà ÌûòÎì† Ïã∏ÏõÄÏù¥ Îê† Í≤É Í∞ôÏäµÎãàÎã§. ÏôúÎÉêÎ©¥ ÏïÑÏßÅÍπåÏßÄ ÏûëÎÖÑÏóê Ïñ¥Îñ§ ÏºÄÏù¥Ïä§Í∞Ä ÏûàÏóàÎäîÎç∞ Í∑∏Í≤å Ïù¥Ï†ú... Ï†ïÎ≥¥Í∏∞Í¥ÄÎì§Ïùò Í≤∞Ï†ïÏùÑ ÎÇ¥Î¶¥ Ïàò ÏûàÎäî Í∂åÌïúÏùÑ ÏïΩÌôîÏãúÌÇ§Îäî Í∑∏Îü∞ Í≤∞Ï†ïÏù¥ ÏûàÏóàÎäîÎç∞ Í∑∏Îü∞ Í≤∞Ï†ïÏù¥ ÏûàÎã§Í≥† Ìï¥ÎèÑ Î≤ïÏõêÎì§ÏùÄ Ïù¥Îü∞ ÏùòÎ£åÎÇò ÌÖåÌÅ¨ÎãàÏª¨ ÌåêÎã®Ïóê ÎåÄÌï¥ÏÑúÎäî FDAÏóê ÏÜêÏùÑ Îì§Ïñ¥Ï§Ñ ÌôïÎ•†Ïù¥ ÍµâÏû•Ìûà ÎÜíÍ≥†Ïöî. Í∑∏ÎûòÏÑú FDAÍ∞Ä Ïù¥ Ïà´Ïûê ÏûêÏ≤¥Í∞Ä inherently diagnosticÌïòÎã§ ÌïòÎ©¥ Í∑∏Í±∏ ÏÜêÏùÑ Îì§Ïñ¥Ï§Ñ ÌôïÎ•†Ïù¥ ÎÜíÍ≥† Í∑∏ Îã§ÏùåÏóê Í∑∏ Ï†ÑÏóê MOBÏù¥ ÏÇ¨Ïö©ÌñàÎçò Í∑∏Îü∞ ÌÅ¥Î†àÏù∏Îì§

Ïù¥Í≤å ÌôïÎ•†Ïù¥ Ï¢Ä Îçî ÌÅ¨Îã§Í≥† ÏÉùÍ∞ÅÌïòÍ≥†, Ï†úÍ∞Ä ÏïÑÏâΩÍ≤å ÏÉùÍ∞ÅÌïòÎäî Í±¥ bad facts make for bad precedents ÎùºÎäî Îã®Ïñ¥Í∞Ä ÏûàÎäîÍ±∞Ï£†. Í∑∏Îü¨ÎãàÍπå ÎÇòÏÅú ÏÇ¨Ïã§Ïù¥ ÏûàÏúºÎ©¥ ÎÇòÏÅú ÏòàÏãúÍ∞Ä ÏÉùÍ∏¥ Í±∞Í±∞Îì†Ïöî. Í∑∏ÎûòÏÑú Ïù¥ ÏòàÏãúÍ∞Ä ÏÇ¨Ïã§ FDAÎ•º Ïã∏Ïö∞Í∏∞ÏóêÎäî, FDAÏùò Ìë∏ÏãúÌå© ÌïòÍ∏∞ÏóêÎäî Í∞ÄÏû• Ï¢ãÏùÄ ÏòàÏãúÎäî ÏïÑÎãàÏóàÏßÄ ÏïäÎÇò ÎùºÎäî ÏÉùÍ∞ÅÏùÑ Ìï©ÎãàÎã§. Ïñ¥Ï®åÎì† ÏßÄÍ∏à Ïù¥Îü∞ Î¶¨Ïä§ÌÅ¨, Ï†úÌíà Í∞úÎ∞úÌïòÎäî Î∂ÑÎì§, Ïä§ÌîºÌÇπ Ï±ÑÎÑêÏùò Ïõ®Îî©Ïä§ Ï†úÌíàÏùÑ Í∞úÎ∞úÌï¥Ï£ºÏãúÎäî Î∂ÑÎì§Ïù¥ ÏûàÎã§Î©¥ Ïù¥Îü∞ Î¶¨Ïä§ÌÅ¨Í∞Ä ÏûàÍ≥†.

</details>

#### Slide 4
![page_004](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_004_6._KAMDA_Sung_Park_Reed_Smith_LLP.jpg)

**ÏöîÏïΩ**
> Clinical Decision Support ÏÜåÌîÑÌä∏Ïõ®Ïñ¥Îäî ÏùòÎ£åÍ∏∞Í∏∞ Ìö®Îä• ÌëúÍ∏∞Î•º ÌïòÎ©¥ÏÑúÎèÑ Í∑úÏ†úÎ•º Î∞õÏßÄ ÏïäÏùÑ Ïàò ÏûàÎäî Ïπ¥ÌÖåÍ≥†Î¶¨ÏûÖÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Îëê Î≤àÏß∏Îäî Ïñ¥ÎñªÍ≤å Î≥¥Î©¥ ÎîîÏßÄÌÑ∏ Ïä§ÏΩîÏñ¥Ïóê ÎåÄÌï¥ÏÑú Ï¢Ä ÌÅ¥ÎûòÏãùÌïú Ïù¥ÏäàÏù∏Îç∞, ÏöîÏ¶òÏùÄ Ï§ÑÏñ¥Îì§ÏóàÏäµÎãàÎã§Îßå ÌÅ¥Î¶¨ÎãàÏª¨ ÎîîÏßÄÌÑ∏ Ïä§ÏΩîÏñ¥ ÏÜåÌîÑÌä∏Ïõ®Ïñ¥ÎùºÎäî Ïπ¥ÌÖåÍ≥†Í∞Ä ÏûàÏäµÎãàÎã§. Í∑∏Îü∞Îç∞ Ï†úÏ°∞ÏÇ¨Îì§Ïù¥ ÎÖ∏Î†•ÏùÑ ÍµâÏû•Ìûà ÎßéÏù¥ ÌñàÏóàÏñ¥Ïöî. Ïôú Ïì∞ÎÉê? ÏùòÎ£åÍ∏∞Í∏∞Ïùò Ïñ¥Îñ§ 80% ÏàòÏ§ÄÏùò Ìö®Îä•ÌëúÍ∏∞Î•º Ìï† Ïàò ÏûàÏúºÎ©¥ÏÑúÎèÑ ÏùòÎ£åÍ∏∞Í∏∞Ïùò Í∑úÏ†úÎ•º Î∞õÏßÄ ÏïäÏïòÏñ¥Ïöî. Í∑∏Îü¨ÎãàÍπå ÏãúÏû•ÏùÑ ÏóÑÏ≤≠ Îπ†Î•¥Í≤å ÏãúÏûëÌïòÎ©¥ Ï†úÌíàÏùÑ ÎÇ¥ÎÜìÏùÑ Ïàò ÏûàÎäî Í±∞ÏòàÏöî. Í∑ºÎç∞ Ïù¥Í≤ÉÎèÑ ÎßàÏ∞¨Í∞ÄÏßÄÎ°ú ÎãπÏó∞Ìûà Î≤ïÏïàÏóê ÏùòÌï¥ÏÑú ÏôºÏ™ΩÏóê ÏûàÎäî Ï†úÌíà Í∞ôÏùÄ Í≤ΩÏö∞Îäî 4Í∞úÏùò ÌÅ¨ÎùºÏù¥Ìã∞ÎÑêÏùÑ SatisfyÌïòÎ©¥ ÏùòÎ£åÍ∏∞Í∏∞Î°ú Í∑úÏ†ïÌïòÏßÄ ÏïäÎäîÎã§ÎùºÎäî Í±∏ Î≤ïÏïàÏóêÏÑú ÌôïÏù∏ÏùÑ Î∞õÏïòÎäîÎç∞ FDAÍ∞Ä ÏóÑÏ≤≠ÎÇòÍ≤å Îòê ÏóÑÍ≤©Ìïú Ïû£ÎåÄÎ•º ÎìúÎ¶ΩÎãàÎã§.

</details>

#### Slide 5
![page_005](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_005_6._KAMDA_Sung_Park_Reed_Smith_LLP.jpg)

**ÏöîÏïΩ**
> CDS Î©¥Ï†úÎ•º ÏúÑÌïú 4Í∞ÄÏßÄ Í∏∞Ï§ÄÏù¥ ÏûàÏßÄÎßå, FDAÍ∞Ä ÏûêÎèôÌôîÏôÄ Í∏âÎ∞ïÌïú ÏÉÅÌô©Ïóê ÎåÄÌïú Ï∂îÍ∞Ä Ï†úÌïúÏùÑ ÎëêÏóàÏäµÎãàÎã§. Î≤ïÎ†πÏóêÎäî Ïù¥Îü∞ Ï†úÌïúÏù¥ ÏóÜÎäîÎç∞ FDAÍ∞Ä ÏûêÏ≤¥Ï†ÅÏúºÎ°ú Ìï¥ÏÑùÌïú Í≤ÅÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

Í∑∏ 4Í∞ÄÏßÄÎ•º Í∞ÑÎã®ÌïòÍ≤å ÌôïÏù∏Ìï¥Î≥¥Î©¥, Ïù¥ 4Í∞ÄÏßÄÎ•º Ï¥ùÏ†ÅÏãúÌÇ§Î©¥ ÏùòÎ£åÍ∏∞Í∏∞Í∞Ä ÏïÑÎãåÍ±∞ÏóêÏöî. Ïù¥Í≤å Î≠êÎÉêÎ©¥, Ï≤´Î≤àÏß∏Î°úÎäî Î©îÎîîÏª¨ Ïù¥ÎØ∏ÏßÄÎÇò ÏãúÍ∑∏ÎÑê, ÏòàÎ•º Îì§Ïñ¥ÏÑú ECGÍ∞ôÏùÄ ÏãúÍ∑∏ÎÑêÏùÑ ÏßÅÏ†ëÏ†ÅÏúºÎ°ú Î∂ÑÏÑùÌïòÏßÄ ÏïäÍ≥† ÎëêÎ≤àÏß∏Î°úÎäî Î©îÎîîÌÅ¥ Ïù∏Ìè¨Î©îÏù¥ÏÖò ÎîîÏä§ÌîåÎ†àÏù¥ÏòàÏöî. ÎëêÎ≤àÏß∏Îäî Ï¢Ä ÏùòÎØ∏Í∞Ä Ï†ÅÏùÄ Í∑∏Îü∞ ÌÅ¨ÎùºÏù¥ÌÖçÏûÖÎãàÎã§. ÏÑ∏Î≤àÏß∏Î°úÎäî, ÏïÑ Ïù¥Í≤å Ï§ëÏöîÌïúÍ±¥Îç∞, ÏùòÎ£åÏßÑÏóêÍ≤å Î∞òÎìúÏãú Í≤∞Ï†ïÏùÑ ÎÇ¥Î¶¨ÏßÄ ÏïäÍ≥†, Í≤∞Ï†ïÏùÑ Ï†ÑÎã¨ÌïòÏßÄÎäî ÏïäÍ≥†, Ï∂îÏ≤úÎßå Ï†ÑÎã¨Ìï¥Ïïº ÎèºÏöî. Ï∂îÏ≤úÎßå. ÎÑ§Î≤àÏß∏Î°úÎäî Í∑∏ Ï∂îÏ≤úÏóê ÎåÄÌï¥ÏÑú ÏùòÎ£åÏßÑÏù¥ ÎèÖÎ¶ΩÏ†ÅÏúºÎ°ú Î¶¨Î∑∞Î•º Ìï† Ïàò ÏûàÎèÑÎ°ù Î≤†Ïù¥Ïä§Î¶¨Ïä§Ìä∏Î•º Ï†úÍ≥µÌï¥Ïïº Ìï©ÎãàÎã§. FDAÍ∞Ä Ïó¨Í∏∞ÏÑú ÌïúÍ≤å Î≠êÎÉêÎ©¥, Ïù¥ ÏÑ∏Î≤àÏß∏ ÌÅ¨ÎùºÏù¥Ìã∞Ïñ¥Ïóê ÎåÄÌï¥ÏÑú, ÌïòÏù¥ÎùºÏù¥Ìä∏ Îêú Î∂ÄÎ∂Ñ Î≥¥Ïù¥ÏãúÏ£†? ÏÑ∏Î≤àÏß∏ ÌÅ¨ÎùºÏù¥Ìã∞Ïñ¥Ïóê ÎåÄÌï¥ÏÑú FDA ÏûêÏ≤¥Ïùò Í∏∞Ï§ÄÏùÑ Îòê ÏßëÏñ¥ÎÑ£ÏäµÎãàÎã§. Îòê ÏßëÏñ¥ÎÑ£ÎäîÎç∞ Í∑∏Í≤å Î≠êÎÉêÎ©¥

Ï∂îÏ≤úÏùÑ ÌïòÎ©¥ÏùÄ Ï∂îÏ≤úÏùÑ ÌïòÎ©¥ Ï∂îÏ≤úÎßå ÌïòÎ©¥ Ïó¨Í∏∞Í∞Ä ÏïÑÎãàÍ∏¥ ÌïúÎç∞ Îã®ÏßÄ ÏÑ∏Í∞ÄÏßÄ Ï°∞Í±¥Ïù¥ ÏûàÏñ¥Ïöî. Ï≤´Î≤àÏß∏ Í∑∏ ÏÜåÌîÑÌä∏Ïõ®Ïñ¥Ïùò Ïò§ÌÜ†Î©îÏù¥ÏÖòÏù¥ ÏûàÏúºÎ©¥ ÏïàÎèºÏöî. ÏûêÎèôÌôîÍ∞Ä ÏûàÏúºÎ©¥ ÏïàÎèºÏöî. Ïôú FDAÍ∞Ä Í∑∏Î†áÍ≤å ÏñòÍ∏∞ÌïòÎäêÎÉê ÌïòÎ©¥ Ïñ¥Îñ§ ÏûêÎèôÌôîÎùºÎäî Í≥ºÏ†ïÏù¥ ÏûàÏúºÎ©¥ ÏùòÎ£åÏßÑÏù¥ÎùºÍ≥† Ìï¥ÎèÑ automation biasÎùºÎäî Í≤É ÎïåÎ¨∏Ïóê ÏûêÎèôÌôî Ìé∏Ìñ•Ïù¥ÎùºÍ≥† ÌïòÎçòÎç∞ Í∑∏Í≤É ÎïåÎ¨∏Ïóê Í≤ÄÏ¶ù ÏóÜÏù¥ ÏûêÎèôÌôîÎêú Í≤∞Í≥ºÎ•º ÎØøÏùÑ ÌôïÎ•†Ïù¥ ÎÜíÎã§Îäî Í±∞ÏòàÏöî FDAÏóê Îî∞ÎùºÏÑúÎäî. Ïã§Ï†úÎ°ú Ïñ¥Îñ§ Ïä§ÌÑ∞ÎîîÎèÑ ÏûàÎäî Í≤É Í∞ôÍ≥†Ïöî. ÏòàÎ•º Îì§Ïñ¥ÏÑú Ï†ÄÌù¨Í∞Ä 70PTÎÇò Ïù¥Îü∞ Í±∏ Ïì∞Î©¥ÏÑú ÏûêÏ†ÑÍ±∞ Ïö¥Ï†ÑÌï¥ÏÑú ÎÇòÏò® Í≤∞Í≥ºÏóêÎäî Ïª¥Ìì®ÌÑ∞Í∞Ä ÎêòÎäî Ï£ºÏöîÍ±¥ÏùÑ ÎØøÍ≤å ÎêúÎã§, Ïù¥Í±¥ Ïù¥Îü∞ Í±∞Í≥† Îëê Î≤àÏß∏Î°úÎäî Í∏âÎ∞ïÌïú ÏÉÅÌô©, Í∏âÎ∞ïÌïú ÏÉÅÌô©ÏóêÏÑú ÏÇ¨Ïö©ÎêòÏñ¥ ÏûàÎäî ÏÜåÌîÑÌä∏Ïõ®Ïñ¥Îäî ÏùòÎ£åÍ∏∞Í∏∞Î°ú Î∂ÑÎ•òÍ∞Ä ÎêúÎã§.

Ïù¥Í±∏ FDAÍ∞Ä ÌïúÍ±∞Í≥†, Í∑ºÎç∞ Îã§Ïãú ÎßêÏîÄÎìúÎ¶¨ÏßÄÎßå Î≤ïÎ†πÏóêÎäî Ïñ¥ÎîîÏóêÎèÑ Í∏âÎ∞ïÌïú ÏÉÅÌô©Ïóê ÎåÄÌïú Î¶¨ÎØ∏ÌÖåÏù¥ÏÖòÏù¥ÎÇò Î∞©Í∏à ÎßêÏîÄÎìúÎ¶∞ Ïò§ÌÜ†Î©îÏù¥ÏÖòÏóê ÎåÄÌïú Î¶¨ÎØ∏ÌÖåÏù¥ÏÖòÏù¥ ÏóÜÏñ¥Ïöî. Í∑∏ÎûòÏÑú Ïñ¥ÎñªÍ≤å Ïù¥Îü∞Í±∏ Î∞úÌëúÎ•º Ìï¥ÏÑú 2022ÎÖÑÏù∏Í∞Ä Î∞úÌëúÎ•º Ìï¥ÏÑú ÌïúÎ≤à ÎÇúÎ¶¨Í∞Ä ÎÇ¨ÏóàÏäµÎãàÎã§. ÏôúÎÉêÎ©¥ CDS Ï†úÌíàÎì§Ïù¥ ÍµâÏû•Ìûà ÎßéÏïòÍ±∞Îì†Ïöî ÏãúÏû•Ïóê.

Í∑∏ÎûòÏÑú Í≥ºÏó∞ FDAÍ∞Ä Ïù¥Í±∞Î•º ÏßëÌñâÌï† Í≤ÉÏù∏Í∞Ä, Í∑∏Î¶¨Í≥† ÏßëÌñâÌïòÎ©¥ ÏÜåÏÜ°ÌïòÍ∏∞ ÏúÑÌï¥ÏÑú Îòê Í±∞Í∏∞ÎèÑ ÌòëÌöåÍ∞Ä ÎßåÎì§Ïñ¥Ï°åÏäµÎãàÎã§. Ìïú 1ÎÖÑÎèôÏïà ÎëêÍ≥†Î≥¥Îã§Í∞Ä FDAÍ∞Ä 2023ÎÖÑ 9ÏõîÏóê ÎìúÎîîÏñ¥ Í≤ΩÍ≥†Ï†êÏùÑ Î≥¥ÎÉÖÎãàÎã§. Ïù¥Í±¥ ÌçºÎ∏îÎ¶≠ Ïó¨Î≥ÑÎ°ú Î≥¥Îäî Ï†ïÎ≥¥Í≥† ÌöåÏÇ¨Ïù¥Î¶ÑÏùÄ Ïó¨Í∏∞ Ïïà Ï†ÅÏóàÏßÄÎßå Ï∞æÏïÑÎ≥¥ÏãúÎ©¥ ÎÇòÏò§Íµ¨Ïöî. Î©¥Ï∂îÌÇ¨Îü¨Ïä§Ìè¨Ìä∏, ÌÅ¨Î¶¨Ìã∞Ïª¨ ÏºÄÏñ¥Ïóê ÏûàÎäî ÌôòÏûêÎì§ÏóêÍ≤å Î©¥Ï∂îÌÇ¨Îü¨Ïä§Ìè¨Ìä∏Î•º Ï†úÍ≥µÌïòÎäî Ï†úÌíàÏóê ÎåÄÌïú Í≤ΩÍ≥†Ïû•Ïù∏Îç∞ Í±∞Í∏∞ÏÑú ÌäπÌûà FDAÍ∞Ä Î¨∏Ï†úÎ•º ÏÇºÏùÄ Î∂ÄÎ∂ÑÏù¥ patient-specific medical information, time-critical settingÏóêÏÑú ÏïåÎûåÏùÑ Ï†úÍ≥µÌïòÍ∏∞ ÎïåÎ¨∏Ïóê Î∂àÎ≤ïÏ†ÅÏù∏ Ï†úÌíàÏù¥Îã§. Í∑∏Î¶¨Í≥† Ïù¥ ÌöåÏÇ¨ Ï†úÌíàÏù¥, Í≤ΩÍ≥†Ïû• Î∞õÏùÄ ÌöåÏÇ¨Í∞Ä

ÏóÑÏ≤≠ ÌÅ∞ ÌöåÏÇ¨Ïùò ÏûêÌöåÏÇ¨ Í±∞Îì†Ïöî Í∑∏Îü∞ ÌöåÏÇ¨ÌïúÌÖåÎèÑ FTÍ∞Ä ÎëêÎ†§ÏõåÌïòÏßÄ ÏïäÍ≥† Ïñ¥ Ïù¥Í±∞ ÌïúÎ≤à Ìï¥Î≥¥Ïûê Ïù¥Îü¨Î©¥ÏÑú Í≤ΩÍ≥†Ïû•ÏùÑ Î≥¥ÎÇ∏Í±∞ÏóêÏöî

Í∑∏ÎûòÏÑú ÏßÄÍ∏à Í≤∞Î°†Ï†ÅÏúºÎ°ú Í∑∏ ÌòëÌöåÍ∞Ä FDAÌïúÌÖå ÏÜåÏÜ°ÏùÑ ÌïòÏßÑ ÏïäÏïòÏßÄÎßå ÏßÄÍ∏à Ïù¥ CBS Ï†úÌíà Ïπ¥ÌÖåÍ≥†Î¶¨ÏóêÏÑúÎèÑ ÍµâÏû•Ìûà FDAÍ∞Ä Í∑úÏ†úÎ•º Í∞ÄÌï† ÌôïÎ•†Ïù¥ ÎÜíÏùÄ ÏÉÅÌô©ÏûÖÎãàÎã§. Í∑∏Î¶¨Í≥† Ï≤òÏùåÏóê Ìä∏ÎüºÌîÑ ÎåÄÌÜµÎ†πÏù¥ Îì§Ïñ¥ÏôîÏùÑ Îïå, Í∑∏Î¶¨Í≥† FD Ï≤úÏïàÏù¥ Î∞îÎÄåÏóàÏùÑ Îïå ÎêòÍ≤å ÎßéÏùÄ ÏÇ¨ÎûåÎì§ Ï†ëÌïòÎ©¥ÏÑú ÏïÑ Ïù¥Í±∞ Í∑úÏ†úÍ∞Ä ÏñïÏïÑÏßà Í±∞Îã§. Í∑∏ÎûòÏÑú ÎßåÏïΩ ÏãúÏû•Ïù¥ ÏßÑÏûÖÌïúÎã§Î©¥ ÏßÄÍ∏àÏù¥ ÏßÑÏûÖÌïòÍ∏∞ Ï¢ãÏùÑ ÎïåÎùºÍ≥† ÌñàÎäîÎç∞ ÌäπÌûà ÎîîÏßÄÌÑ∏Ïä§ Î∂ÑÏïºÏùò Í∑úÏ†úÎ•º Î≥¥Î©¥ Ï†ÑÌòÄ Í∑∏Î†áÏßÄ ÏïäÍ≥†Ïöî. Ïò§ÌûàÎ†§ Ïù¥Îü∞ ÏºÄÏù¥Ïä§Îì§Ïù¥ Í≥µÏãùÏ†ÅÏúºÎ°úÎÇò ÎπÑÍ≥µÏãùÏ†ÅÏúºÎ°ú Í∑úÏ†úÎ•º Î∞õÎäî Í≤ΩÏö∞Îì§Ïù¥ ÎäòÏñ¥ÎÇòÍ≥† ÏûàÏäµÎãàÎã§.

</details>

#### Slide 6
![page_006](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_006_6._KAMDA_Sung_Park_Reed_Smith_LLP.jpg)

**ÏöîÏïΩ**
> Ï†úÌíà Í∞úÎ∞ú Ïãú Ïñ¥Îäê Ï†ïÎèÑ Î¶¨Ïä§ÌÅ¨ Í∞êÏàòÎäî ÌïÑÏöîÌïòÏßÄÎßå, Ï†ïÎßê Í±¥ÎìúÎ†§ÏÑúÎäî Ïïà ÎêòÎäî Í≤ÉÏù¥ Î≠îÏßÄ ÏïåÏïÑÏïº Ìï©ÎãàÎã§. FDA Í∑úÏ†úÎ•º Î∞õÏùÑ ÌïÑÏöîÍ∞Ä ÏûàÎäîÏßÄÎèÑ Í≥†Î†§Ìï¥Î≥¥ÏÑ∏Ïöî.

<details>
<summary>üìÑ Slide Transcript</summary>

Í∑∏ÎûòÏÑú Ïù¥Í±∏ Î¥§ÏùÑ Îïå ÏÉùÍ∞ÅÌï¥Ïïº ÎêòÎäîÍ≤å Î¨¥ÏóáÏùºÍπå? ÎùºÍ≥† Î≥¥Î©¥ ÏùºÎã® ÎëêÍ∞ÄÏßÄ, Ï†úÌíà Í∞úÎ∞ú, Í∑∏ Îã§ÏùåÏóê Ïª§Î®∏ÏÖúÎùºÏù¥Ï†úÏù¥ÏÖò ÎòêÎäî Ïù∏Î≤†Ïä§Î©òÌä∏ Ïä§ÌÖåÏù¥ÏßÄÏóêÏÑú ÏÉùÍ∞ÅÌï† Ïàò ÏûàÎäîÍ≤å ÏûàÏùÑ Í≤É Í∞ôÏïÑÏöî. ÏïÑÍπå ÏßÄÎ¢∞Ï∞æÍ∏∞Î•º Ï†úÍ∞Ä Ïû†Íπê ÎßêÏîÄÎìúÎ†∏ÎäîÎç∞ Ï†úÌíàÏùÑ ÌäπÌûà ÎîîÏßÄÌÑ∏Ïä§ Î∂ÑÏïºÏóêÏÑú Ï†úÌíà Í∞úÎ∞úÌï† ÎïåÎäî Ïñ¥ÎäêÏ†ïÎèÑÏùò Ïñ¥Ï©î Ïàò ÏóÜÏù¥ Î¶¨Ïä§ÌÅ¨Î•º ÌÖåÏù¥ÌÅ¨Ìï¥Ïïº ÎêòÎäî Í±¥ ÎßûÏäµÎãàÎã§. ÏùºÎã® Ï≤´Î≤àÏß∏Î°ú Í∑úÏ†ú ÏûêÏ≤¥Í∞Ä Î∂àÎ™ÖÌôïÌïú Í≤ÉÎèÑ ÏûàÍµ¨Ïöî. Í∑∏ Îã§ÏùåÏóê Ï°∞Í∏à Îçî ÎÇ®Îì§Î≥¥Îã§ ÏñµÎ•º ÏäµÌïòÍ≤å ÎÇòÍ∞ÄÏïºÏßÄ ÏãúÏû• Ï†êÏú†Ïú®ÏùÑ ÏñªÎäî Í≤ΩÏö∞ÎèÑ ÏûàÏäµÎãàÎã§.

Í∑∏Í≤å ÏûàÎäîÎç∞, Ï†ïÎßê Ï§ëÏöîÌïú Ïï†Î¶¨ÏïÑ, ÏßÑÏßú Í±¥ÎìúÎ†§ÏÑúÎäî ÏïàÎêòÎäî Í≤ÉÏù¥ Î≠îÏßÄ ÏïåÏïÑÏïº ÎèºÏöî. Í±¥ÎìúÎ†§ÏÑú ÏïàÎêòÎäî Í≤ÉÏù¥ Î≠îÏßÄ ÏïåÏïÑÏïº ÎêòÍ≥†, ÏïÑÍπå ÎßêÏîÄÎìúÎ¶∞ Í≤ÉÏ≤òÎüº FDAÎäî Í∑∏Î†áÍ≤å ÌÅ∞ ÌöåÏÇ¨Îì§ÎèÑ Ïã¨ÏßÄÏñ¥ ÌÖåÏù¥ÌÅ¨ÏïÑÏõÉ ÌïòÎäî Í≤ÉÏùÑ ÎëêÎ†§ÏõåÌïòÏßÄ ÏïäÍ∏∞ ÎïåÎ¨∏Ïóê, Ïñ¥Îñ§ Í±∏ FDAÍ∞Ä Ï†ïÎßê Ï§ëÏöîÌïòÍ≥†, Ïñ¥Îñ§ Í±∏ Ï§ëÏöîÌïòÏßÄ ÏïäÎäîÏßÄÎ•º Ïûò ÌåêÎã®ÌïòÏÖîÏïº Îê©ÎãàÎã§. Í∑∏Î¶¨Í≥† Ï†úÍ∞Ä Ìïú Í∞ÄÏßÄ Îçî ÏÉùÍ∞ÅÌï† Î∂ÄÎ∂ÑÏùÄ ÎßåÏïΩÏóê Í∞ÄÎä•ÌïòÎã§Î©¥, Í≥ºÏó∞ ÎÇ¥Í∞Ä Ï†ïÎßê FDAÏùò Í∑úÏ†úÎ•º Î∞õÏùÑ ÌïÑÏöîÍ∞Ä ÏûàÏùÑÍπå? Ï°∞Í∑∏Îßå ÌîÑÎ°úÎìÄÏä§ ÌéëÏÖÄÎü¨ÎãàÌã∞Î•º Î∞îÍøîÏÑú Í∑úÏ†ú Ïïà Î∞õÎäî Ï™ΩÏúºÎ°ú ÎÇòÏïÑÍ∞ÄÎäî Í≤ÉÎèÑ Í¥úÏ∞ÆÏßÄ ÏïäÏùÑÍπå?

Îã§Î•∏ Í≤ÉÎèÑ ÏÉùÍ∞ÅÌï¥Î≥º ÎßåÌïú Í∞ÄÏπòÍ∞Ä ÏûàÎã§Í≥† ÏÉùÍ∞ÅÌï¥Ïöî. ÏòàÎ•º Îì§Ïñ¥ÏÑú Ïñ¥Ï†ú Ï†úÍ∞Ä Ïª®ÌçºÎü∞Ïä§ÏóêÏÑú ÎèåÏïÑÏôîÎäîÎç∞ Í±∞Í∏∞ÏÑú Ìà¨ÏûêÏûêÎì§Ïù¥ Î™á Î∂ÑÌïòÍ≥† ÌïòÎ©¥ÏÑú ÏñòÍ∏∞ÌñàÎçò ÎÖºÏùò Ï§ëÏóê ÌïòÎÇòÍ∞Ä Î¨ºÎ°† Ï†úÌíà ÏÇ¨Ïù¥Ï¶à, ÌååÏö¥Îçî, ÏãúÏû• ÏÇ¨Ïù¥Ï¶à Ïù¥Îü∞ Í≤ÉÎì§ÏùÄ Îã§ Îã§Î•¥Í≤†ÏßÄÎßå ÏùºÎ∞òÏ†ÅÏúºÎ°ú Ìó¨Ïä§ÏºÄÏñ¥ Î∂ÑÏïºÏóêÏÑú Í∑úÏ†úÎ•º Î∞õÎäî Ï†úÌíàÏùÑ ÏõêÌïòÎäîÏßÄ ÏïÑÎãàÎ©¥ Í∑úÏ†úÎ•º Î∞õÏßÄ ÏïäÎäî Ï†úÌíàÏùÑ ÏõêÌïòÎäîÏßÄÏóê ÎåÄÌï¥ÏÑú ÏñòÍ∏∞ÌñàÏùÑ Îïå ÎåÄÎ∂ÄÎ∂ÑÏùò Í≤ΩÏö∞Îäî Í∑úÏ†ú Î∞õÏßÄ ÏïäÎäî Í≤ÉÏùÑ Îçî ÏÑ†Ìò∏ÌïúÎã§Í≥† Î¥êÏöî. ÎãπÏó∞ÌïòÏ£†. Í∑∏Î¶¨Í≥† Í∑∏ Í≤ΩÏö∞ÎèÑ Ï†úÌíàÏù¥ Îçî Îπ†Î•¥Í≤å Ìçº ÎÇòÍ∞à ÏàòÎèÑ ÏûàÍ≥†Ïöî. Í∑∏Î†áÏßÄÎßå ÏïÑÍπå ÎßêÏîÄÌïòÏã† Í≤ÉÏ≤òÎüº Í∑úÏ†úÎ•º ÏûàÎäî Í≤ΩÏö∞Îäî Ïò§ÌûàÎ†§

Î∞©Ïñ¥ÏÑ† Ï≤òÎüº ÏûëÏö©Ìï† Ïàò ÏûàÏúºÎãàÍπå Ïñ¥Îñ§Í≤å Îçî ÌöåÏÇ¨Ïùò ÏÑ±Ïû•Ïóê ÎèÑÏõÄÏù¥ ÎêòÎäîÏßÄÎäî ÌåêÎã®ÌïòÏÖîÏïº Ìï† Î¨∏Ï†úÎùºÍ≥† ÏÉùÍ∞ÅÌïòÎäîÎç∞ Îã®ÏßÄ ÏÉùÍ∞ÅÌï†Í±∞Î©¥ Íº≠ FD Ìú¥ÏßÄÎ•º Î∞õÎäî Ï†úÌíàÏùÑ ÎßåÎì§ ÌïÑÏöîÍ∞Ä ÏûàÎã§. Îëê Î≤àÏß∏, Î∞©Í∏à ÎßêÏîÄÎìúÎ¶∞ Í≤ÉÏ≤òÎüº Ïã§Ï†úÎ°ú ÏïÑÍπå Î∞õÏùÄ Ìà¨ÏûêÏùò Í∏àÏï°Ïóê ÎåÄÌï¥ÏÑú Ìà¨ÏûêÎ•º Î∏åÎ†àÏù¥ÌÅ¨ ÌïòÎäî Í±∏ Î≥¥ÎãàÍπå Ïã§Ï†úÎ°ú ÏßàÎ≥ëÏùÑ Ï¶ùÍ∞ÄÌïòÎäî Ï†úÌíà Í∞ôÏùÄ Í≤ΩÏö∞Îäî Ï†ÑÏ≤¥ Ìà¨ÏûêÏùò Ìïú 29%Ïóê ÎπÑÌï¥ÏÑú Ìó¨Ïä§ÏºÄÏñ¥ ÌôòÍ≤ΩÏóêÏÑú Ïù¥Î£®Ïñ¥ÏßÄÎäî Îã§Î•∏ ÎßéÏùÄ ÌñâÏúÑÎì§, ÏòàÎ•º Îì§Ïñ¥ÏÑú ÌéòÏù¥ÏÖò ÏóîÍ≤åÏù¥ÏßÄÎ®ºÌä∏ ÏïÑÎãàÎ©¥ ÎπåÎî© Î†àÎπÑÎâ¥ ÏÇ¨Ïù¥ÌÅ¥ Îß§ÎãàÏßÄÎ®ºÌä∏ ÏïÑÎãàÎ©¥ ÎπåÎî© ÏÑúÌè¨Ìä∏ ÏúÑÎ≤ÑÏä§ÎßåÌïú Îç∞Îäî Ï¢Ä Îçî ÏâΩÍ≤å ÎßåÎì§Ïñ¥ÏßÄÎäî Ïù¥Îü∞ Ï†úÌíàÎì§, ÏïÑÎãàÎ©¥ Î≠ê AI Ï≤¥Ìè¨ Ïù¥Îü∞ Í≤ΩÏö∞Îì§ÏùÄ Ïò§ÌûàÎ†§ Îçî Ìà¨ÏûêÎ•º ÏâΩÍ≤å Î∞õÎäîÎã§Îäî Í∑∏Îü∞ Ìï¥ÏÑùÏùÑ Ìï† Ïàò ÏûàÎäî Ïà´ÏûêÎì§ÎèÑ ÏûàÏóàÍ≥†, Í∑∏Î¶¨Í≥† Ïã§Ï†úÎ°ú Ï†ÄÌù¨Í∞Ä Ïñ¥Ï†ú Î∞©Í∏à ÎßêÏîÄÎìúÎ¶∞ Í≤ÉÏ≤òÎüº ÎßåÎÇòÎçò Ïà´ÏûêÎì§ÎèÑ ÎπÑÏä∑Ìïú ÏñòÍ∏∞Î•º ÌñàÏäµÎãàÎã§.

ÎîîÏßÄÌÑ∏Ïä§Ïùò Í≤ΩÏö∞, ÌäπÌûà AIÍ¥ÄÎ†® ÏïÑÎãàÎ©¥ Îç∞Ïù¥ÌÑ∞ Í¥ÄÎ†®Ìï¥ÏÑúÎäî Federal Î≥¥Í¥ÄÎì§ ÎøêÎßå ÏïÑÎãàÎùº Ï£ºÍ±∞ Î≥¥Í¥ÄÎì§ÎèÑ ÎÑàÎ¨¥ ÎßéÏïÑÏöî. Í∑∏ÎûòÏÑú ÏñºÎßàÏ†ÑÏóêÎäî ÏòàÎ•º Îì§Ïñ¥ÏÑú ÏùºÎ¶¨ÎÖ∏Ïù¥Ï£ºÏóêÏÑú Î©òÌÉàÏä§ Í¥ÄÎ†®Ìï¥ÏÑú CheckboxÏùÑ ÏÇ¨Ïö©Ìï† Ïàò ÏóÜÍ≤å ÌïòÎäî Í∑∏Îü∞ Î≥¥Í¥ÄÎèÑ ÎÇòÏò§Í≥†. ÏßÄÍ∏à ÏïÑÌôâÍ∞úÏù∏Í∞Ä Ï£ºÏóêÏÑú Îç∞Ïù¥ÌÑ∞ ÌîÑÎùºÏù¥ÎπÑÏãú Í¥ÄÎ†®Ìï¥ÏÑú Ïó¨Í∏∞ÏÑú ÎßåÏïΩ ÎîîÏßÄÌÑ∏ÏóêÏÑú Îç∞Ïù¥ÌÑ∞Î•º Îã§Î£®Îäî ÌöåÏÇ¨Îì§Ïù¥ ÏûàÏúºÏãúÎã§Î©¥ Îî∞Î°úÎî∞Î°ú Í∑úÏ†úÌïòÎäî Í∑∏Îü∞ Î≤ïÏïàÎèÑ Í≥ÑÏÜç ÎÇòÏò§Í≥† ÏûàÍ≥†Ïöî. Í∑∏ÎûòÏÑú Ïù¥Îü∞ Í≤ÉÎì§ÏùÑ Í≥ÑÏÜç Î™®ÎãàÌÑ∞ÎßÅ ÌïòÏÖîÏïºÏßÄ ÏïÑÍπå ÎßêÏîÄÎìúÎ¶∞ Í≤ÉÏ≤òÎüº Ï†ïÎßê ÌÅ∞ Î¶¨Ïä§ÌÅ¨Ïùò ÏóòÎ¶¨Ïï†Î•º ÌîºÌï¥Í∞à Ïàò ÏûàÎäî Í∑∏Îü∞ Ï†úÌíàÏùÑ Í∞úÎ∞úÌï† Ïàò ÏûàÏßÄ ÏïäÎÇò ÏÉùÍ∞ÅÌï©ÎãàÎã§.

</details>

#### Slide 7
![page_007](Session%20I%20Strategies%20and%20FDA%20Considerations%20for%20U%20/page_007_6._KAMDA_Sung_Park_Reed_Smith_LLP.jpg)

**ÏöîÏïΩ**
> ÌïúÍµ≠ÏóêÎèÑ Ï¢ãÏùÄ Ï†úÌíàÏùÑ Í∞ÄÏßÑ ÌöåÏÇ¨Îì§Ïù¥ ÎßéÏùÄÎç∞, Ïª®ÌçºÎü∞Ïä§ Îì±Ïóê ÎßéÏù¥ ÎÇòÍ∞ÄÏÖîÏÑú Ï†úÌíàÏùÑ ÌôçÎ≥¥ÌïòÏãúÎ©¥ Îçî ÎÑìÏùÄ Í∏∞ÌöåÏôÄ ÏãúÏû•Ïù¥ Ïó¥Î¶¥ Í≤ÉÏûÖÎãàÎã§.

<details>
<summary>üìÑ Slide Transcript</summary>

ÎßàÏßÄÎßâÏúºÎ°ú ÏÉùÍ∞ÅÌñàÎçò Í≤ÉÏùÄ Ï†úÍ∞Ä Ïñ¥Ï†ú Î≥¥Î©¥ÏÑú Í∞ÄÎÅîÍ∞ÄÎã§ Ïù¥Î†áÍ≤å ÎØ∏Íµ≠ ÌöåÏÇ¨Îì§, ÎØ∏Íµ≠ Ìà¨ÏûêÌöåÏÇ¨Îì§Ïùò Ìè¨Ìä∏Ìè¥Î¶¨Ïò§Î•º Î≥¥Î©¥ÏùÄ ÌïúÍµ≠ÏóêÎèÑ Ï†úÍ∞Ä ÎßåÎÇú ÌöåÏÇ¨ Ï§ëÏóêÏÑúÎèÑ ÎêòÍ≤å ÏÜåÌîºÏä§Ìã±Ìï¥ ÏûàÎã§Í≥† Í∑∏Î¶¨Í≥† Ï†úÌíàÎì§Ïù¥ Ï¢ãÏùÄ ÌöåÏÇ¨Îì§ÎèÑ ÎßéÏùÄÎç∞ Íº≠ ÎØ∏Íµ≠ ÌöåÏÇ¨Îì§Ïù¥ÎùºÍ≥† Ìï¥ÏÑú Ìà¨ÏûêÎ•º Îçî Ïûò Î∞õÍ≥† ÏùºÌï¥Ïïº ÎêòÎäî Í±¥ ÏïÑÎãåÎç∞ ÎùºÎäî ÏÉùÍ∞ÅÏù¥ Îì§ ÎïåÍ∞Ä Í∞ÄÎÅî ÏûàÏäµÎãàÎã§. Í∑∏ÎûòÏÑú Ïª®ÌçºÎü∞Ïä§ÎùºÎì†ÏßÄ Ïñ¥Îñ§ Ïù¥Î†áÍ≤å Îòê Ïù¥Îü∞ Îç∞ ÎßéÏù¥ ÎÇòÍ∞ÄÏÖîÏÑú Ï†úÌíàÏùÑ ÎßéÏù¥ ÌôçÎ≥¥ÌïòÏãúÎ©¥ Îçî ÎÑìÏùÄ Í∑∏Îü∞ Í∏∞ÌöåÏôÄ Îçî ÎßéÏùÄ ÏãúÏû•Ïù¥ Ïó¥Î¶¨ÏßÄ ÏïäÏùÑÍπå Í∑∏Î†áÍ≤å ÏÉùÍ∞ÅÌï©ÎãàÎã§.

20Î∂ÑÍ∞Ñ Ï≤¥ÌóòÏùÑ ÌïòÏòÄÏäµÎãàÎã§. Í∞êÏÇ¨Ìï©ÎãàÎã§.

</details>

---

<details>
<summary>üìù Full Transcript</summary>

Î®ºÏ†Ä Ïù¥ ÌòëÌöå ÎßåÎìúÏã† Í±∞ Ï∂ïÌïòÎìúÎ¶¨Í≥†Ïöî. Ï†úÍ∞Ä Îã§Î•∏ ÎïåÎèÑ ÏñòÍ∏∞ÌñàÏùÑ Îïå Ìï≠ÏÉÅ ÌïúÍµ≠ ÌöåÏÇ¨Îì§ÏóêÍ≤å Î™©ÏÜåÎ¶¨Í∞Ä ÌïÑÏöîÌïòÎã§Í≥† ÏÉùÍ∞ÅÌïòÍ≥† ÏûàÏóàÎäîÎç∞ Ïù¥Î†áÍ≤å ÎßåÎì§Ïñ¥Ï†∏ÏÑú Îã§ÌñâÏûÖÎãàÎã§. ÏòàÎ•º Îì§Ïñ¥ÏÑú FDAÍ∞ôÏùÄ ÏÉàÎ°úÏö¥ Í∑úÏ†ïÏù¥ÎÇò Î≤ïÏïàÏù¥ ÎÇòÏôîÏùÑ ÎïåÎäî ÎØ∏Íµ≠ ÌòëÌöåÎÇò ÌöåÏÇ¨Îì§Ïù¥ Ïª§Î©òÌä∏Î•º ÌÜµÌï¥ÏÑú Federal RegistryÎ•º ÏÑ†ÎØ∏Ïã†ÏùÑ Ìïú Í≤ΩÏö∞Í∞Ä ÎßéÏùÄÎç∞ Í∑∏Îü∞ Í±∏ Î≥¥Î©¥ÏÑú Ìï≠ÏÉÅ ÌïúÍµ≠ ÌöåÏÇ¨Îì§ÎèÑ... Îòê Ïù¥Í≤å ÏûàÏúºÎ©¥ Î≤†ÎÑ§ÌîºÏÖúÌïòÍ≤†Îã§Í≥† ÏÉùÍ∞ÅÌñàÎäîÎç∞ Ïù¥Î≤àÏóê Í∑∏Îü∞ Í∏∞Í¥ÄÏù¥ ÏÉùÍ∏¥ Í≤É Í∞ôÏäµÎãàÎã§. Ï†ÄÎäî Î∞ïÏÑ±ÏõêÏù¥ÎùºÍ≥† ÌïòÍ≥†Ïöî. Í∑∏ Îã§Ïùå Î¶¨Îìú Ïä§ÎØ∏Ïä§Ïùò FDAÎ≤ï Í¥ÄÎ†® Î≥ÄÌò∏ÏÇ¨ÏûÖÎãàÎã§.

Ï†ÄÎäî Ï†úÍ∞Ä ÌïòÎäî ÏùºÏùÑ ÌîåÎü¨Î®∏ ÎòêÎäî ÌéòÏù∏ÌÑ∞ÎùºÍ≥† ÌïòÎäîÎç∞ ÌîåÎü¨Î®∏Îäî Î¨∏Ï†ú ÏÉùÍ≤ºÏùÑ Îïå FDA Í¥ÄÎ†® ÏùºÏùÑ Í≥†ÏπòÍ∏∞ ÎïåÎ¨∏Ïóê ÌîåÎü¨Î®∏Í≥†Ïöî. ÌéòÏù∏ÌÑ∞ Í∞ôÏùÄ Í≤ΩÏö∞Îäî Ìà¨ÏûêÏûêÎì§ÏóêÍ≤å FDA Í¥ÄÎ†® Î¶¨Ïä§ÌÅ¨Ïóê ÎåÄÌï¥ÏÑú ÏÑ§Î™ÖÏùÑ ÌïòÍ∏∞ ÎïåÎ¨∏Ïóê

Ïò§Îäò ÎÇòÎàà ÎÇ¥Ïö©Îì§Ïù¥ Î≥ÄÌò∏ÏÇ¨ ÌÅ¥ÎùºÏù¥Ïñ∏Ìä∏ Î¶¥Î†àÏù¥Ïã±Ïù¥ÎÇò Ïù¥Í±∏ ÎßêÏîÄÎìúÎ¶¨ÎùºÍ≥† Ï†ÄÎäî ÌöåÏÇ¨ÏóêÏÑú Í≥ÑÏÜç ÍµêÏú°Î∞õÍ≥† ÏûàÏäµÎãàÎã§.

Ïò§Îäò ÎÖºÏùòÌï† ÎÇ¥Ïö©ÏùÄ Ï≤´ Î≤àÏß∏Î°úÎäî ÏßÄÍ∏à ÎîîÏßÄÌÑ∏ ÏóëÏä§ ÏãúÏû•ÏóêÏÑú ÏñºÎßàÎÇò ÎßéÏùÄ ÌòÅÏã†Í∞êÏù¥ ÏùºÏñ¥ÎÇòÍ≥† ÏûàÎäîÏßÄ, Ìà¨Ïûê ÏãúÏû•ÎèÑ ÏñºÎßàÎÇò Ïª§ÏßÄÍ≥† ÏûàÎäîÏßÄ Í∑∏Ïóê Í¥ÄÌï¥ÏÑú Í∑úÏ†úÍ∞Ä Ïñ¥ÎñªÍ≤å Î∞úÎ™©ÏùÑ Ïû°Í≥† ÏûàÎäîÏßÄÏóê Í¥ÄÌïú Í±∞Í≥†Ïöî. ÌîåÎ†àÏù∏ÌïÑÎìúÎ°ú Î¥§ÏùÑ Îïå, Î¨ºÎ°† ÏïÑÍπå ÎßêÏîÄÎìúÎ¶∞ Í≤ÉÏ≤òÎüº Ïª§Î©òÌä∏Î•º ÏÑ†ÎØ∏ÏÖòÌïòÎäî Í∑∏Îü∞ Ïï°Ìã∞ÎπÑÌã∞Î•º ÌÜµÌï¥ÏÑú ÌîåÎ†àÏù∏ÌïÑÎìúÎ•º Î∞îÍæ∏Î†§Í≥† ÌïòÏã§ Ïàò ÏûàÍ≤†ÏßÄÎßå Î∞îÎÄåÏßÄ ÏïäÎäî Í≥ºÏ†ïÏóêÏÑú Ïù¥Îü∞ ÌîåÎ†àÏù∏ÌïÑÎìúÎäî Ïö∞Î¶¨ÏóêÍ≤å Ï£ºÏñ¥ÏßÑ Í±¥Îç∞ Ïù¥Í±∏ Ïñ¥ÎñªÍ≤å ÌôúÏö©Ìï¥ÏÑú ÏÑ±Í≥µÏùÑ ÏãúÌÇ¨ Ïàò ÏûàÏùÑÏßÄÏóê Í¥ÄÌïú ÎÇ¥Ïö©ÏûÖÎãàÎã§.

ÎîîÏßÄÌÑ∏Ïä§, Îã®Ïñ¥ ÎîîÏßÄÌÑ∏Ïä§Î•º Î¥§ÏùÑ Îïå Ïó¨Í∏∞Ïóê Î≤ïÏ†Å Îç∞ÌîºÎãàÏÖòÏùÄ ÏóÜÏßÄÎßå Ï£ºÏöî ÎîîÏßÄÌÑ∏ Í∏∞Ïà†ÏùÑ Ïù¥Ïö©Ìï¥ÏÑú Í±¥Í∞ïÏù¥ÎÇò ÏûÑÏÉÅ Í≤∞Í≥ºÎ•º Ìñ•ÏÉÅÏãúÌÇ§Îäî Í≤ÉÏù¥ÎùºÍ≥† Î≥¥Î©¥ Îê† Í≤É Í∞ôÏäµÎãàÎã§. Ïù¥ Îç∞ÌîºÎãàÏÖòÏù¥ ÍµâÏû•Ìûà Î∏åÎùºÎçîÏ£†. Í∑∏Îü∞Îç∞ ÏùºÎ∞òÏ†ÅÏúºÎ°ú Ïö∞Î¶¨Í∞Ä ÏÇ¨Ïö©ÌïòÎäî ÎîîÏßÄÌÑ∏Ìó¨Ïä§ Îã®Ïñ¥Ïùò ÏùòÎØ∏Îäî ÏïÑÍπå ÎßêÏîÄÌïòÏã† ÎåÄÎ°ú SAMT Í∑∏Îü¨ÎãàÍπå ÏòàÎ•º Îì§Ïñ¥ÏÑú AIÎ•º ÏÇ¨Ïö©Ìïú ÏÜåÌîÑÌä∏Ïõ®Ïñ¥ Ï†ïÎèÑÍ∞Ä Îê† Ïàò ÏûàÍ≤†Ï£†. Í∑∏Î¶¨Í≥† ÏÇ¨Ïã§ ÏöîÏ¶ò Í∑∏Îü∞ Í∏∞Îä•Îì§ÏùÄ ÏõåÎÇô Í±∞Ïùò Î™®Îì† ÏùòÎ£åÍ∏∞Í∏∞Ïóê ÎßéÏïÑÏ†∏ÏÑú ÎîîÏßÄÌÑ∏Ìó¨Ïä§ ÏùòÎ£åÍ∏∞Í∏∞ÎùºÍ≥† ÌïòÏßÄ ÏïäÏùÑ Ïàò ÏûàÎäî ÏùòÎ£åÍ∏∞Í∏∞Í∞Ä Ïò§ÌûàÎ†§ Ï†ÅÏùÑ Ï†ïÎèÑÏûÖÎãàÎã§. FDAÏóêÏÑú ÏßÄÍ∏à ÌòÑÏû¨ÍπåÏßÄ ÌóàÍ∞ÄÎ•º Î∞õÏùÄ Ï†ïÌôïÌûà ÎßêÌïòÎ©¥ 510 DifferenceÎ•º Î∞õÏùÄ G-SERVICE AI ÏùòÎ£åÍ∏∞Í∏∞Í∞Ä 1250Í∞ú Ï†ïÎèÑ ÎêòÍ≥†Ïöî. Í∑∏ Îã§ÏùåÏóê Í∑∏ Ï§ë Í±∞Ïùò Ï†ïÌôïÌïòÍ≤å 75%Ïù∏ 956Í∞ú Ï†ïÎèÑÍ∞Ä Radiology PhilatelyÏóêÏÑú ÌóàÍ∞ÄÎ•º Î∞õÏùÄ

Í∑∏Î¶¨Í≥† Ïù¥ Ï§ëÏóêÏÑúÎäî ÏÇ¨Ïã§ ÌïúÍµ≠ ÌöåÏÇ¨Îì§ÎèÑ ÍµâÏû•Ìûà ÎßéÏäµÎãàÎã§. Í∑∏ÎûòÏÑú Ï†úÍ∞Ä ÏÉùÍ∞ÅÌïòÍ∏∞ÏóêÎäî ÌïúÍµ≠ ÌöåÏÇ¨Îì§Ïù¥ ÏÉÅÎãπÌïú Ïù¥Ï†êÏùÑ Í∞ÄÏßÄÍ≥† Í≤ΩÏüÅÎ†•ÏùÑ Í∞ÄÏßà Ïàò ÏûàÎäî Î∂ÑÏïºÍ∞Ä ÎîîÏßÄÌÑ∏Ïä§ ÎùºÍ≥† ÏÉùÍ∞ÅÌïòÎäîÎç∞ Í∑∏ Ïù¥Ïú†Îäî Ï≤´ Î≤àÏß∏Î°úÎäî Î∞©Í∏à ÎßêÏîÄÌïòÏã† Î≤ïÏ†Å ÎòêÎäî regulatory Í∑úÏ†ú Ï†ÑÎûµÏù¥ Îã§Î•∏ ÌïÑÎìúÏóê ÎπÑÌï¥ÏÑúÎäî Ï¢Ä Îçî Ï†ÅÏùÄ Ìé∏Ïù¥Íµ¨Ïöî. ÎëêÎ≤àÏß∏Î°úÎäî ÌïúÍµ≠Ïóê ÏõåÎÇô Ïû¨Îä•Ïù¥ ÏûàÏúºÏã† Î∂ÑÎì§ÎèÑ Ïù¥Ï™ΩÏúºÎ°ú ÎßéÏïÑÏÑú ÎîîÏßÄÌÑ∏ ÏÇ¨ÏóÖÏù¥ ÏïûÏúºÎ°úÎèÑ ÌÅ¨ÏßÄ ÏïäÏùÑÍπå Í∞úÏù∏Ï†ÅÏúºÎ°ú ÏÉùÍ∞ÅÌïòÍ≥† ÏûàÍ≥† Îòê ÏßÄÎÇú Î™áÎÖÑÎßå Ï†úÍ∞Ä Í≤ΩÌóòÌï¥ ÏôîÎçò Î∂ÄÎ∂ÑÏûÖÎãàÎã§. Ìà¨Ïûê ÏãúÏû• Í∞ôÏùÄ Í≤ΩÏö∞Îäî 2024ÎÖÑÏóê ÎπÑÌï¥ÏÑú Ìà¨ÏûêÍ∞Ä Í∑∏ÎûòÎèÑ ÎßéÏù¥ ÎäòÏñ¥ÎÇú Ìé∏Ïù∏Îç∞Ïöî. ÏßÄÍ∏à 3Ïõî 3ÏùºÏóê ÎÅùÎÇ¨ÏùÑ Îïå 9.9Î∞ÄÎ†àÎãå Îã¨Îü¨

Average deal sizeÎèÑ ÏûëÎÖÑÏóê 20.4Î∞ÄÎ¶¨Ïñ∏ÏóêÏÑú 28.1Î∞ÄÎ¶¨Ïñ∏Ï†ïÎèÑ Ïò¨ÎûêÍ≥†, Ïó¨Í∏∞ÏÑú ÌïúÍ∞ÄÏßÄÎäî Ïù¥ Ïà´ÏûêÏùò ÏÉÅÎãπÎ∂ÄÎ∂ÑÏù¥ Î©îÍ∞ÄÎùºÏö¥ÎìúÎùºÍ≥† Î∂àÎ¶¨Îäî ÏÉÅÎãπÌûà ÌÅ∞ Ìä∏ÎûúÏÑπÏÖòÏùò ÌöåÏÇ¨Í∞Ä ÎßéÏäµÎãàÎã§. 19Í∞úÏ†ïÎèÑÏùò ÌöåÏÇ¨Îì§Ïù¥ 100Î∞ÄÎ¶¨Ïñ∏Ï†ïÎèÑ, ÎòêÎäî Îçî ÌÅ∞ Î©îÍ∞ÄÎùºÏö¥ÎìúÎùºÍ≥† Î∂àÎ¶ΩÎãàÎã§. Í∑∏ Îã§ÏùåÏóê Ïù¥Í±∞Îäî ÏïûÏúºÎ°ú ÏûàÏùÑ AURA, Í±∞Ïùò 900Î∞±ÎßåÏõê Îê†Í±∞ÎùºÍ≥† ÌïòÎäîÎç∞, AURAÎ•º Ïì∞Ïã† Î∂Ñ ÏûàÎÇòÏöî? Í∑∏ ÌéÄÎî©ÏùÄ ÏïÑÏßÅ Ïπ¥Ïö¥Ìä∏ÌïòÏßÄ ÏïäÏùÄ Í∑∏Îü∞ Ïà´ÏûêÏûÖÎãàÎã§. M&A Ïï°Ìã∞ÎπÑÌã∞ÎèÑ ÎäòÏñ¥ÎÇòÏÑú ÏûëÎÖÑ 120Í∞ú Ï†ïÎèÑÏóêÏÑú ÏßÄÍ∏à 165Í∞úÎ•º ÎÑòÏóàÎã§Í≥† Ìï©ÎãàÎã§.

Í∑∏Î†áÍ≤å ÏãúÏû•Ïù¥ Ïª§ÏßÄÍ≥† ÏûàÍ≥† ÌòÅÏã†ÎèÑ ÎßéÏïÑÏßÄÍ≥† ÏûàÎäî FDA Í∑úÏ†ú ÌóàÍ∞ÄÎ•º Î∞õÎäî Î∞òÎ©¥ÏóêÏÑú Î∞úÎ™©ÏùÑ Ïû°Í≥† ÏûàÎäî Î∂ÄÎ∂ÑÏùÄ Ï†ú ÏÉùÍ∞ÅÏóêÎäî FDA Í∑úÏ†ú Î∂ÄÎ∂ÑÏûÖÎãàÎã§. FDA ÏùòÎ£åÍ∏∞Í¥ÄÎ†® Î≤ïÎ†πÏùÄ 1976ÎÖÑÏóê Î®ºÏ†Ä ÎßåÎì§Ïñ¥Ï°åÍ≥† Í∑∏ÎûòÏÑú ÏùºÎã®ÏùÄ ÏÉÅÎãπÌûà ÏùòÌöåÏóêÏÑúÎèÑ Í∑∏Î†áÍ≥† FDA Î∂ÄÎ∂ÄÎèÑ Í∑∏Î†áÍ≥† Î≠ê Ïä§ÌÉúÏ∏ÑÎì§Í≥º Í∞ÄÏù¥Îì†Ïä§Îì§ ÌÜµÌï¥ÏÑú ÎßéÏùÄ Î≥ÄÌôîÎ•º ÏïÑÏßÅ ÏÉÅÎãπÎ∂ÄÎ∂ÑÏù¥ ÎîîÏßÄÌÑ∏Ïä§ÏóêÎäî Ï°∞Î™ÖÏù¥ ÎêòÏßÄ ÏïäÏäµÎãàÎã§. ÎëêÎ≤àÏß∏, Ïù¥Í±∞Î≥¥Îã§ Îçî Ï†úÍ∞Ä Ìï≠ÏÉÅ ÏïÑÏâ¨Ïö¥ Î∂ÄÎ∂ÑÏùÄ Î≠êÎÉêÎ©¥ FDAÏóêÏÑú Í≥ÑÏÜç Ïù¥ ÏÉàÎ°úÏö¥ Î≤îÏ£ÑÎì§Ïù¥ÎÇò Í∏∞Ï°¥ Î≤îÏ£ÑÎì§ÏùÑ ÍµâÏû•Ìûà aggressiveÌïòÍ≤å Ìï¥ÏÑùÏùÑ Ìï©ÎãàÎã§. Í∑∏Î¶¨Í≥† Í∑∏ aggressiveÌïú Ìï¥ÏÑùÏùÑ ÏßÄÌÇ§Í∏∞ ÏúÑÌï¥ÏÑú ÍµâÏû•Ìûà ÎßéÏùÄ Î¶¨ÏÜåÏä§Î•º Ï†ÄÎäî ÎÇ≠ÎπÑÌïòÍ≥† ÏûàÏäµÎãàÎã§.

ÏÉùÍ∞ÅÌï©ÎãàÎã§. Ïù¥Í±∞Ïóê ÎåÄÌï¥ÏÑú ÎëêÍ∞ÄÏßÄ ÏòàÏãúÎ•º ÏÉùÍ∞ÅÌï¥ Î≥ºÍ±∞Íµ¨Ïöî. Í∑∏ÎûòÏÑú Ï†úÍ∞Ä Ïù¥ ÏñòÍ∏∞Î•º ÌïòÎäîÍ±¥ Î¨¥ÏóáÏù¥ÎÉêÎ©¥, Í∑∏ Î¶¨ÏÜåÏä§Í∞Ä ÎÇ≠ÎπÑÍ∞Ä ÎêòÍ≥† ÏûàÎçò ÏïÑÎãàÎ©¥ Ïñ¥Îñ§ ÏóÖÍ∑∏Î†àÏù¥ÎìúÍ∞Ä Îê† Ïàò ÏûàÎçò Í∞ÑÏóê Ï†ÄÌù¨Í∞Ä Ìï† ÏùºÏùÄ Í∑∏ ÎÇòÏ§ëÏóê Î≥¥ÏãúÍ≤†ÏßÄÎßå ÏßÄÎ¢∞Ï∞æÍ∏∞Ï≤òÎüº Í∞ÄÏßÄ ÏïäÏùÑ ÎïåÎ•º ÏïåÎ©¥ ÎêòÎäîÍ±∞Í±∞Îì†Ïöî. Í±∞Í∏∞Îäî ÌîºÌï¥Í∞ÄÎ©¥ÏÑú Í∞ÄÏû• ÏãúÏû•Ïóê Îπ®Î¶¨ Ïª§Î®∏ÏÖúÎùºÏù¥Ï¶à Ìï† Ïàò ÏûàÎèÑÎ°ù Ï†úÍ∞Ä ÌîåÎûòÎãõ Î∂ÑÎì§Í≥º Ìï≠ÏÉÅ ÎÖºÏùòÌïòÎäî Î∂ÄÎ∂ÑÏù¥ Ïù¥Îü∞ Ï†êÏûÖÎãàÎã§. ÏïÑÍπå ÏºÄÏù¥Ïä§ ÎëêÍ∞úÎ•º ÎÖºÏùòÌïòÍ≤†Îã§Í≥† ÌñàÎäîÎç∞ ÌòπÏãú

Ïó¨Í∏∞ WOOP!ÎùºÎäî Ï†úÌíà Ïì∞Ïã† Î∂Ñ ÏûàÏúºÏã†Í∞ÄÏöî? ÏïÑÎãà, Î≥¥Ïã† Î∂Ñ? ÏïÑ, Ïì∞Ïã† Î∂ÑÏù¥Ïöî? ÎÑ§, ÌòπÏãú Î™®Î•¥ÏãúÎäî Î∂ÑÎì§ÏùÄ...

Ïù¥ Ï†úÌíàÏù∏Îç∞Ïöî. Ïò§Î•∏Ï™ΩÏóê ÌåîÎ™©Ïóê Ï∞®Í≥† ÏûàÎäî Ï†úÌíàÏù¥ ÏûàÏ£†. Í∑∏Î¶¨Í≥† Ïó¨Í∏∞ Í∑∏ÎûòÌîΩ ÌïúÎ≤à Î¥êÏ£ºÏÑ∏Ïöî. 118, 78. Í∑∏ Îã§ÏùåÏóê Ï¥àÎ°ùÏÉâ, ÎÖ∏ÎûÄÏÉâ, Ï£ºÌô©ÏÉâ ÏûàÏ£†. Ïó¨Í∏∞ Ï¥àÎ°ùÏÉâ, ÎÖ∏ÎûÄÏÉâ, Ï£ºÌô©ÏÉâÎèÑ ÏòàÏ†ÑÏóê ÎπÑÌï¥ÏÑú Î∞îÏÅúÎç∞, Ïù¥Í≤å Ïôú Ï§ëÏöîÌïúÏßÄ Ï°∞Í∏à Ïù¥Îî∞Í∞Ä ÎßêÏîÄÎìúÎ¶¥Í≤åÏöî. Ï†úÍ∞Ä ÏßÄÍ∏à ÏñòÍ∏∞Ìï† Î∂ÄÎ∂ÑÏùÄ General WellnessÎùºÎäî Í≤ÉÏóê Í¥ÄÌïú Ïª®ÏÖâ, General WellnessÎùºÎäî regulatory pathwayÏóêÏöî. Í∏∞ÏóÖÏù¥ ÌÅ¨ÏßÄ ÏïäÏùÄ ÏùºÎ∞òÏ†ÅÏù∏ Ìó¨Ìã∞Ìïú ÎùºÏù¥ÌîÑÏä§ÌÉÄÏùºÏùÑ Î©îÏù∏ÌÖåÏù∏ÌïòÍ±∞ÎÇò Ïù∏ÏΩîÎ¶¨Ï¶àÌïòÎäî ÏÜåÌîÑÌä∏Ïõ®Ïñ¥ Ï†úÌíàÏóê ÎåÄÌï¥ÏÑúÎäî FDAÍ∞Ä ÏùòÎ£åÍ∏∞Í∏∞Î°ú Í∑úÏ†úÌïòÏßÄ ÏïäÎäîÎã§. Í∑úÏ†úÌïòÏßÄ ÏïäÏùÑ ÎøêÎßå ÏïÑÎãàÎùº Î≤ïÏ†ÅÏúºÎ°ú ÏùòÌöåÍ∞Ä Í∑úÏ†úÎ•º Î™ªÌïòÍ≤å Ìï¥ÎÜ®Ïñ¥Ïöî.

Ï†ïÌôïÌïú Î≤ïÏ†Å ÎÇ¥ÎπÑÏ£ºÏùòÏûÖÎãàÎã§. Í∑∏Î†áÍ≤å Ìï¥ÎÜ®Í≥†, Í∑ºÎç∞ ÏïÑÍπå Ï†úÍ∞Ä ÎßêÏîÄÎìúÎ†∏Îçò Í≤ÉÏ≤òÎüº FDAÏóêÏÑú Ïù¥Îü∞ Î∂ÄÎ∂ÑÏóê ÎåÄÌï¥ÏÑú ÍµâÏû•Ìûà ÏóÑÍ≤©ÌïòÍ≤å Ïù¥ Î≤ïÏïàÏùÑ Ìï¥ÏÑùÏùÑ ÌïòÍ≥† ÏûàÏäµÎãàÎã§.

FTAÏóê ÏÇ¨Îäî ÎßêÏùÄ, ÏßÄÍ∏à Ïó¨Í∏∞ Ïö∞Ìù°Í∏∞Í∏∞ ÏûàÏ£†? Ïö∞Ìù°Í∏∞Í∏∞ 5ÏõîÎã¨Ïóê ÏÉàÎ°ú ÎÇòÏò§Îäî Blood Pressure Insight ÌòàÏïï, ÌòàÏïï Ïù∏ÏÇ¨Ïù¥Ìä∏, ÌòàÏïï Î≠ê Ïù∏ÏÇ¨Ïù¥Ìä∏Î©¥ ÏïÑ, ÌïòÏó¨Ìäº ÌòàÏïïÏóê ÎåÄÌï¥ÏÑú Ïà´ÏûêÎ•º ÌëúÏãúÌï¥Ï£ºÎäî Ïù¥ ÌñâÏúÑ ÏûêÏ≤¥Í∞Ä Ïù¥ Í∏∞Í∏∞Î•º ÏùòÎ£åÍ∏∞Í∏∞Î°ú Î∞îÍæºÎã§ Ïù¥ ÎßêÏûÖÎãàÎã§. Í∑∏Î¶¨Í≥† Movi, FD ÌÅ¥Î¶¨Ïñ¥ÎßÅÏä§Í∞Ä ÏóÜÏóàÍ∏∞ ÎïåÎ¨∏Ïóê Ïù¥ Ïú†Î†•Ïù¥Í∏∞Îäî Î∂àÎ≤ï Ïú†Î†•Ïù¥Í∏∞Îã§.

Ïù¥Î†áÍ≤å ÌñàÎäîÎç∞, ÍµâÏû•Ìûà Ï¢Ä Ïù∏Ìä∏Î°úÏä§ÌåÖ ÌïúÍ±∞Îäî ÏÇ¨Ïã§ Ïö∞Î¶¨Í∞Ä Ïó¨Í∏∞ Ïò®ÎèÑÍ≥Ñ ÏûàÏûñÏïÑÏöî.

ÏùºÎ∞òÏ†ÅÏúºÎ°ú ÏâΩÍ≤å ÏÇ¨Ïö©Ìï† Ïàò ÏûàÎäî Ïò®ÎèÑÍ≥Ñ.

ÏùºÎ∞òÏ†ÅÏù∏, ÎòêÎäî Heart Rate Monitor, ÎòêÎäî Oxygen Saturation Monitor, Ïù¥Îü∞ Í≤ΩÏö∞Îäî ÏùòÎ£åÍ∏∞Í∏∞Î°ú ÏÇ¨Ïö©ÌïòÎäî Í≤ΩÏö∞ÎèÑ ÏûàÍ≥†, ÏïÑÎãàÎ©¥ ÏùòÎ£åÍ∏∞Í∏∞Í∞Ä ÏïÑÎãå Í≤ΩÏö∞Î•º ÏÇ¨Ïö©ÌïòÎäî Í≤ΩÏö∞ÎèÑ ÏûàÏñ¥Ïöî. ÏòàÎ•ºÎì§Ïñ¥ÏÑú Ï†úÍ∞Ä ÏûêÏ†ÑÍ±∞ Ïûò ÌÉÄÎäîÎç∞, ÏûêÏ†ÑÍ±∞ ÌÉà Îïå ÌóàÎ∏åÎ†àÏù¥Ìä∏ Î™®ÎãàÌÑ∞ÎßÅ ÌïòÎäîÍ±¥ ÏùòÎ£åÍ∏∞Í∏∞ Ïö©ÎèÑÎäî ÏïÑÎãàÍ≤†Ï£†? Í∑∏ Îã§ÏùåÏóê SPO2ÎèÑ FDAÎèÑ Ïù∏Ï†ïÌï©ÎãàÎã§. ÏùòÎ£åÍ∏∞Í∏∞Î°ú ÏÇ¨Ïö©ÌïòÎäî Í≤ΩÏö∞Í∞Ä ÏûàÍ≥†, ÏùòÎ£åÍ∏∞Í∏∞Î°ú ÏÇ¨Ïö©ÌïòÏßÄ ÏïäÎäî Í≤ΩÏö∞Í∞Ä ÏûàÎã§Í≥†. Ïã§Ï†ú ÌîÑÎ°úÌÜ†ÏΩúÏùÑ Îëê Í∞ú Îã§Î•¥Í≤å ÎßåÎì§Ïñ¥ÎÜ®Ïñ¥Ïöî. FDAÍ∞Ä Ïó¨Í∏∞ÏÑú ÏñòÍ∏∞ÌïòÎäîÍ±∞Îäî...

ÌôîÎ©¥Ïù¥ ÏûòÎ™ªÎì§Ïñ¥ÏôîÎÑ§Ïöî. FDAÍ∞Ä Ïó¨Í∏∞ÏÑú ÏñòÍ∏∞ÌïòÎäî Í≤ÉÏùÄ Î∏îÎ°Ø ÌîÑÎ†àÏÖîÎ•º ÎÇòÌÉÄÎÇ¥Í∏∞ ÎïåÎ¨∏Ïóê Î∏îÎ°Ø ÌîÑÎ†àÏÖîÎ•º ÎÇòÌÉÄÎÇ¥Í∏∞ ÎïåÎ¨∏Ïóê Ïñ¥, Ïù∏Ìó§Î•ºÎ¶¨ Í∑∏ ÏûêÏ≤¥Í∞Ä ÏùòÎ£åÍ∏∞Í∏∞Î°ú Íµ¨Î∂ÑÏù¥ Îê† ÏàòÎ∞ñÏóê, Í∑úÏ†úÍ∞Ä Îê† ÏàòÎ∞ñÏóê ÏóÜÎã§. Ïù¥Í±∞ÏòàÏöî. ÏòàÎ•º Îì§Ïñ¥ÏÑú Ï†úÍ∞Ä Ïò®ÎèÑÍ≥ÑÍ∞Ä ÏûàÏñ¥Ïöî. Ïò®ÎèÑÍ≥ÑÍ∞Ä ÏûàÎäîÎç∞ Ïò®ÎèÑÎ•º ÎÇòÌÉÄÎÇ¥Í∏∞ ÎïåÎ¨∏Ïóê Í∑∏ ÏûêÏ≤¥Í∞Ä ÏùòÎ£åÍ∏∞Ïù¥Îã§. ÏßàÎ≥ëÏùÑ ÏßÑÎã®ÌïòÎäî ÌñâÏúÑÎã§. ÎòêÎäî ÌóêÌéòÏù¥ Î™®ÎãàÌÑ∞Í∞Ä ÏûàÏñ¥Ïöî. Í∑ºÎç∞ Ï†úÍ∞Ä Î≠ê Îõ∞Í∏∞ÎèÑ ÌïòÍ≥† ÏûêÏ†ÑÍ±∞ÎèÑ ÌÉÄÎäîÎç∞ Í∑∏Îïå ÌóêÌéòÎ•º Ïû¨Í∏∞ ÏúÑÌï¥ÏÑú ÏÇ¨Ïö©Ìïú Í±¥Îç∞ Í∑∏ ÌñâÏúÑ ÏûêÏ≤¥Í∞Ä ÏùòÎ£åÏßÑÎã® ÌñâÏúÑÎã§. Ïù¥Î†áÍ≤å ÌåêÎã®Ìïú Í±∞ÏòàÏöî. Ïã§Ï†úÎ°ú Í∑∏ Î≠êÎû¨ÎäîÏßÄ Î≥¥Î©¥ inherently means diagnosis ÎùºÎäî Îã®Ïñ¥Îì§Ïù¥ ÎÇòÏòµÎãàÎã§.

Î≤ïÏ†ÅÏúºÎ°ú Î¥§ÏùÑÎïå ÍµâÏû•Ìûà ÍµâÏû•Ìûà Ïñ¥Í∑∏Î†àÏãúÎ∏åÌïú Ìï¥ÏÑùÏù¥Íµ¨Ïöî. Í∑ºÎç∞ Ï†úÍ∞Ä ÎÜÄÎûêÎçòÍ±∞Îäî Ïù¥ ÌöåÏÇ¨Ïóê ÎåÄÌï¥ÏÑú Îçî ÎÜÄÎûêÏäµÎãàÎã§. Ïù¥ ÌöåÏÇ¨Í∞Ä 5ÏõîÎã¨Ïóê Ï†úÌíà Ï∂úÏãúÌïòÍ≥† 7ÏõîÎã¨ FDAÎ∂ÄÌÑ∞ ÏõêÏù∏ÏùÑ Î∞õÏïòÏñ¥Ïöî. ÍµâÏû•Ìûà Îπ®Î¶¨ Î∞õÏùÄÍ±∞Í±∞Îì†Ïöî. Î∞õÏûêÎßàÏûê CNNÏùò Will AhmedÍ∞Ä LinkedInÏóê Ïä§ÌÖåÏù¥ÌÅ¨ÎßÅÏùÑ ÌÜµÌï¥ ÎßêÌñàÏäµÎãàÎã§. Í∑∏Îü¨Î©¥ÏÑú Ïö∞Î¶¨Îäî FDAÏóê ÎåÄÌï¥ Ï†ïÎ≥¥Î•º Ï†ÑÎã¨ÌñàÏäµÎãàÎã§. Ïö∞Î¶¨Îäî FDAÏùò Ïï±ÏóêÏÑú ÎØ∏Î™®Î•º Í≥ÑÏÇ∞ÌïòÏßÄ ÏïäÏùÑ Í≤ÉÏûÖÎãàÎã§. Ï£ºÎ°ú FDAÌïòÍ≥† Ïã∏Ïö∏ ÎïåÎäî Ï°∞Ïö©Ìûà Ïã∏Ïö∞ÎäîÎç∞ CEOÍ∞Ä ÌôàÌéòÏù¥ÏßÄÏôÄ Í∞úÏù∏ ÎßÅÎî©Ïóê Ïö∞Î¶¨Îäî FDA Í≥ÑÏÜç Ïã∏Ïö∞Í≤†Îã§ Ïù¥Î†áÍ≤å ÌëúÍ∏∞Î•º ÌïúÍ≤ÅÎãàÎã§. Í∑∏Îü¨Í≥†ÏÑúÎäî Ï†úÍ∞Ä Ïù¥Í≤å Ïò§Îäò ÏÇ¨ÏßÑÏù∏Îç∞ ÏïÑÏßÅÎèÑ Ïïà ÎÇ¥Î†∏Ïñ¥Ïöî. Í≥ÑÏÜç Ïã∏Ïö∞Í≤†Îã§ Ïù¥Í±∞Ï£†. Í∑ºÎç∞ ÌïúÍ∞ÄÏßÄ Î∞îÎÄê Ï†êÏùÄ ÏòàÏ†ÑÏóê Î≥¥Î©¥ÏùÄ Ïó¨Í∏∞Í∞Ä Ï¥àÎ°ùÏÉâ Ï£ºÌô©ÏÉâÏù¥ÏóàÎÇò Îπ®Í∞ÑÏÉâ Ïù¥Î†áÍ≤å Îèº ÏûàÏóàÎäîÎç∞ ÏßÄÍ∏à ÏÉâÏùÑ ÏÇ¥Ïßù Î∞îÍø®ÎçîÎùºÍµ¨Ïöî.

Í∑∏ÎûòÏÑú ÏïÑÏßÅ Î≠îÍ∞Ä Î∞∞ÌÅ¨Îüº ÎîîÏä§Ïª§Ïã±Ïù¥ ÏûàÏßÄ ÏïäÎÇò Í∑∏Îü∞ ÏÉùÍ∞ÅÏùÑ ÌïòÍ≤†ÏäµÎãàÎã§. Ïù¥Í±∞Îäî Ï†ú Î≤ïÏ†Å ÏÉùÍ∞ÅÏùÄ Í∑∏Î†áÎã§Í≥† ÌïòÏßÄÎßå ÌïòÏßÄÎßå Í∑∏Î†áÎã§Í≥† Ìï¥ÏÑú Ï†ú ÏÉùÍ∞ÅÏóêÎäî ÏïÑÎßà 5B Ïã∏Ïö∞Í∏∞Ïóê ÍµâÏû•Ìûà ÌûòÎì† Ïã∏ÏõÄÏù¥ Îê† Í≤É Í∞ôÏäµÎãàÎã§. ÏôúÎÉêÎ©¥ ÏïÑÏßÅÍπåÏßÄ ÏûëÎÖÑÏóê Ïñ¥Îñ§ ÏºÄÏù¥Ïä§Í∞Ä ÏûàÏóàÎäîÎç∞ Í∑∏Í≤å Ïù¥Ï†ú... Ï†ïÎ≥¥Í∏∞Í¥ÄÎì§Ïùò Í≤∞Ï†ïÏùÑ ÎÇ¥Î¶¥ Ïàò ÏûàÎäî Í∂åÌïúÏùÑ ÏïΩÌôîÏãúÌÇ§Îäî Í∑∏Îü∞ Í≤∞Ï†ïÏù¥ ÏûàÏóàÎäîÎç∞ Í∑∏Îü∞ Í≤∞Ï†ïÏù¥ ÏûàÎã§Í≥† Ìï¥ÎèÑ Î≤ïÏõêÎì§ÏùÄ Ïù¥Îü∞ ÏùòÎ£åÎÇò ÌÖåÌÅ¨ÎãàÏª¨ ÌåêÎã®Ïóê ÎåÄÌï¥ÏÑúÎäî FDAÏóê ÏÜêÏùÑ Îì§Ïñ¥Ï§Ñ ÌôïÎ•†Ïù¥ ÍµâÏû•Ìûà ÎÜíÍ≥†Ïöî. Í∑∏ÎûòÏÑú FDAÍ∞Ä Ïù¥ Ïà´Ïûê ÏûêÏ≤¥Í∞Ä inherently diagnosticÌïòÎã§ ÌïòÎ©¥ Í∑∏Í±∏ ÏÜêÏùÑ Îì§Ïñ¥Ï§Ñ ÌôïÎ•†Ïù¥ ÎÜíÍ≥† Í∑∏ Îã§ÏùåÏóê Í∑∏ Ï†ÑÏóê MOBÏù¥ ÏÇ¨Ïö©ÌñàÎçò Í∑∏Îü∞ ÌÅ¥Î†àÏù∏Îì§

Ïù¥Í≤å ÌôïÎ•†Ïù¥ Ï¢Ä Îçî ÌÅ¨Îã§Í≥† ÏÉùÍ∞ÅÌïòÍ≥†, Ï†úÍ∞Ä ÏïÑÏâΩÍ≤å ÏÉùÍ∞ÅÌïòÎäî Í±¥ bad facts make for bad precedents ÎùºÎäî Îã®Ïñ¥Í∞Ä ÏûàÎäîÍ±∞Ï£†. Í∑∏Îü¨ÎãàÍπå ÎÇòÏÅú ÏÇ¨Ïã§Ïù¥ ÏûàÏúºÎ©¥ ÎÇòÏÅú ÏòàÏãúÍ∞Ä ÏÉùÍ∏¥ Í±∞Í±∞Îì†Ïöî. Í∑∏ÎûòÏÑú Ïù¥ ÏòàÏãúÍ∞Ä ÏÇ¨Ïã§ FDAÎ•º Ïã∏Ïö∞Í∏∞ÏóêÎäî, FDAÏùò Ìë∏ÏãúÌå© ÌïòÍ∏∞ÏóêÎäî Í∞ÄÏû• Ï¢ãÏùÄ ÏòàÏãúÎäî ÏïÑÎãàÏóàÏßÄ ÏïäÎÇò ÎùºÎäî ÏÉùÍ∞ÅÏùÑ Ìï©ÎãàÎã§. Ïñ¥Ï®åÎì† ÏßÄÍ∏à Ïù¥Îü∞ Î¶¨Ïä§ÌÅ¨, Ï†úÌíà Í∞úÎ∞úÌïòÎäî Î∂ÑÎì§, Ïä§ÌîºÌÇπ Ï±ÑÎÑêÏùò Ïõ®Îî©Ïä§ Ï†úÌíàÏùÑ Í∞úÎ∞úÌï¥Ï£ºÏãúÎäî Î∂ÑÎì§Ïù¥ ÏûàÎã§Î©¥ Ïù¥Îü∞ Î¶¨Ïä§ÌÅ¨Í∞Ä ÏûàÍ≥†.

Îëê Î≤àÏß∏Îäî Ïñ¥ÎñªÍ≤å Î≥¥Î©¥ ÎîîÏßÄÌÑ∏ Ïä§ÏΩîÏñ¥Ïóê ÎåÄÌï¥ÏÑú Ï¢Ä ÌÅ¥ÎûòÏãùÌïú Ïù¥ÏäàÏù∏Îç∞, ÏöîÏ¶òÏùÄ Ï§ÑÏñ¥Îì§ÏóàÏäµÎãàÎã§Îßå ÌÅ¥Î¶¨ÎãàÏª¨ ÎîîÏßÄÌÑ∏ Ïä§ÏΩîÏñ¥ ÏÜåÌîÑÌä∏Ïõ®Ïñ¥ÎùºÎäî Ïπ¥ÌÖåÍ≥†Í∞Ä ÏûàÏäµÎãàÎã§. Í∑∏Îü∞Îç∞ Ï†úÏ°∞ÏÇ¨Îì§Ïù¥ ÎÖ∏Î†•ÏùÑ ÍµâÏû•Ìûà ÎßéÏù¥ ÌñàÏóàÏñ¥Ïöî. Ïôú Ïì∞ÎÉê? ÏùòÎ£åÍ∏∞Í∏∞Ïùò Ïñ¥Îñ§ 80% ÏàòÏ§ÄÏùò Ìö®Îä•ÌëúÍ∏∞Î•º Ìï† Ïàò ÏûàÏúºÎ©¥ÏÑúÎèÑ ÏùòÎ£åÍ∏∞Í∏∞Ïùò Í∑úÏ†úÎ•º Î∞õÏßÄ ÏïäÏïòÏñ¥Ïöî. Í∑∏Îü¨ÎãàÍπå ÏãúÏû•ÏùÑ ÏóÑÏ≤≠ Îπ†Î•¥Í≤å ÏãúÏûëÌïòÎ©¥ Ï†úÌíàÏùÑ ÎÇ¥ÎÜìÏùÑ Ïàò ÏûàÎäî Í±∞ÏòàÏöî. Í∑ºÎç∞ Ïù¥Í≤ÉÎèÑ ÎßàÏ∞¨Í∞ÄÏßÄÎ°ú ÎãπÏó∞Ìûà Î≤ïÏïàÏóê ÏùòÌï¥ÏÑú ÏôºÏ™ΩÏóê ÏûàÎäî Ï†úÌíà Í∞ôÏùÄ Í≤ΩÏö∞Îäî 4Í∞úÏùò ÌÅ¨ÎùºÏù¥Ìã∞ÎÑêÏùÑ SatisfyÌïòÎ©¥ ÏùòÎ£åÍ∏∞Í∏∞Î°ú Í∑úÏ†ïÌïòÏßÄ ÏïäÎäîÎã§ÎùºÎäî Í±∏ Î≤ïÏïàÏóêÏÑú ÌôïÏù∏ÏùÑ Î∞õÏïòÎäîÎç∞ FDAÍ∞Ä ÏóÑÏ≤≠ÎÇòÍ≤å Îòê ÏóÑÍ≤©Ìïú Ïû£ÎåÄÎ•º ÎìúÎ¶ΩÎãàÎã§.

Í∑∏ 4Í∞ÄÏßÄÎ•º Í∞ÑÎã®ÌïòÍ≤å ÌôïÏù∏Ìï¥Î≥¥Î©¥, Ïù¥ 4Í∞ÄÏßÄÎ•º Ï¥ùÏ†ÅÏãúÌÇ§Î©¥ ÏùòÎ£åÍ∏∞Í∏∞Í∞Ä ÏïÑÎãåÍ±∞ÏóêÏöî. Ïù¥Í≤å Î≠êÎÉêÎ©¥, Ï≤´Î≤àÏß∏Î°úÎäî Î©îÎîîÏª¨ Ïù¥ÎØ∏ÏßÄÎÇò ÏãúÍ∑∏ÎÑê, ÏòàÎ•º Îì§Ïñ¥ÏÑú ECGÍ∞ôÏùÄ ÏãúÍ∑∏ÎÑêÏùÑ ÏßÅÏ†ëÏ†ÅÏúºÎ°ú Î∂ÑÏÑùÌïòÏßÄ ÏïäÍ≥† ÎëêÎ≤àÏß∏Î°úÎäî Î©îÎîîÌÅ¥ Ïù∏Ìè¨Î©îÏù¥ÏÖò ÎîîÏä§ÌîåÎ†àÏù¥ÏòàÏöî. ÎëêÎ≤àÏß∏Îäî Ï¢Ä ÏùòÎØ∏Í∞Ä Ï†ÅÏùÄ Í∑∏Îü∞ ÌÅ¨ÎùºÏù¥ÌÖçÏûÖÎãàÎã§. ÏÑ∏Î≤àÏß∏Î°úÎäî, ÏïÑ Ïù¥Í≤å Ï§ëÏöîÌïúÍ±¥Îç∞, ÏùòÎ£åÏßÑÏóêÍ≤å Î∞òÎìúÏãú Í≤∞Ï†ïÏùÑ ÎÇ¥Î¶¨ÏßÄ ÏïäÍ≥†, Í≤∞Ï†ïÏùÑ Ï†ÑÎã¨ÌïòÏßÄÎäî ÏïäÍ≥†, Ï∂îÏ≤úÎßå Ï†ÑÎã¨Ìï¥Ïïº ÎèºÏöî. Ï∂îÏ≤úÎßå. ÎÑ§Î≤àÏß∏Î°úÎäî Í∑∏ Ï∂îÏ≤úÏóê ÎåÄÌï¥ÏÑú ÏùòÎ£åÏßÑÏù¥ ÎèÖÎ¶ΩÏ†ÅÏúºÎ°ú Î¶¨Î∑∞Î•º Ìï† Ïàò ÏûàÎèÑÎ°ù Î≤†Ïù¥Ïä§Î¶¨Ïä§Ìä∏Î•º Ï†úÍ≥µÌï¥Ïïº Ìï©ÎãàÎã§. FDAÍ∞Ä Ïó¨Í∏∞ÏÑú ÌïúÍ≤å Î≠êÎÉêÎ©¥, Ïù¥ ÏÑ∏Î≤àÏß∏ ÌÅ¨ÎùºÏù¥Ìã∞Ïñ¥Ïóê ÎåÄÌï¥ÏÑú, ÌïòÏù¥ÎùºÏù¥Ìä∏ Îêú Î∂ÄÎ∂Ñ Î≥¥Ïù¥ÏãúÏ£†? ÏÑ∏Î≤àÏß∏ ÌÅ¨ÎùºÏù¥Ìã∞Ïñ¥Ïóê ÎåÄÌï¥ÏÑú FDA ÏûêÏ≤¥Ïùò Í∏∞Ï§ÄÏùÑ Îòê ÏßëÏñ¥ÎÑ£ÏäµÎãàÎã§. Îòê ÏßëÏñ¥ÎÑ£ÎäîÎç∞ Í∑∏Í≤å Î≠êÎÉêÎ©¥

Ï∂îÏ≤úÏùÑ ÌïòÎ©¥ÏùÄ Ï∂îÏ≤úÏùÑ ÌïòÎ©¥ Ï∂îÏ≤úÎßå ÌïòÎ©¥ Ïó¨Í∏∞Í∞Ä ÏïÑÎãàÍ∏¥ ÌïúÎç∞ Îã®ÏßÄ ÏÑ∏Í∞ÄÏßÄ Ï°∞Í±¥Ïù¥ ÏûàÏñ¥Ïöî. Ï≤´Î≤àÏß∏ Í∑∏ ÏÜåÌîÑÌä∏Ïõ®Ïñ¥Ïùò Ïò§ÌÜ†Î©îÏù¥ÏÖòÏù¥ ÏûàÏúºÎ©¥ ÏïàÎèºÏöî. ÏûêÎèôÌôîÍ∞Ä ÏûàÏúºÎ©¥ ÏïàÎèºÏöî. Ïôú FDAÍ∞Ä Í∑∏Î†áÍ≤å ÏñòÍ∏∞ÌïòÎäêÎÉê ÌïòÎ©¥ Ïñ¥Îñ§ ÏûêÎèôÌôîÎùºÎäî Í≥ºÏ†ïÏù¥ ÏûàÏúºÎ©¥ ÏùòÎ£åÏßÑÏù¥ÎùºÍ≥† Ìï¥ÎèÑ automation biasÎùºÎäî Í≤É ÎïåÎ¨∏Ïóê ÏûêÎèôÌôî Ìé∏Ìñ•Ïù¥ÎùºÍ≥† ÌïòÎçòÎç∞ Í∑∏Í≤É ÎïåÎ¨∏Ïóê Í≤ÄÏ¶ù ÏóÜÏù¥ ÏûêÎèôÌôîÎêú Í≤∞Í≥ºÎ•º ÎØøÏùÑ ÌôïÎ•†Ïù¥ ÎÜíÎã§Îäî Í±∞ÏòàÏöî FDAÏóê Îî∞ÎùºÏÑúÎäî. Ïã§Ï†úÎ°ú Ïñ¥Îñ§ Ïä§ÌÑ∞ÎîîÎèÑ ÏûàÎäî Í≤É Í∞ôÍ≥†Ïöî. ÏòàÎ•º Îì§Ïñ¥ÏÑú Ï†ÄÌù¨Í∞Ä 70PTÎÇò Ïù¥Îü∞ Í±∏ Ïì∞Î©¥ÏÑú ÏûêÏ†ÑÍ±∞ Ïö¥Ï†ÑÌï¥ÏÑú ÎÇòÏò® Í≤∞Í≥ºÏóêÎäî Ïª¥Ìì®ÌÑ∞Í∞Ä ÎêòÎäî Ï£ºÏöîÍ±¥ÏùÑ ÎØøÍ≤å ÎêúÎã§, Ïù¥Í±¥ Ïù¥Îü∞ Í±∞Í≥† Îëê Î≤àÏß∏Î°úÎäî Í∏âÎ∞ïÌïú ÏÉÅÌô©, Í∏âÎ∞ïÌïú ÏÉÅÌô©ÏóêÏÑú ÏÇ¨Ïö©ÎêòÏñ¥ ÏûàÎäî ÏÜåÌîÑÌä∏Ïõ®Ïñ¥Îäî ÏùòÎ£åÍ∏∞Í∏∞Î°ú Î∂ÑÎ•òÍ∞Ä ÎêúÎã§.

Ïù¥Í±∏ FDAÍ∞Ä ÌïúÍ±∞Í≥†, Í∑ºÎç∞ Îã§Ïãú ÎßêÏîÄÎìúÎ¶¨ÏßÄÎßå Î≤ïÎ†πÏóêÎäî Ïñ¥ÎîîÏóêÎèÑ Í∏âÎ∞ïÌïú ÏÉÅÌô©Ïóê ÎåÄÌïú Î¶¨ÎØ∏ÌÖåÏù¥ÏÖòÏù¥ÎÇò Î∞©Í∏à ÎßêÏîÄÎìúÎ¶∞ Ïò§ÌÜ†Î©îÏù¥ÏÖòÏóê ÎåÄÌïú Î¶¨ÎØ∏ÌÖåÏù¥ÏÖòÏù¥ ÏóÜÏñ¥Ïöî. Í∑∏ÎûòÏÑú Ïñ¥ÎñªÍ≤å Ïù¥Îü∞Í±∏ Î∞úÌëúÎ•º Ìï¥ÏÑú 2022ÎÖÑÏù∏Í∞Ä Î∞úÌëúÎ•º Ìï¥ÏÑú ÌïúÎ≤à ÎÇúÎ¶¨Í∞Ä ÎÇ¨ÏóàÏäµÎãàÎã§. ÏôúÎÉêÎ©¥ CDS Ï†úÌíàÎì§Ïù¥ ÍµâÏû•Ìûà ÎßéÏïòÍ±∞Îì†Ïöî ÏãúÏû•Ïóê.

Í∑∏ÎûòÏÑú Í≥ºÏó∞ FDAÍ∞Ä Ïù¥Í±∞Î•º ÏßëÌñâÌï† Í≤ÉÏù∏Í∞Ä, Í∑∏Î¶¨Í≥† ÏßëÌñâÌïòÎ©¥ ÏÜåÏÜ°ÌïòÍ∏∞ ÏúÑÌï¥ÏÑú Îòê Í±∞Í∏∞ÎèÑ ÌòëÌöåÍ∞Ä ÎßåÎì§Ïñ¥Ï°åÏäµÎãàÎã§. Ìïú 1ÎÖÑÎèôÏïà ÎëêÍ≥†Î≥¥Îã§Í∞Ä FDAÍ∞Ä 2023ÎÖÑ 9ÏõîÏóê ÎìúÎîîÏñ¥ Í≤ΩÍ≥†Ï†êÏùÑ Î≥¥ÎÉÖÎãàÎã§. Ïù¥Í±¥ ÌçºÎ∏îÎ¶≠ Ïó¨Î≥ÑÎ°ú Î≥¥Îäî Ï†ïÎ≥¥Í≥† ÌöåÏÇ¨Ïù¥Î¶ÑÏùÄ Ïó¨Í∏∞ Ïïà Ï†ÅÏóàÏßÄÎßå Ï∞æÏïÑÎ≥¥ÏãúÎ©¥ ÎÇòÏò§Íµ¨Ïöî. Î©¥Ï∂îÌÇ¨Îü¨Ïä§Ìè¨Ìä∏, ÌÅ¨Î¶¨Ìã∞Ïª¨ ÏºÄÏñ¥Ïóê ÏûàÎäî ÌôòÏûêÎì§ÏóêÍ≤å Î©¥Ï∂îÌÇ¨Îü¨Ïä§Ìè¨Ìä∏Î•º Ï†úÍ≥µÌïòÎäî Ï†úÌíàÏóê ÎåÄÌïú Í≤ΩÍ≥†Ïû•Ïù∏Îç∞ Í±∞Í∏∞ÏÑú ÌäπÌûà FDAÍ∞Ä Î¨∏Ï†úÎ•º ÏÇºÏùÄ Î∂ÄÎ∂ÑÏù¥ patient-specific medical information, time-critical settingÏóêÏÑú ÏïåÎûåÏùÑ Ï†úÍ≥µÌïòÍ∏∞ ÎïåÎ¨∏Ïóê Î∂àÎ≤ïÏ†ÅÏù∏ Ï†úÌíàÏù¥Îã§. Í∑∏Î¶¨Í≥† Ïù¥ ÌöåÏÇ¨ Ï†úÌíàÏù¥, Í≤ΩÍ≥†Ïû• Î∞õÏùÄ ÌöåÏÇ¨Í∞Ä

ÏóÑÏ≤≠ ÌÅ∞ ÌöåÏÇ¨Ïùò ÏûêÌöåÏÇ¨ Í±∞Îì†Ïöî Í∑∏Îü∞ ÌöåÏÇ¨ÌïúÌÖåÎèÑ FTÍ∞Ä ÎëêÎ†§ÏõåÌïòÏßÄ ÏïäÍ≥† Ïñ¥ Ïù¥Í±∞ ÌïúÎ≤à Ìï¥Î≥¥Ïûê Ïù¥Îü¨Î©¥ÏÑú Í≤ΩÍ≥†Ïû•ÏùÑ Î≥¥ÎÇ∏Í±∞ÏóêÏöî

Í∑∏ÎûòÏÑú ÏßÄÍ∏à Í≤∞Î°†Ï†ÅÏúºÎ°ú Í∑∏ ÌòëÌöåÍ∞Ä FDAÌïúÌÖå ÏÜåÏÜ°ÏùÑ ÌïòÏßÑ ÏïäÏïòÏßÄÎßå ÏßÄÍ∏à Ïù¥ CBS Ï†úÌíà Ïπ¥ÌÖåÍ≥†Î¶¨ÏóêÏÑúÎèÑ ÍµâÏû•Ìûà FDAÍ∞Ä Í∑úÏ†úÎ•º Í∞ÄÌï† ÌôïÎ•†Ïù¥ ÎÜíÏùÄ ÏÉÅÌô©ÏûÖÎãàÎã§. Í∑∏Î¶¨Í≥† Ï≤òÏùåÏóê Ìä∏ÎüºÌîÑ ÎåÄÌÜµÎ†πÏù¥ Îì§Ïñ¥ÏôîÏùÑ Îïå, Í∑∏Î¶¨Í≥† FD Ï≤úÏïàÏù¥ Î∞îÎÄåÏóàÏùÑ Îïå ÎêòÍ≤å ÎßéÏùÄ ÏÇ¨ÎûåÎì§ Ï†ëÌïòÎ©¥ÏÑú ÏïÑ Ïù¥Í±∞ Í∑úÏ†úÍ∞Ä ÏñïÏïÑÏßà Í±∞Îã§. Í∑∏ÎûòÏÑú ÎßåÏïΩ ÏãúÏû•Ïù¥ ÏßÑÏûÖÌïúÎã§Î©¥ ÏßÄÍ∏àÏù¥ ÏßÑÏûÖÌïòÍ∏∞ Ï¢ãÏùÑ ÎïåÎùºÍ≥† ÌñàÎäîÎç∞ ÌäπÌûà ÎîîÏßÄÌÑ∏Ïä§ Î∂ÑÏïºÏùò Í∑úÏ†úÎ•º Î≥¥Î©¥ Ï†ÑÌòÄ Í∑∏Î†áÏßÄ ÏïäÍ≥†Ïöî. Ïò§ÌûàÎ†§ Ïù¥Îü∞ ÏºÄÏù¥Ïä§Îì§Ïù¥ Í≥µÏãùÏ†ÅÏúºÎ°úÎÇò ÎπÑÍ≥µÏãùÏ†ÅÏúºÎ°ú Í∑úÏ†úÎ•º Î∞õÎäî Í≤ΩÏö∞Îì§Ïù¥ ÎäòÏñ¥ÎÇòÍ≥† ÏûàÏäµÎãàÎã§.

Í∑∏ÎûòÏÑú Ïù¥Í±∏ Î¥§ÏùÑ Îïå ÏÉùÍ∞ÅÌï¥Ïïº ÎêòÎäîÍ≤å Î¨¥ÏóáÏùºÍπå? ÎùºÍ≥† Î≥¥Î©¥ ÏùºÎã® ÎëêÍ∞ÄÏßÄ, Ï†úÌíà Í∞úÎ∞ú, Í∑∏ Îã§ÏùåÏóê Ïª§Î®∏ÏÖúÎùºÏù¥Ï†úÏù¥ÏÖò ÎòêÎäî Ïù∏Î≤†Ïä§Î©òÌä∏ Ïä§ÌÖåÏù¥ÏßÄÏóêÏÑú ÏÉùÍ∞ÅÌï† Ïàò ÏûàÎäîÍ≤å ÏûàÏùÑ Í≤É Í∞ôÏïÑÏöî. ÏïÑÍπå ÏßÄÎ¢∞Ï∞æÍ∏∞Î•º Ï†úÍ∞Ä Ïû†Íπê ÎßêÏîÄÎìúÎ†∏ÎäîÎç∞ Ï†úÌíàÏùÑ ÌäπÌûà ÎîîÏßÄÌÑ∏Ïä§ Î∂ÑÏïºÏóêÏÑú Ï†úÌíà Í∞úÎ∞úÌï† ÎïåÎäî Ïñ¥ÎäêÏ†ïÎèÑÏùò Ïñ¥Ï©î Ïàò ÏóÜÏù¥ Î¶¨Ïä§ÌÅ¨Î•º ÌÖåÏù¥ÌÅ¨Ìï¥Ïïº ÎêòÎäî Í±¥ ÎßûÏäµÎãàÎã§. ÏùºÎã® Ï≤´Î≤àÏß∏Î°ú Í∑úÏ†ú ÏûêÏ≤¥Í∞Ä Î∂àÎ™ÖÌôïÌïú Í≤ÉÎèÑ ÏûàÍµ¨Ïöî. Í∑∏ Îã§ÏùåÏóê Ï°∞Í∏à Îçî ÎÇ®Îì§Î≥¥Îã§ ÏñµÎ•º ÏäµÌïòÍ≤å ÎÇòÍ∞ÄÏïºÏßÄ ÏãúÏû• Ï†êÏú†Ïú®ÏùÑ ÏñªÎäî Í≤ΩÏö∞ÎèÑ ÏûàÏäµÎãàÎã§.

Í∑∏Í≤å ÏûàÎäîÎç∞, Ï†ïÎßê Ï§ëÏöîÌïú Ïï†Î¶¨ÏïÑ, ÏßÑÏßú Í±¥ÎìúÎ†§ÏÑúÎäî ÏïàÎêòÎäî Í≤ÉÏù¥ Î≠îÏßÄ ÏïåÏïÑÏïº ÎèºÏöî. Í±¥ÎìúÎ†§ÏÑú ÏïàÎêòÎäî Í≤ÉÏù¥ Î≠îÏßÄ ÏïåÏïÑÏïº ÎêòÍ≥†, ÏïÑÍπå ÎßêÏîÄÎìúÎ¶∞ Í≤ÉÏ≤òÎüº FDAÎäî Í∑∏Î†áÍ≤å ÌÅ∞ ÌöåÏÇ¨Îì§ÎèÑ Ïã¨ÏßÄÏñ¥ ÌÖåÏù¥ÌÅ¨ÏïÑÏõÉ ÌïòÎäî Í≤ÉÏùÑ ÎëêÎ†§ÏõåÌïòÏßÄ ÏïäÍ∏∞ ÎïåÎ¨∏Ïóê, Ïñ¥Îñ§ Í±∏ FDAÍ∞Ä Ï†ïÎßê Ï§ëÏöîÌïòÍ≥†, Ïñ¥Îñ§ Í±∏ Ï§ëÏöîÌïòÏßÄ ÏïäÎäîÏßÄÎ•º Ïûò ÌåêÎã®ÌïòÏÖîÏïº Îê©ÎãàÎã§. Í∑∏Î¶¨Í≥† Ï†úÍ∞Ä Ìïú Í∞ÄÏßÄ Îçî ÏÉùÍ∞ÅÌï† Î∂ÄÎ∂ÑÏùÄ ÎßåÏïΩÏóê Í∞ÄÎä•ÌïòÎã§Î©¥, Í≥ºÏó∞ ÎÇ¥Í∞Ä Ï†ïÎßê FDAÏùò Í∑úÏ†úÎ•º Î∞õÏùÑ ÌïÑÏöîÍ∞Ä ÏûàÏùÑÍπå? Ï°∞Í∑∏Îßå ÌîÑÎ°úÎìÄÏä§ ÌéëÏÖÄÎü¨ÎãàÌã∞Î•º Î∞îÍøîÏÑú Í∑úÏ†ú Ïïà Î∞õÎäî Ï™ΩÏúºÎ°ú ÎÇòÏïÑÍ∞ÄÎäî Í≤ÉÎèÑ Í¥úÏ∞ÆÏßÄ ÏïäÏùÑÍπå?

Îã§Î•∏ Í≤ÉÎèÑ ÏÉùÍ∞ÅÌï¥Î≥º ÎßåÌïú Í∞ÄÏπòÍ∞Ä ÏûàÎã§Í≥† ÏÉùÍ∞ÅÌï¥Ïöî. ÏòàÎ•º Îì§Ïñ¥ÏÑú Ïñ¥Ï†ú Ï†úÍ∞Ä Ïª®ÌçºÎü∞Ïä§ÏóêÏÑú ÎèåÏïÑÏôîÎäîÎç∞ Í±∞Í∏∞ÏÑú Ìà¨ÏûêÏûêÎì§Ïù¥ Î™á Î∂ÑÌïòÍ≥† ÌïòÎ©¥ÏÑú ÏñòÍ∏∞ÌñàÎçò ÎÖºÏùò Ï§ëÏóê ÌïòÎÇòÍ∞Ä Î¨ºÎ°† Ï†úÌíà ÏÇ¨Ïù¥Ï¶à, ÌååÏö¥Îçî, ÏãúÏû• ÏÇ¨Ïù¥Ï¶à Ïù¥Îü∞ Í≤ÉÎì§ÏùÄ Îã§ Îã§Î•¥Í≤†ÏßÄÎßå ÏùºÎ∞òÏ†ÅÏúºÎ°ú Ìó¨Ïä§ÏºÄÏñ¥ Î∂ÑÏïºÏóêÏÑú Í∑úÏ†úÎ•º Î∞õÎäî Ï†úÌíàÏùÑ ÏõêÌïòÎäîÏßÄ ÏïÑÎãàÎ©¥ Í∑úÏ†úÎ•º Î∞õÏßÄ ÏïäÎäî Ï†úÌíàÏùÑ ÏõêÌïòÎäîÏßÄÏóê ÎåÄÌï¥ÏÑú ÏñòÍ∏∞ÌñàÏùÑ Îïå ÎåÄÎ∂ÄÎ∂ÑÏùò Í≤ΩÏö∞Îäî Í∑úÏ†ú Î∞õÏßÄ ÏïäÎäî Í≤ÉÏùÑ Îçî ÏÑ†Ìò∏ÌïúÎã§Í≥† Î¥êÏöî. ÎãπÏó∞ÌïòÏ£†. Í∑∏Î¶¨Í≥† Í∑∏ Í≤ΩÏö∞ÎèÑ Ï†úÌíàÏù¥ Îçî Îπ†Î•¥Í≤å Ìçº ÎÇòÍ∞à ÏàòÎèÑ ÏûàÍ≥†Ïöî. Í∑∏Î†áÏßÄÎßå ÏïÑÍπå ÎßêÏîÄÌïòÏã† Í≤ÉÏ≤òÎüº Í∑úÏ†úÎ•º ÏûàÎäî Í≤ΩÏö∞Îäî Ïò§ÌûàÎ†§

Î∞©Ïñ¥ÏÑ† Ï≤òÎüº ÏûëÏö©Ìï† Ïàò ÏûàÏúºÎãàÍπå Ïñ¥Îñ§Í≤å Îçî ÌöåÏÇ¨Ïùò ÏÑ±Ïû•Ïóê ÎèÑÏõÄÏù¥ ÎêòÎäîÏßÄÎäî ÌåêÎã®ÌïòÏÖîÏïº Ìï† Î¨∏Ï†úÎùºÍ≥† ÏÉùÍ∞ÅÌïòÎäîÎç∞ Îã®ÏßÄ ÏÉùÍ∞ÅÌï†Í±∞Î©¥ Íº≠ FD Ìú¥ÏßÄÎ•º Î∞õÎäî Ï†úÌíàÏùÑ ÎßåÎì§ ÌïÑÏöîÍ∞Ä ÏûàÎã§. Îëê Î≤àÏß∏, Î∞©Í∏à ÎßêÏîÄÎìúÎ¶∞ Í≤ÉÏ≤òÎüº Ïã§Ï†úÎ°ú ÏïÑÍπå Î∞õÏùÄ Ìà¨ÏûêÏùò Í∏àÏï°Ïóê ÎåÄÌï¥ÏÑú Ìà¨ÏûêÎ•º Î∏åÎ†àÏù¥ÌÅ¨ ÌïòÎäî Í±∏ Î≥¥ÎãàÍπå Ïã§Ï†úÎ°ú ÏßàÎ≥ëÏùÑ Ï¶ùÍ∞ÄÌïòÎäî Ï†úÌíà Í∞ôÏùÄ Í≤ΩÏö∞Îäî Ï†ÑÏ≤¥ Ìà¨ÏûêÏùò Ìïú 29%Ïóê ÎπÑÌï¥ÏÑú Ìó¨Ïä§ÏºÄÏñ¥ ÌôòÍ≤ΩÏóêÏÑú Ïù¥Î£®Ïñ¥ÏßÄÎäî Îã§Î•∏ ÎßéÏùÄ ÌñâÏúÑÎì§, ÏòàÎ•º Îì§Ïñ¥ÏÑú ÌéòÏù¥ÏÖò ÏóîÍ≤åÏù¥ÏßÄÎ®ºÌä∏ ÏïÑÎãàÎ©¥ ÎπåÎî© Î†àÎπÑÎâ¥ ÏÇ¨Ïù¥ÌÅ¥ Îß§ÎãàÏßÄÎ®ºÌä∏ ÏïÑÎãàÎ©¥ ÎπåÎî© ÏÑúÌè¨Ìä∏ ÏúÑÎ≤ÑÏä§ÎßåÌïú Îç∞Îäî Ï¢Ä Îçî ÏâΩÍ≤å ÎßåÎì§Ïñ¥ÏßÄÎäî Ïù¥Îü∞ Ï†úÌíàÎì§, ÏïÑÎãàÎ©¥ Î≠ê AI Ï≤¥Ìè¨ Ïù¥Îü∞ Í≤ΩÏö∞Îì§ÏùÄ Ïò§ÌûàÎ†§ Îçî Ìà¨ÏûêÎ•º ÏâΩÍ≤å Î∞õÎäîÎã§Îäî Í∑∏Îü∞ Ìï¥ÏÑùÏùÑ Ìï† Ïàò ÏûàÎäî Ïà´ÏûêÎì§ÎèÑ ÏûàÏóàÍ≥†, Í∑∏Î¶¨Í≥† Ïã§Ï†úÎ°ú Ï†ÄÌù¨Í∞Ä Ïñ¥Ï†ú Î∞©Í∏à ÎßêÏîÄÎìúÎ¶∞ Í≤ÉÏ≤òÎüº ÎßåÎÇòÎçò Ïà´ÏûêÎì§ÎèÑ ÎπÑÏä∑Ìïú ÏñòÍ∏∞Î•º ÌñàÏäµÎãàÎã§.

ÎîîÏßÄÌÑ∏Ïä§Ïùò Í≤ΩÏö∞, ÌäπÌûà AIÍ¥ÄÎ†® ÏïÑÎãàÎ©¥ Îç∞Ïù¥ÌÑ∞ Í¥ÄÎ†®Ìï¥ÏÑúÎäî Federal Î≥¥Í¥ÄÎì§ ÎøêÎßå ÏïÑÎãàÎùº Ï£ºÍ±∞ Î≥¥Í¥ÄÎì§ÎèÑ ÎÑàÎ¨¥ ÎßéÏïÑÏöî. Í∑∏ÎûòÏÑú ÏñºÎßàÏ†ÑÏóêÎäî ÏòàÎ•º Îì§Ïñ¥ÏÑú ÏùºÎ¶¨ÎÖ∏Ïù¥Ï£ºÏóêÏÑú Î©òÌÉàÏä§ Í¥ÄÎ†®Ìï¥ÏÑú CheckboxÏùÑ ÏÇ¨Ïö©Ìï† Ïàò ÏóÜÍ≤å ÌïòÎäî Í∑∏Îü∞ Î≥¥Í¥ÄÎèÑ ÎÇòÏò§Í≥†. ÏßÄÍ∏à ÏïÑÌôâÍ∞úÏù∏Í∞Ä Ï£ºÏóêÏÑú Îç∞Ïù¥ÌÑ∞ ÌîÑÎùºÏù¥ÎπÑÏãú Í¥ÄÎ†®Ìï¥ÏÑú Ïó¨Í∏∞ÏÑú ÎßåÏïΩ ÎîîÏßÄÌÑ∏ÏóêÏÑú Îç∞Ïù¥ÌÑ∞Î•º Îã§Î£®Îäî ÌöåÏÇ¨Îì§Ïù¥ ÏûàÏúºÏãúÎã§Î©¥ Îî∞Î°úÎî∞Î°ú Í∑úÏ†úÌïòÎäî Í∑∏Îü∞ Î≤ïÏïàÎèÑ Í≥ÑÏÜç ÎÇòÏò§Í≥† ÏûàÍ≥†Ïöî. Í∑∏ÎûòÏÑú Ïù¥Îü∞ Í≤ÉÎì§ÏùÑ Í≥ÑÏÜç Î™®ÎãàÌÑ∞ÎßÅ ÌïòÏÖîÏïºÏßÄ ÏïÑÍπå ÎßêÏîÄÎìúÎ¶∞ Í≤ÉÏ≤òÎüº Ï†ïÎßê ÌÅ∞ Î¶¨Ïä§ÌÅ¨Ïùò ÏóòÎ¶¨Ïï†Î•º ÌîºÌï¥Í∞à Ïàò ÏûàÎäî Í∑∏Îü∞ Ï†úÌíàÏùÑ Í∞úÎ∞úÌï† Ïàò ÏûàÏßÄ ÏïäÎÇò ÏÉùÍ∞ÅÌï©ÎãàÎã§.

ÎßàÏßÄÎßâÏúºÎ°ú ÏÉùÍ∞ÅÌñàÎçò Í≤ÉÏùÄ Ï†úÍ∞Ä Ïñ¥Ï†ú Î≥¥Î©¥ÏÑú Í∞ÄÎÅîÍ∞ÄÎã§ Ïù¥Î†áÍ≤å ÎØ∏Íµ≠ ÌöåÏÇ¨Îì§, ÎØ∏Íµ≠ Ìà¨ÏûêÌöåÏÇ¨Îì§Ïùò Ìè¨Ìä∏Ìè¥Î¶¨Ïò§Î•º Î≥¥Î©¥ÏùÄ ÌïúÍµ≠ÏóêÎèÑ Ï†úÍ∞Ä ÎßåÎÇú ÌöåÏÇ¨ Ï§ëÏóêÏÑúÎèÑ ÎêòÍ≤å ÏÜåÌîºÏä§Ìã±Ìï¥ ÏûàÎã§Í≥† Í∑∏Î¶¨Í≥† Ï†úÌíàÎì§Ïù¥ Ï¢ãÏùÄ ÌöåÏÇ¨Îì§ÎèÑ ÎßéÏùÄÎç∞ Íº≠ ÎØ∏Íµ≠ ÌöåÏÇ¨Îì§Ïù¥ÎùºÍ≥† Ìï¥ÏÑú Ìà¨ÏûêÎ•º Îçî Ïûò Î∞õÍ≥† ÏùºÌï¥Ïïº ÎêòÎäî Í±¥ ÏïÑÎãåÎç∞ ÎùºÎäî ÏÉùÍ∞ÅÏù¥ Îì§ ÎïåÍ∞Ä Í∞ÄÎÅî ÏûàÏäµÎãàÎã§. Í∑∏ÎûòÏÑú Ïª®ÌçºÎü∞Ïä§ÎùºÎì†ÏßÄ Ïñ¥Îñ§ Ïù¥Î†áÍ≤å Îòê Ïù¥Îü∞ Îç∞ ÎßéÏù¥ ÎÇòÍ∞ÄÏÖîÏÑú Ï†úÌíàÏùÑ ÎßéÏù¥ ÌôçÎ≥¥ÌïòÏãúÎ©¥ Îçî ÎÑìÏùÄ Í∑∏Îü∞ Í∏∞ÌöåÏôÄ Îçî ÎßéÏùÄ ÏãúÏû•Ïù¥ Ïó¥Î¶¨ÏßÄ ÏïäÏùÑÍπå Í∑∏Î†áÍ≤å ÏÉùÍ∞ÅÌï©ÎãàÎã§.

20Î∂ÑÍ∞Ñ Ï≤¥ÌóòÏùÑ ÌïòÏòÄÏäµÎãàÎã§. Í∞êÏÇ¨Ìï©ÎãàÎã§.

Ï≤´ Î≤àÏß∏ ÏÑπÏÖòÏùÑ ÎßàÏπòÎèÑÎ°ù ÌïòÍ≤†Í≥†Ïöî.

</details>

---

*Session I Ï¢ÖÎ£å - 02:40 PM*
